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Summary of Thesis: 
P-glycoprotein (P-gp – MDR-1), a 170 kDa glycosylated membrane bound protein, is a member of 
the ATP-binding cassette transporter family.  The potential for P-gp to reduce drug absorption 
across lung epithelia is of significant interest; this is particularly so, given P-gp’s broad substrate 
specificity mediating efflux transport of a range of structurally unrelated substrates.  Within lung, P-
gp expression is evident in bronchial and alveolar epithelia with functional characterisation of P-gp 
transport capacity within lung epithelial cells currently restricted to respective in-vitro cell culture 
models. 
The aims of this project were to establish the relative mRNA expression of several ATP Binding 
Cassette (ABC), Solute Carrier (SLC) and Solute Carrier Organic Anion (SLCO) drug transporters 
within rat lung samples through use of RT-PCR; expression suggesting the potential to serve as 
targets for pulmonary drug delivery.  Further, validation of an Isolated Perfused Rat Lung 
preparation for use in assessment of drug transport across the lung was conducted.  In order to 
assess the functional significance of the ABC drug transporter, P-glycoprotein, on drugs instilled 
intra-tracheally to the IPRL set-up, use of the P-gp substrates; Rhodamine 123 (Rh123), digoxin, and 
flunisolide and the P-gp inhibitor, GF120918 was employed.  Further, use of kinetic modelling was 
employed to establish pharmacokinetic parameters involved. 
Using the IPRL, the P-gp dependent pulmonary absorption of the P-gp substrate, Rh123, was 
demonstrated.  Dose-dependent absorption, consistent with a saturable component in the 
molecule’s pulmonary absorption, was demonstrated.  Further, the absorption of low dose Rh123 
was promoted by the presence of the highly selective P-gp inhibitor GF120918, consistent with a 
functional role of P-gp mediated efflux within an intact lung; an efflux process which may limit the 
pulmonary absorption of a lung administered molecule.  Further studies using this system and 
extending the range of molecules studied will provide greater understanding of the quantitative 
significance of P-gp in limiting pulmonary absorption across lung epithelium.  
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1. Introduction 
1.1. Structure and function of the lung: barriers to drug absorption 
The primary role of the respiratory system is gaseous exchange, providing a continuous supply of 
oxygen for cellular respiration and allowing removal of the waste product carbon dioxide.  In 
consequence of this essential function, pulmonary morphology allows airflow from the oropharynx 
through the conducting airways to the deeps lungs where the lung epithelial surfaces are in close 
proximity to the pulmonary circulation. These features also afford the lungs to represent a route for 
the delivery of drugs for both local or indeed systemic actions [1].  Drugs delivered to the lungs are 
in the form of an aerosol; be this a solution aerosol or dry powder.  However, the branching 
architecture of the lung airways and an individual’s breathing pattern leads to significant technical 
demands on inhaler device design and aerosol production.  For example, with aerosol inhalation via 
the mouth in humans, particles of ≥ 10 µm diameter will encounter impaction upon the trachea and 
upper airway divisions.  Generally, particle sizes of 5-10 µm in diameter are then removed by 
mucociliary clearance, with particles 2-5 µm in diameter having the most potential to reach the 
deeper parts of the lung, including the alveolar airspace [2].  Figure 1.1 illustrates the lung’s 
branching architecture and highlights the multifaceted surfaces available for drug delivery.  
Nevertheless, as a drug delivery route, the lung presents an extensive, somewhat potentially more 
permeable absorptive surface with a reduced metabolic barrier in comparison to the gastro-
intestinal tract and first-pass through the liver [3]. 
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Figure 1.1 Diagrammatic representation of the human respiratory system.  Shown, is a simplified 
model of the branching architecture of the lungs.  Further, cell morphology and depth of the epithelial 
cell barrier to drug delivery decreases as the number of bronchial bifurcations increases and decreases 
even further with increased depth into the respiratory zone.  Taken from [4-6]. 
 
The human lung has a large surface area available for drug delivery.  Studies have estimated the 
surface area of the alveolar region alone to be approximately 100 m² which would represent more 
than half of the surface area of a singles tennis court [7].  To function optimally the respiratory 
system, and in particular the mucosal barrier, is comprised of many morphologically different and 
specialised cells; to serve not only respiratory requirements but also to act as a defence against 
inhaled foreign particles [1].  In order for the successful delivery of a drug to the submucosal regions 
and beyond to blood, the compound in question has to pass through a number of barriers.  These 
would include; the airway luminal cells, the mucus barrier covering the epithelium lining the airways, 
and the lung epithelium itself, which is represented by many different histological cell types from the 
trachea, through the bronchi to the bronchioles, and the alveolar air sacs themselves.  This varied 
lung epithelial cell barrier decreases in thickness with increasing depth into the lung; from an 
epithelial layer of approximately  50-60 µm at the trachea, to only a single-celled barrier of less than 
0.5 micron in the deep lung, all of which may present this region to be a more favourable target for 
systemic drug delivery [1, 8]. 
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The physical organisation of the respiratory system alone provides a number of barriers to drug 
delivery and molecule absorption: 
Trachea The trachea itself is a significant component of the respiratory system being 
approximately 11 cm long with a diameter of 2-2.5 cm [4].  The trachea branches to two main 
bronchi which subdivide for 23 generations [1, 6].   
Generation 1–4  Bronchi (cartilaginous airway) 
Generation 5-16 Non-respiratory bronchioles that conclude as terminal bronchi 
Generation 17-22 Respiratory bronchioles 
Generation 23 Alveolar ducts 
 
The airways of the trachea-to-bronchi, of approximately 2 mm diameter, are cartilaginous airways 
and are comprised of incomplete cartilage rings and smooth muscle.  Bronchi of approximately 2 
mm to 0.6 mm are deficient in cartilage; generations 13-17, (cartilage ends at generation 12) but do 
have smooth muscle and it is the smooth muscle contraction that increases rigidity and regulates the 
airways during respiration [1].    
Mucosal barrier  The process of mucociliary clearance (MCC), which represents a substantial 
barrier, accounts for the removal of particulate matter through the sweeping action of ciliated cells 
moving particles ‘trapped’ within mucus upward toward the oropharynx.  Mucus itself is a hydrated 
mucosal layer which, in mammals, is mainly comprised of mucin glycoproteins secreted, in part, by 
goblet cells [9].  The pseudostratified, ciliated columnar epithelial cells of the larger airways 
gradually transform to a single layer of cuboidal ciliated cells at the terminal bronchioles.  With 
mucociliary clearance only involving ciliated cells, which decrease in number toward the terminal 
bronchioles, the impact of mucociliary clearance lessens, i.e., the rate of MCC is reduced the 
narrower the airways become, i.e., in the higher airway generations [10].   
Surfactant Airway surfactant is composed of approximately 90 % lipids; namely the 
phospholipids phosphatidylcholine and phosphatidylglycerol, with smaller quantities of 
phosphatidylethanolamine, phosphatidylinositol and phosphatidylserine.  The remaining 10 % is 
comprised of surfactant-specific proteins (SP) -A, -B, -C and -D.  These proteins are divided to two 
subgroups; hydrophilic SP-A and SP-D, and hydrophobic SP-B and SP-C [11, 12] and function in 
pulmonary host defence.  As a whole surfactant act to reduce lung surface tension and decrease the 
Alveoli – gas 
exchange 
Conducting airway – 
no gas exchange 
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possibility of alveolar collapse and have a role in pulmonary host defence systems.  Lung surfactant 
has also been suggested to aid mucociliary clearance via interactions with inhaled particles [13]. 
Cells There are over 40 different cell types within the lung, presenting a substantially varied 
barrier for any molecule.  The upper airway is mainly comprised of 3 cell types; basal cells; which are 
thought to possess an ability to differentiate, goblet cells; which secrete mucus and ciliated cells; 
which specialise in ciliary action [14].  While perhaps the more extensive barrier, the alveolar region, 
contains 2 major cells types(not including macrophage); alveolar epithelial type I (AEI) cells and the 
type II (AEII) cells [7].  AEI cells are squamous in appearance, constitute approximately 95 % of the 
alveolar epithelial surface area and yet only approximately 30 % of the total alveolar epithelia (AE) 
cell population. These squamous pneumocytes in their more peripheral attenuated regions form a 
cellular barrier of only 0.1 – 0.3 µm in thickness; this thin cell phenotype is considered important in 
to gaseous exchange.  The AEII cells are cuboidal in shape and although are more numerous 
(approximately 66 % total AE cell population), account for only  approximately 5 % of the alveolar 
surface area [14].  These granular pneumocytes possess microvilli and lamellar inclusion bodies 
involved in surfactant production, surfactant protein secretion and recycling [13].   
Interstitium The interstitium is regarded as the extracellular and extravascular space between 
cells and is mainly comprised of collagen fibres, fibroblasts and basement membrane or extracellular 
fibres.  This barrier acts as both a tough fibrous filter and an extracellular matrix for the attachment 
of cells [7].  Despite the interstitium presenting an obvious physical barrier, studies have suggested 
that it does not contribute considerably as an obstacle to absorption.  For example, Schneeberger-
Keeley and co-workers have demonstrated, by ultrastructural cytochemistry, the ability of 
horseradish peroxidase (40 kDa) to readily traverse the basement membrane [15] from the 
vasculature, i.e. the limiting barrier from airspace to blood is the lung epithelium.  
1.2. Advantages and disadvantages of pulmonary drug delivery 
Regardless of the obvious anatomical barriers to inhaled particles, the lung is an important drug 
delivery route for the local treatment of pulmonary diseases such as asthma and chronic obstructive 
pulmonary disease (COPD), and with certain examples as a route for the systemic delivery of drugs 
[8].  This delivery route was first exploited in 1925 by Gänsslen who delivered insulin via a number of 
inhalation devices (Stӓubli-Inhaler, Riviera-AA-inhaler) to five diabetic subjects and in turn noted a 
decrease in blood glucose level [16].  Therapeutic molecules delivered via this route generally show 
more extensive absorption than by other routes of administration and permeation enhancers; such 
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as sodium deoxycholate or sodium laureth sulphate, are not generally a feature of a pulmonary 
formulation [7, 17].  Advances in aerosol science have allowed for more efficient and reproducible 
delivery of particles to the lung and improved penetration to the deep lung, where clearance of 
particles is slower [18].  For local lung disease, administration by the pulmonary route provides for 
higher concentration of drug at the target site, permitting rapid onset of action and lower systemic 
exposure, with reduced potential of systemically-mediated side effects [19].    
As mentioned above, the lungs provide a relatively large area for drug absorption, with the potential 
for aerosolised drug to almost simultaneously reach a significant proportion of this surface. The 
lungs receive full cardiac output from the right-hand side of the heart and in the alveolar region, the 
blood flowing through the pulmonary vasculature is separated from the luminal epithelial surface by 
only a short distance (less than 1 µm); comprising the thin attenuated regions of the AEI and 
pulmonary microvascular cells.  This extremely well vascularised, thin air-blood barrier provides 
great capacity for rapid absorption of dissolved molecules.   Further, the lung has a comparatively 
low metabolising enzyme activity when compared to the liver (i.e. liver is of influence when 
delivering drugs via the [very common] oral route).  Analysis of phase I and II metabolising enzymes 
in lung parenchymal cells and hepatocytes by Somers and colleagues indicated phase I activity to be 
< 10 % of that in hepatocytes when comparing rates of probe substrate metabolism (mL/min/106 
cells) in freshly isolated parenchymal cells to hepatocytes; negligible expression of CYP3A4 in 
parenchymal cells was also reported [3].  In summary it is clear why the lungs are an important route 
for the delivery of locally acting drugs in pulmonary disease, and why this route has also attracted 
significant attention in terms of the systemic delivery of drugs, particularly biologics such as 
antibodies (e.g. monoclonal antibodies that target bacterial antigens such as those of Yersinia pestis 
have been investigated) [7, 20, 21].   
However, despite the lungs representing a very attractive means of non-invasive delivery, it is by no 
means without issue.  There are several anatomical, technical, and lung defence factors that need to 
be considered.  As mentioned previously, there is a marked difference in cell morphology, i.e. cell 
barrier, from the upper lung airspace to deep lung.  This not only provides an array of barriers to 
traverse in terms of systemic delivery but also raises the issue of different permeability profiles 
down the respiratory tract.  Clearly, for local drug delivery, there will likely be the need to target 
specific regions of the airways for optimum local action, the same is true when systemic delivery is 
the aim, where more preferential deposition in the deeper lungs will be important [22].   
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The delivery of drugs to the lung is technically challenging, requiring the reproducible generation of 
an aerosol particle population emitted from an inhalational device that displays appropriate particle 
size and population size distribution; hygroscopic aerosol particles sizes can change significantly 
upon exposure to humid conditions.  The drug formulated into the inhaler device must be stable for 
prolonged periods of storage as a dry powder, in organic propellant or in solution.  How the device is 
used by patient and the patient’s breathing pattern can all influence the deposition pattern of the 
aerosol within the respiratory tract.  Particle deposition within the conducting airways involves 
susceptibility to clearance by the mucociliary escalator.  Particle deposition beyond the conducting 
airways is subject to macrophage engulfment within the alveolar sacs.  Due to the virtual lack of fluid 
movement in the alveoli, sequestration in lining fluid, and the delicate nature of the epithelium, drug 
retention and possible onset of toxic effects or immune/phagocyte induction/activation within the 
alveoli cannot be overlooked [8, 22, 23]. 
1.3. Techniques for pulmonary drug delivery 
Aerosol devices to enable the delivery of drugs to the lung have been in existence since the 1900’s, 
however, these early devices were inefficient and impractical [18].  In order to fully utilise the 
pulmonary system as a delivery route, new more efficient devices were required.  This necessity for 
development is, and remains, not without issue [22]. 
Continued improvements in aerosol device and particle technology have allowed production of 
stable formulations and accurate delivery methods (over 25 inhalation drugs on the market for lung 
diseases by development peak of 2004; by 2010, 27 breath-activated and metered-dose products 
exist for the treatment of asthma and COPD alone) [20, 24].  Drug aerosols with optimum 
aerodynamic characteristics can be delivered to the lung with efficiencies as high as 90 %, however, 
this is highly dependable upon patient compliance.  Several different devices have been developed. 
These include pressurised metered-dose inhalers (pMDI), dry powder inhalers and nebulisers; each 
one of which has undergone significant technical development to ensure ‘fit-for-purpose’ 
functionality.   These devices allow controlled dose metering, producing delivery of a single dose of 
drug with a specific formulation which has been developed to meet the requirements of pulmonary 
delivery.  However, as with any patient-controlled dosing device, issues of education and compliance 
arise.  Incorrect usage having the potential to impact upon release of drug from a device and drug 
deposition/sedimentation within the lung [25].   
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Pressurised metered-dose inhalers (pMDI) Development of pMDI’s has allowed delivery of 
aerosol particles at high velocity, which can increase lung penetration but also lead to significant 
impaction on the oropharnyx [22].  Such devices are highly desirable as they are portable, easy to 
use, tamper proof and allow accurate multi-dosing [25].  Initially however, many pMDI devices 
utilised chlorofluorocarbons (CFC’s) to provide the pressure needed for drug delivery.  In 1991, 
under the Montreal protocol [26], these propellants were withdrawn from use in all technology due 
to the threat they posed on the environment.  At this time pharmaceutical companies began 
researching alternative propellants and began using hydrofluoroalkanes (HFA’s) while 
simultaneously focussing further upon delivery methods such as dry powder inhalers and liquid 
aerosol nebulisers for the pulmonary delivery of therapeutic drugs [18]. 
Dry powder inhalers (DPI) Many therapeutic molecules are not readily formulated into pMDI 
but nevertheless require to be formulated in a way that enables efficient delivery of drug to the lung 
surfaces and provide protection of the drug against chemical degradation.  The use of dry powder 
formulation devices represents an alternative aerosol device technology which can afford a 
reproducible and convenient inhalation method [27].  Dry powder preparations provide pre-metered 
drug packed in ‘blisters’, producing a metered dose that can be accurately assessed.  However, dry 
powder inhalers only deliver drugs when a patient inhales, thus raising patient technique compliance 
issues.  Further, both pMDI and dry powder devices suffer from dose retention within the device and 
dose deposition in the oropharynx region therefore influencing dose deposition in the lung and drug 
bioavailability  [25].   
Nebulisers The nebulisation of liquids to generate aerosols is an efficient means of pulmonary 
delivery.  Drugs in a nebulised solution allow deposition of larger drug doses (which are sometimes 
seen as more ‘respirable’ by patients) to the deep lung.  
There are two main types of nebuliser device, the air-jet nebuliser and ultrasonic nebuliser.  These 
devices create highly respirable drug aerosol droplets of optimum aerodynamic parameters for 
effective pulmonary delivery.  However these systems require reasonable aqueous drug solubility 
and are often not very portable, negatively impacting as a delivery device in this way [25].  Further, 
drug stability issues in the nebulisation process itself and dose retention in the nebuliser are 
considerations.  
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1.4. Examples of pulmonary drug delivery for both local and systemic action 
The delivery of drugs to the pulmonary system is well established for the treatment of respiratory 
diseases such as asthma, COPD, cystic fibrosis and pulmonary infections and so the delivery of drugs 
such as bronchodilators and anti-inflammatory steroids is well recognised.  Increasingly, the lungs 
have been utilised for the delivery of a variety of molecules including peptides, proteins and 
antibiotics with the delivery of the first nebulised protein, DNase, for cystic fibrosis in 1994 and 
nebulised antibiotic, tobramycin, in 1998 [22]. 
Perhaps the most publicised protein to be delivered to the lung is insulin for the treatment of 
diabetes.  The work of Gӓnsslen gave the first example of the efficacy of insulin after pulmonary 
administration in 1925; however, studies then lay dormant for many years.  Several animal studies 
sought to demonstrate the potential of inhaled insulin and gave direct evidence of the absorption 
and efficacy of insulin following administration by aerosol [16, 28]. Work progressed to human 
proof-of-concept with Skyler et al. demonstrating the capability of inhaled insulin to treat type I 
diabetes in 2001 [29].  Inhaled insulin in the DPI product  Exubera (Pfizer) was approved in 2005 in 
both Europe and America for the treatment of adults with diabetes [22] but it was approved for use 
only in limited indications which resulted in Pfizer eventually withdrawing the product from the 
market.  
Despite the withdrawal of inhaled insulin, predominantly on commercial grounds, it is this work 
together with the very early groundbreaking work of Gӓnsslen [16] that has served as proof-of-
concept for the delivery of peptides and proteins to the systemic circulation via the lung.  While 
there are few licensed inhaled drugs for systemic action, this area of pulmonary delivery has 
produced a number of preclinical and clinical development examples for the delivery of peptides, 
proteins and other small molecules to the systemic circulation.  For example, the work of Dershwitz 
and co-workers found that administering inhaled morphine to human lung produced a bioavailability 
of 59 % absorption displaying similar kinetics to that of intravenous bolus administration.  Rapid 
absorption would provide swift onset of drug action (pain relief) whilst avoiding problems of slow 
absorption and metabolism associated with oral administration [30].  Another successful example is 
that of inhaled human growth hormone (hGH).  Together with improvements in aerosol technology, 
inhaled hGH; termed somatropin inhalation powder (SIP) has been successfully introduced via the 
pulmonary system and has recently undergone extensive toxicology, pharmacokinetic (PK) and 
pharmacodynamic (PD) studies in primates and adult human males and has proved to be safe and 
tolerable as a treatment regimen [31, 32].  Other examples of treatments being investigated for 
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systemic delivery via the pulmonary system include; Interferon β for multiple sclerosis, leuprolide 
acetate to treat prostate cancer, calcitonin and parathyroid hormone to treat osteoporosis, heparin 
to prevent thrombosis, and dihydroergotamine for treatment of migraine [18]. 
1.5. Mechanisms of drug transport and absorption across the lung      
The precise mechanism(s) of drug absorption from the lung, especially for large macromolecules 
remain relatively unknown.  Further, for small molecules the role of active transport processes as a 
component of the drug absorption process remains unquantified; indeed for some molecules the 
overall penetration across lung epithelium will reflect a combination of different processes. The 
majority of drugs and solutes are probably absorbed from the airspace by two general transport 
mechanisms; transcellular passive diffusion and paracellular passive diffusion (Figure 1.2).  Clearly 
active transport will also be important for some drugs.  In particular, higher molecular weight 
biologic-based drugs, such as proteins, will also have a component of their transport that is managed 
by an endocytic vesicular-mediated process such as clathrin-mediated uptake.  There will also be 
some low molecular weight drugs whose transport is determined by active or facilitated carriers [7]. 
 
 
Figure 1.2 Mechanisms of drug transport across lung epithelia.  Adapted from [33]. 
Paracellular transport Major mechanism by which hydrophilic molecules pass across an epithelial 
barrier through the fibrillar network of intercellular tight junctional proteins which circumvent the 
apical border of each epithelial cell forming the epithelial barrier layer [8].  
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Transcellular transport Mechanism by which hydrophobic molecules possessing the physico-
chemical properties that afford membrane partitioning can enter the epithelial cell and diffuse from 
the apical membrane through to the basal—lateral membrane to access the sub-epithelial layers [8]. 
During the 1970’s and 80’s the body of work of Shanker and co-workers, examining the 
disappearance from the intact lung of a diverse range of compounds following intratracheal and 
aerosol administration, illustrated that most compounds are absorbed and transported via passive 
diffusional pathways [34, 35].  From this data, it was predicted that macromolecules with a 
molecular weight under 40 kDa and hydrophilic molecules will traverse cell membrane barriers via 
tight junctions while lipophilic compounds will permeate predominantly via transcellular diffusion; 
n.b., these lipophilic compounds will also access the paracellular route, albeit with the paracellular 
route contributing, to a minor extent, to overall lipophilic drug absorption [7, 36].  The density of 
membrane vesicles within the alveolar region also provides the opportunity for vesicle-mediated 
transcytosis as a transport mechanism in the lungs.  Many of these vesicles are morphologically 
recognised as caveolae and are involved in the active vesicular transcytosis of macromolecules 
across endothelial cells [37].  The transport of proteins, such as albumin, in rat pulmonary 
endothelial cells has been shown to be mediated by caveolae, suggesting vesicle-mediated transport 
to contribute to the mechanism of protein transport at the air-blood barrier [38]. 
Active transport Molecule transport that is energy-dependent and can be inhibited by other 
molecules that can compete for common or alternative binding sites on membrane carrier proteins. 
There are a variety of mechanisms by which membrane carrier proteins can transport a drug across 
the biological membrane.  
The presence and contribution of carrier-mediated active transport in the lung is relatively poorly 
defined.  Influx transporters such as the peptide transporter PEPT2 have been localised to several 
lung regions and cell types [39].  The efflux transporter P-gp/MDR1 and many other ATP-binding 
cassette (ABC) transporters have also been localised to the lung epithelial cells [40].  While there is 
increasing evidence as to the presence of active transporters in the lung, the data accumulated by 
Schanker and colleagues between the 1970s and 80s, suggest that molecules that are substrates for 
active transporters do not significantly deviate in their absorption profile from other molecules of 
similar molecular weight or lipophilicity [20]. Schanker et al. studied tens of lipid insoluble 
substrates, with molecular weights ranging from 60 - 70,000 kDa and reported that; overall, 
absorption within the lung was inversely related to molecular weight.  For example, guanidine (59 
MW) displayed an absorption half-life of 6.3 ± 0.2 min., mannitol (130 MW), a half-life of 60 ± 6 min 
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and dextran (20,000 MW) a half-life of 688 ± 51 min in adult rat lung, highlighting a relationship that 
is dependent upon properties such as molecular weight and lipid-solubility regardless of any active 
transport mechanisms that may be present [34, 41]. 
1.6. Drug transporter proteins 
There are many examples of drug permeability at epithelial and endothelial membranes that is 
influenced by membrane transporter proteins that recognise drug substrates and facilitate or indeed 
limit their transport across these barriers [42].  Drug transporters have been broadly classified into 
either uptake or efflux proteins (Figure 1.3) [43]. 
 
Figure 1.3 Diagrammatic representation of the types of solute carrier transporter; SLC, and ABC 
transporters present within a cell.  Adapted from Hediger et al., 2004 [44]. 
 
A large number of genes encoding membrane transporters have been identified in both eukaryotic 
and prokaryotic genomes.  However, not all of these membrane transporters act as functional drug 
transporters, many have constrained substrate specificity and only a small percentage are associated 
with the disposition of compounds involved in drug discovery and clinical use [45]. 
Drug transporters are characterised into two main families; the solute carrier family or SLC 
transporters and the ATP-binding cassette family, or ABC transporters. 
Solute Carrier (SLC) Transporters  
The SLC transporter family is comprised of 43 families containing some 298 members.  Members of 
this super-family are assigned based on amino acid sequence identity; family members share 20-25 
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% sequence identity while subfamily members share at least 40 % sequence identity.  It is generally 
thought that >2000 (5 %) of all human genes are transporter-related, with the SLC family holding a 
significant number of these genes (currently ~300 SLCs identified) illustrating deep ancestry and 
affirming the significance of transporter proteins in maintaining cell homeostasis [44].  In order to 
identify members of each transporter family and subfamily, each gene is labelled using a root 
symbol, i.e., SLC or ABC.  SLC members are identified with a numeral to indicate family; SLC1, 
followed by a letter divider; SLC1A, and finally a number to identify an individual gene; SLC1A1.  
While this system of nomenclature easily and accurately identifies the majority of SLC family 
members by gene (note - a selection of transporters can be identified by more than one protein 
name), the SLC21 family required modification of the classification system.  Originally SLC21, the 
family number and letter divider were replaced with the letter ‘O’ representing ‘organic transporter’.  
This alteration occurred in order to accommodate species-independent identification of transporter 
isoforms that arose due to rapid family evolution [44, 46]. 
In comparison to ABC transporters, SLC transporters are a very diverse family and contain genes that 
are known to encode facilitative transporters, ion-coupled transporters and exchangers [44].   
Despite this diversity, SLC transporters share the same basic structure as their ABC counterparts, 
comprising transmembrane domains (TMD) for anchoring and some form of functional domain(s) to 
facilitate transport of specific substrates.  For example, the passive urea transporter UT-B1 is 
comprised of 10 TMD and 1 glycosylated extracellular loop, while the ion-coupled transporter 
SLC14A1 is comprised of 12 TMD which are flanked by hydrophobic NH2 and COOH- terminal 
domains with an extracellular loop at TMD 7-8 [47, 48].  Because SLC transporters do not utilise ATP, 
the secondary topology of these transporters appears much simpler than transporters of the ABC 
family, however, their diverse nature and expansive substrate specificity suggest them to be more 
complex than they initially appear.  
In contrast to ABC transporters, many SLC transporters do not achieve the driving force for substrate 
transport from ATP hydrolysis but rather from the electrochemical gradient of their substrates and 
are therefore termed secondary active transporters [49].  While drug transporter secondary 
topology is comparable between SLC transporter families, their mechanism of action varies from 
simplistic to complex.  For example, mammalian sodium-proton exchanger transporters have a 
simple 1:1 exchange mechanism where 1 Na+ and 1 H+ traverse the membrane down 
electrochemical gradients (Figure 1.4) [49].  In comparison, long chain fatty acid (LCFA) transporters 
of the SLC27 family are proposed to have a more complex mechanism of action where extracellular 
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LCFA bind directly to fatty acid transporter complexes to be transported into cells and then couple to 
intracellular coenzyme-A (CoA) via long chain fatty acid acyl-CoA synthetase, to prevent LCFA efflux 
[50].  Unlike many other SLC family transporters, fatty acid transporters require ATP binding to 
facilitate LCFA transport [50]. 
 
Figure 1.4 Diagram illustrating the mechanism of action of simple Na+/H+ exchanger proteins (SLC9 
family) present in mammalian cells.  Adapted from Orlowski et al., 2004 [49]. 
 
ATP Binding Cassette (ABC) transporters  
Examples of ABC family transporters are found in eukaryotes and prokaryotes and evidence of 
prokaryotic and eukaryotic ancestry suggest that many subfamily members began to specialise early 
in the ancestry of these proteins, perhaps highlighting significant physiological roles for these 
proteins.  Paralleling SLC transporters, ABC family members are also assigned based on amino acid 
sequence identity, which is influenced by ABC family divergence from a common ancestor into 7 
subfamilies denoted with a letter; ABCA - ABCG.  To allow individual identification of ABC 
transporters, a letter corresponding to the subfamily; ABCA and a number to identify an individual 
member; ABCA1 are added [51, 52].     
Transporters of the ABC family can be divided into two groups based on the direction of substrate 
transport; (1) ABC importers which are present only in prokaryotes, and (2) ABC exporters.  All ABC 
exporters share a basic structure of transmembrane domains (TMD), which provides passage for 
substrates; and at least one nucleotide-binding domains (NBD), which binds and hydrolyses ATP [53].   
Nucleotide-binding domains (NBD)  These structures act as the motor unit of ABC transporters 
and consist of RecA-like and helical sub-domains.  Within each NBD there are conserved sequence 
motifs that are involved in either ATP binding and hydrolysis or in aiding interface formation in the 
assembled protein.  A comprehensive review by Hollenstein et al. describes these conserved 
sequences, briefly motifs include: Walker-A domain or P-loop, which binds the nucleotide;  LSGGQ 
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motif which contacts the nucleotide in an ATP bound state; Walker-B domain which provides a 
conserved glutamate residue that coordinates nucleophilic attack on ATP via a water molecule; Q-
loop which is thought to sense the γ-phosphate moiety and aid in interfacial contact with the TMD; 
D-loop which is involved in formation of a contact loop between the two NBD; A-loop which 
provides an aromatic side residue that stacks against the adenine moiety of the bound nucleotide, 
and finally the Switch motif that is thought to contribute a histidine side chain to the catalytic 
reaction [53].  In the case of full ABC transporters bearing two nucleotide-binding domains, these 
NBD domains arrange themselves in a ‘head-to-tail’ conformation creating two ATP binding sites 
between a Walker-A domain of one NBD and a LSGGQ motif of the other.  Transporters do exist and 
function with only one NBD, for example, the half-transporter BCRP bears only a single NBD and 
then creates a homodimer with another BCRP protein to create a functional transporter.  Figure 1.5A 
illustrates the arrangement of these conserved motifs in each NBD [53-56].  
Transmembrane domains (TMD) These domains are membrane-spanning and are highly 
variable in primary sequence, length, architecture and number of helices.  As can be seen in figure 
1.5A, ABC export proteins generally consist of 12 transmembrane (TM) helices although BCRP is an 
example of a half-transporter with 6 TMDs and MRPs-1,-2,-3 each have 17 TMDs.  These helices form 
a channel within the membrane for substrate passage and protrude into the cytoplasm, splitting into 
two distinct arrangements, sometimes referred to as ‘wings’, towards the extracellular side of the 
membrane [53, 57, 58]. 
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Figure 1.5 (A) Diagram illustrating the organization of conserved sequence motifs in the nucleotide-
binding domain of ATP transporter proteins.  (B)  Example of the predicted secondary structure of an 
ABC transporter.  Structural information is assumed from the homologous Sav1886 S. aureus 
transporter protein, for which the structure has been determined [53, 59, 60]. 
The binding and hydrolysis of ATP to drive drug transport by ABC transporters creates a complex 
mechanism of action.  Structural data obtained for the ABC drug transporter ABCB1/P-gp/MDR1 
combined with data obtained from the homologous Sav1886 transporter of S. aureus have given rise 
to the ATP switch model.  This model is the most widely accepted model to explain the mechanism 
of ABC drug transport, the driving force for transport being a switch between two conformations of 
the NBD dimer [59]. 
While there is only moderate information available regarding ABC drug transporter structure 
especially when substrate-bound, more information [57, 58, 61-67] is available on the mechanism of 
action of ABC substrate transport, essentially:  
Two TMB form a chamber in the membrane which they ‘capture’ substrate molecules from the inner 
leaflet of the lipid bilayer.  Two NBD then form a ‘head-to-tail’ sandwich dimer so that each NBD 
contacts both TMB.  Two ATP binding pockets are then formed at the NBD dimer interface and ATP 
binding causes a rigid rotation of the domains within each NBD creating a closed dimer with 2 ATP 
molecules sandwiched at the interface.   ATP hydrolysis and ADP + Pi release return the dimer to an 
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open configuration.  The ATP-binding at the NBD and the formation of a closed dimer induce 
conformational changes in the TMDs which aids substrate translocation, causing a reduction in drug-
binding affinity and reorientation of the drug binding site to expose it to the extracellular membrane 
face for release [57, 58, 61-67]. 
1.7. Drug transporter proteins of interest to drug discovery 
For many drugs and clinically relevant compounds, there are a number of significant determinants of 
PK profile and elicited therapeutic response and there are often contributions from passive diffusion, 
metabolising enzymes and active transporter processes.  In order to minimise, or indeed utilise such 
contributions, preclinical drug evaluation has focussed on examining the contribution of drug-drug 
interactions (DDI) and drug metabolising enzymes (DME) to the safety and efficacy of drugs in 
development.  The role and influence of drug transporters has been increasingly recognised as of 
importance to in vivo drug absorption and disposition, efficacy and adverse reactions [68]. 
In 2007 a group of scientists formed the International Transporter Consortium to identify 
transporters of interest, discuss techniques to differentiate drug transporter interactions and 
recommend guidelines for drug transporter scientists working in the preclinical and clinical studies 
arena.  In 2010, the consortium published a set of decision trees to support those involved in clinical 
studies and advised upon investigations.  Decision trees posed questions regarding assay flux ratios 
and the effect of inhibitors on transport assays.  The full publication can be reviewed in a publication 
by Giacomini et al. [68].  
Relative to the total number of recognised drug transporter proteins, only a small number of families 
are currently thought to impact significantly upon the absorption or disposition of therapeutic 
compounds.  Variation in the function and expression of drug transporter proteins has the potential 
to produce unexpected and variable pharmacokinetic profiles in vivo and the distribution or entry of 
compounds to specific organs or tissues can often be positively or negatively influenced by uptake 
and efflux transporters.  Understanding the importance of drug transporters and transporter-
dependent pathways may aid in the drug discovery process by allowing transporters to be used for 
target site entry or to avoid developing drug candidates whose pharmacokinetics are negatively 
affected by transporters [45]. 
For drug discovery and development, transporters that are expressed in the liver, kidney and 
intestine, and the endothelium of the blood brain barrier are of particular focus, figure 1.6 
represents the membrane localisation of a number of these transporters in organs of interest.  
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Traditionally these transporters function to uptake vital endogenous substrates or protectively 
function to eliminate harmful or toxic compounds from the body and it is these physiological 
functions and expression profiles that have highlighted the transporters of these organs as worthy of 
investigation in the field of pharmaceuticals [45, 68].  These sites also represent the major tissues or 
barriers known to affect drug pharmacokinetics, be that from oral absorption and first-pass, through 
both metabolic and excretory elimination pathways to accessing the brain across a most distinctive 
barrier. 
 
Figure 1.6 Examples of human drug transporter with the ability to transport a number of clinically 
relevant drugs and endogenous substrates.  Transporter proteins of the kidney, liver, brain and 
intestines are displayed.  Adapted from [68]. 
Drug transporters can either function as targets for drugs, or indeed as processes which can either 
positively or negatively affect a drugs pharmacokinetics.  Of the 400+ identified human ‘drug 
transporter’ proteins, many could be considered for their influence in drug disposition and 
therapeutic response.  For example, glucose transporters of the SLC5 family have been targeted to 
treat glucose malabsorption, neurotransmitter transporters of the SLC6 family have been targeted 
with antidepressants and antiepileptics for the treatment of epilepsy, depression and schizophrenia, 
and peptide transporters of the SLC15 family have been targeted with drug analogues, such as 
DOPA-Phe, and nucleoside based antivirals to improve bioavailability via PEPT1 [44].  Other sub-
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families of interest include; SLC16, SLC17, SLC22, SLC29 and SLCO [69].  Highlighted in table 1.1 is a 
selection of SLC drug transporters of particular interest to drug discovery and development. 
Transporter 
Family 
Substrates (S)/ 
Inhibitors (I) 
 
Expression Disease 
association 
Therapeutic 
implications 
Ref. 
SLCO1 
OATP1B1 (SLCO1B1) 
OATP-B (SLCO2B1) 
S: Bile acids, Bilirubin, 
Oestrone-3-sulphate, 
Statins, Fexofenadine 
I: Saquinavir, 
Rifampicin, Cyclosporine 
Hepatocytes, 
Endothelia 
Link of 
polymorphisms 
with 
hepatotoxicity 
• Influence upon drug 
disposition and 
elimination 
• DDI 
• Clinically relevant 
polymorphisms 
[68] 
 
SLC7 
CAT-1 (SLC7A1) 
S: Cationic L-amino 
acids 
I: Many substrates act 
as competitive 
inhibitors 
Ubiquitous - 
except human 
adult liver 
Link to retroviral 
infection 
susceptibility 
• Influence upon drug 
disposition and 
elimination 
• DDI 
[68] 
 
 
SLC22 
OAT1 (SLC22A6) 
OCT1 (SLC22A1) 
OCTN1 (SLC22A4) 
S: Methotrexate, 
Zalcitabine, Metformin, 
Tetraethylammonium 
I: Novobiocin, 
Probenecid, Quinidine 
Kidney 
proximal 
tubule, 
Placenta, 
Hepatocytes, 
Intestinal 
enterocytes, 
Skeletal muscle 
Gene mutations of 
OAT1 result in 
gyrate atrophy 
• Influence upon drug 
disposition and 
elimination 
• DDI 
• Clinically relevant 
polymorphisms/mutations 
[68] 
 
 
SLC5 
SGLT1 (SLC5A1) 
SLGT2 (SLC5A2) 
NIS (SLC5A5) 
S: Glucose, Galactose, 
Biotin, Iodine 
I: Phlorizin 
Small intestine, 
Kidney, Heart, 
Lung, Skeletal 
muscle, 
Thyroid, 
Placenta 
Gene defects can 
result in Familial 
renal glycosuria, 
Glucose and 
galactose 
malabsorption 
and Thyroid 
hormonogenesis 
• SGLT1 cytoprotective 
function has potential to 
be exploited during 
chemotherapeutic 
treatment with cisplatin  
• Increased transporter 
expression can aid in 
overcoming Insulin 
resistance. 
[68] 
 
 
SLC6 
GAT1 (SLC6A1) 
GAT3 (SLC6A11) 
DAT (SLC6A3) 
S: GABA, 
Norepinephrine, 
Dopamine, Serotonin, 
Glycine, Creatine 
I: ACHC, DABA, Cocaine, 
Benztrophine, Many 
antidepressants 
GABAergic 
neurons, 
Adrenal gland, 
Placenta, 
Dopaminergic 
neurons, Spinal 
cord. 
Gene defects can 
result in Epilepsy, 
Schizophrenia, 
Anorexia nervosa, 
Parkinsonism, 
Tourette 
syndrome, Cardio-
myopathy 
• GABA transporters targets 
for anti-epileptic drugs 
• DAT transporter target for 
blocking dopamine uptake 
in Parkinson’s disease 
[68] 
 
 
SLC16 
MCT1 (SLC16a1) 
S: Lactate, Pyruvate 
I: Quercetin, Phloretin 
Ubiquitous Link to muscle 
weakness 
associated with 
exercise 
• Influence upon substrate 
ADME 
[68] 
 
 
SLC15 
PEPT1 (SLC15A1) 
PEPT2 (SLC15A2) 
S: Di- and Tri-peptides, 
Glycylsarcosine, 
Cephalexin, 
Cefadroxil 
I:  Glycyl-proline,  
Zofenopril, Fosinopril 
Intestine, 
Kidney, Lung, 
Brain 
Suggested link 
with Crohn’s 
disease and 
Ulcerative colitis 
• Influence upon drug 
disposition and 
elimination 
• DDI 
• Numerous splice variants – 
may have relevance in 
future drug discovery 
• Potential target for 
treatment of IBD 
 
    [68] 
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Table 1.1 SLC transporters of clinical significance.  Each transporter has the capacity to in some way 
influence a drugs’ pharmacokinetic profile in vivo.  The selected transporters below represent the 
transporter families of interest; other family members may also be of clinical significance.  Note that 
only examples of transporter substrates and inhibitors are included and that listed diseases do not 
necessarily correlate to specific members mentioned here.  (GABA) γ-aminobutyric acid, (DDI) drug-
drug interaction, (ACHC) cis-3-aminocyclohexane carboxylic acid, (DABA) 1-2, 4-diamino-N-
butyric acid [68, 70-75]. 
Active transporters of the ABC family are extremely influential upon the behaviour of many clinically 
relevant drugs.  In terms of drug discovery, ABC transporters that have been of particular focus are 
members of the ABCB, ABCC and ABCG families [60].  For example, P-gp/MDR1 (ABCB1) was the first 
cloned and characterised human ABC transporter and was discovered through its ability to confer 
drug resistance in tumour cells [70].  It has been reported that three genes; P-gp (ABCB1), MRP1 
(ABCC1), and BCRP (ABCG2) are responsible for the majority of all transporter-related multidrug 
resistance observed in both human and rat tumours [71].  Those members of the ABC superfamily 
that are influential to drug discovery are mainly expressed in the same tissues mentioned for the 
SLCs, namely liver, kidney and intestine, and the endothelium of the blood brain barrier.  ABC efflux 
transporters function to remove toxic metabolites protecting cells from chemical toxicity and 
oxidative stress [72].  Table 1.2 highlights a selection of ABC transporters that have evidential 
influence upon the transport and action of a large number therapeutic compounds and thus are very 
significant to the drug discovery process. 
Transporter 
Family 
Substrates(S)/Inhibitors(I) 
 
Expression Disease/condition 
association 
General therapeutic 
implications 
ABCB 
P-gp/MDR1 (ABCB1) 
S: Many hydrophobic substrates, 
lipids, Steroids, Xenobiotics, 
peptides, Drugs e.g. 
Fexofenadine, Vinblastine, 
Digoxin. 
I: Verapamil, Cyclosporin, 
Elacridar (GF120918) [70-75]. 
Mainly secretory 
cells such as those 
of the Kidney, 
Liver, Intestine, 
and adrenal gland. 
Brain endothelia, 
Pulmonary 
epithelia [70-75]. 
Immune deficiency, 
Ivermectin 
susceptibility [70-75]. 
 
• Influence upon drug 
absorption, disposition 
and elimination 
• DDI 
• Influence upon drug 
bioavailability 
• Influence on brain entry 
of drugs (barrier) 
• Influence on multidrug 
resistance 
• Clinically relevant 
polymorphisms 
 
[68, 70-75] 
ABCC 
MRP1 (ABCC1) 
MRP2 (ABCC2) 
MRP3 (ABCC3) 
MRP4 (ABCC4) 
S: Diverse range of endogenous 
substrates and xenobiotics 
including glutathione, 
Glucuronide conjugates, 
Methotrexate, Etoposide, 
Mitoxantrone, Valsartan, 
Olmesartan. 
I: Cyclosporin, Emtricitabine, 
Delaviridine, Efavirenz [70-75]. 
Kidney proximal 
tubule, choroid 
plexus, 
hepatocytes, 
intestinal 
enterocytes [70-
75]. 
 
 
Cystic Fibrosis, 
Dubin-Johnson 
syndrome, 
Pseudoxanthoma 
elasticum, 
CBAVD, FPHHI [71]. 
ABCG 
BCRP (ABCG2) 
S:  Mitoxantrone, Methotrexate, 
Topotecan, Imatinib, Irinotecan. 
I: Fumitremorgin C, Elacridar 
(GF120918), Oestrone [70-75]. 
Placenta, BBB, 
mammary glands, 
Kidney proximal 
tubule, Intestinal 
enterocytes, 
Hepatocytes [70-
75]. 
Sitosterolemia [71]. 
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Table 1.2 ABC transporters of clinical significance.  Each transporter has the capacity to in some way 
influence a drug’s pharmacokinetic profile in vivo.  The selected individual transporters included 
represent the transporter family of interest; other family members may also be of clinical significance.  
Note that only examples of transporter substrates and inhibitors are included and that listed diseases 
do not necessarily correlate to specific members mentioned here.  (DDI), drug-drug interaction, 
(CBAVD), congenital bilateral absence of the vas deferens, (FPHHI) familial persistent 
hyperinsulinemic hypoglycaemia of infancy.  [68, 71-74].   
The interplay between drug transporters present in the lung and drugs targeted to this region will 
influence greatly drug discovery processes involving the pulmonary system.  Combined with the 
need for a comprehensive review of drug transporters expressed in the lung, it is important to 
exploit a model that accurately represents the morphological environment and transport processes 
present in this region.   
1.8. Experimental models to assess pulmonary drug transport 
In order to reproduce conditions within the lung, and specifically at epithelial barriers which are 
regarded as a prominent obstacle to drug absorption, four main model types are employed.  These 
are; cell culture models, in vivo whole animal models, ex vivo isolated perfused lung organ models 
and tissue explants [23, 75].   
Cell culture models The use of cell culture models is now widely accepted within the 
pharmaceutical industry and is promoted by some as having predictive ability (this is particularly so 
in the intestinal oral absorption field) and certainly provide high throughput.  In the lung discipline, 
in vitro model systems are particularly used for mechanistic investigation.  The use of in vitro models 
to study permeability and relate this to in vivo lung absorption is, for the most part, poorly 
developed; mainly limited to academic laboratories.  It should be of note that the use of in vitro 
models for the intestine gained acceptance only after many years of experimentation and thousands 
of compounds addressing in vitro to in vivo relationships.  Almost every pharmaceutical company 
had an interest in oral drug delivery and contributed to the knowledge base; this is not the case for 
pulmonary delivery which represents a more limited commercial market.  
Both models of the alveolar epithelium and also of the bronchial epithelium are used in studies of 
lung transport [76].   Alveolar models are used as this epithelium represents the largest epithelial 
surface area in the lung; however model systems most often involve the isolation of primary AEII 
from human [77], rat [78] or other species, e.g. pig [79]. These cells undergo a phenotypic change in 
primary culture moving from a type II phenotype at isolation and initial culture to more of a type I-
like phenotype by day 6 to 8 post-seeding.  These type I–like cells can form (depending upon the 
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enzymes used to isolate the type II cells) a highly restrictive monolayer with functional tight 
junctional complexes.  Bronchial models of the conducting airways are more readily available for 
study and include normal human bronchial epithelial cells (NHBE cells) that can be purchased as low 
passage cell lines through to a range of transformed continuous bronchial cell lines of human origin; 
16HBE14o-, Calu-3, BEAS-2B cell lines.  In terms of drug delivery, cell culture models allow 
examination of drug permeability, absorption mechanisms, drug metabolism and toxicology and also 
some correlation to the in vivo state [76].  
Rapidly developing methods of cell culture and cell-lines, along with a plethora of drug permeability 
data in prevalent cell-lines, together with a cost-effective, high throughout nature, may mean lung 
cell culture models could serve as a possible alternative to more costly, time-consuming in vivo or ex 
vivo models.  In vitro models will certainly allow an opportunity for simpler experimental design to 
address aspects of mechanism of transport in the lung [75]. However, as noted in comments above, 
so little has been done with in vitro to in vivo correlations that this ideal is a long way off.  Further, 
the absorptive surface in the lung will be complex comprising a range of different epithelial cell types 
very much dependent upon the deposition pattern of the inhaled aerosol.  
In vivo whole animal models The area of in vivo animal testing to evaluate drug permeability was 
pioneered by the works of Schanker and colleagues in the 70’s and 80’s (for a comprehensive review 
see reference [23]).  In vivo experimentation provides an opportunity to examine drug absorption, 
disposition and candidate pharmacokinetics within a fully intact organ.   Many laboratories use small 
animal models such as mouse or rat, at least initially in early drug discovery.  These models afford 
the use of smaller amounts of candidate compound. The ability to catheterise these animals for 
serial blood sampling affords in vivo animal experimentation real value in the study of drug 
candidate fate in the lung  [23].  However, there are significant issues for in vivo experimentation 
including ethical considerations and correlation to the human patient.  More technical issues 
include: conscious versus anaesthetised animals, use and variations in anaesthetic, delivery device 
used and the posture of the animal during delivery. Development of more accurate dosing 
techniques for small animals is essential.  
Ex vivo isolated perfused lung organ models Isolated perfused lung models act as an 
intermediate between in vivo and in vitro models.  While they are quite complicated in nature, they 
provide an excellent representation of the in vivo state whilst allowing division and study of the 
many mechanisms involved in drug delivery to the lung [75].  The isolated perfused lung (IPL) 
maintains in vivo architecture while separating the lung from whole body complications of tissue 
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distribution and clearance and as such the model can be used to define closely the pulmonary 
transport of drugs.  However, such a technique is technically demanding and time-consuming and 
unlike cell culture models could not be used as a screening process for drug discovery [23].     
Table 1.3 summarises the advantages and disadvantages of each model type and highlights model 
applicability when examining the effect of drug transporter proteins upon drug delivery to the lung. 
 
Table 1.3 Advantages and disadvantages of 3 main techniques employed to examine drug transport in 
the lung.  The Ex vivo isolated perfused organ model marries the advantages of both in vivo and in 
vitro techniques providing an excellent model to examine drug delivery to the lung. [23, 75, 76, 80, 
81].   
 
The selection of a model type should meet the requirements of each experimental design together 
with being as efficient and accurate as possible.  While there are many advantages and 
 Advantages Disadvantages Ref 
In vitro cell culture 
models 
• High-throughput 
• Simple methodology 
• Reasonable amount of permeability 
data from multiple labs can be readily 
obtained  
• Cost-effective 
• Transformed cells – of known origin 
• Primary cells – closer representation 
of in vivo state 
• Only represent single cell-line 
• May not accurately represent in vivo 
metabolising enzyme activity 
• Primary cells – limited number of 
cells and lifespan 
• Tight junctions and cell cycles are 
less representative of in vivo state 
• Drug transporter activity highly 
culture dependent 
[23] 
[75] 
[76] 
[80] 
In vivo whole animal 
models 
• Many methodologies available 
• Number of animal models available 
• More representative data 
• Allows species comparison 
• Blood sampling allows examination of 
serum/plasma interactions 
• Costly 
• Not high throughput 
• High inter-laboratory variation 
• Difficult to determine individual 
processes 
• Challenges in dosing 
 
[23] 
Ex vivo isolated 
perfused organ 
models 
• Very close representation of in vivo 
state 
• Removes whole body complications 
• Maintains architecture and 
functionality of organ 
• Intact drug transporter activity 
• Limited lifespan 
• Complex methodology 
• Not high throughput 
• Costly 
• Both in vivo and ex vivo models 
represent but are not identical to 
human lung structure.  i.e. human 
lung structure dichotomous and 
symmetrical, rat lung more 
monopodial – impact on 
extrapolation of particle deposition 
data 
[23] 
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disadvantages for each experimental model, the use of an ex vivo Isolated perfused lung marries the 
advantages from other main techniques while overcoming the disadvantages they produce.   
1.9. Isolated Perfused Rat Lung (IPRL) 
Isolated organ preparations have been exploited since the mid 19th century and while the lung was 
initially utilised for blood oxygenation in organ preparations, as interest increased, refinement of the 
isolated perfused lung (IPL) allowed the creation of an excellent model for the examination of non-
respiratory lung processes [82-84].   
Examples of IPL use flourished in the 1960s and 70s and allowed development of isolation 
techniques for somewhat routine application of the IPL to examine lung processes and mechanisms.  
Such applications included examination of lung circulatory and ventilatory mechanisms, gaseous 
exchange and oedema formation, pulmonary glycolytic activity and drug metabolism [85-91].   
A range of IPL techniques now exist, allowing method variation and preparation adaptations to suit 
experimental needs.  One major variable is animal selection, decisions being based upon the nature 
of the experiment, cost, availability and animal maintenance and requirement for specific genetic 
characteristics.  Of the range of suitable animal models, rat and rabbit preparations prove most 
popular [84].  Here, the isolated perfused rat lung will be considered.     
Table 1.3 highlighted the advantages and disadvantages of isolated organ preparations, the IPRL 
shares many of these and provides many advantages over other lung model techniques:  
• Isolation of the organ avoids limitations imposed by in vivo models while allowing access to 
deliver compounds of interest via physiological routes [83] 
• The model provides structural and functional lung integrity, maintaining membrane barriers 
and cell-cell interactions thus accurately mimicking in vivo state [83, 84] 
• Ex situ lung isolation provides many IPRL uses and applications such as toxological, 
metabolism and drug delivery studies [84] 
• IPRL methodology allows control over important experimental parameters such as ventilation 
and perfusion [83, 84] 
• Perfusate reservoirs provide the possibility to take multiple samples and organ isolation allows 
mass balance of compounds administered to the lung to be established [84] 
• Assessment of biochemical and physiological processes following toxic exposure is possible 
[84] 
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• IPRL provides opportunity to assess the lungs role in drug disposition [83, 84] 
However, disadvantages that are associated with IPRL preparations must also be taken into 
consideration: 
• A major limitation of the IPRL is the relatively short period of preparation stability and 
integrity [83] 
• The complex methodology involved requires extensive operator training and renders the IPRL 
as a less time-efficient model to set-up than other preparations [92]  
• There is potential for the recognised cellular heterogeneity of the lung may negatively impact 
data interpretation and results, i.e. which specific cell surfaces are accountable for observed 
results; this is avoided with in vitro models. [92] 
• IPRL perfusion rate is generally only ~ ½ that of physiologic rate [83, 84] 
The inherent nature of the IPRL produces a complex methodology with many factors contributing to 
a successful preparation.  Aspects for consideration include; surgery, ventilation, perfusion and 
apparatus.   
Surgery  The increase in use of the isolated perfused lung as an individual technique in the 
1960s and 70s led to a generalised surgical protocol for the isolation of the lungs.  In essence, the 
animal is anaesthetised with an agent such as pentobarbital sodium, gaseous agents having the 
potential to adversely affect the organ and subsequent results.  A tracheotomy is performed to allow 
ventilation and access for dosing and the lungs are exposed via the diaphragm.  The pulmonary 
circulation is then perfused and the lungs isolated.  Distinction in methodology typically arises from a 
variety of factors associated with ventilation, perfusion and apparatus [93]. 
Ventilation Generally, within IPRL methodology the lungs are ventilated as soon as access is 
established.  This is to mimic, as well as possible, physiological conditions and to minimise damage to 
the lungs [93].  In terms of ventilation of the lung, volume and pressure are the two main issues to 
be considered.  To allow inspiration and expiration of lungs in an IPRL setup, either positive pressure 
ventilation or negative pressure ventilation is employed; however, both methods are essentially 
equal within the setup as they are both required to establish a pressure gradient to facilitate 
ventilation.  To achieve perfusate oxygenation and to avoid injury, lung tidal volume is also 
important.  Optimum tidal volume will allow even and rhythmical lung ventilation and aid in 
maintaining the IPRL preparation.  Generally, a small animal ventilator is used to achieve ventilation 
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with parameters of 60 cycles/min and a volume of 2 mL/cycle reasonable for an IPRL preparation 
[83].  A further important consideration of IPRL ventilation is ventilation gas.  Of main physiological 
concern are O2 and CO2 which are required to be present at optimum levels to maintain normal 
metabolic processes and to control perfusate and intracellular pH.  A typical gas mix for IPRL is 95 % 
O2 5 % CO2, especially if a bicarbonate buffer system is being used, where this gas mix will aid in 
maintaining perfusate pH [83]. 
Perfusion The perfusion of an IPRL preparation is largely determined by two main factors; 
perfusion method and perfusate type.  Each main factor is dependent on a number of choices and 
issues that are interlinked between perfusion method and perfusion media.  IPRL perfusion is either 
‘single-pass’ or ‘recirculating’ and each has a number of important advantages and disadvantages.   
A recirculating method of IPRL perfusion allows for a small volume of perfusate to be used 
(especially important if using whole blood perfusate) and is an important method for facilitating 
assessment of slowly metabolised drug candidates.  In contrast, single-pass perfusion produces a 
simpler IPRL system but does involve a larger volume of perfusate media [94].  Both perfusion 
methods require a pump to perfuse the IPRL preparation and perfusion is controlled by flow rate 
which, in an IPRL preparation, is typically set at half the physiological resting cardiac output (e.g. 15 
mL/min for a 250 g rat).  Many IPRL preparations also include a bubble trap within their perfusion 
circuit to avoid air bubble facilitated oedema formation [83]. 
The second major consideration of IPRL perfusion is the perfusion media itself; either natural or 
artificial perfusate.  Again, each perfusate type offers advantages and disadvantages.  Natural, whole 
blood perfusate mimics the in vivo state, delays oedema formation and allows examination of serum 
and plasma drug binding.  However, the volumes of perfusate required result in large numbers of 
animal sacrifice, the blood perfusate requires addition of an anticoagulant, and using whole blood 
creates sourcing and storage issues.  Artificial perfusate media, while not identically reproducing the 
in vivo state, allows control over constituents and properties such as ionic composition, osmolarity 
and pH, requires less animal sacrifice, is easier to store and source and produces fewer problems of 
binding and metabolising toxins and xenobiotics [83, 94].           
Apparatus The choice of apparatus for an IPRL is largely dependent on experimental 
parameters such as choice of pressure ventilation, perfusion technique and dosing mechanism.  For 
example, if positive pressure ventilation is employed then lungs can remain in situ, however, if 
negative pressure ventilation is employed then an artificial, air tight, thorax is required.  To create an 
easily accessible dosage point, lungs can remain horizontal (a means of ‘hanging’ the lungs is 
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required).  To maintain the lungs and perfusate at a representative temperature, a form of 
temperature control is also required.  This commonly takes the form of a water-jacketed setup thus 
creating the need for water-jacketed apparatus of an inert material and a heated water pump, 
producing a large IPRL setup.   
Viability/metabolic function One major disadvantage of the IPRL preparation is its viability; 
however, experimental parameters can be optimised and monitored in order to prolong model life-
span.  For example, inclusion of albumin in artificial perfusion media and running perfusate flow rate 
at half the physiological rate both aid to reduce oedema formation [83].  Further, the monitoring of 
parameters such as lung weight, ventilation, pressure and lung appearance allow visual 
determination of lung viability and may provide confidence on result interpretation [84].       
The correlation of the IPRL to in vivo state is very important and allows use of the model in a number 
of experimental situations.  It is essential to establish the extent of ‘normal’ activity within the IPRL 
to allow correct model use and data interpretation.  Issues such as extent of tissue perfusion and 
metabolic activity are of importance.  During lung isolation the bronchial circulation is severed 
therefore it is only the pulmonary circulation that is intact and is used to perfuse the lung.  While this 
could influence experimental uses, studies have illustrated the necessity for only intact pulmonary 
circulation for successful lung perfusion and preparation viability [83].  The extent of metabolic 
activity within the IPRL is also of importance.  Many studies of isolated perfused lung preparations 
have shown that these models are under normal metabolic control and exhibit normal metabolic 
activity with the inclusion of glucose in perfusion media, providing confidence when using an IPRL 
for metabolic studies [92]. 
Applications The variety of IPRL methodology available allows this model to be utilised for a 
number of applications.  Use of the IPRL has flourished since the mid 20th century when interest in 
the lung and non-respiratory processes increased [85, 88, 91].  In recent times, significant uses of the 
IPRL have included research in to pulmonary drug deposition and metabolic processes.  The work of 
Byron et al. during the 1980s examined closely the fate of aerosolised drugs delivered to the lung 
and provided excellent reference data regarding the absorption of a range of molecular weight 
markers across the IPRL [95].  These works led to the development of the IPRL as a screen for aerosol 
formulations and provided data to allow improvement of aerosolised drug dissolution and release 
[96].  Other major uses of the IPRL include the examination of xenobiotic metabolism in the lung and 
the damage to the lung caused by agents such as cigarette smoke and NO2 [92]. 
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The isolated perfused lung is an excellent lung model with extensive uses within pulmonary 
research.  The large number of experimental variables and flexible methodology creates excellent 
opportunity to optimise the IPRL for individual experimental needs.  The maintenance of structural 
and functional integrity, ability to dose via a number of techniques and the ability to investigate lung 
specific pharmacokinetics provides the IPRL as a particularly advantageous model for the 
investigation of specific pulmonary mechanisms involved in the delivery of drugs to the lung.  
Previous application of this model to investigate drug dissolution and absorption mechanisms, drug 
disposition and metabolism provides evidential support and reference points for future IPRL use in 
biopharmaceutical research [42, 97-102]. 
1.10. Thesis aims and objectives 
• To establish the relative mRNA expression of several ABC, SLC and SLCO drug transporters within 
the rat lung through use of reverse transcription polymerase chain reaction (RT-PCR) 
• To set-up and fully validate an isolated perfused rat lung preparation for use in assessment of 
drug transport across the lung 
• To assess the functional significance of the ABC drug transporter P-glycoprotein on drugs intra-
tracheally instilled to an ex vivo IPRL set-up.   
•      Use of the P-gp substrates; Rhodamine 123, digoxin, and flunisolide and the P-gp 
inhibitor, GF120918 will be employed. 
•      Use of kinetic modelling to establish pharmacokinetic parameters  
• To examine whether any effects in substrate transport can be conclusively attributed to P-gp. 
•       Consider contribution from other drug transporters, substrate lipophilicity, cell 
membrane fluidity and permeability. 
• To assess the functional significance of the ABC drug transporter P-glycoprotein on drugs 
delivered to the perfusate of an ex situ IPRL model.  i.e. possible insight into significance of P-gp 
on drugs delivered to the systemic circulation. 
•       Use of P-gp substrates; Rhodamine 123 and flunisolide and the P-gp inhibitor GF120918 
• To establish comparability between two IPRL setups (ex situ and in situ). 
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CHAPTER 2 
RT-PCR derived analysis of drug transporter expression  
in cell models and whole lung 
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2.1. Introduction 
Drug transporter genes code for a wide number of proteins that belong to transporter superfamilies, 
(e.g. ABC or SLC/SLCO superfamilies), these drug transporters are further defined based upon amino-
acid sequence identity, into smaller families, subfamilies and eventually individual protein isoforms.   
Drug transporters have the ability to recognise and transport a diverse range of endogenous 
substrates, xenobiotics and pharmaceutically relevant drugs.  Through the interaction of these 
proteins with structurally differing compounds, drug transporters have the potential to critically alter 
the systemic exposure and bioavailability of drug substrates and therefore influence the fields of 
drug discovery and development.  Such proteins are increasingly recognised as important factors in 
determining drug absorption and disposition and affecting drug concentrations in target or non-
target tissues.  This has implications not only in terms of the therapeutic management of patients 
but also in terms of identifying new chemical entities during the drug discovery process which may 
be subject to active transport.  
Many drug transporter proteins have been discovered and initially investigated through their 
mediation of multidrug resistance to chemotherapy agents, e.g. transporters P-gp, BCRP, MRPs.  
However, despite the potential for a large number of drug transporters to have impact upon the 
absorption and disposition of drugs, only a few transporters have to date been shown to have a 
significant influence.  It is fair to say that the most widely studied is the adenosine triphosphate 
(ATP)-dependent binding cassette (ABC) efflux transporter, P-glycoprotein, which is a clinically 
significant cause of multidrug resistance.  Further, P-gp has a clinically important role in limiting 
absorption from the intestine and limiting transport across the blood-brain barrier (BBB).  A number 
of other transporters are also recognised to affect drug absorption and disposition, including 
members of the ABC-C family, i.e. MRPs, the ABCG2 protein, i.e. BCRP, as well as members of the 
SLC/SLCO superfamily; including polypeptide transporters (PEPT1/PEPT2), organic cation 
transporters (OCT/OCTN) and organic anion transporters (OAT) and organic anion polypeptide 
transporters (OATP) [45].   
Pharmaceutical companies provide major investment into assessing the in vivo distribution of any 
drug candidate.  For example, metabolic stability assays are utilised to design and optimise drugs to 
avoid various undesirable metabolic pathways such as first-pass metabolism and P450 metabolism.  
However, in-depth knowledge of drug transporter contribution is minimal in comparison.  A deeper 
understanding could give further insight to variable factors such as efficacy and bioavailability, with 
continued exploitation allowing either targeting of specific organs (through small changes to drug 
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molecular structure to induce specificity to organ-specific transporters) or avoidance of such 
transporters that would limit entry to desired site of action [45].  A number of pharmaceutical drugs 
have been developed through exploiting attributes of a drug transporter.  The HMG-CoA reductase 
inhibitor pravastatin, for example, achieves liver-selective distribution through interaction with the 
organ specific uptake transporter OATP1B1, thus prolonging exposure to the target and aiding in 
reducing adverse effects in non-target organs.  Furthermore, knowledge of transporter activity in the 
blood-brain barrier has aided development of the newer generations of H1-antagonists, such as 
fexofenadine and cetirizine.  These drugs are called ‘non-sedating’ as they do not penetrate the BBB 
line of defence, thus resulting in a reduction of CNS mediated side effects.  Continued application of 
such knowledge would also allow assessment of both organ toxicity and drug-drug interactions and 
give rise to more efficient drug discovery, drug targeting and lead optimization strategies [103].   
In contrast to the knowledge gained of drug transporter expression and functionality in a number of 
tissues and organs important to drug absorption and disposition i.e. intestine, liver, kidney and 
increasingly the BBB [103], there exists a very poor knowledge on  the potential impact of active 
efflux and uptake transporters upon the absorption and disposition of drug molecules delivered to 
the lung, or indeed of uptake of molecules from the blood into the lung.  Such active transporters 
may have the capacity to influence not only the bio-distribution of inhaled therapeutic compounds 
but also any foreign molecules and toxins that enter the lung leading to issues of toxicity [104] and 
can lead to accumulation of drugs in the lung that have been administered or gained entry into the 
body from other routes.  
As stated above, the biological transporters that appear relevant to xenobiotic transport fall into a 
number of distinct superfamilies; (i) ABC transporters, (ii) the SLC and the recently reclassified SLCO 
transporters.  Not all family members/isoforms of the above superfamilies serve as functional 
transporters for drugs and many have constrained substrate selectivity.  It is mainly the members 
with the capacity to transport relevant (or specific) compounds that have been the focus of research 
[105]. 
Solute carrier transporters represent the largest of the three families.  Initially the SLC super-family 
was sub-divided to 47 subfamilies with a total of 300 members.  Both uptake and efflux SLC’s have 
the ability to alter a drugs absorption, disposition and function and subgroups of interest include 
amongst others the; amino acid transporters, organic cation transporters and organic anion 
transporters [71].  In 2004, Hagenbuch and co-workers reclassified the OATP subfamily to SLCO using 
an open-ended nomenclature system that was species independent [46].  The newly classified SLCO 
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family contains several organic anion transporters and is comprised of 37 family members to date 
[104].  Of interest to drug discovery and development are OATP1B1, OATP1A2 and OATP1B3 [106]. 
The ABC transporters comprise a family of approximately 50 members classified into 7 subfamilies; 
ABCA-G.  Many members, for example P-glycoprotein (ABCB1), MRP1 (ABCC1) and BCRP (ABCG2), 
are widely recognised for their ability to transport a wide variety of structurally diverse substrates 
and for  their diverse expression profiles, thus underlining the considerable role of these 
transporters within the body and the, as yet, reasonably unappreciated significance in drug 
discovery and development [71]. 
The expression of several of these transporters has been investigated within the human lung, with 
implications made relevant to inhaled drug discovery.  As an illustration, table 2.1 gives examples of 
the techniques used to investigate the expression of ABC transporters of interest in various lung 
samples. 
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Transporter (Protein name)   Reference 
P-gp  Intact Lung Tissue  
RT-PCR (+) 
Immuno-histochemistry (+) 
Primary Peripheral Lung Cells 
RT-PCR (+) 
Immuno-histochemistry (+) 
Primary Bronchial Epithelial Cells 
RT-PCR (+) 
Immuno-histochemistry (+) 
Primary Alveolar Epithelial Cells 
RT-PCR (+) 
Immuno-histochemistry (+) 
Western blot (+) 
 
 
[107] 
[108], [109], [110], [43] 
 
[111] 
[111]  
 
 
[104, 111, 112]  
[111] [112] 
 
[113], [104] 
[16] 
[113] 
MRP1  Intact Lung Tissue 
RNA Microarray (+) 
Primary Peripheral Lung Cells 
RT-PCR (+) 
Immuno-histochemistry (+) 
Primary Bronchial Epithelial Cells 
RT-PCR (+) 
Immuno-histochemistry (+) 
Primary Alveolar Epithelial Cells 
RT-PCR (+) 
 
 
[69]  
 
[14] 
[111, 114] 
 
[104, 111, 115] 
[43, 111, 114, 115] 
 
[104] 
 
BCRP Intact Lung Tissue 
RT-PCR (+) 
Immuno-histochemistry (+) 
Flow cytometry (+) 
RNA Microarray (+) 
Primary Bronchial Epithelial Cells 
RT-PCR (+) 
Primary Alveolar Epithelial Cells 
RT-PCR (+) 
 
[40] 
[43] 
[116] 
[69] 
 
[104] 
 
[104] 
 
 
Table 2.1 Studies examining the expression of three ABC transporters of interest to drug discovery in 
human lung cell tissue and primary cell culture.  (+) signifies reported presence within a sample.  
Primary peripheral cells were cultured from human distal bronchial tree samples.  Adapted from 
Gumbleton et al., 2010 [117]. 
There exists growing evidence of active transporter expression within the human lung; however, the 
significance of transporters is essentially unknown.  Even in animal models the role of drug 
transporters in pulmonary absorption and disposition is very poorly defined.  Techniques used to 
investigate drug transporter expression within the lung include microarray technologies, Western 
blotting, RT-PCR and immunohistochemistry.  In particular, the recent microarray studies completed 
by Bleasby et al. are of note.  Here the mRNA expression of 50 clinically relevant drug transporters 
was examined and translated to comprehensive quantitative expression profiles representative of 40 
human and pre-clinical animal tissues.  The expression profiles generated allow both comparison of 
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inter-individual variation between human tissue samples and data extrapolation from pre-clinical to 
human tissues [69].  Table 2.1 illustrates immunohistochemistry is a well utilised tool for examining 
transporter expression and protein localisation, the technique is generally undertaken using a low 
throughput approach with a single tissue sample on a glass slide but can be adapted for much higher 
sample processing using tissue microarray technologies.  The other techniques listed provide no 
indication of the localisation of transporter within a tissue/organ.  For the lung, the spatial 
expression of a transporter is vital as the lung contains greater than forty different cell types.    
Reverse-transcriptase polymerase chain reaction allows recognition of individual transporter genes 
through uniquely designed transporter primer sequences and provides a more high-throughput 
system for examining transporter expression in a variety of tissues.  However this technique is semi-
quantitative at best, only indicating transporter mRNA presence or absence in a specific sample and 
requires the assumption that gene presence will result in the presence and functional activity of an 
active protein.  Individual experimental techniques exhibit specific advantages and disadvantages 
and choice of technique should reflect the nature of the study.  For example, if an investigator 
wishes to examine the localisation of a specific drug transporter then immunohistochemistry is 
applicable; however, if a broader study wanting to assess the number of drug transporter genes 
present in a tissue or cell culture sample is required, then a technique with ease-of-use and high 
data yield is perhaps more relevant.  Table 2.2 outlines the advantages and disadvantages of a 
number of frequently used techniques, as can be seen; RT-PCR stands out as a rapid, efficient and 
simple methodology which provides a high yield of data.  For the purposes of this chapter, RT-PCR 
was identified as the technique of choice.     
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Technique Advantages Disadvantages 
RT-PCR • No critical sample size  
• Tolerates partially degraded 
sample material 
• Excellent limit of detection 
• Efficient 
• Rapid 
• Very sensitive 
• Simple methodology 
• High level of optimization 
required 
• Unable to localise mRNA 
expression within cells or 
tissues 
• Unable to detect alternatively 
spliced transcripts 
• Only shows presence of mRNA  
Immunohistochemistry • Very sensitive 
• Able to localise specific 
component within cell or 
tissue 
• Can illustrate presence of 
protein 
• Time consuming 
• Labour intensive 
• Expensive 
• Can require optimization 
Western blotting • Relatively rapid technique 
• Sensitive 
• Allows localisation of target to 
specific tissue or cell 
• Number of detection methods 
possible 
• Labour intensive 
• Limited flexibility in choice of 
primary antibody (for less well-
known transporters) 
• Non-specific staining is possible 
Northern blotting • Widely accepted technique 
• Simple methodology 
• Versatile protocol 
• Often radioactivity is used – 
disposal issues 
• Time consuming 
• Does not tolerate degraded 
sample material 
• Not as sensitive as other 
techniques 
DNA Microarray • High throughput 
• Only small sample size 
required 
• Easily automated 
• Good limit of detection 
• Only evaluates expression at 
transcriptional level 
• Time consuming and labour 
intensive 
• Expensive 
Flow cytometry • Rapid, quantitative and 
detailed 
• Low error rate 
• Guaranteed to reveal non-
uniformity in cell population 
• Other methods are more rapid 
and less expensive 
• Can overwhelm with detailed 
data 
Table 2.2 Overview of the advantages and disadvantages of several experimental techniques with the 
capacity to identify the presence of specific drug transporter mRNA/gene/protein target within an 
experimental sample [118-124]. 
In order to examine the presence of drug transporter genes within the lung, a comprehensive range 
of lung cell models are available.  The use of primary cell culture is highly advantageous with 
protocols for isolation in existence since the 1970s.  Isolation if primary cells provides a well-
differentiated monolayer with a diverse phenotype which can be more closely physiologically 
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representative of the in vivo state thus rendering results obtained from such culture systems more 
comparable to in vivo whole organ experiments [125].  The use of immortalised or cancer cell line 
models has also been well documented.  Such cell lines models bear many advantageous features, 
such as ease of use, low cost and reproducibility.  These models also allow swift setup of the culture 
system and therefore afford a rapid turnover of results [75]. 
Aims and Objectives 
In this chapter, the following will be sought: 
• Examine the expression at mRNA level of selected ABC, SLC and SLCO transporters in rat lung 
tissue and cell samples. 
• Identify transporters of interest based upon reported evidence of it influencing drug 
disposition in other tissues of the body at least. 
• Develop an expression profile for each transporter - Each expression profile illustrating not 
only a transporter’s presence within the rat lung, but also to some degree, presence within 
specific regions of the lung, i.e. primary alveolar epithelial cell versus a primary bronchial 
epithelial cells. 
• Utilise primary alveolar epithelial cell culture to provide a physiological representation of 
active transporter expression at the alveolar epithelial surface. 
• Utilise SPOC1, a rat tracheal goblet cell line with the potential to differentiate to both 
secretory and squamous cells in culture [126], to provide evidence of transporter presence 
in this area of the lung. 
• Utilise whole rat lung tissue to give an overall picture of active transporter expression within 
the whole rat lung. 
Overall Aim of Chapter: 
It is hypothesised that development of such a transporter expression profile will give insight into a 
specific transporter’s presence within rat lung and will support some of the later studies conducted 
in this thesis involving the use of intact rat lung.  It is also hoped that, once developed, an expression 
profile will provide useful species specific information for research in drug discovery particularly, but 
not exclusively, those involved in inhalational drug delivery.   
 
  Chapter 2 
37 
 
2.2. Materials and Methods 
2.2.1. Rat whole lung tissue harvest for RNA isolation 
Materials 
Animals 
Male-specified pathogen-free Sprague-Dawley rats (Harlan UK Limited, Bicester, UK) were used 
throughout and housed in rooms controlled between 19 ⁰C – 21 ⁰C and 40-60 % humidity with dark-
light cycling every 12 h.  The animals had free access to food and water and were acclimatised for at 
least 2 days prior to experimentation.  All animal experiments adhered to the Animal (Scientific 
Procedures) Act 1986, UK and were approved by Cardiff University.  
Consumables 
0.9 % Sodium chloride solution; NaCl, (Fisher Scientific, Loughborough, UK, Cat: S/3105/63).  NaCl 
solution was prepared by dissolving 0.9 g NaCl in 100 mL distilled water and autoclaving at 121 °C 
70 % Ethanol; EtOH, (Fisher Scientific, Loughborough, UK, Cat: E/0551DF/17)   
Method 
Surgery 
Animals (Male-CD, 300-350 g) were terminated using schedule 1 technique (The Animals (Scientific 
Procedures) Act 1986).  The abdomen was liberally covered with 70 % EtOH and an arc dissection 
made to expose the diaphragm.  The diaphragm was dissected and ribs cut to expose the lungs.  
Care was taken to avoid damage to the lung tissue.  The trachea was exposed and taking hold of this, 
the lungs were cut free.  Tissue was placed in 0.9 % NaCl in a Petri dish before RNA isolation. 
2.2.2. Isolation and primary cell culture of rat alveolar epithelial cells 
Materials 
Animals 
Male-specified pathogen-free Sprague-Dawley rats, 120-180 g body weight (Harlan UK Limited, 
Bicester, UK) were used for cell isolation and were housed as described previously. 
Consumables 
Beakers (Sterile covered with foil; 250 mL), (Fisher Scientific, Loughborough, UK, Cat: FB33112) 
Centrifuge tubes (Sterile; 50 mL and 15 mL), (Fisher Scientific. Loughborough, UK, Cat: FB55956 & 
FB55951) 
Syringes (Sterile; 10 mL), (Fisher Scientific, Loughborough, UK, Cat: SZR-150-041H) 
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Syringe filters (Sterile; 0.2 µm pore, 25 mm), (Fisher Scientific, Loughborough, UK, FDR-050-071N)  
Filter syringe units (Sterile; 20 mL), (Beckton Dickenson, Oxford, UK) 
Filter membranes, attached to filter syringe units: 
(a) Gauze (NHS Quality) 
(b) Nylon mesh (150 µm and 30 µm mesh), (Lockertex Warrington, Cheshire, UK) 
Intravenous catheter without injection port; Tro-venocath 20G, (Troge, Hamburg, Germany) 
Cell scraper, (Fisher Scientific, Loughborough, UK, FB55199) 
Chemicals and Enzymes 
Sodium chloride; NaCl, (Fisher Scientific, Loughborough, UK, Cat: S/3105/63)   
Potassium chloride; KCl, (Fisher Scientific, Loughborough, UK, Cat: P/4280/53) 
Calcium chloride dihydrate; CaCl2.2H2O, (Fisher Scientific, Loughborough, UK, Cat: C/1500/50) 
Magnesium sulphate heptahydrate; MgSO4.7H2O, (Acros Organics, Belgium, Cat: 124900010) 
di-Sodium hydrogen orthophosphate dehydrate; Na2HPO4.2H2O (Fisher Scientific, Loughborough, 
UK, Cat: S/4450/53) 
Sodium dihydrogen orthophosphate dehydrate; NaH2PO4.2H2O (Fisher Scientific, Loughborough, UK, 
Cat: S/3760/53) 
N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid; HEPES (Fisher Scientific, Loughborough, UK, 
Cat: BPE310-100) 
D-Glucose anhydrous; C6H12O6, (Fisher Scientific, Loughborough, UK, G/0450/60) 
Percoll™ (Sterile), (GE Healthcare, Buckinghamshire, UK, Cat: 17-0891-01) 
Foetal Bovine Serum; FBS, (Invitrogen Corporation (Gibco), Renfrew, UK, Cat: 10108-16) 
Dulbecco’s Modified Eagle’s Medium; DMEM; with 25 mM HEPES, (Invitrogen Corporation    (Gibco), 
Renfrew, UK, Cat: 42430-025) 
Penicillin G, (Sigma-Aldrich, Dorset, UK, Cat: P7794) 
Gentamicin; (10 mg/mL), Invitrogen Corporation (Gibco), Renfrew, UK, Cat: 15710-031) 
Dexamethasone, (Sigma-Aldrich, Dorset, UK, Cat: D4902) 
Phenol red, (Fisons, Ipswich, UK, Cat: P/2420/44) 
Sodium hydroxide; NaOH Solution; (5 M), (Fisher Scientific, Loughborough, UK, Cat: S/3105/63) 
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Saline intravenous bag, (500 mL), Baxter, Berkshire, UK, Cat: FE1306) 
Pentobarbital sodium; (200 mg/mL); Euthatal, (Vericore Ltd, Dundee, UK) 
70% Ethanol; EtOH, (Fisher Scientific, Loughborough, UK, Cat: E/0551DF/17)   
Stock solutions: to be prepared 24 h before cell isolation 
The following solutions were prepared one day prior to cell isolation and stored under appropriate 
conditions.  Glassware was washed and dried thoroughly before use with solutions being filter 
sterilised and aliquoted in a laminar flow cabinet. 
10X solution:  500 mL, for approximately 20 rats, stable up to 3 months at 4°C.  
Chemicals listed below were dissolved in distilled water (≈ 400 mL) and the volume adjusted to 500 
mL.  Solution pH (~pH 6.5) was adjusted to pH 7.4 with 5 M NaOH and the solution filter-sterilised 
and aliquoted to 50 mL centrifuge tubes for storage in the dark at 4-8 °C. 
Chemical Molecular Weight g / 500 mL 
NaCl 58.44 38.86 
KCl 74.55 1.94 
Na2HPO4.2H2O 177.99 1.42 
NaH2PO4.2H2O 156.01 0.78 
HEPES 238.30 11.92 
Glucose 180.20 5.00 
 
100X CaCl2 and 100X MgSO4:  100 mL, for approximately 40 rats, stable up to 6 months at 4 °C. 
Chemicals listed below were dissolved in distilled water (≈ 90 mL) and the volume adjusted to 100 
mL.  Each solution was filter-sterilised and stored in the dark at 4-8 °C. 
Chemical Molecular Weight g / 500 mL 
CaCl2.2H2O 147.00 2.77 
MgSO4.7H2O 246.40 3.18 
   
Dexamethasone: 20 µM 
Dexamethasone, (7.85 mg), was dissolved in 5 mL EtOH and mixed with 995 mL of distilled water.  
This yielded a 20 µM solution which was filter-sterilised and stored at -20 °C. 
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Penicillin and gentamicin 
Penicillin G, (126.6 mg, 1580 U/mg), was dissolved in 10 mL gentamicin solution (10 mg/mL).  This 
solution was filter-sterilised, aliquoted into 300 mL volumes and stored at -20 °C 
0.9% sterile saline:  (1 x 100 mL/rat) 
NaCl (0.9 g) was dissolved in 100 mL distilled water and autoclaved at 121 °C 
Double-distilled water; sterile (3 x 100 mL/rat) 
Double-distilled water was prepared by aliquoting 3 x 100 mL in suitable bottles and autoclaving at 
121 °C. 
Phenol red-coloured double-distilled water; sterile (100 mL) 
A trace amount of phenol red was dissolved in 100 mL distilled water and autoclaved at 121 °C. 
Filter syringe unit preparation: to be sterilised overnight before cell isolation 
Gauze webbing or nylon mesh cloth (150 µm or 30 µm) were cut into square pieces and fixed over 
filter syringes to create 3 separate filter syringe units of decreasing mesh size.  Each unit was first 
soaked in distilled water and then 70 % EtOH for 10 minutes to remove particulate matter and 
sterilize.  Syringes were then stored under UV light overnight for further sterilization. 
Preparation of solutions immediately before cell isolation 
The following solutions were prepared immediately before cell isolation in a laminar flow cabinet. 
Buffer A (1 bottle/rat)  
10X solution (11 mL) was added to 100 mL bottle of sterile water = 1 bottle 
Buffer B (2 bottles/rat) 
The below listed solutions were added to 100 mL bottle of sterile water.  Two bottles were prepared. 
Solution Volume (mL) 
10X solution 11.0 
100X CaCl2 1.1 
100X MgSO4 1.1 
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Buffer B (2 x 40 mL) from one bottle was placed in 2 x 50 mL centrifuge tubes for elastase suspension 
preparation.  The remaining 160 mL of Buffer B was placed in a 250 mL beaker, covered with foil and 
stored in a water bath at 37 °C 
Heavy and light Percoll™ gradient solutions 
Two of each of the following solutions were prepared in separate 50 mL centrifuge tubes and stored 
on ice 
Heavy Percoll™ solution Light Percoll™ solution 
6.49 mL of Percoll™ 2.72 mL of Percoll™ 
50 µL of FBS 50 µL of FBS 
2.51 mL of distilled water 6.28 mL of phenol red-coloured water 
1 mL of 10X solution 1 mL of 10X solution 
 
DNase I solution 
To 11 mL of Buffer A, 8500 U of DNase I was added in a 15 mL centrifuge tube.  The solution was 
shaken vigorously and filter-sterilised. 
Low concentration DNase:  4.5 mL of the above solution was placed in a 50 mL centrifuge tube 
and the volume adjusted to 35 mL with Buffer A solution. 
High concentration DNase:  6.5 mL of the above solution was placed in a 15 mL centrifuge tube 
and the volume adjusted to 10 mL with Buffer A solution. 
Both DNase solutions were stored on ice. 
Cell culture medium; stored for use in 37 °C water bath.  
Solution Volume (mL) 
DMEM 45.0 
FBS 5 
Dexamethasone, 20 µM 0.25 
Penicillin/gentamicin 0.25 
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Prior to lung isolation: 
In a 37 °C water bath: 
 1 bottle of NaCL for lung lavage 
 160 mL of Buffer B in 250 mL beaker covered with foil 
 40 mL of Buffer B in a 50 mL centrifuge tube for elastase suspension 
 5 mL FBS for terminating elastase digestion 
 50 mL cell culture medium. 
On ice: 
 Heavy Percoll™ 
 Light Percoll™ 
 High concentration DNase 
 Low concentration DNase 
 
Method (adapted from laboratory protocol)  
 
Surgery & lung isolation 
The surgical procedure requires two operators and was conducted in the surgery room of Joint 
Services.  Prior to surgery, all surfaces and kit were wiped with 70 % EtOH and dried thoroughly. 
A Male CD rat was anesthetised with 0.2 mL Euthatal via intraperitoneal injection.  Sufficient 
anaesthesia was checked by tail or paw pinch. 
The rat was placed on its back on a surgical mat and its neck and abdomen liberally covered with 70 
% EtOH.  A midline incision (1-2 cm) was made in the neck and the trachea exposed by careful 
dissection through the salivary glands and muscle layers.  The trachea was cannulated between the 
2nd and 3rd cartilage rings using a 20G intravenous catheter.  The catheter was tied securely using 
linen thread. 
The abdomen was exposed in an arc dissection and the diaphragm revealed.  The diaphragm was 
then dissected away using Spencer Wells forceps to hold the xiphisternum, and the lungs visualised.  
The ribs were then carefully cut towards the sternum with blunt scissors.  To allow access to the 
thorax, the xiphisternum was clamped with Spencer Wells forceps and the cut chest wall turned 
over.  The weight of the clamp was used to maintain this access.  The thymus, now visible, was 
removed using two pairs of forceps.   
Flow was released from an intravenous saline bag.  Immediately following this, an incision was made 
in the left atrium to allow saline/blood drainage.  Next, the pulmonary artery was located through 
slight displacement of the heart to the left.  A small incision was then made in the right ventricle.  
Once an incision was made, the saline catheter was inserted through the right ventricle and its tip 
visualised in the pulmonary artery.  With the catheter maintained in the pulmonary artery, the lungs 
were manually inflated with 4-6 mL of air using a 10 mL syringe attached to the tracheal cannula.  Air 
  Chapter 2 
43 
 
was released by removal of the syringe and this was repeated 5-6 times or until the lungs appeared 
clear of blood.  Saline perfusion was then stopped. 
The lungs were removed from the thorax by holding the trachea and pulling gently in a downwards 
direction.  At the same time, the connective tissue between the lungs and the abdomen was cut 
away.  Care was taken not to touch the lung tissue.  Once removed, lungs were washed with normal 
saline and placed in a Petri dish of the same solution. 
The procedure was then repeated with a second animal. 
Lung Lavage 
This procedure was performed on the bench top 
The plunger was removed from a 10 mL syringe and the remaining barrel clamped in a retort stand.  
The tracheal cannula (in the trachea of the isolated lungs) was firmly attached to the syringe.  The 
lungs, via the attached syringe, were filled slowly with 6-8 mL of warm saline.  Simultaneously, 2 x 80 
U of elastase was added to 40 mL of Buffer B and stored in a 50 mL centrifuge tube in a 37 °C water 
bath. 
Once the lungs had fully inflated (no more saline was able to enter the tissue), the tracheal cannula 
was disconnected from the syringe and the lungs inverted to allow drainage of lavage fluid.  Initially 
lavage fluid was white in colour due to the presence of alveolar macrophage.  Lavage was repeated 
until fluid appeared clear. 
Enzymatic digestion of lung tissue 
This procedure was performed in the 37 °C water bath 
Lung tissue was submerged in 160 mL of warm Buffer B.  Warm elastase, in 5 mL volumes, was then 
slowly added via the 10 mL syringe.  Drainage of the elastase solution was slow, requiring 
approximately 15-20 minutes for 40 mL of solution. 
Isolation and purification of alveolar type II epithelial cells 
This procedure was carried out in a laminar flow cabinet. 
High concentration DNase solution was placed in 37 °C water bath.  Lung tissue (glassy in 
appearance and soft in texture) was placed in a sterile Petri dish (1 pair of lungs/Petri dish) in a 
laminar flow cabinet.  The trachea and bronchi were carefully cut free then lung tissue was finely 
chopped (~ 1-2 mm
2 pieces) using sharp scissors. 
Once lung tissue was sufficiently dissected, 5 mL of warm FBS was added to each Petri dish to 
terminate elastase action.  10 mL of warm high concentration DNase was then added to prevent cell 
clumping.  Using a cell scraper, both tissue suspensions were added to one 50 mL centrifuge tube.  
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Cell suspension was then slowly added to the widest gauze syringe filter, with the resulting filtrate 
solution being collected in a fresh 50 mL centrifuge tube.  The filtrate was then added to the 150 µm 
filter unit, filtrate collected and finally added to the 30 µm filter unit.  The filtrate from the 30 µm 
was the crude alveolar cell suspension.  (Figure 2.1) 
The crude alveolar cell suspension was stored in the 37 °C water bath until the Percoll™ 
discontinuous centrifugation gradients were prepared.  
Two Percoll™ gradients were prepared using a Power Pipetter on the lowest power setting to very 
carefully layer the light Percoll™  solution (10 mL) onto the heavy Percoll™ solution (10 mL).  Once 
finished, the first Percoll™ gradient was stored on ice, this helping the interfaces to settle, until the 
second gradient was prepared.  
Very slowly and carefully, half of the crude cell suspension was added to the top of each Percoll™ 
gradient, figure 2.2.  Each gradient was then centrifuged at 250 x g at 6 °C for 20 minutes (1050 rpm 
on Allergra 6 KR Centrifuge, Beckman Coulter and 1100 rpm on Avanti J-25 centrifuge, Beckman 
Coulter).  Centrifuge buckets were pre-cooled.  Maximum acceleration and no brake were employed.   
After centrifugation, cell debris and the majority of the light Percoll™ layer (Figure 2.2) was 
discarded.  AEII cells were contained in the opaque band between the two Percoll™ solutions. 
The opaque band and the Percoll™ solutions interface was removed (25 % of the light layer and 50 % 
of the heavy layer i.e. ~7.5 – 12.5 mL on the centrifuge tube volume markings) and placed in 35 mL 
low concentration DNase solution.  This was then repeated for the second Percoll™ gradient. 
Low concentration DNase/cell suspension was centrifuged as previously described, using both 
maximum acceleration and deceleration.  The resulting supernatant was removed and the cell 
pellets re-suspended in 10 mL warm cell culture media.  This cell suspension was then transferred to 
a sterile Petri dish and placed for 1 h in the CO2 incubator to allow removal of contaminating 
macrophage.  After 1 h the ATII cells remained free from the Petri dish while macrophage had 
attached to the plastic, appearing as large granular cells.  The cell suspension was transferred to a 
sterile 50 mL centrifuge tube, 100 µL sample removed for cell counting, fluid volume recorded, and 
centrifuged at 250 x g at 6 °C for 10 minutes.  50 µL cell suspension was added to an equal volume of 
Trypan blue solution and left for 10 minutes at room temperature.  The percentage of viable cells 
was then calculated using a haemocytometer and the centrifuged cell pellet re-suspended in the 
correct volume of media to allow a seeding density of 0.9 – 1.2 x 106 cells/cm2. 
Primary cell culture 
Successfully isolated alveolar epithelial cells were maintained in a culture flask in a humidified 
incubator (37 °C; 95 % air; 5 % CO2).  To induce differentiation of type II alveolar epithelial cells to 
type I-like cells, 0.1 µM dexamethasone was added to culture medium.  Spent culture medium was 
replaced every 48 h.  Cells seeded to Transwell™ plates were pre-washed with warm PBS to remove 
debris prior to culture medium replacement.  In order to monitor monolayer confluence, 
  Chapter 2 
45 
 
Transepithelial electrical resistance (TEER) was measured from day 4 of cell culture, with cells 
typically reaching confluence on day 8 of culture.       
 
Figure 2.1 Gauze-syringe filter unit used to retrieve crude alveolar suspension 
  
Figure 2.2 Percoll™ discontinuous gradient centrifugation of crude alveolar cell suspension to allow 
isolation of alveolar epithelial Type II cells.  Adapted from laboratory protocol. 
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2.2.3 SPOC1 Cell culture 
Materials 
Cell line 
SPOC1 cells were a kind gift from Professor Davis, Cystic Fibrosis/Pulmonary research & 
treatment centre, University of North Carolina.  
Consumables 
Dulbecco’s Modified Eagle’s Medium: Nutrient mixture F12; DMEM/F12, (Invitrogen, 
Renfrew, UK, Cat: 11039-021) 
Insulin, (Sigma-Aldrich, Dorset, UK, Cat: I1882) 
Hydrocortisone, (Sigma-Aldrich, Dorset, UK, Cat: H6909) 
Cholera toxin, (Sigma-Aldrich, Dorset, UK, Cat: C3012) 
Transferrin, (Invitrogen, Renfrew, UK, Cat: 11108-016) 
Phosphoethanolamine, (Sigma-Aldrich, Dorset, UK, Cat: P0503) 
Ethanolamine, (Sigma-Aldrich, Dorset, UK, Cat: E0135) 
Epidermal growth factor; EGF, (Collaborative Research, Waltham, MA, USA, Cat:  40001) 
Bovine pituitary extract; BPE, (Invitrogen, Renfrew, UK, Cat: 13028014) 
N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid; HEPES (Fisher Scientific, 
Loughborough, UK, Cat: BPE310-100) 
Bovine serum albumin; BSA, fraction V, very low endotoxin, (Serologicals, Livingston, UK, 
Cat:  81-068-2) 
 Trypsin, (Invitrogen, Renfrew, UK, Cat: 15400-054) 
 Tissue culture flasks, (Fisher Scientific, Loughborough, UK, Cat: TKT-130-150L) 
Method 
SPOC1 cells, passage 9, were seeded at a density of 9-10x103 cells per cm2 in a 25 cm2 tissue culture 
flask in 6 mL of culture medium.  Culture flasks were housed in an incubator (37 °C; 5 % CO2; 95 % 
air) and culture medium changed every 48 h.  Culture medium consisted of a base medium of 
DMEM/F12 (50 mL) to which, the following additives were supplemented. 
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Additive Stock concentration Volume added to 50 
mL DMEM/F12 
Final concentration 
Insulin 10 mg/mL 50 µL 10 µg/mL 
Hydrocortisone 50 µg/mL 100 µL 0.1 µg/mL 
Cholera toxin 0.1 mg/mL 50 µL 0.1 µg/mL 
Transferrin 5 mg/mL 50 µL 5 µg/mL 
Phosphoethanolamine 50 mM 50 µL 50 µM 
Ethanolamine 80 mM 50 µL 80 µM 
EGF 25 µg/mL 50 µL 25 ng/mL 
BPE 15 mg/mL 333 µL 0.1 mg/mL 
HEPES 0.5 M 3 mL 30 mM 
BSA (low protein 
concentration) 
150 mg/mL 167 µL 0.5 mg/mL 
  
Once confluent, cells were sub-cultured to further tissue culture flasks.  To subculture, spent media 
was removed and cells washed with 3 mL sterile PBS.  To dislodge cells, 3 mL trypsin was added to 
the cell monolayer and the culture flask incubated at 37 °C for 10 minutes or until cells were 
observed to be dissociating from the culture flask.  Trypsin activity was neutralized by the addition of 
5 mL fresh culture medium.  Cells were counted, diluted appropriately and seeded at a density of 9-
10x103 cells per cm2. 
2.2.4. Isolation and quantitation of total RNA from animal cells and animal tissue 
Materials 
Consumables 
 β-mercaptoethanol; β-ME, molecular biology, ≥98 % (GC/titration), (Sigma-Aldrich, Dorset, 
 UK, Cat: M3148-25ml) 
70% Ethanol; EtOH, (Fisher Scientific, Loughborough, UK, Cat: E/0551DF/17)   
RNeasy® Mini Kit, (Qiagen, Crawley, UK, Cat: 74104) 
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Method 
Isolation of total RNA from cultured cells  
The cell samples included SPOC1 cells, AEII freshly isolated cells, AEII cells cultured for 2 days, and 
AEI-like cells cultured for 8 days.  All cells were grown in monolayers.  Total RNA was isolated from 
all cell samples through use of an RNeasy® Mini Kit.  RNeasy® Mini Kit third edition protocol was 
followed.  Before use, 10 µL of β-ME was added to 1 mL of Buffer RLT in a fume hood.  Cell culture 
medium was completely aspirated from the culture flask and 350 µL Buffer RLT was added.  Buffer 
volume is dependent upon culture vessel size, with vessel size governing cell number and therefore 
volume of Buffer RLT to be added, p18 of RNeasy® Mini Handbook.  Cell monolayers were disrupted 
through use of Buffer RLT and a cell scraper.  Cell lysate was then collected using a pipette and 
added to a 1.5 mL microcentrefuge tube which was vortexed to mix the cell sample. 
Each cell sample was homogenised by passing the lysate through a 20G needle attached to an 
RNase-free syringe (BD Plastipak. Cat: 300185).  This was repeated 5 times to ensure complete 
disruption of the cell sample.  A volume of 70 % EtOH equal to the volume of Buffer RLT (350 µL) was 
then added and mixed well by pipette. 
Each sample (700 µL) was then added to an RNeasy® mini column which was placed in a 2 mL 
collection tube and centrifuged at 10,000 rpm for 15 s at 20 °C.  The through-flow was discarded and 
700 µL Buffer RW1 added to the same RNeasy® mini column.  Again this was centrifuged at 10,000 
rpm for 15 s at 20 °C.  (Eppendorf Centrifuge 5417R).  The through-flow and collection tube were 
then discarded and the RNeasy® mini column placed in a new collection tube. To this, 500 µL Buffer 
RPE added and each sample was centrifuged at 10,000 rpm for 15 s at 20 °C.  Before use, Buffer BPE 
was reconstituted with 4 volumes of 100 % EtOH to obtain a working solution.  The through-flow 
was discarded and a second volume (500 µL) of Buffer RPE was added to the RNeasy® mini column.  
This was then centrifuged at 10,000 rpm for 2 min at 20 °C in order to dry the RNeasy® silica-gel 
membrane to avoid any residual ethanol affecting further reactions. 
Finally, each RNeasy® mini column was then placed in a 1.5 mL microcentrefuge tube and 30 µL 
RNase-free water was added directly to the RNeasy® silica-gel membrane.  Samples were then 
centrifuged at 10,000 rpm for 1 min at 20 °C to allow elution of the total RNA sample.  Samples were 
stored at 4 °C for use in RT-PCR reactions or at -20 °C for prolonged storage. 
Isolation of total RNA from animal tissue 
Total RNA was isolated from rat whole lung samples through use of an RNeasy® Mini Kit.  RNeasy® 
Mini Kit, third edition protocol was followed. 
Whole lung tissue was placed in a mortar and a small volume (approx. 3 mL) of liquid nitrogen 
added.  The tissue was then homogenized and added to 1.5 mL microcentrifuge tubes where 600 µL 
Buffer RLT+β-ME was added before the tissue could thaw.  Each sample was then further 
homogenised through use of a 20G needle attached to an RNase-free syringe (BD Plastipak. Cat: 
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300185).  The crude lysate was centrifuged at maximum speed (14,000 rpm) for 3 min and the 
resulting supernatant transferred to a new 1.5 mL microcentrifuge tube.  A volume of 70 % EtOH 
equal to the volume of Buffer RLT (600 µL) was then added and mixed well by pipette. 
The procedure then continued in the same manner as total RNA isolation from cell samples.   
Each sample (700 µL) was then added to an RNeasy® mini column which was placed in a 2 mL 
collection tube and centrifuged at 10,000 rpm for 15 s at 20 °C.  The through-flow was discarded and 
700 µL Buffer RW1 added to the same RNeasy® mini column.  Again this was centrifuged at 10,000 
rpm for 15 s at 20 °C.  (Eppendorf Centrifuge 5417R).  The through-flow and collection tube were 
then discarded and the RNeasy® mini column placed in a new collection tube. To this, 500 µL Buffer 
RPE added and each sample was centrifuged at 10,000 rpm for 15 s at 20 °C.  Before use, Buffer BPE 
was reconstituted with 4 volumes of 100 % EtOH to obtain a working solution.  The through-flow 
was discarded and a second volume (500 µL) of Buffer RPE was added to the RNeasy® mini column.  
This was then centrifuged at 10,000 rpm for 2 min at 20 °C in order to dry the RNeasy® silica-gel 
membrane to avoid any residual ethanol affecting further reactions. 
Finally, each RNeasy® mini column was then placed in a 1.5 mL microcentrefuge tube and 30 µL 
RNase-free water was added directly to the RNeasy® silica-gel membrane.  Samples were then 
centrifuged at 10,000 rpm for 1 min at 20 °C to allow elution of the total RNA sample.  Samples were 
stored at 4 °C for use in RT-PCR reactions or at -20 °C for prolonged storage. 
Total RNA was spectrophotometrically analysed to measure the concentration and purity of each 
sample.  Using a Genequant DNA/RNA calculator, (Pharmacia Biotech, St Albans, UK), the UV 
absorbance ratio at 260 nm/280 nm was established to show purity of sample, a ratio of 1.8-2.0 
indicating high purity.  The concentration (ng/mL) of each sample was also given.  Samples were 
measured against DNPC treated water as a blank using a path length of 0.5 mm.  All other 
parameters remained as standard. 
2.2.5. Primer design 
Method 
Specific DNA primers were designed against drug transporters of interest in order to determine DNA 
fragments for amplification and thus establish presence of those drug transporters in rat lung cells 
and tissue.  Final primer sequences for each drug transporter of interest can be viewed in tables 2.1-
2.8 below. 
Drug transporter gene sequences were searched using the National Center for Biotechnoloy 
Information ‘ENTREZ’ database, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene.  Both 
mRNA and nucleotide sequences were visualised and compared using ‘BLAST’ (Basic Local Alignment 
Search Tool), http://www.ncbi.nlm.nih.gov/BLAST/, to locate a universal sequence from which to 
design the primer for a specific gene.  Results from this were then copied to Primer3, an internet 
based program for the design of DNA primers  
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(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi), where primers were automatically 
picked.  Primers for use were then chosen based on Guanine Cytosine percentage (45-60 %), 
optimum annealing temperature (2-4 °C lower than melting temperature), and predicted product 
size (150-300 bp).  Chosen primer sequences were then entered into a BLAST search in order to 
ensure the results, i.e. primer sequences, were only present in the gene of interest.  BLAST results 
showing sequences from clones and other species were ignored as these are unlikely to be present 
in the reaction mixture; sequences from human genes were taken into consideration as there is 
possibility for these to be present due to contamination. 
Once chosen, primers were manufactured at Invitrogen, stock lyophilized powder diluted to 10 
pmol/mL in STERILE water. 
NOTE:  ALL TRANSPORTER NAMES AND GENE DESIGNATIONS ARE DENOTED AS REPRESENTED 
EXACTLY IN BLAST RESULTS.  Transporter names/gene names have remained consistent throughout 
this thesis.  When referring to a human transporter that is traditionally denoted by the transporter 
name used here (including notations involving letter case), a reference has been made in the text to 
differentiate between human and rat gene.   
Transporter 
name 
Gene Primer pair 
5’ to 3’ 
Product 
size (bp) 
Gen Bank 
Accession 
No. 
mdr1a ABCB1a F: 5’-CATCCAGAACGCAGACTTGA-3’ 
R: 5’-CTCGCATGGTCACAGTTCAT-3’ 
152 NM_133401 
 
mdr1b ABCB1b 
 
F: 5’-ACCATCCAGAACGCAGACTT-3’ 
R: 5’-ACCTCAAATACTCCCAGCTCA-3’ 
150 NM_012623 
 
mrp1 ABCC1 F: 5’-GCGATCACCCATGAGTTTCT-3’ 
R: 5’-GGATGATGATGACAGCTCCA-3’ 
155 NM_022281 
 
mrp 2 ABCC2 F: 5’-GACGGTTGGATTCTGTCACC-3’ 
R: 5’-CACCTGTTGGAGGTAATCCAG-3’ 
172 NM_012833 
 
mrp 3 ABCC3 F: 5’-CGCCTCAGTCCTTCTTTGAC-3’ 
R: 5’-CTGCACGAAGCCATAGAACA-3’ 
215 NM_080581 
 
mrp 4 ABCC4 F: 5’-GAGGTCTGGCCTCTTCCTG-3’ 
R: 5’-GTGCGACGTTGAGAGAATCA-3’ 
194 NM_133411 
 
mrp 5 ABCC5 F: 5’-CTTCTCCAGCTGGTCGTTTC-3’ 
R: 5’-TGAGAATTCACGGTGCTCTG-3’ 
157 NM_053924 
 
mrp 6 ABCC6 F: 5’-CTGAGGATGGCCTTGAACAT-3’ 
R: 5’-GCCAGTTTGAGCAAGAGACC-3’ 
215 NM_031013 
 
mrp 8 ABCC7 F: 5’-CGTCAATAGTGACAACGCAAT-3’ 
R: 5’-TGACGACTTTATTCTGTAGACATATCC-3’ 
150 NM_013039 
 
CFTR ABCC8 F: 5’-CCTGGTACTGACCCTGCTGT-3’ 
R: 5’-AAAGCGTGACAGCCAACTCT-3’ 
238 NM_031506 
 
White1 ABCG1 F: 5’-AGACTCTCCCAACCCAACCT-3’ 
R: 5’GTGTGTCCTAGACCCCTGGA-3’ 
231 NM_053502 
 
BCRP ABCG2 F: 5’-CTTGATAAATCAGGGCATCG-3’ 
R: 5’-CAATAGTCCTTTCAAGGGGAAA-3’ 
152 NM_181381 
 
β-actin ACTB F: 5’-AGCCATGTACGTAGCCATCC-3’ 
R: 5’-CTCTCAGCTGTGGTGGTGAA-3’ 
228 NM_031144 
 
 Table 2.3 Forward (F) and reverse (R) primer sequences designed for each individual rat ABC 
transporter to be studied. 
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Transporter 
name 
Gene Primer pair 
5’ to 3’ 
Product size 
(bp) 
Gen Bank 
Accession No. 
Eaac1 Slc1a1 F: 5’-AAGCTACAGCCTGACCCTCA-3’ 
R: 5’-GATGACCCCAGTGAACTCGT-3’ 
208 NM_013032 
 
ASCT2 Slc1a5 F: 5’-CCTGCTCTTTTTCCTGGTCA-3’ 
R: 5’-AGGAAGGAATCCAGCACCTC-3’ 
159 NM_175758 
 
rBAT Slc3a1 F: 5’-ATACCCATGCCGTTTCTCTG-3’ 
R: 3’-TACAGAGCTGCCTAGCACGA-3’ 
169 NC_005105 
 
GLYT2 Slc6a5 F: 5’-ACCAACATCTTGGAGGCAAC-3’ 
R: 5’-CATCCGCAGACTGGAAAGTT-3’ 
166 NM_203334 
 
Cat-1 Slc7a1 F: 5’-GGCTGCAAAAACCTGTTGAG-3’ 
R: 5’-AGCGATCAGGAAGGAGATGA-3’ 
216 NM_013111 
 
Cat-3 Slc7a3 F: 5’-ATGCCTGAGCACTCTCGACT-3’ 
R: 5’-CAGCCAACACAGAGGACAGA-3’ 
152 NM_017217 
 
Asc-1 Slc7a10 F: 5’-GGACAAGCCCTTGAAGACAC-3’ 
R: 5’-GAGAAGCTAGCAGGGCATTG-3’ 
214 NM_053726 
 
PHT1 Slc15a4 F: 5’-TCTTCATGGGCCTCACCTAC-3’ 
R: 5’-GATCCCCGCAGAGAAAAGAG-3’ 
168 NM_144758 
 
Lyaat1 Slc36a1 F: 5’-TATGGGTGTGCTCCCTTTAC-3’ 
R: 5’-TGTAGCCCAGGTTACCCAAG-3’ 
151 NM_130415 
 
SNAT1 Slc38a1 F: 5’-TCAGCATCCCCCTAGTCATC-3’ 
R: 5’-TGAGTCTCTGTGTCGCAACC-3’ 
194 NM_138832 
 
SNAT3 Slc38a3 F: 5’-CCAAGGACAAAAGGAAGCTC-3’ 
R: 5’-CTGCTTCGTGGGGTATGAGT-3’ 
157 NC_005107 
 
β-actin ACTB F: 5’-AGCCATGTACGTAGCCATCC-3’ 
R: 5’-CTCTCAGCTGTGGTGGTGAA-3’ 
228 NM_031144 
 
 
 
Transporter 
name 
Gene Primer pair 
5’ to 3’ 
Product size 
(bp) 
Gen Bank 
Accession No. 
Glut1 Slc2a1 F: 5’-GCCTGAGACCAGTTGAAAGC-3’ 
R: 5’-GAGTGTCCGTGTCTTCAGCA-3’ 
154 NM_138827 
 
Glut2 Slc2a2 F: 5’-TCCTGGTCTTCACCCTGTTC-3’ 
R: 5’-ACCTGGTTCCCTTCTGGTCT-3’ 
204 NM_012879 
 
Glut4 Slc2a4 F: 5’-AATGACTGAGGGGCAAAATG-3’ 
R: 5’-GGGAGAAAAGCCCATCTAGG-3’ 
235 NM_012751 
 
Glut5 
 
Slc2a5 F: 5’-ACTCAGTGGGGCACCTGAC-3’ 
F: 5’-AGGaCCGTCACGTCTTGTCT-3’ 
226 NM_031741 
Glt-1 Slc5a1 F: 5’-GTCAGGGCTGGATGCTAAAG-3’ 
R: 5’-CACCTCGTCGTTCTTCTTCC-3’ 
172 NC_005113 
β-actin ACTB F: 5’-AGCCATGTACGTAGCCATCC-3’ 
R: 5’-CTCTCAGCTGTGGTGGTGAA-3’ 
228 NM_031144 
 
 
 
 
Table 2.4 Forward (F) and reverse (R) primer sequences designed for each individual rat amino acid 
transporter to be studied. 
Table 2.5 Forward (F) and reverse (R) primer sequences designed for each individual rat glutamine 
transporter to be studied. 
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Transporter 
name 
Gene Primer pair 
5’ to 3’ 
Product size 
(bp) 
Gen Bank 
Accession No. 
Cnt1 Slc28a1 F: 5’-GGGACTCGTCACTACCTCCA-3’ 
R: 5’-AGGTTCCCAAGGAAAGAGGA-3’ 
162 NM_053863 
 
rENT1 Slc29a1 F: 5’-CTTCCTGCTCACTTCCTTCG-3’ 
R: 5’-CAGTCAGCCATCTGTCTCCA-3’ 
243 NM_031684 
 
Ent2 Slc29a2 F: 5’-CCCTCATGACCTTCTTCCTG-3’ 
R: 5’-CCAAGAGACCCGGTATAGCA-3’ 
166 NM_031738 
 
Ent3 Slc29a3 F: 5’-ACTACATGAGGCCGGTTGTC-3’ 
R: 5’-GAAGATAAGGGCGGTGATGA-3’ 
194 NM_181639 
 
β-actin ACTB F: 5’-AGCCATGTACGTAGCCATCC-3’ 
R: 5’-CTCTCAGCTGTGGTGGTGAA-3’ 
228 NM_031144 
 
 
 
Transporter 
name 
Gene Primer pair 
5’ to 3’ 
Product size 
(bp) 
Gen Bank 
Accession No. 
MCT Slc16a2 F: 5’-ATTCGCCTTTCAACCATCAC-3’ 
R: 5’-GCCAGCTTGATTCTGTCTCC-3’ 
150 NM_147216 
 
MCT1 Slc16a1 F: 5’-CCCTGGAGTCCTCCTAGTCC-3’ 
R: 5’-GCGGGAGGTGGGTACTTACT-3’ 
239 NM_012716 
 
Mct7B Slc16a6 F: 5’-CGCTGCATTCTTACTGTCCA-3’ 
R: 5’-AAGGTGAAGGCGAACAGAGA-3’ 
150 NM_198760 
 
β-actin ACTB F: 5’-AGCCATGTACGTAGCCATCC-3’ 
R: 5’-CTCTCAGCTGTGGTGGTGAA-3’ 
228 NM_031144 
 
 
 
Transporter 
name 
Gene Primer pair 
5’ to 3’ 
Product size 
(bp) 
Gen Bank 
Accession No. 
Pept1 Slc15a1 F: 5’-CCAGCTGACAAGCATAAACG-3’ 
R: 5’-CCCACACTAGAAGGGTGTGC-3’ 
101 NM_057121 
 
Pept2 Slc15a2 F: 5’-CGGGTCTGCTAAGTTTGAGG-3’ 
R: 5’-CAAGCTAGCCTCTGGATTGG-3’ 
181 NM_031672 
 
β-actin ACTB F: 5’-AGCCATGTACGTAGCCATCC-3’ 
R: 5’-CTCTCAGCTGTGGTGGTGAA-3’ 
228 NM_031144 
 
 
 
 
 
 
Table 2.6 Forward (F) and reverse (R) primer sequences designed for each individual rat nucleoside 
transporter to be studied. 
Table 2.7 Forward (F) and reverse (R) primer sequences designed for each individual rat 
monocarboxylate transporter to be studied. 
Table 2.8 Forward (F) and reverse (R) primer sequences designed for each individual rat peptide 
transporter to be studied. 
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Transporter 
name 
Gene Primer pair 
5’ to 3’ 
Product size 
(bp) 
Gen Bank 
Accession No. 
Oct1 Slc22a1 F: 5’-CTCCCATCTATGTGGGCATC-3’ 
R: 5’-CTGGTTCCAGTCCACCTCAT-3’ 
197 NM_012697 
 
rOCT2 Slc22a2 F: 5’- ATCTACGTGGGCATCGTTTT-3’ 
R: 5’-ACAGTGGGTCCACACAGTCA-3’ 
220 NM_031584 
 
OCTN2 Slc22a5 F: 5’-ACTCAGGCTGCCAGACACTT-3’ 
R: 5’-ATATTGGCAACTGCACACCA-3’ 
197 NM_019269 
 
β-actin ACTB F: 5’-AGCCATGTACGTAGCCATCC-3’ 
R: 5’-CTCTCAGCTGTGGTGGTGAA-3’ 
228 NM_031144 
 
 
 
Transporter 
name 
Gene Primer pair 
5’ to 3’ 
Product 
size (bp) 
Gen Bank 
Accession No. 
oatp1 Slco1a1 F: 5’-ATCAGTTTCATCTACTCACTTACAGCC-3’ 
R: 5’- AGAAACAGGAAATGACACAGGAGTGAG-
3’ 
162 NM_017111 
 
oatp2 Slco1a4 F: 5’-CTCATATTCAGGGGGCTTCA-3’ 
R: 5’- GTTCGGTGGCAAACAGTTCT-3’ 
151 NM_131906 
 
oatp3a1 Slco3a1 F: 5’-GGCACTGCCTGAATTCCTTA-3’ 
R: 5’-CACGTGGTAGTACCTGTAGG-3’ 
250 NM_177481 
 
oatp-H Slco4c1 F: 5’-CAGGTGGAGGTCTGCTGT-3’ 
R: 5’-CCTCAAGCTCGCTTAGCTGT-3’ 
157 NM_001002024 
 
oatp-E Slco4a1 F:5’-CTGGGACGTGCCTGACTAAT-3’ 
R: 5’- GGCGAATAGCTCGACTTGAC-3’ 
175 NM_133608 
 
moat1 Slco2b1 F: 5’-TTTCCATCACAGCCTCCTTT-3’ 
R: 5’-AAGAGCGGCAAGCTGAGTAG-3’ 
178 NM_080786 
 
β-actin ACTB F: 5’-AGCCATGTACGTAGCCATCC-3’ 
R: 5’-CTCTCAGCTGTGGTGGTGAA-3’ 
228 NM_031144 
 
 
 
2.2.6. Digestion of potential DNA contamination 
Materials 
Consumables 
 TURBO DNase Buffer, (Ambion, Huntingdon, UK, Cat: 8176G) 
 TURBO DNase, (Ambion, Huntingdon, UK, Cat: 2238G) 
 DNase inactivation reagent, (Ambion, Huntingdon, UK, Cat: 8174G) 
 Sterile water for RNA work, (Fisher Scientific, Loughborough, UK, Cat: BPE561-1) 
Table 2.9 Forward (F) and reverse (R) primer sequences designed for each individual rat organic cation 
transporter to be studied. 
Table 2.10 Forward (F) and reverse (R) primer sequences designed for each individual rat organic anion 
transporter to be studied. 
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Method 
Removal of contaminating DNA from RNA samples was essential to avoid false positive results.  A 
TURBO DNA-free™ kit which itself is RNase free, was used for DNA removal, this avoided damage to 
the RNA sample.  All kit reagents were stored at -20 °C. 
All RNA samples were diluted to 200 µg/mL with sterile water before DNA contamination; samples 
of a lower initial concentration were not diluted. 
To a sterile PCR tube: 
Ingredient Volume added (µL) 
RNA sample (200 µg/mL or less) 40  
10 x TURBO DNase Buffer 5  
TURBO DNase (2 U/µL). 1  
 
Samples were incubated at 37 °C for 30 min on a PCR block (Peltier thermal cycler, PTC-200, MJ 
research) after which 5 µL of DNAse Inactivation Reagent was added.  Samples were then incubated 
for a further 2 min at room temperature. 
After incubation, samples were centrifuged in a PCR micro-centrifuge (Technico Mini centrifuge, 
Fisher Scientific) for 2 min and supernatants transferred to a new sterile PCR tube and stored at -20 
°C. 
2.2.7. Reverse transcriptase – polymerase chain reaction (RT-PCR) 
Overview 
RT-PCR is a variant of PCR in which isolated messenger RNA (mRNA) is reverse transcribed to 
complimentary DNA (cDNA) using a reverse transcriptase enzyme; Moloney Murine Leukemia Virus 
Reverse Transcriptase in this instance. 
A tradition polymerase chain reaction technique is then employed to amplify the cDNA produced.  
Use of RT-PCR is preferred as mRNA contains only genetic information transcribed from DNA, i.e. the 
mRNA does not contain spurious information and is considered a ‘purer’ information form. 
Materials 
Consumables 
5x first strand buffer; [250 mM Tris-HCl (pH 8.3), 375 mM KCl, 15 mM MgCl2], (Invitrogen, 
Renfrew, UK, (Included with MMLV-RT, Cat: 28025-013)) 
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dNTP mix; 2.5 mM, (Bioline, London, UK, Cat: BIO-39044) 
Dithiothreitol; DTT; 0.1 M, (Invitrogen, Renfrew, UK, (Included with MMLV-RT, Cat: 28025-
 013)) 
pd(N)6; 50 ng/mL, (Ambion, Huntingdon, UK, Cat: 313453) 
RNasin; 40 U/µL, (Promega, Southampton, UK, Cat: N211A) 
Moloney Murine Leukemia Virus Reverse Transcriptase; M-MLV RT; 200 U/µL, (Invitrogen, 
Renfrew, UK, Cat: 28025-013) 
Sterile water for RNA work, (Fisher Scientific, Loughborough, UK, Cat: BPE561-1) 
Method 
All reagents and RNA samples were stored at -20 °C or were kept on ice when in use for RT-PCR 
reactions.  DNase/RNase free PCR tubes and sterile tips were used for all reactions to avoid cross-
contamination. 
To a sterile PCR tube: 
Ingredient Volume added (µL) 
H2O 3.5 
5x first strand buffer 4 
dNTP mix (2.5 mM) 2 
DTT (0.1 M) 2 
pd(N)6 (50 ng/µL) 2 
RNA sample (≤ 164 ng/µL) 5 
 
Sample Concentrations; If RNA sample concentration was 200 µg/ml before DNase treatment, the 
concentration will be 164 µg/ml after treatment. It is not essential to achieve this concentration as 
experience has shown that DNAse treatment of less concentrated samples (≥ 180 µg/ml) does not 
affect RT-PCR reagent volumes used. 
Samples were incubated at 80-95 °C for 4-5 min  to denature the RNA strands then quenched on ice 
for a further 2 min Both RNasin and M-MLV RT were then added to each sample, changing tips 
between each addition.  A control sample excluding RNasin and M-MLV RT was also prepared to 
ensure the integrity of the RT-PCR reaction.   
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Samples were then placed on a PCR thermocycler under the following conditions: 
Thermocycling procedure Reaction conditions 
Step 1; Annealing of primers 25 °C for 10 min. 
Step 2; Amplification of cDNA 42 °C for 42 min. 
Step 3; Termination of reaction 95 °C for 5 min. 
Step 4; Cooling 4 °C for 10 min. 
 
Samples were removed from thermocycler and stored on ice for PCR or stored at -20 °C. 
2.2.8. Polymerase chain reaction (PCR) 
Materials 
Consumables 
Custom designed primers; diluted to 10 pmol/mL with RNase-free water 
dNTP mix; 2.5 mM, (Bioline, London, UK, Cat: BIO-39044) 
RT-PCR grade water, (Ambion, Huntingdon, UK, Cat: AM9935) 
MgCl2; 25 mM, (Bioline, London, UK, Cat: BIO-37026) 
10x ThermoPol reaction buffer, (New England Biolabs, Hitchin, UK, (Included with Taq 
Polymerase, Cat: M0267S) 
 Taq polymerase, (New England Biolabs, Hitchin, UK, Cat: M0267S) 
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Method 
 To a sterile PCR tube: 
Ingredient Volume added (µL) 
H2O 6.4 
MgCl2 (1.5 mmol)  0.75 
dNTP mix (2.5 mM) 1 
cDNA sample (from RT-PCR) 1 
Custom primer, forward (10 pmol/µL) 1 
Custom primer, reverse (10 pmol/µL) 1 
10x Taq buffer 1.25 
Taq polymerase 0.1 
 
The above PCR mix was prepared for each custom primer and run using cDNA samples from whole 
lung tissue, SPOC1 cells, AEII – freshly isolated cells, AEII - day 2 of culture cells and also AEI-like cells. 
A control sample excluding cDNA was also prepared to ensure integrity of the reaction.   
Samples were placed on a PCR thermocycler under the following conditions: 
Thermocycling procedure Reaction conditions 
Step 1; Initial denaturation of cDNA  94 °C for 5 min. 
Step 2; Denaturation  94 °C for 30 s 
Step 3; Annealing of primers 60 °C for 45 s 
Step 4; Extension of new DNA strand 72 °C for 45 s 
Step 5; Repeat cycle, multiplying product Repeat stages 2-4 34 times 
Step 6; Final extension 72 °C for 10 min. 
Step 7; Cooling of reaction 4 °C for 1 h 
 
Samples were removed from thermocycler and stored on ice for PCR or stored at -20 °C. 
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2.2.9. PCR optimisation 
Method 
PCR was optimised to yield one product band for each custom primer, i.e. drug transporter under 
investigation.  Optimisation was achieved using a range of primer annealing temperatures, 
increasing volume of cDNA sample and addition of dimethyl sulfoxide; DMSO (0.25 µL).  For all ABC 
transporter and PEPT transporter primers, the annealing temperature was increased to 61 °C.  
Addition of DMSO was included for OAT transporter primer PCR reactions and the volume of cDNA 
was increased by 1 µL for Amino acid transporter primer reactions. 
2.2.10. Agarose gel electrophoresis 
Overview 
Agarose gel electrophoresis works on the principle of protein charge or size.  Nucleic acid molecules 
are separated by applying an electric field to move the negatively charged molecules through an 
agarose matrix. Shorter molecules move faster and migrate farther than longer ones because 
shorter molecules migrate more easily through the pores of the gel. This phenomenon is called 
sieving.  Proteins are separated by charge in agarose because the pores of the gel are too large to 
sieve proteins. 
Gel electrophoresis uses the gel as an anticonvective medium and/or sieving medium during 
electrophoresis.  The gel suppresses the thermal convection caused by application of an electric field 
retarding the passage of molecules [127]. 
Materials 
Consumables 
 Agarose, (Bioline, London, UK, Cat: bio-41025) 
 Tris (hydroxymethyl) aminomethane; Tris, (Fisher scientific, Loughborough, UK, Cat: 
 T/P630/60) 
 Boric acid, (Fisher scientific, Loughborough, UK, Cat: B/3750/60) 
Disodium ethylenediaminetetraacetic acid; Na2EDTA.2H2O, (Fisher scientific, Loughborough, 
UK, Cat: D/0700/53) 
 Ethidium bromine; EtBr, (Pharmacia biotech, Buckinghamshire, UK, Cat: 17-1328-01) 
 Bromophenol blue, (Pharmacia biotech, Buckinghamshire, UK, Cat: 17-1329-01) 
 Hyperladder V, (Bioline, London, UK, Cat: BIO-33031) 
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Method 
PCR products were run on a 2% agarose gel to visualize product bands.  Correct products were 
identified by band size. 
Stock Tris boric acid EDTA (TBE) buffer was prepared by adding the following to 1 L dH2O: 
 54 g Tris 
 27.5 g boric acid 
 3.72 g Na2EDTA.2H2O 
This was diluted 1:10 to give 0.5x buffer concentration. 
To 100 mL 0.5x TBE buffer, 2 g agarose was added.  This solution was heated to dissolve the agarose 
and then left to cool.  While cooling, a gel tank was prepared by taping the ends to create a mold. 
Once the gel solution was cool, 1 µL EtBr was added to allow visualization of the cDNA products by 
UV light.  The gel was poured into the tank mold and a comb added to create lanes for the addition 
of PCR product. 
The gel was then left to set while 0.5x TBE running buffer was prepared through addition of 50 mL 5x 
TBE stock to 450 mL dH2O. 
Once the gel was set it was immersed in running buffer and 10 µL volumes of cDNA samples were 
loaded.  Before sample loading, each cDNA sample was mixed with a trace of bromophenol blue 
which allowed ease of loading and allowed each sample to sink into a gel lane.  A molecular weight 
marker was also loaded for reference. 
Gels were then run by applying 90 V to each electrophoresis tank for 45 min or until bromophenol 
blue could be seen at a point approximately two thirds through the length of the gel. 
Final cDNA sample visualization was undertaken under UV light through use of a Bio Rad Geldoc 
1000 and products identified through band size by comparison to a molecular weight marker. 
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2.3. Results and Discussion 
Below are the results and discussion of RT-PCR expression-based analysis of drug transporter 
proteins in rat lung cell models and whole lung tissue. 
Through use of RT-PCR and agarose gel electrophoresis, the semi-quantitative expression of 46 drug 
transporter proteins, spanning 8 families, was examined in rat lung samples.  The highly conserved 
cytoskeletal protein β-actin was used as a positive control for each set of PCR experiments with 
cDNA and RT-negative reactions serving as negative controls.  Gel electrophoresis signal intensities 
were interpreted in a semi-quantitative manner with a weak signal intensity indicating low 
expression and a strong signal intensity indicating high expression.  Figure 2.3 illustrates typical 
signal intensities and the corresponding expression index assigned, i.e., (-) no expression, (+) low 
expression, (++) moderate expression, and (+++) high expression.  The derived mean mRNA 
expression profiles for each drug transporter family are shown in tables 2.11 to 2.18; individual 
expression profiles can be seen in appendix i. 
 
Figure 2.3 Typical signal intensities and the corresponding expression index assigned i.e. (-) no 
expression, (+) low expression, (++) moderate expression, and (+++) high expression. The mRNA 
signal intensity for each drug transporter was examined and assigned an expression index in order to 
allow semi-quantitative analysis, a weak signal intensity indicating low expression and a strong signal 
intensity indicating high expression within the rat lung. 
2.3.1. Expression analysis of ATP Binding Cassette transporters 
The ATP Binding Cassette (ABC) transporter superfamily is comprised of approximately 50 members 
classified into 7 subfamilies; Families are constructed based upon amino acid structure and domain 
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organization with relatively modest similarity in domain organization between family groups [52].  
Table 2.11 summarises the mRNA expression profile of 12 key ABC transporter members in whole  
rat lung sample, the rat SPOC1 cells,  rat AEII – freshly isolated cells, rat AEII – cells at day 2 of 
culture, and rat AEI-‘like’ cells (day 8). 
Transporter Gene 
Whole 
Lung 
SPOC-1 
AEII – 
Freshly 
Isolated 
AEII – 
Day 2 of 
Culture 
AEI-‘like’ 
Day 8 of 
Culture 
mdr1a 
mdr1b 
ABCB1a 
ABCB1b 
++ 
++ 
+ 
+ 
+ 
+ 
+ 
++ 
+ 
++ 
mrp1 ABCC1 ++ ++ + +++ ++ 
mrp2 ABCC2 - - + + - 
mrp3 ABCC3 + ++ ++ ++ + 
mrp4 ABCC4 + - - - - 
mrp5 ABCC5 +++ + + ++ +++ 
mrp6 ABCC6 ++ - + -/+ + 
CFTR ABCC7 -/+ + + + + 
mrp8 ABCC8 +++ + + - ++ 
White1 ABCG1 ++ ++ ++ +++ +++ 
BCRP ABCG2 + - + + ++ 
β-actin ACTB +++ + ++ ++ +++ 
 
Table 2.11 Expression profile of 12 ATP Binding Cassette transporter family members, profile was 
determined from RT-PCR analysis in pulmonary cell samples.  Transporter expression was 
‘quantitated’ by signal intensity and assigning of an expression index.  Mean data are shown, n=3.  
The corresponding RT-PCR samples visualised by gel electrophoresis can be seen in figure 2.4 and 
illustrate variation in intensity of transporter mRNA expression within the rat lung cell samples 
studied.  
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Figure 2.4 Representative gel electrophoresis images illustrating selected ABC transporter mRNA 
expression in 5 rat lung cell samples.  Each set of RT-PCR reactions included a β-actin positive 
control and an RT-negative negative control to ensure result integrity.  
The present study concentrated on ABC transporters that exhibited potential roles in drug 
absorption and disposition.  Within the ABC-B sub-family, ABCB1/MDR1/P-glycoprotein (P-gp) was 
the only member to be studied.  P-gp was first documented through its over-expression in mutant 
Chinese hamster ovary cells that exhibited resistance to a number of amphiphilic drugs [70].  P-gp 
has an extensive array of transportable substrates which include anti-cancer drugs, antibiotics, 
cardiac drugs, immunosuppressants and steroids and transport these by binding them in the 
cytosolic lipid leaflet of the plasma membrane [128, 129].  P-glycoprotein is expressed in a number 
of biological barriers and organs involved with absorption and disposition such as the blood-brain 
barrier, where P-gp is highly expressed, the intestine, the liver and kidney.  For example, strong 
expression in the liver and kidney is indicative of P-glycoprotein involvement in the removal of toxic 
compounds from cells into the bile or urine [40, 130, 131].   
P-glycoprotein is encoded by two isoforms of the mdr1 gene in rats.  Within the results of this 
chapter, the mdr1a isoform exhibited low expression (all semi-quantitative expression discussed 
here was approximated based upon typical expression intensities displayed in figure 2.3) in all cell 
culture samples and showed moderate expression in whole lung.  In contrast, the mdr1b isoform 
showed low expression in SPOC1 culture and freshly isolated AEII cells but increased in expression 
intensity with time to show moderate expression in both AEII cells at day 2 of culture and AEI-‘like’ 
cells.  Moderate expression was also seen in whole lung (Figure 2.4).  
There exists some literature documenting the expression of P-glycoprotein in the lung.  At both the 
mRNA and protein level, P-gp has been identified in human and rat lung tissue, including crude 
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alveolar tissue, bronchial tissue and nasal mucosa [43, 107-110, 113, 131-133].  The transporter has 
been immunohistochemically localised to both the apical and basolateral membranes of epithelial 
cells of the human lung and has exhibited a similar pattern of localisation in rat lung tissue [58, 134-
136].  Specifically P-gp has been localised to the apical membrane of human ciliated epithelial cells, 
the apical and basolateral membrane of serous cells and the membranes of AEII and AEI-‘like’ cells 
[112, 113].  Within the rat lung, P-gp has also been localised to AEII cells whose phenotype was 
maintained to day 8 of culture and in AEI-‘like’ cells, but interestingly mdr1a and mdr1b isoforms 
have been reported to be absent in freshly isolated AEII samples examined by RT-PCR [113, 137]. 
Overall, the data presented here agrees with current literature evidence; Endter and co-workers 
have also reported P-gp mRNA to be expressed, on average, at low levels in a primary human lung 
cells and a number continuous cell models [104].  This trait was also observed by Bleasby and co-
workers who reported the mRNA of human P-glycoprotein gene, MDR1, to be expressed at a low 
level in lung tissue, the rat isoform mdr1a was, however, found to be expressed at a relatively higher 
level in rat lung samples [69].  The moderate mRNA expression of mdr1b in whole lung has been 
reported by Brady, who examined expression via a DNA assay [138]. 
The ABCC subfamily is one of the larger transporter subfamilies and contains 12 full transporters.   
The most studied transporters of this family are the nine MRP transporters, while other family 
members include the sulfonylurea transporters, SUR1 & 2, and the cystic fibrosis related protein, 
CFTR.  Within this study, the mRNA expression of the MRP transporters mrp 1-7, mrp8 and the CFTR 
(ABCC7) ‘transporter’ were studied.     
Of the ABCC family members, mrp1 exhibited relatively moderate expression in the majority of 
samples (Figure 2.7).  However, in a similar manner to mdr1b, expression intensity of mrp1 increased 
from low expression in AEII freshly isolated cells to a high level of expression in AEII cells at day 2 of 
culture.  MRP1 expression within the lung is well recognised and the transporter is thought to play a 
role in protecting lung tissue from inhaled xenobiotics [43, 114, 139].  There is less literature 
evidence to support the presence of many other MRP transporters within the lung, however, Endter 
and co-workers have shown all 9 MRP transporters to be present at mRNA level in human bronchial 
epithelial cells and human alveolar epithelial cells (AEII and AEI-‘like’) [104].  Similarly, the work of 
Bleasby and co-workers has produced an mRNA expression profile which demonstrates the various 
levels of expression of eight of the MRP transporters in both human and rat lung [69].  However, the 
remaining MRP transporters are thought to have a much more restricted expression profile. 
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Rodent mrp2 was barely detectable (present at only low levels) in both freshly isolated AEII cells and 
AEII cells at day 2 of culture.  Human MRP2 is primarily expressed in the apical membranes of the 
kidney and liver where it effluxes a large number of endogenous compounds and xenobiotics to the 
bile and urine [139, 140].  Within the lung, there is conflicting evidence of MRP2 expression.  Positive 
antibody staining for MRP2 on the apical side of human bronchial epithelium has been reported and 
transporter presence in several lung cell lines including PLC and NHBEC lines has been indicated 
though immunohistochemistry [114, 141].  The work of Endter et al., shows human MRP2 expression 
at moderate levels in the vast majority of lung samples examined including both freshly isolated cells 
and continuously grown cell lines.  The absence of mrp2 from whole lung tissue and the SPOC1 cell 
culture line is puzzling, however, the expression of several MRP transporters has been reported in 
primary lung cells and yet the same transporters have been absent in cell culture models [104].  
Further, MRP2 was the only MRP transporter reported to be absent in human lung through the 
Bleasby et al., expression profiling study [69].  The apparent restricted expression of mrp2 within the 
rat lung could represent a specific role for the transporter within this region.  Rat mrp2 could 
function at apical cell membranes as an efflux transporter to extrude inhaled xenobiotics to the 
airspace, in a similar manner to its proposed function within the kidney and intestine.  The low level 
of expression observed could represent its functional significance behind transporters such as MDR1 
and MRP1.   
Paralleling the observed results of mrp1, the mrp3 product also showed a moderate level of 
expression in the majority of lung cell samples.  Interestingly, as AEII cell sample time in culture 
progressed from freshly isolated through to day 2 and then day 8 of culture, the expression level of 
mrp3 appeared to decrease visually, from a moderate to a low level.  MRP3 has been localised to the 
basolateral membrane of the human intestine and has also been localised to hepatocytes where the 
transporter is thought to have a protective role [138, 139, 142].  There are conflicting results in the 
literature as to the presence of MRP3 in the human lung.  Low levels of MRP3 have been reported in 
total lung RNA and the transporter has been localised to human primary bronchial and peripheral 
epithelial cells [114, 143-145].  In contrast to this, Scheffer and co-workers have reported the 
absence of MRP3 RNA in bronchial epithelial cells creating confusion over the presence of this 
transporter in the lung [43, 133, 135].  In the liver and kidney MRP3 participates in defence by 
eliminating a multiplicity of toxic organic anions and other compounds and could perform the same 
function in the lung.  Recent works have reported MRP3 mRNA expression in a number of cells 
within the lung and Bleasby and co-workers also report moderate expression of mrp3 in rat lung 
samples [69, 104].  Literature evidence in combination with the results of this chapter suggests mrp3 
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to have a wide expression profile within the rat lung where mrp3 could be performing a defensive 
role.   
The mrp4 drug transporter was absent in all lung cell samples examined in this study with the 
exception of whole lung tissue where a low level of expression was seen.  Human MRP4 is 
predominantly expressed in the prostate, effluxing prostaglandins and in the kidney, effluxing drugs 
such as AZT [139, 146, 147].  The transporter is thought to be basolaterally expressed within the 
lung, with van der Deen reporting the presence of MRP4 mRNA in whole lung tissue and bronchial 
epithelia [141].  Chen & Klaassen have also reported presence of this transporter in whole rat lung 
through the use of PCR and oligonucleotide probes [141, 148]. With this current work, mrp4 was 
only present in whole lung samples.  Since the major bronchi were not afforded individual sample 
status within this study, expression in ‘whole lung’ samples could represent expression within 
bronchial epithelia, particularly when combined with reported evidence of human MRP4 bronchial 
expression [141].  This specific lung expression is in contrast to the work of Endter and co-workers 
who reported clear MRP4 expression in human lung bronchial and alveolar epithelial cell samples 
[104]. These conflicting reports could indicate a differing species-specific expression profile for 
MRP4.                           
The fifth member of the ABCC family, mrp5, was expressed at a low level in SPOC1 cells and AEII 
freshly isolated cells with expression in the AE cells increasing in intensity with time in culture to a 
high level by day 8, i.e. AEI-‘like’ cells.  This increase in expression intensity over time could be 
explained by the need for a cell isolated from the lung to establish itself in in vitro culture before 
being fully able to function with regard to transcriptional capability; a decrease in expression 
intensity i.e. mrp1, mrp3, could also be reasoned by the need for cell DNA transcriptional capacity to 
become established.  Further, this result could also mean that a regulatory stimulus is missing in 
culture.  Ideally, if one wished to study the effect of alveolar cell phenotype upon expression then 
the primary AEII cell phenotype should be retained in culture over the same time frame used to 
study the AEI-‘like’ cell phenotype.  This strategy was used by Campbell et al., whilst examining the 
phenotypic dependence upon caveolin-1 expression in alveolar epithelial cells [149].   A high level of 
mrp5 expression was also seen in whole lung samples.  The transporter mrp6 was found to have 
negligible expression in all samples excluding the whole lung, where a moderate level of expression 
was seen.  Similarly, CFTR was also expressed at a low level in all samples including whole lung 
tissue.  The cystic fibrosis conductance regulator protein (CFTR) was also studied here and is unique 
among all ABC transporters as it functions as a chloride ion channel.  Mutations in CFTR form the 
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genetic basis of the pulmonary disease cystic fibrosis (CF), with the ΔF508 mutation (deletion of the 
phenylalanine codon at position 508) attributed to 50-80 % of CF cases in the Caucasian population 
[71].  CFTR has been localised to the apical surface of pulmonary epithelial cells such as ciliated cells, 
Clara cells and AEI cells.  Expression has also been reported in AEII cells and nasal mucosa [150-154].  
The results of this chapter show CFTR to be expressed at low levels in all rat lung cells examined 
suggesting the protein to function as a chloride channel in a number of regions throughout the lung.   
The remaining ABC subfamily investigated was ABCG; specifically ABCG1 and ABCG2 isoforms were 
examined.  The ABCG family is comprised of half-transporters that dimerise to form functional 
transporter proteins.  White1 (ABCG1) was found to be expressed at a moderate level in whole lung 
tissue, SPOC1 cells and freshly isolated AEII cells.  The expression level increased in intensity in the 
alveolar cells with time in culture, where a high level of expression was seen in both AEII cells at day 
2 of culture and AEI-‘like’ cells (day 8 of culture).  The breast cancer resistance protein 
(BCRP/ABCG2) was expressed at low levels in whole lung tissue and both freshly isolated and ‘day 2’ 
AEII cells.  The level of expression increased in intensity where BCRP was found to be moderately 
expressed in AEI-‘like’ cells; again the requirement for stability in transcriptional capacity could be 
attributed to observed results.  BCRP was absent in SPOC1 cells.  ABCG1/White1 is reported to be 
expressed at high levels in tissues such as the thymus, spleen, lungs and brain [155, 156].  ABCG1 has 
been identified in human and rodent lung at RNA and protein level and is important in cholesterol 
efflux and maintaining pulmonary lipid homeostasis [40, 157].  The moderate-to-high levels of 
ABCG1/White1 expression observed in the rat lung cells studied show this transporter to have a 
stable expression profile across the rat lung.  The second ABCG transporter, BCRP, typically shows 
strong expression in the mammary gland, brain and placenta and has also been localised to the 
apical membrane of the liver, kidney and intestine.  Within the lung, BCRP expression has been 
shown to be present in human whole lung tissue, bronchial and alveolar epithelial cells, bronchial 
smooth muscle cells [40, 43, 116].  The results generated here show BCRP to be expressed at mainly 
low levels in all studied lung cells with the exception of SPOC1 cells where the transporter was 
absent. Within the lung BCRP expression could be restricted to more distal regions and would be 
absent from a tracheal cell line such as SPOC1. 
Overall, the mRNA transcript for each ABCC transporter studied exhibited some degree of expression 
within the rat lung.  Notable exceptions include mrp2 and mrp4, which were absent in many of the 
samples examined; the presence of both positive and negative reaction controls served to validate 
the results.  Generally, these results are consistent with the existing literature where transporters 
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MRP1, MRP5, MRP6, and MRP8 are known to be ubiquitously expressed within the body of a 
number of species therefore reasoning the presence of such ABC transporters in the lung [40, 123, 
139, 158-160].   
ATP binding cassette transporters can have a crucial influence upon drugs delivered to the body.  For 
example, transporters ABCB1 (P-gp), ABCC2 (MRP2) and ABCG2 (BCRP), all limit exogenous 
substances and xenobiotics entering the GI tract through the intestine while ABCB1, ABCC1, ABCC2, 
ABCC4, ABCC5 and ABCG2 all act at the blood-brain barrier to protect the central nervous system 
[161].  The influence of transporters upon drug substrates has been exploited in many instances to 
enhance therapeutic action or avoid toxic side-effects.  For example, studies have shown that co-
administration of the P-gp modulator elacridar with the anti-cancer drug doxorubicin can reduce 
doxorubicin-induced concentration dependent drug resistance [161]. 
The presence of drug transporters, including many ABC transporters, within the lung is becoming 
increasingly realised.  ABC transporters that are expressed in the lung may have marked effects on 
drugs delivered to this region. It is notable that many ABC transporters are known to have a very 
broad substrate specificity able to mediate the transport of a range of diverse chemistries. P-
glycoprotein for instance is known to transport hundreds of substrates including; anti-cancer drugs, 
antibiotics, antiemetics, cardiac drugs, Ca2+ blockers, β-blockers, CNS drugs, antihistamines, HIV 
protease inhibitors, immunosuppressants and steroids [103, 162].  Extensive knowledge of the 
expression and localisation of drug transporters within the lung will aid in drug design where 
transporter presence can be factored in to the design process.  In this way, the effects of drug 
transporters upon therapeutic substrates can either be exploited or avoided and a maximal 
therapeutic effect can be achieved. 
The results of this chapter have generated an expression profile of several ABC transporters in the 
rat lung.  Overall, each transporter examined exhibited some level of mRNA expression in the rat cell 
samples.  Extending and confirming the expression profile of important ABC transporters in a pre-
clinical model such as the rat will help to advance knowledge of the effects such transporters have 
on drug disposition, drug excretion, drug toxicity and therapeutic effect.  Knowledge of differences 
within pre-clinical models will aid in the extrapolation of data to humans. 
 
 
  Chapter 2 
69 
 
2.3.2. Expression analysis of Amino Acid transporters 
The Solute carriers comprise 43 families containing approximately 300 members [44].  The amino 
acid transporters are not restricted to one family group but instead span several transporter 
families.  Within this study, members of the SLC1, SLC3, SLC6, SLC7, SLC15, SLC36 and SLC38 families 
were examined.  Table 2.12 summarises the expression of 11 amino acid transporter members from 
the above seven families.   
Transporter Gene 
Whole 
Lung 
SPOC-1 
AEII – 
Freshly 
Isolated 
AEII – 
Day 2 of 
Culture 
AEI-‘like’ 
Day 8 of 
Culture 
rBAT Slc3a1 - -/+ + -/+ - 
SNAT3 Slc38a3 - ++ ++ ++ ++ 
Asc-1 Slc7a10 - - - - - 
ASCT2 Slc1a5 ++ + + + ++ 
Eaac1 Slc1a1 +++ - ++ +++ ++ 
Lyaat1 Slc36a1 -/+ - + ++ + 
SNAT1 Slc38a1 - - - ++ + 
PHT1 Slc15a4 - - - -/+ - 
GLYT2 Slc6a5 - - - + -/+ 
Cat-1 Slc7a1 + ++ + ++ + 
Cat-3 Slc7a3 - - - -/+ - 
β-actin ACTB ++ ++ ++ ++ +++ 
 
Table 2.12 Expression profile of 12 amino acid transporter family members, profile was determined 
from RT-PCR analysis in pulmonary cell samples.  Semi-quantitative analysis of transporter 
expression was undertaken by examining signal intensity and assigning an appropriate expression 
index.  Mean data are shown, n=3.  
The SLC1 transporter family is comprised of five high affinity glutamate transporters and two neutral 
amino acid transporters [163].  Within this study, the mRNA expression of two family members; 
Eaac1 and ASCT2, was examined in rat lung cell samples.  Figure 2.5 represents the corresponding 
gel electrophoresis images obtained. 
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Figure 2.5 Representative gel electrophoresis images illustrating selected amino acid transporter 
mRNA expression in rat lung cell samples.  Each set of RT-PCR reactions included a β-actin positive 
control and an RT-negative negative control to ensure result integrity.  
Eaac1/SLC1A1 functions as a high affinity glutamate transporter and transports substrates, namely L-
glutamate and D- and L-aspartate, by coupling to the electrochemical gradients of Na+, H+ and K+ 
  Chapter 2 
72 
 
[164].  Eaac1/SLC1A1 has been localised to the neurons of the hippocampus, cerebral cortex, 
olfactory bulb, striatum, superior colliculus and thalamus and also to the apical membrane of 
proximal tubules of the kidney [165-168].  Within the rat lung samples studied, Eaac1/SLC1A1 
displayed moderate levels of expression in freshly isolated AEII cells and AEI-‘like’ cells.  High 
expression levels were observed in AEII cells at day 2 of culture and whole lung tissue while 
Eaac1/SLC1A1 was found to be absent in SPOC1 cells.  Within the literature, Northern blot analysis 
has shown Eaac1/SLC1A1 presence in rat and human lung supporting the evidence obtained through 
mRNA expression in this chapter [169, 170].  Absence of Eaac1/SLC1A1 in the SPOC1 sample 
suggests expression to be restricted to more peripheral regions of the lungs however, a lack in 
localisation data within the literature does not allow confirmation of this.   
The SLC1 transporter ASCT2 exhibits a wider substrate range than its family member Eaac1/SLC1A1 
and has been localised to the intestine and kidney where it functions as a neutral amino acid 
transporter [163, 171].  Examining mRNA expression in rat lung cell samples revealed ASCT2 to be 
present at low levels in SPOC1 cells, freshly isolated AEII cells and AEII cells at day 2 of culture.  
Expression intensity increased with time and ASCT2 exhibited moderate expression in AEI-‘like’ cells.   
A moderate level of expression was also seen in whole lung tissue.  ASCT2 cDNA was first isolated 
from mouse testis and was first confirmed in the lung of this animal [172].  Both Northern and 
Western blot techniques have also illustrated ASCT2 expression in rat and mouse lung [173, 174]. 
The SLC3 family consists of only two proteins; rBAT and 4F2hc, neither of which functions as an 
amino acid transporter in their own right; only rBAT was studied.  The rBAT protein functions as the 
heavy subunit of a heteromeric amino acid transporter and was first identified through expression 
cloning in Xenopus oocytes [175].  Predominantly functioning with characteristics representative of 
the amino acid transport system bo,+, (mediated by heteromeric amino acid transporters), rBAT has 
been localised to the apical plasma membrane of epithelial cells of the intestinal mucosa and renal 
proximal tubule and has also been reported in the brain, pancreas and liver [150, 154, 164, 176-182].  
Investigation of the mRNA expression of rBAT in rat lung cells revealed negligible expression levels in 
all samples, except freshly isolated AEII cells where rBAT was expressed at a low level.  Through the 
formation of a heterodimer with bo,+AT (SLC7A9), rBAT functions as the primary re-absorption 
system for cystine in the kidney and has been localised to microvilli of the straight and convoluted 
proximal tubule of human, mouse and rat [175, 177, 183].  Literature evidence documenting rBAT 
expression in the lung is scarce.  While there is little direct evidence available, a splice variant of 
rBAT has been reported to be absent from the human lung [184].  Within the rat lung, rBAT was 
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positively expressed at a low level in only freshly isolated AEII cells which could suggest a very 
narrow expression range for this transporter protein.  The rBAT protein, in heterodimeric form, is 
recognised as being responsible for cystine re-absorption, suggesting this to be the transporter’s 
function.  Within the lung, several mechanisms for cystine transport have been identified, including 
system XAG and system XC.  It is thought that, in a Na
+ independent manner, cystine transport occurs 
by system Xc or system b
o,+ (of which rBAT is involved); rat bo,+ mRNA has been reported to be absent 
from rat lung by Northern blotting [176, 185].  The rBAT protein could be present at minimal levels 
within the rat lung and not function as a cystine transporter due to the absence of bo,+AT.  Further, 
the association of the rBAT protein with cystine transport could provide an explanation for the 
presence of rBAT in freshly isolated AEII cells.  The type I alveolar epithelia of the lung are 
particularly vulnerable to hyperoxic damage and are replaced by the more rapidly proliferating AEII 
cells that then differentiate to AEI cells.  The presence and continual synthesis of the antioxidant 
glutathione (GSH) within the AEII cells is very important to avoid hyperoxia-related lung damage, 
however, in order to maintain GSH levels, the lung is dependent on an extracellular supply of 
cysteine [186].  The availability of cysteine is the rate-limiting step in GSH synthesis [187] and 
because cysteine is readily oxidised to cystine, the transport of cystine is fundamental in the 
maintenance of cellular GSH levels and the avoidance of lung damage [185].  While it is unlikely that 
rBAT is responsible for cystine transport within alveolar epithelia (due to the absence of rat bo,+), the 
protein could simply be present because it was once part of a functioning system bo,+ transport 
system within the lung.  With no literature evidence to support these assumptions, together with 
the absence of rBAT in all other rat lung samples, they remain purely speculation. 
The SLC7 family transporter, Asc-1, was absent from all studied rat lung cell samples. Typically, Asc-1 
is expressed in the brain, lungs, small intestine and placenta and functions as a transporter of small 
neutral amino acids such as L-alanine, L-serine and L-cystine, [188].  Expression of Asc-1 at an mRNA 
level has been reported in mouse and human lung rendering the observations of this study a 
surprising result [188-190].  Each PCR reaction included both a positive and negative control 
suggesting the absence of Asc-1 in rat lung to be a true observation rather than an artifact of poor 
PCR.  Due to the existence of many different amino acid transporters, it could be possible that the 
role of Asc-1 in this rat species is taken over by another protein which could explain absence of Asc-1 
in the samples studied.   
Many of the other amino acid transporters also exhibited negligible expression levels or were found 
to be absent in the majority of samples.  The neuronal glycine transporter GLYT2, which functions to 
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control the accessibility of the neurotransmitter to glycinergic synapses, the peptide/histidine 
transporter, PHT1 and Cat-3, which functions to transport cationic amino acids independent of 
sodium [191], were absent in all lung samples with the exception of AEII cells at day 2 of culture.  
Additionally, both Lyaat1 (lysosomal amino acid transporter) and SNAT1 (sodium-coupled neutral 
amino acid transporter) displayed a pattern where expression was not observed or observed at low 
levels in all other cell samples and yet displayed moderate levels in ‘day 2’ and ‘day 8’ samples of 
alveolar epithelia.  This observation of predominant expression in either the AEII cells at day 2 of 
culture or AEI-‘like’ cells could be the result of a burst of mRNA expression; either in preparation for 
or as a result of cell differentiation.  Both GLYT2 and Cat-3 are reported to be restricted to the CNS of 
adult human or adult mouse and rat.  Both transporters, however, are known to be widely expressed 
during embryonic development and therefore could be functionally active during the differentiation 
of AEII cells to AEI-‘like’ cells [120, 192, 193].  The transporters PHT1, Lyaat1 and SNAT1 have all 
been reported to be present in the lung of either human, rat or mouse.  Expression limited to 
alveolar epithelium could represent a restricted expression profile for these transporters within the 
rat [190, 194-196].    
The remaining amino acid transporter proteins studied in this section exhibited, overall, modest 
expression profiles.  The SLC7 family transporter, Cat-1 showed low levels of expression in whole 
lung and freshly isolated AEII cells with expression increasing with time to a moderate level in AEII 
cells at day 2 of culture.  Expression levels decreased to a low level with continuing time in culture 
i.e. as the AE II cell took on the characteristics of AEI-‘like’ cells.  A moderate Cat-1 expression level 
was seen in SPOC1 cells. Cat-1 acts as a major system y+ transporter in most cells and is thought to 
be ubiquitously expressed; system y+ is a sodium-independent, basic amino acid transport system 
which favours amino acids such as lysine, arginine and ornithine [188, 197, 198].  Within the lung, 
Cat-1 has been localised to human and rodent lung in RT-PCR and Western blot studies [199].  Cat-1 
has also been found in human and rodent alveolar macrophage and is involved in the production of 
nitric oxide through system y+ stimulation [200].  The final transporter SNAT3 was found to be 
expressed at a moderate level in all studied lung samples with the exception of whole lung where 
the transporter was found to be absent.  Traditionally SNAT3 functions as a sodium-coupled neutral 
amino acid transporter and is known to be expressed in brain astrocytes, adipose tissue, skeletal 
muscle tissue, and within the liver, kidney and heart [122, 201-203].  Within the lung, SNAT3 has 
been shown to display a low mRNA signal in human lung, supporting results observed in the rat lung 
cell samples studied here [190].  
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Overall, each of the amino acid transporters studied exhibited an observable level of expression 
within the rat lung.  Given the critical importance of amino acids, expression within the lung of at 
least one of the studied transporters is not surprising.  The generated mRNA expression profile 
indicates few of the transporters to have comparatively strong expression in the lung areas studied, 
nevertheless, a discernable pattern of mRNA expression within alveolar epithelium was noted 
allowing these transporters to represent either a viable target or obstacle for pulmonary drugs 
systemic delivery; note -  many drugs delivered via inhalation are for local targets, i.e. treatment of 
asthma, COPD, and therefore would target submucosal tissues of the conducting airways and not 
the alveolar epithelium.  Several amino acid transporters have already presented themselves as 
therapeutic targets.  For example, cationic amino acid transporters, such as Cat-1, which was 
observed at moderate levels in the rat lung, are capable of transporting nitric oxide synthase (iNOS) 
inhibitors [188].  In situations such as chronic inflammation, where iNOS activity could be 
detrimental, transporters such as Cat-1 present themselves as a potential drug target [188].  The 
lysosomal amino acid transporter, Lyaat1, is responsible for the intestinal absorption of orally 
administered D-serine and D-cycloserine which are used for treatment of affective disorders, such as 
bipolar disorder and schizophrenia [204, 205].  Lyaat1 has a known tissue distribution in the lung and 
was expressed at low-to-moderate levels in the rat lung samples, therefore,  delivery of Lyaat1 
substrates of potential therapeutic interest to the lungs could be an attractive target and provide 
improved bioavailability and therapeutic action for novel drugs [206].   
The lack of strong lung expression from any of the amino acid transporters studied creates 
uncertainty surrounding the impact of the examined transporters on drug discovery and delivery to 
the lung, however, this family of transporters provide obvious potential within the field of drug 
discovery and should be factored in to a drug design rationale when targeting the pulmonary system 
for delivery.   
2.3.3. Expression analysis of Glucose transporters 
Research into the glucose transporter family began in the mid 1980’s, prompted by investigations 
into the facilitated diffusion of glucose across plasma membranes, which began more than a decade 
before [207, 208].  Glucose transporters belong to the SLC2 transporter family and account for 12 of 
the 13 family members.  Each transporter consists of a 12 transmembrane domain structure which 
has the capacity to transport glucose and other hexoses across the plasma membrane in a direction 
imposed by the electrochemical gradient of the substrate [209].   The first glucose transporter to be 
discovered, GLUT1, was cloned from a human hepatoma cell line and is the most intensely studied 
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family member, it is  thought to act as the primary glucose transporter in a large number of cells 
[210].  The second family member, GLUT2, was first described through cloning from a human liver 
cDNA library using a GLUT1 probe.  GLUT2 functions as a high affinity glucosamine transporter but 
also has the capacity to transport glucose, galactose, mannose and fructose [209].  Other 
transporters considered in this study include the rat orthologs of GLUT4, which has been cloned 
from human, rat and mouse tissues, and is a transporter of both glucose and glucosamine, GLUT5, 
which was isolated from human, rat and rabbit intestinal tissue, and functions as a fructose 
transporter and finally GLT-1, which belongs to the Slc5 family and is a sodium-dependent glucose 
cotransporter [209, 211].   
Table 2.13 displays typical expression signals for each glucose transporter in 5 rat lung cell samples. 
 
Table 2.13 Expression profile of 5 glucose transporter members; expression profile was determined 
from RT-PCR analysis in pulmonary cell samples.  Semi-quantitative analysis of transporter 
expression was undertaken by examining signal intensity and assigning an appropriate expression 
index.  Mean data are shown, n=3.    
Each of the glucose transporter family members exhibited poor/insufficient expression in all lung cell 
samples.  Illustrated in figure 2.6 are the gel electrophoresis images obtained which proved to be 
difficult to document and ‘quantify’ in relation to an expression index.  
Transporter Gene 
Whole 
Lung 
SPOC-1 
AEII – 
Freshly 
Isolated 
AEII – 
Day 2 of 
Culture 
AEI-‘like’ 
Day 8 of 
Culture 
Glut1 Slc2a1 - + + + + 
Glut2 Slc2a2 - ++ - - - 
Glut4 Slc2a4 - -/+ - - - 
Glt-1 Slc5a1 - -/+ - - - 
Glut5 Slc2a5 - -/+ - - - 
β-actin ACTB ++ +++ ++ +++ +++ 
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Figure 2.6 Representative gel electrophoresis images illustrating mRNA expression of selected 
Glucose transporters in 5 rat lung cell samples.  Each set of RT-PCR reactions included a β-actin 
positive control and an RT-negative negative control to ensure RT-PCR reaction/result integrity.  
Noteworthy is the presence of Glut1 in all samples at an expression index of low; except in whole 
lung samples where this transporter was absent.  Glut1 is thought to have ubiquitous expression, 
transporting glucose to provide metabolic energy, and has been shown to be highly expressed in the 
blood-brain barrier [209, 212, 213].  Within the lung, glucose transporters function to maintain a low 
glucose concentration in airway surface liquid, contributing to pulmonary host defences [214].  Glut1 
has been reported in human lung tissues by use of Western blotting, immunohistochemistry and RT-
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PCR [215-217] and in freshly isolated rat AEII cells through RT-PCR [218].  The results obtained within 
this chapter are comparable to those reported in the literature; however, this study indicates an 
absence of Glut1 in rat whole lung samples.  Given the positive results obtained for Glut1 in all other 
lung samples and the evidence of Glut1 lung expression in the literature, experimental error could 
explain the transporter’s absence seen here.  It is possible that such a result could be explained by 
the very high number of cell types within whole lung tissue not all of which will express a particular 
transporter.  All other results indicate transporter absence, with negligible expression in few cases.  
The positive control β-actin showed good expression in all samples suggesting that the lack of 
transporter expression was not an artifact of poor PCR. 
Unlike Glut1, the second glucose transporter, Glut2, has a more specific profile and is known to be 
expressed in the basolateral membrane of both intestine and kidney epithelial cells [219].  Glut2 
expression has also been noted in human airway and pulmonary epithelial cells through RT-PCR and 
mRNA expression [214, 217].  This chapter’s results illustrate the presence of Glut2 in the SPOC1 cell 
model while the transporter was found to be absent from all other lung cell samples.  The SPOC1 cell 
line is derived from rat tracheal goblet cells and acts as a mucus secreting cell model [75].  Mucin, of 
which glucosamine is a known precursor [220], would be present in this cell line.  Glut2 functions as 
a high affinity glucosamine transporter and could therefore be present in the tracheal airway region 
to function as a glucosamine transporter and facilitate mucin production.  Due to this functional 
activity, it is likely that Glut2 mRNA be expressed at a detectable level in SPOC1 cell samples and yet 
be absent from all other lung samples.  As a consequence of the suggested specific localisation of 
Glut2 within the lung, overall mRNA expression for this transporter within a whole lung sample 
would attribute to a very small percentage of the total mRNA present resulting in an insufficient 
concentration of specific template mRNA for PCR amplification.    
Of the remaining glucose transporters studied here, Glut4 has been localised to both brown and 
white adipose tissue, skeletal and cardiac muscle and is the major transporter of glucose in these  
regions [209].  Glut5 is thought to be expressed mainly in the jejunal region of the small intestine, 
low mRNA levels have also been detected in kidney, skeletal muscle and blood-brain barrier [209, 
221].  Finally, GLT-1 has been localised to the proximal tubule of nephrons, acting as a sodium-
glucose symporter in this region [211].  There exists conflicting evidence regarding the expression of 
these transporters within the lung.  Mamchaoui and co-workers have reported detection of Glut4, 
Glut5 and GLT-1 in freshly isolated rat AEII cells through RT-PCR, while these same transporters were 
not detected in other studies through Western blotting and immunohistochemistry in human, rat 
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and rabbit lung [215, 218].  Given the conflicting results within the literature it is difficult to interpret 
the results seen here, however; known presence of Glut1 and Glut2 in the lung and the documented 
specificity of Glut4, Glut5 and GLT-1 in other regions suggest the results obtained for these 
transporters to be true observations.   
The presence of glucose transporters in the lung opens up possibilities for targeting these 
transporters and thus maintaining blood-glucose levels via the inhalation route, however, with 
regards to the impact of such transporters upon drug discovery it seems unlikely that there would be 
major therapeutic implications given the specific substrate nature of these transporters and the 
apparent absence of expression in the lung of a number of glucose transporters.  
2.3.4. Expression analysis of Monocarboxylate transporters 
Investigations into the existence of monocarboxylate transporters first began in the early 1990’s 
soon after the discovery that the transport of lactate and pyruvate could be inhibited.  To date there 
are 14 family members who each share a common 12 transmembrane domain structure and have a 
unique tissue distribution [222].  Monocarboxylate transporters play an essential role in cellular 
metabolism through rapid transport of substrates, such as lactate, in association with the transport  
of a proton [223].  Of the transporters studied here, MCT1 has been most extensively researched.  
MCT1 can transport a number of substrates such as pyruvate and ketone bodies, but most 
importantly, lactate.  The transport of lactate by this transporter is essential and prevents both the 
decrease of cytosolic pH and the inhibition of glycolysis [224].  Of the remaining monocarboxylate 
transporters studied here MCT, which is also known as MCT8 in humans, is thought to be linked to 
the transport of the thyroid hormones thyroxine and triiodothyronine, while Mct7B or MCT7 in 
humans is a known orphan transporter, that is, a transporter that has no defined substrates or 
functions to date [224]. 
Table 2.14 summarises the expression of each of the three monocarboxylate transporter members 
in the lung cell samples examined.   
Transporter Gene 
Whole 
Lung 
SPOC-1 
AEII – 
Freshly 
Isolated 
AEII – 
Day 2 of 
Culture 
AEI-‘like’ 
Day 8 of 
Culture 
MCT Slc16a2 + ++ +++ ++ ++ 
MCT1 Slc16a1 ++ ++ +++ +++ +++ 
Mct7B Slc16a6 + + +++ ++ ++ 
β-actin ACTB + +++ +++ ++ +++ 
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Table 2.14 Expression profile of 5 Monocarboxylate transporter family members, profile determined 
from RT-PCR analysis in 5 pulmonary cell samples.  Transporter expression was determined by 
signal intensity and assigning of an expression index.  Mean data are shown, n=3.  
 
 
Figure 2.7 Representative gel electrophoresis images illustrating selected MCT transporter mRNA  
expression in 5 rat lung cell samples.  Each set of RT-PCR reactions  included a β-actin positive 
control  and  an RT-negative negative control to ensure result integrity.  
As can be seen in figure 2.7, MCT exhibited relatively high expression levels in freshly isolated AEII 
cells.  A decrease to a moderate level of expression intensity was observed with continued culture 
time.  MCT also exhibited a moderate level of expression in SPOC1 cell culture, while only low levels 
were observed in whole rat lung samples.  MCT1 displayed a relatively similar expression pattern to 
MCT (Figure 2.10); however, MCT1 was expressed at a high level in all primary AEII samples.  The 
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final transporter to be studied in this group was the transporter Mct7B.  This transporter exhibited 
an almost identical expression to the MCT transporter (Figure 2.10), with the exception of its 
relatively low expression index level in SPOC1 cell culture compared to a moderate level observed 
for MCT.  Within the restrictions of this semi-quantitative approach, the primary cell culture samples 
displayed the highest expression levels for all 3 monocarboxylate transporters.  Conversely, crude 
whole lung samples and the immortalised cell culture model SPOC1 produced only moderate or low 
expression levels for all transporters studied. 
All three studied monocarboxylate transporters were expressed to some degree in each of the 
regions of rat lung examined.  These results are perhaps none too surprising given the knowledge of 
MCT1 involvement in cellular metabolism.  Through Northern and Western blotting, MCT1 has been 
found to be expressed in many human tissues, with expression levels varying in accordance with 
mitochondrial content [222].  The transporter has also been localised to the apical surfaces of many 
tissue in other species including both chicken and rat [198, 222, 225].  Within the lung, this chapter’s 
findings are very comparable to those in the literature.  MCT1 has been reported in hamster lung 
through Northern blotting, immunoblotting and immunofluorescence microscopy [181, 226, 227] 
and in mouse lung through RT-PCR and Western blotting [228].   
Both MCT and Mct7B have been much less extensively researched and there exists little published 
data on these monocarboxylate isoforms.  Within human tissues, MCT8 (rat MCT) is widely 
expressed, with high levels detected in liver and heart, while MCT7 (rat Mct7B) has been found in 
human brain, pancreas and muscle tissue and has given a very faint Northern blot result in human 
lung [229].  While it is very difficult to assume the presence of these MCT transporters in rat lung, 
the suggested ubiquitous expression of MCT8 in humans and the single report of MCT7 expression in 
the lung suggest the results obtained here through RT-PCR to be representative.  Further, several 
other MCT family members have been localised to human lung lending further reasonable support 
to the current findings [230, 231].  Very little is known about these latter transporters and their 
family relation to MCT1 could hint at important cellular functions hence a somewhat ubiquitous 
expression.   
Several monocarboxylate transporters are known to play a role in the transport of relevant drugs 
such as atorvastatin, salicylate and valproic acid [232].  The potential for such transporters to 
interfere with drug discovery through drug substrate interactions does exist.  While there is real 
potential to inhibit the action of monocarboxylate transporters, currently, such inhibitors exert 
major effects on non-intended cellular targets and create devastating effects for cellular and whole 
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organ well being [223].  At present, it appears that the most effective strategy for evading negative 
interactions with monocarboxylate transporters and thus avoiding drug discovery issues would be to 
induce conformational changes in potential transporter substrates and thus prevent an interaction 
with these monocarboxylate transporters. 
2.3.5. Expression analysis of Nucleoside transporters 
Nucleosides, the primary substrate of nucleoside transporters, have a role in a number of biological 
functions including; catalysis, transfer of energy, coenzyme function, blood pressure control, 
regulatory function and mediation of hormone signals [233].  Both purine and pyrimidine 
nucleosides are involved in many cellular processes and some synthetic analogues are known to 
have activity against bacteria, fungi, viruses, yeast and neoplastic tissues [233].  The majority of 
mammalian cells display some level of nucleoside transport and therefore possess one or more 
known nucleoside transporter proteins, all of which possess ability to transport adenosine but differ 
in their ability to transport other nucleosides and nucleobases (nitrogenous base alone) [234]. 
Table 2.15 illustrates the nucleoside transporters studied here and summarises their semi-
quantitative expression as determined by RT-PCR. 
Transporter Gene 
Whole 
Lung 
SPOC-1 
AEII – 
Freshly 
Isolated 
AEII – 
Day 2 of 
Culture 
AEI-‘like’ 
Day 8 of 
Culture 
rENT1 Slc29a1 + + -/+ + + 
Cnt1 Slc28a1 - - -/+ -/+ -/+ 
Ent2 Slc29a2 - - -/+ + -/+ 
Ent3 Slc29a3 + -/+ + ++ ++ 
β-actin ACTB +++ +++ +++ +++ +++ 
 
Table 2.15 Expression profile of 4 Nucleoside transporter family members; transporter expression 
profile was determined from RT-PCR analysis in 5 pulmonary cell samples.  Expression was semi-
quantitated assigning an expression index to signal intensity.  Mean data are shown, n=3. 
  
Nucleoside transporters belong to two SLC families; SLC28 and SLC29.  The SLC28 family has 3 
members, each of which acts as a sodium-dependent concentrative transporter.  These proteins are 
membrane bound and actively transport natural and synthetic nucleosides into cells along a sodium 
gradient.  Cnt1, the only concentrative nucleoside transporter studied here, is the first member of 
the SLC28 family and acts primarily as a pyrimidine transporter, having a higher affinity for these 
nucleosides.  Cnt1 also has a number of pharmaceutically relevant substrates including AZT, 
zalcitabine, cytarbine and gemcitabine thus playing an important role in the treatment of leukaemia, 
  Chapter 2 
83 
 
HIV and several tumours [235].  Cnt1 has been shown to be expressed in rat intestine and kidney 
through Northern blot analysis with RT-PCR also displaying Cnt1 expression in the brain [236, 237].  
Within the rat lung Cnt1 was absent or negligibly expressed in the majority of samples (Table 
2.15/Figure 2.8).   
The SLC29 family contains 4 members, all functioning in the facilitated diffusion of nucleosides, 3 
members are considered here.  ENT1 (rENT1 in rats) was the first identified equilibrative nucleoside 
transporter and is known to be crucial in nucleotide synthesis.  This transporter has a broad 
substrate range, capable of transporting a number of purine and pyrimidine nucleosides [234].  
Within the rat lung cell samples studied, rENT1 displayed negligible or low expression with the 
exception of AEII cells in culture, with expression level increasing with time (Figure 2.8).  The 
remaining proteins studied here, rat orthologs of transporters ENT2 and ENT3, display many 
similarities to ENT1.  Each transporter has comparable substrate specificity to ENT1 mediating, to a 
lower affinity, a wide variety of both natural and synthetic nucleosides and nucleobases [234].  Mean 
expression of these transporters, as determined by assignation of an expression index, can be seen 
in table 2.15.  From this and figure 2.8, it can be seen that Ent2 was absent or negligibly expressed in 
the majority samples, however, did display a low level of expression in primary AEII cells at day 2 of 
culture.  Ent3 exhibited an increase in expression level with time in culture in the primary AEII 
samples but displayed only negligible or low expression in all other samples examined. 
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Figure 2.8 Representative gel electrophoresis images illustrating selected Nucleoside transporter 
mRNA expression in 5 rat lung cell samples.  Each set of RT-PCR reactions included a β-actin 
positive control and an RT-negative negative control to ensure result integrity.  
Nucleosides themselves are responsible for a number of actions within the pulmonary system 
including; stimulation of mucus and surfactant secretion and cilliary beating action, contraction and 
relaxation of airway smooth muscles and the modulation of inflammatory cells involved in lung 
disease [238].  Human equivalents of transporters studied here have been localised to a number of 
organ or tissue systems.  For example, mRNA and protein levels of ENT2 have been found in human 
heart, brain, placenta, kidney, pancreas, thymus and skeletal muscle [239-241].  Similarly, ENT3 has 
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been localised to human placenta while ENT1 has been found to be ubiquitously expressed in both 
human and rat with expression levels varying between tissues [240-244].  
Few reports have discussed nucleoside transporter expression within the lung, however, given the 
recognised functions of nucleosides within the lung and the lungs role in removing adenosine from 
the circulation, the presence of more than one such transporter within this organ system is 
predicted [245].  In the early 1980’s Shi and co-workers illustrated the presence of ‘nucleoside 
transporters’ in both rat and guinea-pig lung through high-affinity binding of a transport inhibitor.  
ENT1 expression has been noted in human lung through Northern blot analysis and has been 
immunohistochemically stained in a number of non-small cell lung cancer (NSCLC) biopsies that 
responded to gemcitabine chemotherapy [246-248].  The results of this chapter illustrate selected 
nucleoside transporter expression to exist at low levels within the rat lung.  
Development of an expression profile of nucleoside transporters has the potential to improve the 
efficacy of a number of nucleoside analog drug therapies.  There are a number of therapeutic 
nucleoside analogs in existence for the treatment of conditions such as HIV, AIDS and AIDS related 
infections, a number of cancers and diseases caused by various infectious agents [249].  The 
presence of nucleoside transporters within the lung gives rise to the potential for inhaled 
therapeutic treatments.  As a comparable example, pentamidine, a known nucleotide transporter 
substrate (nucleotide is nucleoside + 1-3 phosphate groups) has been trialed as an inhaled therapy in 
the treatment of P. carinii pneumonia in patients with AIDS.  The nucleoside adenosine is known to 
indirectly provoke bronchoconstriction in asthma patients.  Inhibition of nucleoside transporters 
would minimise adenosine transport and reduce bronchoconstriction in these patients.  Finally, 
stimulation of calcium channels by inhaled ATP and uridine triphosphate (UTP) could help in 
hydrating the hypophase of CF patients [250].   
The presence of nucleoside transporters within the lung opens up many therapeutic possibilities 
however; to fully exploit this, transporter activity within the lung should be further examined.  Only 
low levels of nucleoside transporter expression were observed in this study, suggesting perhaps 
nominal impact of these nucleoside transporters on drug discovery of inhaled nucleoside drugs 
therapies.   
2.3.6. Expression analysis of Peptide transporters 
The proton-coupled oligopeptide transporter family contains 4 peptide transporter genes designated 
SLC15A1 to SLC15A4.  Of the corresponding proteins, members PEPT1 (Pept1 in rat) and PEPT2 
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(Pept2 in rat) have been thoroughly investigated while the remaining members are relatively 
unknown.  Both PEPT1 and PEPT2 act as integral membrane proteins capable of transporting a large 
number of short chain peptides along a proton gradient [251].  PEPT1, characterised as the intestinal 
isoform, is a low affinity, high capacity transporter, absorbing peptide fragments created by food 
digestion.  PEPT2 acts as a renal isoform, and has a higher affinity yet lower capacity for its 
substrates.  This isoform (PEPT2) has major importance in the reabsorption and renal handling of 
peptide substrates and peptide-mimetic drugs [252].  Due to their promiscuous nature, both 
isoforms have the potential to transport every di- and tri- peptide, resulting in a potentially large 
number of therapeutic compounds acting as substrates for these transporters.  Such drug substrates 
include; β-lactam antibiotics (e.g. cyclacillin), cephalosporins (e.g. cefibuten), angiotensin-converting 
enzyme inhibitors (e.g. captopril), peptidase inhibitors (e.g. bestatin), receptor antagonists (e.g. 
sulpiride), novel prodrugs (e.g. enalapril) and other peptide-mimetic drugs (e.g. valacyclovir), 
suggesting peptide transporters to be very important in drug discovery [251, 253]. 
In this study the pulmonary expression of the two major rat peptide transporter orthologs was 
examined in 5 lung cell samples.  Table 2.16 summarises the expression of these transporters in 
whole lung, SPOC1 cells, AEII – freshly isolated cells, AEII – cells at day 2 of culture, and the AEI-‘like’ 
cells.   
Transporter Gene 
Whole 
Lung 
SPOC-1 
AEII – 
Freshly 
Isolated 
AEII – 
Day 2 of 
Culture 
AEI-‘like’ 
Day 8 of 
Culture 
Pept1 Slc15a1 - - - - - 
Pept2 Slc15a2 ++ ++ ++ ++ ++ 
β-actin ACTB +++ +++ +++ +++ ++ 
 
Table 2.16 Expression profile of 2 Peptide transporter family members; transporter expression profile 
was determined from RT-PCR analysis in 5 pulmonary cell samples.  Expression was semi-
quantitated assigning an expression index to signal intensity.  Mean data are shown, n=3.  
 
The transporter Pept1 was found to be absent in all studied samples (Figure 2.9).  The positive 
control, β-actin, was present at a high level in all samples except the AEI-‘like’ sample where the 
positive control gene was moderately expressed.   The second transporter studied, Pept2, was 
expressed at a moderate level in all samples, again figure 2.9 demonstrates this observed expression 
profile. 
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Figure 2.9 Representative gel electrophoresis images illustrating selected Peptide transporter mRNA 
expression in 5 rat lung cell samples.  Each set of RT-PCR reactions included a β-actin positive 
control and an RT-negative negative control to ensure result integrity.  
The expression profile of both PEPT1 and PEPT2 is well documented, with the observations of this 
study mirroring those reported in the literature, supporting the documented expression profile of 
peptide transporters within the lung and adding knowledge to help combat the potential problems 
facing drug discovery is this area.  PEPT1 is known to possess a narrow expression profile, mainly 
localising to the apical plasma membrane of enterocytes in the small intestine [254].  The 
transporter has also been localised in the liver, kidney and pancreas of humans and a number of 
small mammals [121, 255, 256].  The localisation of PEPT1 in the small intestine renders this 
transporter the primary mechanism for transport of peptides and peptide-mimetic drugs that are 
delivered orally.  While this has the potential to be advantageous to drug discovery, providing a 
target with the capacity to alter an ‘oral’ drug’s systemic exposure, the transporter also has the 
capability to negatively influence a drugs absorption profile and create toxicity issues [253].       
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Both PEPT1 and PEPT2 transporters have significant pharmacological relevance; they are able to 
transport a wide variety of compounds and therapeutic agents to treat a number of conditions such 
as AIDS (saquinqvir), hypertension (captopril) and cancer (bestatin) [257].  The rational design of 
compounds that possess improved oral bioavailability through utilising, for example, PEPT1 as an 
absorption mechanism could well improve many therapeutic treatments.  PEPT1 represents an 
excellent target for enhancing absorption, not only due to its location but also by its potential 
substrates.  Rational design of nucleoside analog antivirals to target CNT/ENT drug transporters and 
thus increase cellular uptake have already yielded successful antiviral drugs via this rationale [249].  
With advances in combinatorial peptide libraries, peptide synthesis strategies and peptidomimetic 
drug design, there is excellent potential for this route to contribute to ever-improving therapeutic 
treatments [257].   
In contrast to PEPT1, PEPT2 holds a more diverse expression profile, being found in kidney tubular 
cells, brain astrocytes, mammary glands, both bronchial and type II alveolar epithelial cells and the 
epithelial cells of the choroid plexus [39, 222, 258].  Within the lung, there is considerable evidence 
supporting the expression of PEPT2.  Groneberg and co-workers have illustrated PEPT2 expression in 
AEII cells, bronchial epithelial cells and the endothelial cells of small vessels through RT-PCR, 
Northern blotting and immunohistochemistry [259].  RT-PCR has also been used to show PEPT2, but 
not PEPT1 expression in human lung tissues, while Bhahadduri et al., have used the technique along 
with Western blotting to illustrate presence of functional PEPT2 in primary human lung cultures 
[260-262].   
PEPT2 also has the potential to influence a therapeutic agent’s absorption and distribution.  For 
example, presence of this transporter in the choroid plexus results in transport of substrates (e.g. 
leptin, growth hormone) from plasma to cerebral spinal fluid [263] affecting regional 
pharmacokinetics [252].   
Due to its low proteolytic activity and ability to bypass hepatic metabolism, the lung represents a 
very attractive route of delivery for therapeutic peptides and peptide-mimetic drugs.   For example, 
the presence of PEPT2 in the lung signifies this transporter as a novel target for delivery of 
antibiotics to the lumen, such as cefadroxil, to treat Gram positive and Gram negative pulmonary 
infections [259]. Further, the work of Groneberg et al., illustrated a similar pattern of PEPT2 
expression in both normal and cystic fibrosis lung [39].  Up to 90 % of lung infections in CF are 
caused by the bacteria Ps. aeruginosa.  This bacterium is very difficult to treat traditionally due to 
high intrinsic antibiotic resistance.  Antimicrobial peptides (AMP) represent an extremely attractive 
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therapy to treat this and other infections as they are fast acting, bactericidal and active against 
multi-drug resistant bacteria.   Theoretically, delivery of AMPs to the lung would allow treatment of 
pulmonary infections without the use of resistance causing antibiotics and allow avoidance of 
hepatic metabolism, thus creating a highly bioavailable therapy delivered directly to the target site 
[264]. 
Pulmonary localisation of PEPT2 combined with available literature evidence suggests the peptide 
transporter to be an excellent therapeutic target within the lung.  Developments of rationally 
designed substrates to target this transporter have the potential to yield excellent drug therapies for 
both local and systemic action.  However, due to this transporter’s highly promiscuous substrate 
profile and widespread expression, altered drug exposure and toxicity issues should also be 
examined. 
2.6.7. Expression analysis of Organic cation transporters 
Organic cation transporters (OCT) are members of the SLC22 family, belonging to a major facilitator 
superfamily which is comprised of uniporters, symporters and antiporters.  Members of this family 
act as polyspecific transporters capable of transporting charged monoamines, small organic cations 
and weak bases.  Many organic cation transporters contain overlapping binding sites allowing access 
to a number of substrates from both sides of the plasma membrane.  OCT1-3 mainly act as 
transporters of organic cations and weak bases, transporting these substrates  in a reversible 
manner independent of Na+, while OCTN1-3 have a more ambiguous substrate specificity and 
function as zwitterions/cation co-transporters [265-267]. 
The first identified transporter of the SLC22 family was cloned from rat in 1994 [268].  Since then 
OCT1 has also been isolated from mouse, rabbit and human [268-271] and acts as a transporter of 
organic cations and weak bases.  Transporter substrates include many drugs, such as acyclovir and 
metformin and also endogenous substrates, such as serotonin and prostaglandins [267].  The second 
member of this subgroup, OCT2, was identified in 1998 [272] and has been successfully cloned from 
rat, human, mouse, rabbit and pig [269, 270, 272].  OCT2 has very similar substrate selectivity to 
OCT1 and shares 70% sequence similarity with this protein.  The final transporter to be studied in 
this current work acts as a Na+-carnitine co-transporter and was cloned in 1998 [273].  OCTN2 has a 
high affinity for carnitine and is responsible for its absorption from the kidney proximal tubule.  
OCTN2 can also transport a number of substrates independently from Na+ including verapamil, 
choline and quinidine [274, 275]. 
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Transporter Gene 
Whole 
Lung 
SPOC-1 
AEII – 
Freshly 
Isolated 
AEII – 
Day 2 of 
Culture 
AEI-‘like’ 
Day 8 of 
Culture 
Oct1 Slc22a1 -/+ - + + -/+ 
rOCT2 Slc22a2 - - - - - 
OCTN2 Slc22a5 + ++ + ++ ++ 
β-actin ACTB  ++ +++ +++ +++ +++ 
 
Table 2.17 Expression profile of 3 organic cation transporter family members where expression 
profile was determined from RT-PCR analysis in 5 pulmonary cell samples.  Expression was 
‘quantified’ by signal intensity and assigning of an expression index.  Mean data are shown, n=3. 
 
Table 2.17 summarises the expression of the 3 organic cation transporters; Oct1 (OCT1 in human), 
rOCT2 (OCT2 in human) and OCTN2; transporter expression was examined in 5 different lung cell 
samples.  OCTN2 displayed a relatively low level of expression in freshly isolated AEII cells, which 
increased to a moderate level over time.  This moderate level of expression was noted in both AEII 
cell samples at day 2 of culture and AEI-‘like’ cells at day 8 of culture (Figure 2.10), rOCT2 was absent 
or expressed at a negligible level in all lung samples studied while OCT1 was clearly expressed, 
although at only a low level in all samples. 
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Figure 2.10 Example gel electrophoresis images illustrating chosen OCT transporter mRNA 
expression in 5 rat lung cell samples.  Each set of RT-PCR reactions included a β-actin positive 
control and  an RT-negative negative control to ensure result integrity.  
 As can be seen from figure 2.10, both Oct1 and OCTN2 were visualised in the lung samples studied 
while rOCT2 was consistently absent.  Traditionally, OCT1 expression has been observed in liver, 
kidney, small intestine, colon and spleen [270].  More specifically, the transporter has been localised 
to the submucosal and myenteric plexuses of mouse intestine through RT-PCR and 
immunohistochemistry [276], to the basolateral membrane of rat kidney proximal tubules by use of 
in situ hybridisation [277] and immunohistochemistry and by RT-PCR to both human and rat primary 
hepatocytes [278].  There exists conflicting results with regards to OCT1 expression within the lung.  
Both Pavlova and co-workers and Zhang and co-workers have conducted Northern blot analysis of 
human lung tissue and have noted the absence of OCT1 [271, 279].  However, several studies have 
also illustrated this transporter to be present within the lung.  The OCT1 transporter has exhibited a 
low level of lung expression through RT-PCR, Northern blotting and immunohistochemistry [119, 
280] and has been successfully localised to the apical membrane of ciliated epithelium in mice [280, 
281], [282] and to the airway epithelium and alveolar macrophage of mouse and rat [282, 283].  This 
current work showed consistent Oct1 expression, albeit at a low level, in AEII – freshly isolated and 
day 2 AEII cells.  Documented localisation of this transporter to ciliated cells and alveolar 
macrophage coupled with reported absence in other studies suggests OCT1 to have a restricted 
localisation within the lung.  Concurrent with this suggested narrow expression profile, results here 
documenting absence in ‘whole lung’ samples could be the result of a low template concentration 
for PCR amplification.  Variation (i.e. no consistency in harvesting of the trachea with lung tissue) in 
lung harvest procedures resulted in the absence of the trachea in some ‘whole lung’ samples and 
therefore could have given rise to a lower number of ciliated cells within ‘whole lung’ samples, thus 
providing less Oct1 RNA for extraction and amplification.  If OCT1 truly does display this specific 
expression profile, then Oct1 absence in ‘SPOC1’ samples is not surprising.  The SPOC1 cell model is 
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derived from a denuded rat trachea and does not display ciliated cell differentiation [126].  Presence 
of Oct1 in samples of alveolar epithelia could be as a result of contaminating alveolar macrophage, 
however, as the results obtained here are averaged from three separate isolations and cultures, it 
seems more likely that Oct1 is also expressed at a low level in these cells. 
OCT2 has a similarly broad expression profile to OCT1 and is known to be expressed in kidney, 
placenta, thymus, choroid plexus and neurons of the central nervous system [267].    
Immunohistochemistry, RT-PCR, Northern blotting and in situ hybridization have been used to 
localise this transporter to the neurons of the cerebral cortex [283], the apical membrane of kidney 
distal tubules [269, 272] and a number of subcortical nuclei [284].  There are conflicting reports as to 
OCT2 presence within the lung and the results of this chapter support the absence of rOCT2.  Okuda 
and co-workers report absence of rOCT2 in rat lung through Northern blotting and RT-PCR [272], 
while Kummer et al. also report absence through immunohistochemistry in mouse lung samples 
[282].  Several techniques including Northern blotting, Western blotting, RT-PCR and 
immunohistochemistry have, however, detected OCT2 presence within the lung and localisation to 
ciliated cells of the bronchi and trachea has been reported [119, 279, 281].  In a similar manner to 
Oct1, expression of rOCT2 within a limited cell phenotype could explain absence in the 5 lung cell 
samples examined here.   
The transporter OCTN2, has previously been found in skeletal muscle, heart, kidney and brain and 
has been localised to the brush-border of renal proximal tubules in rat [273, 285-288].  Within the 
lung, Horvath and co-workers have localised OCTN2 to the apical membrane of human epithelial 
cells through immunofluorescence and quantitative RT-PCR [289].  Other studies using RT-PCR have 
also illustrated the presence of this transporter in human and rat lung [280, 283].  The results of this 
chapter also show OCTN2 to be at least moderately expressed in the lung and it is thought that this 
transporter is involved in the absorption of several bronchodilators, such as ipratropium and 
tiotropium, delivered through inhalation [289]. 
In view of conflicting literature, it is difficult to definitively conclude the presence of these OCT 
transporters within the lung.  Documented expression of OCT1 and OCT2 to ciliated cells of the 
airway coupled with the low or negligible expression observed in this study suggests these 
transporters to have a restricted expression profile within ciliated cells of the lung.  Literature 
reports of OCTN2 expression within the lung is supported through the results of this chapter and 
within the scope of this study; it is OCTN2 that presents itself as a transporter that could act as a 
therapeutic target and influence drug discovery and delivery to the lung.   
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The role of organic cation transporters in other organs and tissues is well recognised.  These 
transporters play a crucial part in regulating plasma concentration of organic cations and in 
excretion of organic cations classed as xenobiotic [290].  Both OCT1 and OCT2 are known to affect 
the pharmacokinetics of drug substrates.  For example, variable inter-patient metformin response is 
thought to be linked to OCT1 and OCT2 polymorphisms while renal handling and toxicity of cisplatin 
is critically influenced by OCT2 [291, 292].  Confirmed OCTN2 expression in the lung presents this 
transporter as a rational target for OCT substrates delivered to the lung, there is already reported 
evidence of OCTN2 involvement in the pH dependent uptake of inhaled cationic bronchodilators 
[289].  Conflicting reports of OCT expression within the lung and lack of supporting evidence 
presently rule out OCT1 and OCT2 as targets for rational inhaled drug design.  It seems unlikely that 
these transporters will have significant impact on the absorption of drug candidates delivered to the 
lung.  Definitive expression profiling of OCT transporters within the lung is needed before such 
transporters should be taken into consideration as a rationale for the targeted design of novel drug 
therapies. 
2.3.8. Expression analysis of organic anion transporting polypeptides 
Organic anion transporting polypeptides comprise a sodium-independent transport family that 
facilitates the transmembrane transport of a large number of endogenous and exogenous 
substances.  Many of these organic anions are toxic to the body and elimination is fundamentally 
important [293]. Such a vital physiological role has resulted in the rapid and independent 
identification of many organic anion transporter members leading to confusing gene and protein 
nomenclature where many transporters failed to conform to a continuous numbering system based 
upon consecutive protein identification [294].  Further, the traditional SLC classification did not allow 
species-independent identification of genes and gene products, creating additional confusion where 
a human ortholog to a mouse or rat OAT did not exist.  As a result of this, the SLC21 family was 
reclassified, with the new SLCO family representing a phylogenetically based, species-independent 
and open-ended classification system [46]. 
Generally, organic anion transporting polypeptides function as active transporters through an 
electroneutral and pH dependent anion exchange transport mechanism.  This means that the family 
can mediate bidirectional substrate transport, rendering substrate directionality dependent upon 
the local concentration gradient [295].  The need to remove harmful organic anions has resulted in 
organic anion transporters displaying broad substrate specificity, with most OATPs capable of 
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transporting endogenous compounds such as bile salts, organic dyes, steroid conjugates, thyroid 
hormones and anionic oligopeptides, as well as a number of xenobiotics and drugs [46, 293, 294]. 
A summary of the mRNA expression and generated expression profile of six OAT members in rat lung 
cell samples can be seen in table 2.18 and figure 2.11. 
Transporter Gene 
Whole 
Lung 
SPOC-1 
AEII – 
Freshly 
Isolated 
AEII – 
Day 2 of 
Culture 
AEI-‘like’ 
Day 8 of 
Culture 
Slco1a1/Oatp1 Slco1a1 - - - - - 
Slco1a4/Oatp2 Slco1a4 - - - - - 
Slco3a1/Oatp-D Slco3a1 + + + + + 
Slco4c1/Oatp-H Slco4c1 + - + + + 
Slco4a1/Oatp-E Slco4a1 - ++ + + + 
Slco2b1/Oatp-B Slco2b1 -/+ + + -/+ + 
β-actin ACTB ++ +++ +++ ++ +++ 
 
Table 2.18 Expression profile of 6 organic anion transporting polypeptides as determined by RT-PCR 
analysis in 5 pulmonary cell samples.  Transporter expression was ‘quantified’ by signal intensity and 
assigning of an expression index.  Mean data are shown, n=3. 
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Figure 2.11 Example gel electrophoresis images illustrating selected OATP transporter mRNA 
expression in rat lung cell samples.  Each set of RT-PCR reactions included a β-actin positive control 
and an RT-negative negative control to ensure result integrity.  
 
Of the six OATP transporters studied, both Slco1a1 and Slco1a4 were absent from all lung cell 
samples.  The transporters, Slco3a1 and Slco4c1, displayed a similar pattern of low expression in all 
samples, except for the SPOC1 cell sample, where Slco4c1 was absent.  Again, the Slco4a1 
transporter exhibited a relatively low mRNA level in the majority of samples, however, was found to 
be moderately expressed in SPOC1 cells but absent in whole lung samples.  Finally, Slco2b1 also 
displayed a low level of expression in many of the studied lung cell samples with the exception of 
whole lung and AEII cells at day 2 of culture where only negligible expression levels were observed. 
 Many of the OAT transporters studied here displayed only low levels of expression in the selected 
lung cell samples.  The majority of OATs have a wide expression profile, with documented expression 
in human blood-brain barrier, choroid plexus, heart, intestine, lung, kidney, placenta and testis 
[296].  The results observed in this chapter could represent a basal expression level of the selected 
organic anion transporters within the lung.   
The first of the organic anion transporters studied here, Slco1a1 (previously Oatp1/Slc21a1), acts as 
a transporter of the largest number of amphipathic substrates and has been localised to the 
basolateral membrane of human hepatocytes, the apical membrane of kidney proximal tubules and 
the apical membrane of the choroid plexus [46, 295, 297].  Within the human lung, hOATP1 
presence has been reported through use of Northern blotting [298].  The same technique aided by 
RT-PCR could not identify Slco1a1 in rat lung, instead illustrating specific expression within the 
kidney and choroid plexus [299, 300].  This discrepancy in reported Slco1a1 lung expression could 
illustrate a varying expression pattern between transporter orthologs.  It is difficult to draw 
significant conclusions with regards to Slco1a1 expression profile as there is a lack of reported 
evidence to support either a presence or absence in rat lung.    
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The second transporter to be studied, Slco1a4 (Oatp2/Slc21a5), predominantly transports substrates 
such as thyroid hormones, cyclic peptides and steroid conjugates.  The expression profile of a 
comparable human protein, OATP2/SLC21A6, is restricted to the basolateral plasma membrane of 
hepatocytes which could suggests the rat protein to also exhibit this specific expression profile [46, 
295, 296, 301-303].  The results of this chapter report an absence of Slco1a4 in all lung cell samples 
studied.  Together with the lack of reported evidence of Slco1a4 lung expression, the specific profile 
documented for OATP2/SLC21A6 seems also to be true for the rat protein.   
The third transporter to be researched was Slco3a1/oatp3a1/Oatp-D.  Based on a combination of RT-
PCR experiments, human SLCO3A1/OATP3A1 is known to exhibit ubiquitous tissue expression.  This 
protein displays 97 % sequence identity with both its rat and mouse orthologs.  Together with wide 
tissue distribution, this highly conserved sequence could hint at an important physiological function 
[46, 295].  Within the lung, Northern blot analysis has shown SLCO3A1/OATP3A1 to be moderately 
expressed.  Similarly, this same technique has also shown the rat ortholog Slco3a1 to be expressed 
at a moderate level within the rat lung [46].  The results of this chapter illustrate Slco3a1 to be 
expressed in all lung cell samples studied.  These results complement the knowledge of this 
transporters ubiquitous tissue expression and could illustrate basal expression throughout the lung.         
The forth transporter to be examined was Slco4c1, also known as Oatp4C1/Oatp-H.  The transporter 
forms part of a very small SLCO subfamily, little is known regarding specific substrates or 
physiological function, however, it has been reported that Oatp-H/SLCO4C1 shows tissue 
distribution within the human kidney [46, 295].  Within the lung cell samples studied in this chapter, 
Slco4c1exhibited a low level of expression in all, with the exception of SPOC1 where no expression 
was noted.  The rat transporter could have specific requirements to facilitate its expression which 
could be absent in the SPOC1 cell line, however, due to the distinct lack of literature evidence with 
regards to Slco4c1/Oatp-H expression, this cannot be confirmed.  The results obtained here suggest 
Slco4c1 to be expressed within cells of rat lung parenchyma and not those of the trachea.    
The fifth protein to be studied, transporter Slco4a1 (OATP-E/Oatp4a1), was originally isolated from 
both human brain and kidney but is known to be ubiquitously expressed in all human tissues.  
Human OATP-E/SLCO4A1 shows strongest expression in the liver, heart, placenta and pancreas [304] 
and is capable of transporting a number of important substrates such as taurocholate, thyroid 
hormones T3, T4 and rT3, a number of prostaglandins and steroid conjugates.  The rat protein 
Slco4a1 shows 76 % sequence identity with its human ortholog, it is therefore possible that Slco4a1 
also exhibits a ubiquitous expression pattern.  Within the lung, human OATP-E/SLCO4A1 cDNA has 
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been cloned from adult lung and has also been detected in the lung through RT-PCR [296].  The 
suggested ubiquitous expression pattern of Slco4a1 combined with evidence of human OATP-
E/SLCO4A1 expression within the lung could be reasoned to complement this chapter’s results for 
the Slco4a1 transporter.  Further, ability of Slco4a1 to transport thyroid hormones could add further 
evidence to its presence within the lung as thyroid hormone T3 and plays a role in late lung 
development [305].   
The final transporter to be studied here was Slco2b1, human OATP-B/SLCO2B1.  The human 
transporter is known to be ubiquitously expressed, displaying a decreasing level of expression from 
the liver to the spleen, placenta, lung, kidney, heart, ovary, small intestine and brain [296, 298, 306].  
There is little literature evidence regarding the rat transporter Slco2b1, however, this transporter 
shares 77 % sequence identity to its human ortholog and is known to display similar functionality, 
therefore it seems plausible that Slco2b1 show a similar expression profile to OATP-B/SLCO2B1.  
Tamai and co-workers have illustrated human OATP-B/SLCO2B1 to be expressed at a low level in 
human lung through RT-PCR [296].  This same technique implemented in our study generated 
complementary results suggesting this transporter to be expressed at a low level within the lung.        
Overall, the results of this chapter seem to illustrate a basal level of expression for several OATP 
transporters within the rat lung.  In order to create a definitive expression profile for this family of 
transporters, extensive expression analysis would need to be completed.   
Combining both the available literature evidence and this chapter’s findings, transporters Slco4c1, 
Slco4a1, Slco3a1, and Slco2b1 have the potential to influence drug discovery directed to the lung.  
Organic anion transporters are capable of transporting several pharmacologically relevant drugs 
such as β-lactam antibiotics, non-steroidal anti-inflammatory drugs, antiviral drugs, several drugs 
that are toxic in overdose and neurotransmitter metabolites [297].  Due to the multispecific 
substrate nature of many OATs there is the potential for these transporters to interact with drugs 
delivered to the lung [293].  Drug transporter–drug interactions would affect a drugs 
pharmacokinetics, create potential toxicity and effect therapeutic response [297].  A broad 
transporter substrate spectrum also provides OATs with important roles in drug absorption, 
disposition and elimination [294].  Several OATs are known to influence both pharmacokinetic 
profiles of drugs and their pharmacological effects.  For example, penicillin G displays an increased 
half life when simultaneously used with probenecid [293].  All OATs examined here were either 
absent or displayed, on average, a low level of expression in all lung samples studied.  Many human 
OATs are known to display ubiquitous tissue expression suggesting the observed expression within 
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the rat lung to be true.  Because of the multispecific substrate range of OATs and the expression of 
such transporters within a number of tissues important to drug pharmacokinetics, much OAT 
research has been focused here.  It is difficult to estimate the impact of OATs on drugs delivered to 
the lung, but it seems likely that transporters of this family present within the lung would interact to 
drugs delivered via both inhalation and instillation.    
Improving knowledge of the potential impact of organic anion transporters on drug discovery and 
drug ADME would have an ever-increasing effect upon the ability to improve medical treatment 
through reducing the risk of toxicity while maximising therapeutic effects.  In an aid to achieve this, a 
comprehensive expression profile of all OATs, consolidating existing evidence is required. 
In this study it was sought to examine the expression, at an mRNA level, of selected, 
pharmaceutically relevant ABC, SLC, and SLCO transporters in specified rat lung cell samples.  The 
comprehensive mRNA expression profiles generated illustrate, to some degree, the localisation of 
these chosen drug transporters within specific regions of the lung.  The development of the 
transporter expression profiles constructed here will give insight into the localisation of these 
proteins within the lung and, through this increased knowledge in transporter localisation, could 
benefit drug discovery research through exploitation of drug transporter functionality and 
improvement of candidate absorption, distribution and accumulation in both target and non-target 
organs.        
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CHAPTER 3 
Development and validation of an Isolated Perfused Rat 
Lung model for pulmonary delivery 
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3.1. Introduction 
The origin of the isolated perfused organ dates back to the 1800s while, during the development of 
pharmacological techniques, it was discovered that isolated organs and tissues were able to remain 
functionally intact for several hours in an aerated bath of physiological salt solution.  Following this 
technical realisation, the concept of organ isolation for experimentation was applied to many organs 
and tissues of interest.  Henrick Magnus first applied this technique to isolated strips of small 
intestine [307].  Claude Bernard followed with work on isolated nerve-muscle preparations in the 
1850’s [307] and in the early 1900’s, Jean-François Heymans performed experiments with isolated 
mammalian hearts [308].  Early works with isolated organ preparations provided vital advances in 
the understanding of in vivo organ and tissue processes.  For example, Claude Bernard made several 
important scientific breakthroughs with the aid of isolated organ preparations including; the role of 
the pancreas in digestion, understanding the glycogenic function of the liver, and discovering the 
vaso-motor system [309].  From this and other works, Claude Bernard went on to become regarded 
as ‘one of the greatest men of all science’, referred to as such by I. Bernard Cohen of Harvard 
University in the Foreword to the Dover edition (1957) of Bernard's book on scientific method, An 
Introduction to the Study of Experimental Medicine; highlighting the significance of works upon 
isolated organ preparations from the mid 1800’s onwards [310].   
Use of the lung in isolated organ preparations first emerged at approximately the same period as 
mammalian heart preparations, in the form of heart-lung models.  Knowlton and Starling utilised the 
lungs as a ‘respirator’ in their model to research the heart [311] and adapted their protocol from 
other heart-lung preparations such as that reported by Newell Martin in 1883 [311, 312].  
Developments such as these could be considered as the birth of isolated perfused lung 
methodology.   
Refinement of the isolated perfused lung as a stand-alone model flourished in the 1950s and 1960s 
with Delaunois and King publishing ‘improvements in an isolated perfused lung technique’ in 1956, 
cementing use of such a model in modern pharmacological research [313].  Much initial work with 
isolated lungs utilised those of the rabbit, guinea-pig and dog, however, Davis and Levy in 1965 
reported use of an isolated rat lung setup to examine removal of bacteria from the lung [314].  This 
published use of an isolated perfused rat lung setup (IPRL) represents one of the first documented 
uses of this model and in 1970, Leary and Smith went on to publish a comprehensive overview of 
their in situ isolated rat lung preparation, marking the beginnings of the use of the rat lung as an 
excellent standard for lung-specific experiments [315].  The Leary and Smith IPRL preparation 
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represented the early development of a ‘standard’ model and provided many techniques and 
measurements which continue to translate to current IPRL preparations.  For example, their model 
consisted of a somewhat typical surgery technique, where the heart and lungs were exposed via the 
ribcage and the right and left ventricles of the heart cannulated.  The preparation was perfused 
through the right heart at a rate of 6 mL/min and the venous affluent collected for sample analysis.  
Lungs were ventilated through a tracheotomy and perfusate was kept at 37 °C, pH 7.4 and aerated 
with 95% O2 : 5% CO2 [315].  The perfusion media utilised by Leary and Smith was first employed by 
Leary and Ledingham [316] and was developed by Hems et al., [317] for use with isolated liver 
preparations.  This medium consisted of physiological saline (Krebs and Henseleit, 1932 [318]), 
bovine serum albumin (fraction V) and washed human red blood cells and essentially represents the 
beginnings of what has now become a standard lung perfusion medium.  To ensure the viability of 
the preparation, Leary and Smith examined the lungs after each experiment by electron microscopy 
to rule out gross lung damage and also examined angiotensin I conversion within the lung to provide 
evidence of the enzymatic competency of the IPRL [316, 319].                      
Development of initial preparations such as that of Leary and Smith have led to the emergence of a 
number of IPRL models and while there exists standard methodology for lung isolation and 
perfusion, there is great variation in a number of technical aspects of each preparation.  There exists 
a large amount of literature describing the establishment and validation of IPRL preparations which 
has highlighted both inter-preparation variability and viability.  Further, many reports of IPRL 
preparations include few parameters that are utilised to examine and evaluate lung viability.  
Generally, viability parameters studied are either morphological or biochemical, with morphological 
parameters including; monitoring wet organ weight, wet: dry ratio of lung weight and visual scoring 
for tissue oedema, and biochemical parameters including assay of the perfusate for; glucose, ATP, 
uric and lactic acid, serum proteins and cholesterol.  Ideally, when validating an IPRL preparation, a 
variety of parameters should be monitored in order to produce an accurate picture of the 
performance of the preparation, however, monitoring biochemical parameters creates the need for 
sophisticated instruments and techniques and so more often monitoring relies on simple 
morphological factors.  It is also important to avoid over-complicating an IPRL protocol and to avoid 
detracting from intended IPRL experimental purpose [320]. 
Many IPRL preparations continue to be exploited in a number of areas of scientific research and are 
now commonly employed in fields such as drug delivery, drug discovery and drug development.  
Recently, Ewing and co-workers have utilised an ex vivo IPRL to examine vasoconstriction after 
budesonide inhalation [321], highlighting not only the sustained applicability of the IPRL from its 
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initial use in the late 1800s but also the continued need for improved understanding of such issues 
as the influence of ADME parameters upon inhaled drugs and the real applicability of drugs 
delivered to the lung for systemic action [322].  The research of Ewing and co-workers also serves to 
highlight the diversity of model use; researchers sought to examine the absorption and metabolism 
of an inhaled model polycyclic aromatic hydrocarbon, (benzo(a)pyrene; BaP), within an IPRL.  It was 
aimed to quantify the saturation of BaP in the IPRL and provide insight as to the reasoning behind 
carcinogenic activity of such compounds at the sight of entry.  In order to achieve reliable results, 
this research group also monitored parameters such as tracheal airflow and thoracic pressure 
change in order to ensure only stable IPRL preparations were used [323].  Further, the IPRL setup of 
Niven, Byron and colleagues and its subsequent use represents a model that has been fully utilised 
within the realms of pharmaceutical research to examine issues such as drug delivery to the lung, 
drug deposition within the lung and drug absorption from the lung [95, 96, 324].  Niven and Byron 
initially used this preparation (Figure 3.1) to study the deposition and absorption of aerosolised 
drugs delivered to the IPRL.  Their studies [95] established the use of the IPRL in examining the 
deposition and transport of inhaled drugs and represents the first documented use of the IPRL 
model for this purpose.   
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Figure 3.1 Byron et al. isolated perfused rat lung setup which was adapted for aerosol administration 
of substrates to the isolated lung.  Key: (A) Carbogen supply, (B) pH electrode, (C) Temperature 
probe, (D) Peristaltic pump, (E) Bubble trap, (F) Syringe (20 ml), (G) Water-jacketed glass thorax, 
(H) Air removal trap, (I) Water-jacketed perfusate reservoir, (J) Perfusate.  Diagram representing 
IPRL of Byron et al. [95].  
Following the establishment of an isolated and perfused rat lung by Byron and colleagues, this 
research group began systematic use of this model, together with two delivery techniques; aerosol 
administration and forced-solution instillation, to examine solute absorption from the airways [324-
327] and, in a similar manner to Schanker et al. [34, 35], began generating a body of disposition and 
absorption data.  Niven and Byron, in 1988, initially began generating this data by examining the fate 
of aerosolised fluorescein dosed to the IPRL [324].  From this, a number of future studies extended 
including; examining the effect of surfactant upon fluorescein absorption, examining the absorption 
of a number of polypeptides dosed to the IPRL and examining the fate of insulin dosed to the lung; a 
study which highlighted the importance of reliable lung deposition and lung region-specific kinetics 
[101, 325-328].  Such research has given further insight to the deposition and transfer mechanisms 
of aerosolised drugs and has provided an excellent adaptation of an IPRL model to allow for target-
relevant dosing systems.       
Use of the IPRL model developed by Byron et al. for the study of drug delivery to the lung 
highlighted this specific model-type, i.e. ex situ lung and artificial thorax, as the basis for models for 
future use in this field.  The use of a novel dosing method involving a pressurised metered dose 
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inhaler and a liquid dose ‘packet’ has also allowed this particular IPRL model to be employed in 
examining the airway-to-perfusate absorption kinetics of a number of liquid formulations [96].  
Research conducted by Tronde et al. also employed a distinct dosing system with an IPRL model; 
delivering nebulised dose to vertically-hung lungs in an artificial glass thorax [102].  Utilising this 
isolated perfused rat lung setup, Tronde and co-workers sought to examine structure-absorption 
relationships of inhaled drugs such as budesonide, formoterol and propranolol and generated a 
significant body of work that provided comparison between drug pulmonary absorption and 
physicochemical properties [329, 330].      
The success of the model developed and modified by Byron et al., and its applicability to pulmonary 
drug discovery offered a very attractive model for use within this and subsequent chapters.  There 
are many essential similarities between the model used here and that used by Byron et al. with 
exceptions mainly involving aspects of preparation monitoring.  However, the availability of 
fluorescein absorption data performed in a very similar model to that of this chapter provides this as 
an internal standard for use in all IPRL experiments, thus providing parameters to employ to data 
and avoid wide data variability.      
It has long been recognised that, compared with other mucosal barriers, the lung offers greater 
permeability to a wide molecular weight range of molecules which can display a fast rate and high 
extent of pulmonary absorption following airway administration [8]. 
Aims and Objectives 
• The main objective of this chapter is to set up and fully validate an isolated perfused rat lung 
model for the study of pulmonary absorption processes in isolation from the rest of the 
body. 
• ‘Transfer’ (in principal) the model developed by Niven and Byron [95] to  Cardiff University 
from Virginia Commonweath University 
• Validate the IPRL in-house as a preparation for the study of pulmonary solute absorption 
through examining the reproducibility of the intra-tracheal dosing method and deposition 
pattern 
• Validate drug deposition following airway administration using Evans blue and sodium 
fluorescein dyes delivered to the IPRL via the intra-tracheal dosing method and examining 
distribution within the lung 
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• Confirm the suitability of the IPRL for the study of pulmonary absorption by examining the 
rate, extent and reproducibility of fluorescent probe transport across the IPRL. 
• Establish preparation viability by examining the wet: dry ratio of lung tissue post IPRL 
procedure and by noting presence or absence of pulmonary oedema.      
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3.2. Materials and Methods 
3.2.1. Validation of IPRL perfusate - extent to which Bovine Serum Albumin contributes to 
perfusate background fluorescence  
Materials 
Consumables 
Whatman Grade No. 91 filter papers, Fisher UK, (Cat No: FDH-200-169A) 
Reagents 
D-glucose anhydrous; C6H12O6, (Fisher Scientific, Loughborough, UK, G/0450/60) 
Potassium chloride; KCl, (Fisher Scientific, Loughborough, UK, Cat: P/4280/53) 
Magnesium sulphate heptahydrate; MgSO4.7H2O, (Fisher Scientific, Loughborough, UK, Cat: 
M/0600/53) 
Sodium bicarbonate; NaHCO3, (Fisher Scientific, Loughborough, UK, Cat: S/4200/60) 
Calcium chloride dihydrate; CaCl2.2H2O, (Fisher Scientific, Loughborough, UK, Cat: C/1500/50) 
Sodium chloride; NaCl, (Fisher Scientific, Loughborough, UK, Cat: S/3105/63)   
Potassium dihydrogen phosphate; KH2PO4, (Fisher Scientific, Loughborough, UK, Cat: P/4800/53) 
Bovine serum albumin; BSA, (Sigma-Aldrich, Dorset, UK, Cat: A7906-1kg) 
Bovine serum albumin; BSA, (Biosera, East Sussex, UK, Cat: P6150) 
Sodium fluorescein; F-Na, (Fluka, Sigma-Aldrich, Dorset, UK, Cat: 46960) 
Method 
Preparation of stock solutions 
Chemical g / L perfusate g / 500 mL stock solution  
KCl 0.35 0.035 
MgSO4.7H2O 0.29 0.029 
CaCl2.2H2O 0.37 0.037 
KH2PO4 0.16 0.016 
 
Chemicals listed above were dissolved in distilled water (~ 400 mL) and the volume adjusted to 500 
mL.   
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Perfusate 
To prepare 1 L 
The below listed chemicals and solutions were added to distilled water (~ 300 mL) and the final 
volume adjusted to 1000 mL.  Order of addition: 
1) Glucose   2.0 g 
2) KCl    0.35 g (10 mL of stock solution) 
3) MgSO4.7H2O   0.29 g (10 mL of stock solution) 
4) NaHCO3   2.10 g 
5) CaCl2.2H2O   0.37 g (10 mL of stock solution) 
6) NaCl    6.92 g 
7) KH2PO4    0.16 g (10 mL of stock solution) 
8) BSA    40.0 g (either ‘Biosera’ or ‘Sigma’ product) 
Order of addition of perfusate components is very important to ensure that the formation of 
precipitate; namely CaCO3, is avoided, isotonicity (300-320 mOsm/kg H2O) and pH (pH 7.4) are 
critical. 
Isotonicity was measured using an osmometer (Advanced® 3D3 Single-Sample Osmometer) and a 
perfusate sample volume of 200 µL.     
Perfusate solution was prepared and filtered using Whatman filter paper with a 15 cm diameter or 
equivalent. 
Preparation of F-Na calibration curve 
Calibration curves for F-Na were prepared by serial dilution with; a) Biosera BSA perfusate, b) Sigma 
BSA perfusate and c) Perfusate minus BSA.  A concentration range F-Na of 0.001 µg/mL – 0.1 µg/mL 
was prepared. 
FLUOstar analysis:  F-Na levels in IPRL perfusate 
F-Na concentrations in perfusate were determined fluorometrically using a microplate fluorometer 
(FLUOstar, Optima, BMG).  Perfusate samples (200 µL) containing F-Na calibration concentrations 
were analysed (λex 485 nm, λem 520 nm) and calibration curves constructed, using perfusate made 
from: (a) Biosera BSA perfusate, (b) Sigma BSA perfusate and (c) Perfusate minus BSA.    Perfusate 
samples without F-Na were also analysed for background fluorescence which was subtracted from 
all F-Na perfusate samples.  The extent to which BSA contributes to background fluorescence and 
the most suitable BSA product in terms of background fluorescence and F-Na limit of quantitation 
were examined by use of each specific perfusate calibration curve.   
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3.2.2. Isolated Perfused Rat Lung 
Materials 
Animals 
Male-specified pathogen-free Sprague-Dawley rats (Harlan UK Limited, Bicester, UK) were used 
throughout and housed in rooms controlled between 19 ⁰C – 21 ⁰C and 40-60 % humidity with dark-
light cycling every 12 h.  The animals had free access to food and water and were acclimatised for at 
least 2 days prior to experimentation.  All animal experiments adhered to the Animal (Scientific 
Procedures) Act 1986, UK and were approved by Cardiff University.  
Equipment list 
Constant volume mechanical ventilator, (Harvard Apparatus Ltd, UK, Model No: 50-1718) 
Artificial glass thorax, (Richmond Glassware, USA, Custom Made) 
Condenser, (Richmond Glassware, USA, Custom Made) 
Perfusate reservoir, (Richmond Glassware, USA, Custom Made) 
95%/5% O2/CO2 (BOC, Manchester, UK) 
Circular tripod, (Fisher Scientific, Loughborough, UK, Cat: STK-940-030W) 
Custom made stainless steel dosing rod (DR), port (DP) and tracheal cannula (TC), (Harvard 
Apparatus Ltd, UK, Figure 3.2A) 
Magnehelic® differential pressure gauge, measuring -5 to +5 cm H2O, (Dwyer® Instruments, High 
Wycome, Bucks, UK, Model: 2300-10cm) 
Hanging rods (HR),(custom made, see Figure 3.2B)  
Syringes (Sterile; 50 mL), (Fisher Scientific, Loughborough, UK, Cat: SZR-CSE-060U) 
pH/ temperature meter (Hanna Piccolo®, Sigma-Aldrich, Dorset, UK, Cat: P9565, or equivalent) 
Peristaltic pumps 
Watson Marlow, (Falmouth, Cornwall, UK, Model: 505S) 
Gilson, Inc., (Middleton, WI, USA, Model: Minipuls 3) 
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Tubing 
Perfusate lines: Masterflex 96400-14 peroxide cured, (Fisher Scientific, Loughborough, UK, Cat: 
PMM-505-515G) 
Water lines: Tygon R-3603, (Fisher Scientific, Loughborough, UK, Cat: TWT-700-150N) 
Connectors 
Perfusate line to condenser: Tubing connector Kartell unequal inlet and outlet, (Fisher Scientific, 
Loughborough, UK, Cat: ADF-610-030D)  
T-piece tubing connectors, (Fisher Scientific, Loughborough, UK, Cat: ADF-715-030L) 
Y-piece tubing connector for ventilator attachment, (Fisher Scientific, Loughborough, UK, Cat: ADF-
690-010W) 
Tubing clips 
Tubing clips 14-19 mm, (Fisher Scientific, Loughborough, UK, Cat: CNK-641-040T) 
Tubing clips 13-17 mm, (Fisher Scientific, Loughborough, UK, Cat: CNK-641-030W) 
Tubing clips 22-30 mm, (Fisher Scientific, Loughborough, UK, Cat: CNK-600-050E) 
Silicone bungs 
Dosing port stopper, (Fisher Scientific, Loughborough, UK, Cat: FB55019) 
Drain stopper, (Fisher Scientific, Loughborough, UK, Cat: FB55015, or equivalent) 
Perfusate reagents 
D-glucose anhydrous; C6H12O6, (Fisher Scientific, Loughborough, UK, G/0450/60) 
Potassium chloride; KCl, (Fisher Scientific, Loughborough, UK, Cat: P/4280/53) 
Magnesium sulphate heptahydrate; MgSO4.7H2O, (Fisher Scientific, Loughborough, UK, Cat: 
M/0600/53) 
Sodium bicarbonate; NaHCO3, (Fisher Scientific, Loughborough, UK, Cat: S/4200/60) 
Calcium chloride dihydrate; CaCl2.2H2O, (Fisher Scientific, Loughborough, UK, Cat: C/1500/50) 
Sodium chloride; NaCl, (Fisher Scientific, Loughborough, UK, Cat: S/3105/63)   
Potassium dihydrogen phosphate; KH2PO4, (Fisher Scientific, Loughborough, UK, Cat: P/4800/53) 
Bovine serum albumin; BSA, (Sigma-Aldrich, Dorset, UK, Cat: A7906-1kg) 
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Filter papers 
Whatman Grade No. 91 filter papers, (Fisher Scientific, Loughborough, UK, Cat: FDH-200-169A) 
Surgery reagents 
Euthatal, (Merial Animal Health Ltd., Harlow, UK) 
Syringes (Sterile; 1 mL), (Fisher Scientific, Loughborough, UK, Cat: SZR-150-011Q) 
Needles (Sterile; 25G x 5/8IN), (Fisher Scientific, Loughborough, UK, Cat: SZR-175-510A) 
Heparin sodium (contains preservative) – previously known as Multiparin®, (1000 I.U. /ml), 
(Wockhardt UK, Wrexham, UK, Order No: FP1086) 
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Figure 3.2 Profile and measurements of equipment custom made for the IPRL.  Figure 3.2A 
represents the Dosing Rod (DR), Dosing Port (DP), and Tracheal Cannula (TC) for use with IPRL.  
Each component was individually custom made/adapted for use with this specific IPRL model.  Also 
depicted is the organisation of each component to allow dosing to the isolated lung via the DR.  
Figure 3.2B represents the specific measurements of the custom made hanging rod for use within an 
individual artificial glass thorax. 
 
A 
B 
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Figure 3.3 Schematic of IPRL equipment setup; kindly provided by Masahiro Sakagami.  The setup is 
adapted from that first described by Byron and Niven.  The isolated lung is situated within a water-
jacketed artificial glass thorax and is dosed whilst ‘hanging’ inside.  Perfusate is maintained at 37 °C 
and flow controlled by a peristaltic pump.  In order to retain a recirculating setup, perfusate is returned 
to the reservoir post-circulation of the pulmonary vasculature.  This recirculating setup also allows 
easy sampling from the reservoir and easy maintenance of perfusate volume.   
Method 
Perfusate solution was prepared with Sigma BSA and filtered using Whatman Grade No. 91 filter 
papers with a 15 cm diameter or equivalent.  Each batch of perfusate was prepared between 16 h 
and 24 h before an IPRL experiment, importantly the solution containing BSA was left stirring for 16 
h at 4 °C prior to use.  Any perfusate batch not used within 48 h of preparation was discarded.  
Pre-surgery 
All glass vessels and perfusate were brought to temperature (37 °C) via the heated water pump.  
Once perfusate had reached temperature, the solution was circulated through the IPRL system and 
initially run to waste (~15 mL) before being set in ‘recirculating’ mode.  All bubbles were removed 
from perfusate lining by flicking the tubing to dislodge.  Surgical instruments, clamps, and cotton (for 
securing both tracheal cannula and pulmonary artery catheter) were ensured to be clean and 
available.  Finally, a heparin dose (0.1 mL of a 1000 U/mL) and a Euthatal dose (50 mg/mL dose i.p. at 
60 mg/kg) were prepared, each in a 1 mL syringe with sterile needle attached.  
Surgery 
A surgical incision was made in the neck to expose the trachea; from this point surgery was aimed to 
be completed in 10-12 min Once the trachea was exposed, a cut was made between the 4th and 5th 
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cartilage rings.  The cut were approximately half of the trachea circumference to allow insertion of 
the tracheal cannula.  Positioning is important as the site of dissection and the length to which you 
insert the tracheal cannula into the trachea influence the deposition of any administered forced 
liquid instillation.  
The tracheal cannula was then inserted into the trachea and secured with cotton and threads 
trimmed.  Care was taken to tie cotton between cartilages rings as tying directly on cartilage may 
result in a loosely secured tracheal cannula.  Note the presence of a tubing connector on the distal 
end of the cannula to allow manual ventilation.  During the remainder of the surgery it was sought to 
avoid changes in the position of the animal that would restrict the airspace, e.g. doubling up of the 
head and neck.  The animal was fixed to surgery tray using autoclave tape if necessary. 
The abdominal cavity was opened in an arc dissection and the sternum clamped and lifted to expose 
the diaphragm and thoracic organs.  Next the diaphragm was dissected around the margins of the 
ribcage to the inferior surface to expose the lungs.  Great care was taken not to touch any lung 
tissue.  Once the ribcage and lungs were exposed, the ribcage was dissected.  The cut was made 
quite high to avoid injury to the lungs through contact with the cut ribcage.  The clamped sternum 
was then lifted towards the head of the animal and the chest wall turned over to fully expose the 
heart and lungs. 
Heparin sodium (0.1 mL of 1000 U/mL) was injected into the heart by firmly grasping the heart with 
forceps.  The injection was aimed for the crinkled surface tissue of the right ventricle and position 
checked by visualising blood leaking back into the syringe neck.  Before injection the pressure of the 
forceps was released but the heart held in place so that heparin was not forced back out through the 
puncture site, heparin was then slowly injected.   
The thymus was removed via forceps to allow visualization of the pulmonary artery.  Sufficient 
removal was ensured to aid both good visualisation of the pulmonary artery and removal of the 
lungs from the animal carcass.   
The heart tissue was gently held to expose the site for incision of the pulmonary artery catheter 
(PAC).  An incision was made at 90 ° to the path of the pulmonary artery for insertion of the PAC. 
Care was taken not to cut too high near the exposed vessel, as it is very difficult to insert PAC from 
here, or too low into the heart tissue as the PAC will have to be forced through tough heart tissue.  
Further, the cut was ensured not to be too shallow as this would likely still be within cardiac tissue.  
Instead the cut was deep enough to access the lumen of the ventricle leading to the pulmonary 
artery.  Next the perfusate line was transferred to the surgical tray and the left and right atrium cut 
to allow free flow of perfusate.  The PAC was then inserted into the pulmonary artery, the way in 
which the forceps were held is critical at this point.  Firstly the heart was held firmly for insertion of 
the PAC, then the catheter held in place between the operators 1st finger and thumb of the left 
hand.  The forceps were then held between the operators 2nd finger and thumb to allow for 
placement of the artery clamp using the freed right hand (Figure 3.4). The artery clamp was placed 
at a sufficient distance from the PAC tip to allow for tying of the PAC within the heart tissue.   
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A 5 mL syringe was next attached to the tracheal cannula tubing connector for manual ventilation of 
the lungs.  Lungs were ventilated with a tidal volume of approx. 4.5-5 mL for at least 5 repetitions or 
until the lungs appeared clear.  The heart was then cut to allow further escape of perfusate and 
redundant heart tissue was removed as much as possible to avoid interfering with the hanging 
position of the lungs in the artificial glass thorax (AGT). 
Next the lungs were gently lifted via the tracheal cannula and all thoracic connections cut away.  
Care was taken not to damage the oesophagus as this was needed to hang the lungs in the AGT.  
Once free, the hanging rod was inserted along the length of the oesophagus and the lungs mounted 
in the AGT.  The tracheal cannula was connected to the dosing port (DP) and the position of the 
tracheal cannula within the trachea checked.  The tip of the tracheal cannula was positioned just 
proximal to the 1st bifurcation. 
The lungs were then gently washed with warmed perfusate and all tubing checked to be correctly 
positioned within the AGT.  The angle of the pulmonary catheter entering the tissue was vital – care 
was taken to ensure that it was free flowing.  
Initial perfusate flowing from the lung was run to waste to remove blood not wanted in the 
reservoir; the perfusate line was then placed in the reservoir to complete the circuit.  Perfusate 
volume within the reservoir was checked and made up to a fixed volume with fresh warmed 
perfusate. 
The interface between the AGT and plastic lid was sealed with perfusate to create a seal and the lid 
fixed in place with parafilm.  Next, negative pressure of approx. 1-2 inches (2-5 cc water) was 
generated to help minimize formation of pulmonary oedema.  Finally, the gas line (95% O2/5% CO2) 
was inserted to the airspace of the perfusate reservoir such that the perfusate bubbled gently and 
the ventilator was attached to the dosing port (DP) with lungs being ventilated with a tidal volume of 
2.5 cm2 and a rate of 20 breaths/min  
Dosing 
As accurately as possible, 100 µL sample dose was inserted to the dosing rod (DR).  The DR was held 
in a horizontal position and the dose inserted slowly to the distal end.  The ventilator was then 
removed from the DP and the DR carefully inserted through to the tracheal cannula.  At this point, 
the tip of the dosing rod could sometimes be seen (through the tracheal tissue) protruding from the 
end of the TC.  A pMDI canister (5.5 mL CFC 11/12, 40:60 %) with a 25 µL valve (Bespak) was primed 
and the actuator placed into Tygon tubing at the proximal end of the dosing rod.  In one quick 
movement, the pMDI actuator was depressed and the lungs observed for expansion, the pMDI and 
DR were immediately removed.  This point was regarded as the start of drug dosing and a stop 
watch used to allow timing of sample removal.   
The DR was immediately placed in dH2O to wash any non-administered dose and at the end of the 
experiment, the tracheal cannula and dosing port were also washed to allow calculation of total 
dose administered.  Total perfusate volume was also measured at the end of the experiment by 
running all remaining perfusate to the reservoir and transferring to a measuring cylinder.   
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All samples were centrifuged for 10 min at 18,000 x g to remove contaminating red blood cells and 
the supernatant stored for analysis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Diagram illustrating the tying off of the pulmonary artery catheter (PAC) after positioning 
in the pulmonary artery. 
3.2.3. Validation of IPRL dosing equipment 
Materials 
Consumables 
Sodium fluorescein; F-Na, (Fluka, Sigma-Aldrich, Dorset, UK, Cat: 46960) 
Method 
An IPRL preparation was conducted as described above.  The lungs were dosed with F-Na (100 µL of 
a 400 µg/mL solution) and the experiment immediately stopped.  All custom dosing equipment; i.e. 
dosing rod, dosing port and tracheal cannula, were collected and thoroughly washed in dH2O.  This 
‘dH2O wash’ was then stored for fluorometric analysis.    
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FLUOstar analysis:  F-Na levels in dosing equipment 
The level of F-Na remaining in IPRL custom dosing equipment after a single actuation of a propellant- 
only pMDI was determined fluorometrically using microplate fluorometry (FLUOstar, Optima, BMG).  
Dosing equipment wash samples (200 µL) were analysed (λex 485 nm, λem 520 nm) and concentration 
determined using a suitable calibration curve constructed in dH2O.  Samples of dH2O without F-Na 
were also analysed for background fluorescence which was subtracted from F-Na dosing wash 
samples.  The amount of F-Na remaining in dosing equipment after dosing was corrected for total 
wash volume and calculated as a percentage of the actual dose.    
3.2.4. Validation of the forced solution instillation technique for IPRL dosing 
Materials 
Consumables 
Sodium fluorescein; F-Na, (Fluka, Sigma-Aldrich, Dorset, UK, Cat: 46960) 
Evans blue, (Fluka, Sigma-Aldrich, Dorset, UK, Cat: 46160-5G-F) 
Phosphate buffered saline; PBS, (0.1 M, pH 7.2), (Fisher Scientific, Loughborough, UK) 
Formamide, (Fisher Scientific, Loughborough, UK, Cat: BPE227-100) 
Method 
Preparation of PBS 
Chemical g / 1000 mL dH2O 
Na2HPO4 10.9 
NaH2PO4 3.2 
NaCl 90 
 
Chemicals listed above were dissolved in ~ 800 mL dH2O and the volume adjusted to 1000 mL,   pH 
was adjusted to 7.4.  PBS was stored at room temperature and diluted 1:10 for use.  All chemicals 
were of the highest available quality from Fisher Scientific.  
Evans Blue lobar deposition 
In order to assess dose deposition reproducibility across the lung, Evans blue (3 mg/mL in dH2O, 
filter sterilized) was instilled to the IPRL using the forced solution instillation technique.  Immediately 
after dosing, the experiment was terminated and the lung tissue removed and dissected into 
individual lobes.  Each lung lobe was transferred to formamide (1 mL) with the exception of the left 
lung lobe which was placed in 2 mL formamide.  After 1 h samples were centrifuged (18,000 g, 10 
min.) and the resulting supernatant (~1 mL) analysed via UV/VIS spectroscopy (Evans blue 
absorbance at 620 nm).  The Evans Blue content of each lobe supernatant was determined using an 
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Evans blue calibration curve constructed in lung tissue supernatant (plus formamide 1 mL) from 
mock IPRL experiments where no dose was instilled into the lung.            
Sodium fluorescein lobar distribution 
Due to poor dye extraction, Evans blue experiments yielded excellent visualization but poor 
quantification of dose deposition pattern within the IPRL.  As Na-F is much more water soluble, this 
was instilled (400 µg/mL in dH2O, filter sterilized) to the IPRL using the forced solution instillation 
technique.  Immediately after dose instillation, the experiment was terminated and lung tissue 
dissected into individual lobes.  Each section of lung i.e. lung lobes, trachea and major bronchi, was 
homogenized in PBS (2 x 5 mL, PowerGen 125 homogeniser, Fisher Scientific, Loughbrough) and then 
centrifuged (18,000 x g, 10 min.) to yield a tissue supernatant.  The F-Na content of each 
supernatant was fluorometrically determined (λex 485 nm, λem 520 nm) using microplate fluorometry 
(FLUOstar, Optima, BMG), supernatant samples (200 µL) and an appropriate F-Na calibration curve 
constructed in control lung tissue homogenate where F-Na was not instilled to the IPRL were 
examined and a dose disposition profile constructed.       
3.2.5. Validation of the IPRL – transport of a molecular weight range of fluorescent probes 
Materials 
Consumables – absorption substrates 
Sodium fluorescein; F-Na, (Fluka, Sigma-Aldrich, Dorset, UK, Cat: 46960) 
        FITC-dextrans (various MW), (Fluka, Sigma-Aldrich, Dorset, UK): 
 (FD4, Cat: FD4-100) 
 (FD20, Cat: FD20-100) 
 (FD70, Cat: FD70-100s) 
Sample time points 
Na-F: 0, 1, 2, 3, 5, 7, 9, 12, 15, 20, 30, 40, 50, & 60 minutes 
FD4&20: 0, 1, 2, 3, 5, 7, 9, 12, 15, 18, 20, 25, 30, 40, 50 and 60 minutes 
FD70: 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80 & 90 minutes 
Method 
An IPRL experiment was conducted as per protocol.  The preparation was dosed with a molecular 
weight probe (dose 100 µL; F-Na, 400 µg/mL; FD4, 2000 µg/mL; FD20, 200 µg/mL, FD70, 2000 
µg/mL) and maintained for 60 or 90 min depending on the probe of choice.  Aliquots (1 mL) were 
sampled from the perfusate reservoir at pre-determined time points and replaced with an equal 
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volume of warmed perfusate.  Perfusate samples were centrifuged (18,000 x g, 10 min., 4 °C) to 
remove trace blood cells and the supernatant stored at -80 °C for fluorometric analysis.  At the end 
of the experiment, deposits of dosing solution within the IPRL dosing equipment were collected for 
quantification by washing each equipment part with 50 mL dH2O to allow determination of actual 
dose deposited into the isolated lung.  To determine the extent of probe transport across the IPRL, 
sample supernatant (200 µL) from each IPRL experiment was fluorometrically analysed (λex 485 nm, 
λem 520 nm) using microplate fluorometry (FLUOstar, Optima, BMG) and concentration determined 
using an appropriate calibration curve constructed in recirculated perfusate.  Perfusate samples 
without fluorescent probe were also analysed for background fluorescence which was subtracted 
from probe perfusate samples.  Cumulative mass of molecular weight probe absorbed was 
calculated by correcting for total perfusate volume and mass removed during sampling. 
Data Analysis 
To determine the significance of dose escalation, both the percentage of deposited F-Na dose 
absorbed at 90 min and the kin of each transport profile was analysed.  A one way Analysis of 
Variance followed by a post-hoc Duncan’s test was performed on each.  A value of p< 0.05 was 
considered significant.  Similarly, to determine the significance of MW escalation of FITC-dextrans, a 
one way analysis of variance followed by a post-hoc Duncan’s test was performed upon the same 
criteria.  Again, a value of p< 0.05 was considered significant.   
3.2.6. Validation of the IPRL – gel filtration analysis of FITC-dextrans 
Overview 
Gel filtration and gel permeation chromatography, also known as size exclusion chromatography, 
allows separation based on differences in the size and/or shape of analyte molecules - a 
characteristic which governs the analytes’ access to the pore volume inside the column packing 
particles. 
 
The PD-10 columns used here are made of chemically inert polypropylene material and filled with 
8.5 mL of Sephadex-25 gel filtration material. The exclusion limit of the Sephadex-25 is 5000 for 
globular protein [331]. 
Materials 
Consumables 
 FITC-dextrans (various MW), (Fluka, Sigma-Aldrich, Dorset, UK): 
 (FD4, Cat: FD4-100) 
 (FD20, Cat: FD20-100) 
 (FD70, Cat: FD70-100s) 
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  PD10 column, Sephadex G-25, (Sigma-Aldrich, Dorset, UK, Cat: G-25-80) 
 Phosphate Buffered Saline; PBS, (0.1 M, pH 7.2), (Fisher Scientific, Loughborough, UK) 
Method 
To rule out FITC-dextrans lung metabolism, (i.e. to ensure perfusate samples represented FITC-
dextrans and not FITC conjugate alone), dose solution and 90 min IPRL perfusate sample of FD4, 
FD20 and FD70 were filtered through a PD10 column and fractions eluted over time. 
Each sample (FITC-dextrans dose and perfusate) was made up to a 2.5 mL volume with dH20.  Gel 
filtration columns were washed with PBS (~20 mL), the column cap replaced and a sample added 
(2.5 mL).  The column cap was then removed and the sample allowed to run through the column.  An 
aliquot of PBS (0.5 mL) was added to the column to elute FITC-dextrans and the fraction collected.  
This was repeated with a total volume of 24 mL PBS (48 fractions in all).      
Each fraction was analysed fluorometrically using microplate fluorometry (FLUOstar, Optima, BMG).  
Fraction samples (200 µL) were analysed (λex 485 nm, λem 520 nm) and results plotted to determine 
absence of FITC-dextrans metabolism through the presence of only 1 peak in gel filtration 
chromatography.   
3.2.7. Validation of the IPRL – determining IPRL viability by wet: dry weight 
Materials 
Consumables 
 Centrifuge tubes (Sterile; 50 mL), (Fisher Scientific, Loughborough, UK, Cat: FB55956) 
 Liquid Nitrogen (BOC, Manchester, UK) 
Method 
IPRL viability was established by determining isolated lung wet: dry weight at the end of each IPRL 
experiment.  Lung tissue was removed from the AGT and blotted dry then placed in a centrifuge 
tube (50 mL) and weighed to give wet weight; centrifuge tube weight was determined and 
subtracted.  Lung samples were then snap-frozen in liquid nitrogen and lyophilised (Thermo 
Systems, UK) until constant weight was established (~48 h).  Samples were then weighed for a 
second time to yield a dry weight.    
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3.3. Results 
3.3.1 Bovine Serum Albumin contribution to perfusate background fluorescence 
Each BSA product was analysed for its contribution to background fluorescence and the lower limit 
to which F-Na could accurately be detected in the perfusate.   Figure 3.5 represents the calibration 
curve for each perfusate sample used, i.e. Biosera BSA, Sigma BSA, no BSA.  The fluorescence reading 
for the lowest F-Na concentration detected was x3 background fluorescence in each perfusate 
sample and so was deemed acceptable as the lower limit of quantitation. 
 
Figure 3.5 Calibration curve representing F-Na in each of the three different perfusate samples; Fig 
3.5A - Sigma BSA, Fig 3.5B - Biosera BSA, Fig 3.5C - no BSA.  Lower limit of detection was 
A 
B 
C 
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deemed to be 1 ng/mL in each perfusate sample, i.e. F-Na fluorescence reading was three times that of 
background.  Data shown are mean ± S.D (n=6 for each treatment).     
Table 3.1 shows the two BSA products tested, the Sigma product displayed a lower level of 
background fluorescence.  Perfusate not containing BSA, i.e., ‘no BSA’, provided an extremely low 
background fluorescence, only some 1.9 –fold higher than that of dH2O (background reading of 66 ± 
4.0 afu.).  The lowest concentration of F-Na to be examined in each BSA product was 1 ng/mL and 
could be detected in each of the perfusate samples. 
BSA product Background Fluorescence (afu) Lowest F-Na Fluorescence (afu) 
[Lowest F-Na concentration 
detected ] 
‘Biosera’ 
(standard quality, lyophilised) 
3717.5 ± 84.4 11178.0 ± 71.3  [1 ng/mL] 
‘Sigma’ 
(≥98% (agarose gel 
electrophoresis), lyophilised) 
1753.8 ± 92.2 5821.7 ± 55.1  [1 ng/mL] 
No BSA 128.2 ± 31.9 520.0 ± 21.0  [1 ng/mL] 
 
Table 3.1 Background fluorescence of three perfusate samples containing either no BSA or BSA from 
different sources.  Data shown are mean ± S.D (n=6 for each treatment).  Fluorescence readings are 
measured in arbitrary fluorescence units (afu).     
3.3.2. Validation of IPRL dosing equipment 
In order to evaluate the fraction of dose remaining in the custom made IPRL dosing equipment 
following a forced instillation procedure, a number of test doses of F-Na were deployed from the 
equipment with each element of the dosing apparatus subsequently analysed.  Experiments were 
performed in the presence and absence of lung tissue.  Each of the test doses that were deployed in 
the absence of lung tissue displayed an average of 1.58 ± 0.09 % of the total dose retained in the 
dosing equipment (Table 3.2).  The majority of the retained dose was found in the dosing rod.  In the 
presence of lung tissue, the total percentage dose remaining in equipment increased to 5.74 ± 1.40 
% (Figure 3.6).  In the presence of lung the majority of retained dose was found in the tracheal 
cannula at 2.53 ± 1.52 % of the dose.  The use of a duplicate pMDI (identical HFA composition) to 
deliver dose in the absence of lung tissue did not significantly alter (p>0.05, one-way ANOVA, post 
hoc Duncan’s test) the total percentage of dose remaining in equipment.   
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 Amount in eqpt. as % of actual dose 
(%) 
Mean (%) 
#1 #2 #3 
  Dosing Rod 2.93 1.84 1.23 2.00 ± 0.86 
Operator 1 Tracheal Cannula 0.0 0.15 0.16 0.16 ± 0.52 
 Dosing Port 0.0 0.05 0.05 0.05 ± 0.49 
 Total 1.62 ± 0.37 
Operator 2 Dosing Rod 1.17 0.93 1.58 1.23 ± 0.33 
In absence 
of lung 
Tracheal Cannula 0.27 0.44 0.27 0.33 ± 0.09 
 Dosing Port 0.05 0.07 0.12 0.08 ± 0.04 
  Total 1.64 ± 0.29 
Operator 1, 
duplicate. 
Dosing Rod 1.57 1.02 1.18 1.26 ± 0.28 
Tracheal Cannula 0.14 0.17 0.22 0.18 ± 0.04 
pMDI Dosing Port 0.05 0.05 0.05 0.05 ± 0.00 
 Total 1.48 ± 0.26 
In presence 
of lung 
 Dosing Rod 2.39 0.32 2.56 1.76 ± 1.25 
Operator 2 Tracheal Cannula 3.06 3.71 0.82 2.53 ± 1.52 
 Dosing Port 1.76 1.57 1.04 1.46 ± 0.37 
  Total 5.47 ± 1.40 
Table 3.2 Amount of dose retained in the custom dosing equipment (expressed as a % of dose) after deployment of a test 
dose.  Each constituent part was analysed separately. Data are expressed as percentage of dose retained in dosing 
equipment in comparison to actual dose instilled to the dosing equipment.  Only dose instilled in the presence of lung 
showed statistical difference (p<0.05) when compared to all other dose instillations, i.e. variation of operator and 
variation of individual pMDI.  Data shown are mean ± S.D (n=3 for each treatment).   
 
Figure 3.6 Mean amount of dose remaining, as %, in custom dosing equipment after deployment of a 
test dose to the IPRL in the presence of a lung.  Overall, when dosing to the IPRL, the largest % of 
dose remaining in equipment was found in the tracheal cannula, the least in the dosing port.  Data 
shown are mean ± S.D. (n=3). 
p> 0.05 
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3.3.3. Validation of the forced solution instillation technique for IPRL dosing 
To validate the deposition pattern of a dose instilled to the IPRL via the forced solution technique, 
Evans blue dye was instilled as a test dose.  Figure 3.7 demonstrates the pattern of dye deposition 
within the lung, as can be seen dye is clearly deposited in the lung parenchyma. 
 
Figure 3.7 Deposition pattern of Evans blue dye dosed to the IPRL via a forced solution instillation 
technique.  Figure 3.7A demonstrates rat lung lobe distribution, the same layout being mimicked in 
Figure 3.7B.  The distribution of dye can be seen in lung parenchyma however, dye can also be 
visualised in the lower trachea and left major bronchi.          
As can be seen in table 3.3, the largest percentage of dye recovered from any lobar region was from 
the left lobe, with 9.43 ± 5.92 % of actual dose delivered to the lung being recovered.  The lowest 
percentage of dye recovered was from the trachea and major bronchi.  Total recovery of Evans blue 
dye from lung tissue averaged 38.4 ± 12.5 % over three experiments, the resulting 61.6 % of dye not 
being extracted from the tissue.  The observed large standard deviation associated with each mean 
percentage dose deposited illustrates poor reproducibility of dose deposition to a particular lobar 
region.  For example, 1.83 % dye was deposited to the accessory lobe in experiment #1 and yet 9.70 
% dose deposited to the same region in experiment #3 (Table 3.3).  Despite this unpredictable 
pattern of distribution, the observed standard deviation of 0.23 % of dose delivered to the trachea 
and major bronchi is relatively small throughout suggesting reproducible deposition to this region.  
 
 
 
A B 
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Amount deposited expressed as % of 
Actual Dose delivered to lung (%) 
 
 
Mean  ± SD (%) 
 
#1 #2 #3 
Trachea & 
Major Bronchi 
3.34 3.02 3.46 3.27  ± 0.23  
Left Lobe 14.08 2.77 11.45 9.43 ± 5.92 
Cranial Lobe 0.52 7.47 8.46 5.48 ± 4.33 
Middle Lobe 7.59 7.13 11.61 8.78 ± 2.46 
Caudal Lobe 5.43 8.87 7.95 7.42 ± 1.78 
Accessory Lobe 1.83 0.38 9.70 3.97 ± 5.02  
Total 32.79 29.64 52.63 38.35 ± 12.46 
 
Table 3.3 Deposition pattern of Evans blue dye to IPRL expressed as % deposited to 
each lobar region.  Percentage deposition was calculated as a percent of the actual 
dose delivered to the lung, actual dose being corrected by subtracting the dose 
deposited in the dosing equipment.  Data are expressed as mean ± S.D, (n=3). 
Due to poor Evans blue dye extraction, dose deposition pattern was also evaluated using F-Na.  Table 
3.4 highlights the deposition pattern of F-Na after forced solution instillation to the IPRL.  In contrast 
to Evans blue, a considerably higher percentage of F-Na dose was recovered from lung tissue, i.e. 
85.9 ± 10.5 % F-Na recovered.  Overall, the forced solution instillation of F-Na dose resulted in 94.8 % 
of actual dose not being present in dose equipment, i.e. assumed to be delivered to the lung.  When 
examining dose recovered from the lung, 81.4 ± 17.8 % was recovered from lobar regions of the lung.  
In a similar manner to Evans blue, deposited dose was not found to show a reproducible pattern 
within the lung lobes, however, the left lobe and right caudal lobe displayed a high percentage of 
deposited dose throughout. 
 Amount deposited expressed as % of Actual Dose 
delivered to lung (%) 
 
 
Mean (%) #1 #2 #3 
Trachea & Major Bronchi 1.79 5.01 6.62 4.47 ± 2.46 
Left Lobe 49.71 21.06 2.91 24.56 ± 23.60 
Cranial Lobe 1.32 5.40 4.21 3.64 ± 2.10 
Middle Lobe 2.35 19.96 0.92 7.74 ± 10.60 
Caudal Lobe 22.38 41.48 67.45 43.77 ± 22.62 
Accessory Lobe 0.20 4.86 0.03 1.70 ± 2.74 
Total 77.76 97.77 82.14 85.89 ± 10.52 
Table 3.4 Deposition pattern of F-Na delivered to the IPRL via intra-tracheal forced solution 
instillation.  Percentage values represent calculated dye deposited to each lobar region expressed 
as a percentage of actual dose delivered to the lung.  Data are expressed as mean ± S.D, (n=3). 
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3.3.4. Validation of the IPRL – transport of a molecular weight range of fluorescent probes 
In order to validate the suitability of the established IPRL setup for pulmonary transport studies, a 
molecular weight range of fluorescent probes were dosed to the IPRL.  As can be seen in figure 3.8, 
the cumulative transport of F-Na across the IPRL initially displayed a more rapid rate of transport 
which began to decline to a slower rate at ~ 20 min onwards.  Increasing nominal F-Na dose from 4 
µg to 40 µg to 160 µg had no apparent effect upon F-Na transport, displaying no significant (p>0.05) 
increase in percentage deposited dose absorbed when increasing nominal F-Na dose.    
 
Figure 3.8 Cumulative % of deposited dose of F-Na absorbed with time across the IPRL.  The 
transport of F-Na was not affected by dose escalation.  Data shown are expressed as mean ± S.D (n=3 
for 4 µg dose, n=17 for 40 µg dose, n=3 for 160 µg dose).  
From table 3.5, it can be seen that dose escalation of F-Na did not increase the percentage of 
deposited dose absorbed, and only increased cumulative mass absorbed in proportion to dose 
deposited.  No significant (p>0.05) effect on initial kin was observed. 
Treatment 
(Nominal dose) 
MW 
(g.mol-1) 
Stokes 
diameter 
(nm) 
Cumulative mass of 
F-Na absorbed by 60 
min(µg) 
Percentage of deposited 
dose absorbed by 60 
min(%) 
kin (min
-1) 
F-Na (4 µg) 
F-Na (40 µg) 
F-Na (160 µg) 
396 
396 
396 
1.5 
1.5 
1.5 
1.56 ± 0.39 
26.44 ± 3.95 
103.86 ± 10.45 
 63.0 ± 16.4 
 67.5 ± 13.4 
 63.8 ± 5.7 
 
0.027 ± 0.005 
0.037 ± 0.008 
0.040 ± 0.014 
 
 
Table 3.5 Transport of airway administered F-Na dose across the IPRL.  Increasing nominal dose of F-
Na had no significant (p> 0.05) effect on F-Na transport.  Data are expressed as mean ± S.D, (n=3 
except F-Na 40 µg where n=17).  kin was determined from the initial linear portion of all absorption 
plots, all F-Na data in table 3.5 was determined by plate-reader assay.   
p>0.05 p>0.05 
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Similarly, a molecular weight range of FITC-labelled dextran (FD) probes were also dosed to IPRL 
preparations.  Figure 3.9 illustrates the cumulative transport of FD4, FD20 and FD70 over a 60 min 
period of time, in a contrasting manner to F-Na studies, MW and not nominal dose was increased.  
Increasing the molecular weight of FTIC-labelled dextran resulted in a disproportionate decrease in 
percentage probe absorbed.  
 
Figure 3.9 Cumulative % of deposited dose of FITC-labelled dextran absorbed with time across the 
IPRL.  The transport of F-Na (40 µg) was included for reference.  Data shown are expressed as mean 
± S.D (n=3, except n=17 for F-Na 40 µg dose).  
Table 3. 6 illustrates that MW escalation of FITC-labelled dextran affected the cumulative mass of FD 
absorbed, the percentage of FD absorbed and initial kin. An increase in MW from 3820 g.mol
-1 to 
20200 g.mol-1 (x5.29 increase) resulted in a x1.97 (p<0.05) decrease in the percentage deposited 
dose absorbed by 60 min An increase from 20200 g.mol-1 to 75090 g.mol-1 (x7.12 increase) in FD 
resulted in a x2.78 (p<0.05) decrease in percentage deposited dose absorbed.  Further, kin for initial 
FD absorption also decreased with increasing MW.  However, only an increase in MW from 3820 
g.mol-1 to 20200 g.mol-1, showed a significant (p<0.05) decrease in initial kin suggesting initial kin to 
plateau with increasing MW.   
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Treatment 
(Nominal 
dose) 
MW 
(g.mol-1) 
Stokes 
diameter 
(nm) 
Cumulative mass of 
FD absorbed by 60 
min(µg) 
Percentage of deposited 
dose absorbed by 60 
min(%) 
Kin (min
-1) 
FD4 (200 µg) 
FD20 (200 µg) 
FD70 (200 µg) 
3820 
20200 
75090 
2.8 
6.6 
12 
95.01 ± 10.40 
41.82 ± 7.20  
18.67 ± 6.27 
     45.2 ± 6.2* 
     23.1 ± 7.6* 
     8.3 ± 2.1* 
 0.022 ± 0.013† 
 0.004 ± 0.013 
 0.002 ± 0.0002 
 
Table 3.6 Transport of airway administered FITC-labelled dextran across the IPRL.  Data shown are expressed 
as mean ± S.D (n=3).  kin was determined from the initial linear portion of all absorption plots, all FD data in 
table 3.6 was determined by plate-reader assay.      
*Percentage deposited dose significantly different (p<0.05) to all other FITC-labelled dextran probes in table 
3.6 
†Kin significantly different (p<0.05) to all other FITC-labelled dextran probes in table 3.6 
3.3.5. Validation of the IPRL – gel filtration of FITC-dextrans 
The potential metabolism of FITC-dextrans in the IPRL was investigated via gel filtration 
chromatography.  Figure 3.10 A-C illustrate that, when transported through the IPRL and collected in 
perfusate, each FITC-dextrans probe only exhibited 1 peak when analysed fluorometrically.  This 
suggests that it was the transport of FITC-dextrans as a whole that was being followed through the 
IPRL. 
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Figure 3.10 Gel filtration chromatography of FITC-dextrans; pre IPRL dose solution and post IPRL 
90 min perfusate sample.  Figure 3.10A represents FD4 chromatography. Figure 3.10B represents 
FD20 and figure 3.10C represents FD70.  A single peak can be observed for each sample.  Data are 
expressed as mean ± S.D. (n=3 for each sample). 
3.3.6. Validation of the IPRL – determining IPRL viability by wet: dry weight 
In order to assess the viability of the IPRL preparation following dosing by a forced solution 
instillation method, the lung wet: dry ratio of each IPRL performed was established.  Table 3.7 
illustrates the mean wet: dry ratio for each of the ‘validation IPRLs’ performed.  A ratio of 4 and 
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below was considered to be normal i.e. no significant lung damage or oedema formation.  Tissue 
water content was also established using the formula:   
W
WWV
wet
drywet
w
mLg
−
=)/(  
Where: 
Tissue water content (Vw); calculated assuming density of 1 g/mL 
As can be seen in table 3.7, the value of wet: dry ratio and water content for each validation 
treatment does not vary significantly (p>0.05) over the entire range of experiments performed, wet: 
dry ratio varying by 1.45 and tissue water content varying by 0.21 g/mL from lowest to highest data 
point, suggesting the IPRL to be reproducibly stable when meeting the wet: dry ratio criteria.    
When examining the wet: dry ratio of failed experiments i.e. visual signs of lung damage/oedema 
formation, the mean ratio obtained was x3.39 higher than the mean ratio for successful 
experiments.  As can be seen in table 3.7, both the lung wet: dry ratio and tissue water content of 
failed experiments was significantly different (p<0.05) from all other experiments.  Statistical 
difference was determined by a one-way ANOVA and post-hoc Duncan’s test.   
Treatment 
(Nominal dose) 
Tissue wet 
weight (g) 
Tissue dry 
weight (g) 
Wet: Dry ratio Tissue water content 
(g/mL) 
F-Na (4 µg) 
F-Na (40 µg) 
F-Na (160 µg) 
2.16 ± 0.93 
2.38 ± 1.04 
1.83 ± 0.58 
0.64 ± 0.26 
2.43 ± 3.12 
0.49 ± 0.23 
3.49 ± 1.00 
2.96 ± 1.28 
3.98 ± 0.62 
0.70 ± 0.09 
0.55 ± 0.29 
0.74 ± 0.04 
FD4 (200 µg) 
FD20 (200 µg) 
FD70 (200 µg) 
3.37 ± 1.24 
1.07 ± 0.48 
1.73 ± 0.20 
1.36 ± 0.13 
0.31 ± 0.04 
0.49 ± 0.12 
2.51 ± 0.93 
3.50 ± 1.56 
3.59 ± 0.38 
0.53 ± 0.25 
0.65 ± 0.20 
0.72 ± 0.03 
Failed 
Experiment 
2.39 ± 0.84 0.22 ± 0.10 11.32 ± 2.27* 0.91 ± 0.02† 
 
Table 3.7 Calculated lung wet: dry ratio and water content of rat lung tissue determined by lyophilisation 
subsequent to an IPRL procedure.  Data shown are expressed as mean ± S.D (n=3 for F-Na treatment except 
F-Na 40 µg where n=11, n=3 for FITC-labelled dextran treatment, n=4 for ‘failed experiment’). 
*Wet: Dry ratio significantly different (p<0.05) to all other fluorescent probes in table 
†Tissue water content significantly different (p<0.05) to all other fluorescent probes in table 
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3.3.7. Relationship between absorption rate and molecular weight across the IPRL 
The principal aim of this chapter was to assess the suitability of the IPRL to the examination of 
pulmonary transport; therefore, the relationship between initial absorption and molecular weight of 
each probe dosed to the IPRL was examined.  Figure 3.11 illustrates the relationship between initial 
transport rate (kin) and the size related characteristic Stokes’ diameter.  The observed decrease in 
initial kin with increasing Stokes’ diameter demonstrating the molecular size dependent transport of 
the fluorescent probes examined.  
 
Figure 3.11 The relationship between initial transport rate (kin) and Stokes’ diameter of four 
fluorescent probes; illustrating the influence of MW upon initial absorption across the IPRL.  (F-Na -
MW 396, FD4 - MW 3820, FD20 - MW 20200, FD70 - MW 75090).  kin was determined from the initial 
linear portion of each cumulative transport curve.  All data are mean ± S.D., (n=3 except F-Na where 
n=17).
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3.4. Discussion 
Investigation of the pulmonary route of administration as an alternative, non-parenteral route of 
delivery for macromolecules to the systemic circulation has advanced greatly in recent times and will 
likely break new ground in aiding the development of new non-invasive therapeutic treatments.  
Further, the pulmonary disposition for many low molecular weight drugs remains unknown but 
whose pharmacokinetics in the lung is important for local pulmonary pharmacology.  From this 
perspective, the development of suitable models of the pulmonary system to examine drug 
transport is of great significance and has led to the development of an ex vivo isolated perfused lung 
model that accurately fulfils the required criteria [8, 22].   
Primarily, this chapter focussed on the development and validation of an ex vivo isolated perfused 
rat lung model.  The inherent nature of this isolated perfused rat lung model, developed from that of 
Byron et al. [95, 96], creates an accurate representation of the in vivo state while allowing full 
control of experimental parameters, maintenance of tissue architecture and importantly, affords 
sufficient determination of the pharmacokinetic parameters involved in pulmonary absorption.  
In order to ensure the applicability of the IPRL to the study of drug transport across the lung, a 
number of experiments were conducted to allow full validation of this lung model.  Validation 
included examination of the extent to which BSA contributes to background fluorescence in IPRL 
perfusate, determination of the reproducibility of the forced instillation dosing method; both in 
terms of dose deposition and amount of dose retained in equipment post-dosing, validation of the 
model as an instrument to examine pulmonary drug transport, i.e. through studying transport of a 
molecular weight range of fluorescent probes, and establishing the viability of each IPRL preparation 
post-dosing.     
The addition of BSA to IPRL perfusate is regarded as a critical addition in order to protect the lung 
from the development of pulmonary oedema [83].  Fisher and colleagues illustrated a 2.47 to 5.25 –
fold decrease in time to oedema formation with the addition of 3 % BSA to perfusate in their 
isolated rat lung preparation [332].  Further, the presence of albumin at the vascular lumen is well 
accepted to modulate protein permeability in pulmonary microvascular beds and Czartolomna and 
colleagues illustrated a >120 % increase in lung ‘permeability - surface area product’ (vasculature to 
lung) when replacing perfusate BSA with a synthetic alternative in perfused lungs; suggesting the 
importance of albumin inclusion in perfusate [333]. 
The illustrated importance of BSA inclusion in IPRL perfusate reflects the importance of its 
contribution to oncotic pressure and indeed contribution to drug transport/absorption where a drug 
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is influenced by albumin binding capacity.  The perfusion media used in this chapter was prepared 
with 4 % BSA, in line with previous reports of perfusate BSA concentration by users of the ‘Byron et 
al.’ model [95, 334].  Whilst the inclusion of BSA to perfusate was unquestionable, it was sought to 
clarify the extent to which this inclusion contributed to background fluorescence and therefore 
limited the ability to detect fluorescence-emitting molecules using non-chromatographic methods. 
As can be seen in table 3.1, both the Biosera and Sigma BSA products displayed much higher 
background readings than perfusate minus BSA, demonstrating that the inclusion of any BSA will 
reduce the limit of quantitation by potentially masking compound fluorescence readings.  Of the two 
products, it was the Sigma BSA that provided the lowest background fluorescence, with a reading 
13.7-fold higher than perfusate not possessing BSA.  The Biosera BSA provided background 
fluorescence x9.0-fold higher than perfusate not possessing BSA.  This obvious difference in 
generated background fluorescence highlighted the Sigma BSA as product of choice for perfusate 
inclusion.  Further, within the literature, this exact product has been previously included in IPRL 
perfusate [334].  Of the two BSA products, Sigma BSA is also of higher quality than Biosera BSA and 
has also been dialysed, reducing its fluorescence.  These results confirmed the selection of the Sigma 
BSA for all subsequent IPRL experiments.            
The novel dosing method employed in this and subsequent chapters has been utilised previously and 
was first exploited in the isolated lung preparation by Byron & Niven in 1988 [96].  During its 
establishment, this method was successfully validated and proved to give highly reproducible dosing 
in terms of both delivered dose and fraction of dose reaching the lobar lung [96].  This forced 
instillation technique has now been extensively utilised in published IPRL work addressing solute 
transport across the rodent lung; an excellent literature database is provided for reference and 
comparison when validating the dosing method used in the current work [324-327, 335, 336]. 
Validation of the forced solution instillation dosing method was undertaken to ensure the technique 
was complete and reproducible.  Lung deposition pattern, together with reproducibility in amount of 
dose delivered, was examined whist employing dosing method to ‘test’ IPRL procedures.  The major 
constituent parts of the forced solution dosing method, i.e. a dosing cartridge extended to the rat 
trachea allowing expulsion of a dose via a propellant only pMDI, creates a proficient dosing method 
capable of efficient dosing to the deep lung.  The custom made dosing rod aids in removing dosing 
inconsistencies by offering a set dose volume to the same position in subsequent preparations, 
further, the MDI actuator influences particle size and thus lung deposition via it’s nozzle diameter 
and the non-toxic MDI propellant aids in delivery by reproducibly inflating the lungs by a set volume 
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[337].  From this, the custom dosing system introduces a coarse spray with enough force to reach 
the deep lungs including reaching the extensive absorptive area offered by the alveolar region [337]. 
The technique also allows determination of the exact dose deposited by the collection of drug 
retained in the dosing rod and tracheal cannula.  Through implementing a number of validation 
techniques, the results of this chapter found the forced solution instillation procedure delivered 
approximately 86 % of a nominal dose of test substrate to the tissue of the IPRL preparation.  Such 
percentages of drug delivered mirror that of other data reported in the ‘Byron IPRL’, for example, 
Sakagami et al. reported delivery of 94.7 ± 1.7 % of a 0.02 mg F-Na dose introduced to the IPRL via 
the forced instillation procedure [101].  As can be seen in table 3.2, only 5.74 ± 1.40 % of a 40 µg F-
Na dose remained in dosing equipment after deployment of dose to the IPRL.  Further, as is 
illustrated in figure 3.6, the majority of remaining dose was found in the tracheal cannula indicating 
that a small percentage (2.53 ± 1.52 %) of dose suffered impaction at the first bifurcation of the 
conducting airways with subsequent rebound into the tracheal cannula.   
The distribution of expelled dose within the lung was examined by introduction of Evans blue and F-
Na by the forced instillation method.  While the dosing of Evans blue provided a visual distribution 
pattern to the lobar lung (Figure 3.7B) poor tissue extraction of the dye rendered the results 
unreliable.  As can be seen in table 3.4, the distribution of F-Na dosed to the IPRL is constrained 
almost exclusively to the lobar region of the lung.  The results illustrate poor reproducibility in terms 
of intra-lobular deposition in certain lung lobes; however, what is consistent is the percentage of 
dose delivered to the trachea and major bronchi suggesting similar consistency in delivery to the 
lobar lung as a whole.  In a similar manner, Sakagami et al. also investigated the initial distribution of 
F-Na in an IPRL following forced solution instillation.  While the presence of dose in specific lobar 
regions illustrated variability, again the percentage of dose deposited to the trachea was consistent.  
Further, when comparing in vivo and ex vivo (IPRL) dose distribution following forced solution 
instillation, Sakagami et al. reported little difference in the deposition patterns, highlighting that 
dose deposition in the IPRL can accurately represent deposition in vivo [101]. 
The findings of the dosing equipment validation experiments performed in this work gave assurance 
to the forced solution instillation dosing strategy. Further, in their validation of this dosing strategy, 
Byron and Niven reported no significant difference in F-Na absorption half-life determined with 
either forced instillation technique or instillation via syringe suggesting the forced instillation 
technique not to damage lung integrity and therefore influence substrate absorption.  In addition to 
this, the establishment of accurate and reproducible dosing to the absorptive surfaces of the lobar 
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lung gives further confidence to the IPRL preparation as a whole in the examination of pulmonary 
drug absorption [96].   
In order to provide support to accurate data interpretation, gravimetric analysis of IPRL tissue post-
preparation was conducted.  Together with the continuous monitoring for visual signs of pulmonary 
oedema, the analysis of tissue wet: dry weight has been extensively used to determine tissue 
viability [101, 338, 339].  Through ascertaining lung wet: dry weight post-IPRL and assuming that 
increase in tissue weight implied alterations in physiology such as oedema formation, each IPRL 
preparation was investigated to ensure that no significant tissue damage was induced by the forced 
instillation of any test substrate to the lung.   
As is illustrated in table 3.7, the calculated wet: dry ratio of validation IPRL preparations deemed to 
be viable varied only between 2.51 ± 0.93 and 3.59 ± 0.38 while the mean wet: dry ratio of unviable 
preparations was 11.32 ± 2.27, a statistically significant increase.  A number of studies have 
established that average lung water content is ~80 % providing a wet: dry ratio of ~4 [338], a ratio 
beyond which no ‘validation IPRL’ exceeded.  Further, when displaying wet: dry weight as lung water 
content, all ‘validation IPRLs’ displayed a water content of between 0.53 ± 0.25 g/mL and 0.74 ± 0.04 
g/mL, a range comparable to that reported in the literature [339-342].  Performance criteria such as 
this gave assurance that pulmonary oedema did not alter tissue physiology or the absorption 
characteristics of the drugs.    
The study of drug transport across the lung follows the complex processes of drug deposition, 
passive and active absorption, metabolism and tissue binding and the interplay of host defences.  
Because of such complex, region-specific processes, it is experimentally difficult to analyse the 
kinetic expressions associated.  One of the more universal descriptors of pulmonary absorption is 
substrate absorption rate.  Within this chapter, an IPRL lung permeability profile using a range of 
varying molecular size hydrophilic probes was constructed and the establishment of initial 
absorption rate, amongst other characteristics, determined.  The choice of F-Na and FITC-labelled 
dextran probes for validation was based upon the properties of these solutes.  Chosen probes were 
hydrophilic and known to be non-metabolised, -degraded, -tissue bound nor sequestered in the lung  
[325, 326, 335, 336, 343].  The probes F-Na and FD4 are also known to be passively transported 
across the lung in vivo and in vitro therefore signifying pulmonary region-specific absorption to be 
dose independent [344]. 
The cumulative percentage transport curves for F-Na across the IPRL, figure 3.7, illustrate no dose 
dependency in transport, indicating a passive absorption mechanism.  Despite dose escalation, the 
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percentage deposited dose absorbed by 60 min was ~ 64 % (63.0 ± 16.4 – 67.5 ± 13.4) across the 
dose range.  Sakagami et al. also report dose independent transport of F-Na across their IPRL and 
witnessed a similar ~ 60 % transport of deposited dose 60 min post-dosing [101].  The calculation of 
initial absorption rate (kin) from the linear portion of cumulative transport curves show F-Na to 
demonstrate kin of 0.027 ± 0.005 to 0.040 ± 0.014 min
-1 across the IPRL, corresponding closely to 
those within the literature [95, 96, 101].   
When examining the transport of FITC-labelled dextran across the IPRL, an inverse relationship with 
molecular weight was observed.  As can be seen in figure 3.9, increasing molecular weight of probe 
administered to the IPRL whilst maintaining the same dose, resulted in a decrease in the percentage 
deposited dose absorbed by 60 min There was also a general trend for the initial rate of transport, 
kin, to decrease with increasing molecular weight of solute.   Together, the transport data of F-Na and 
FD’s across the IPRL, i.e. the smaller F-Na traversing faster that FD4 etc, suggest macromolecule 
absorption to be somewhat influenced by diffusion.  The data is also consistent with the recognition 
that the lung generally shows higher permeability compared to other mucosal barriers [46].     
Previous efforts have been made to consolidate lung permeability data and expose specific trends.  
Throughout the literature, there are many instances of molecular size influencing transport across 
the lung, [35, 101, 345-347]. In 1983, Effros and Mason compiled available data for solutes of ≤ 500 
kDa and reported that permeability of the lung to a wide molecular weight range of solutes 
displayed a linear relationship between the absorption rate as a dependent variable (kin in this 
chapter) and  as an independent variable.  Note that comparison of  between each solute 
approximates to relative free diffusion coefficients as defined by Stokes’ equation [36].   The F-Na 
and FD data in this chapter agree with this trend and figure 3.11 highlights that an increase in Stokes’ 
diameter resulted in a decrease in initial absorption across the IPRL.   
The permeability of the lung to such an extensive molecular weight range of hydrophilic solutes is 
widely regarded and the results of this chapter confirm and complement such findings.  Within the 
IPRL, the absorption of test probes examined appears to conform to a first-order rate, as determined 
from cumulative absorption curves.  This again conforms to the literature database where works 
such as that of Niven and Byron [96] report passive absorption from the airway to be a first-order 
process. 
The agreement of data generated from this IPRL to that within the wider literature allow several 
assumptions to be made regarding this model.  Firstly, together with advanced kinetic modelling, the 
IPRL can allow accurate and reliable examination of complex disposition mechanisms, clarifying the 
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contribution of each [23].  Secondly, the accurate control of experimental parameters and the 
confirmation that dosing method and dose distribution echo that of in vivo state give confidence to 
IPRL generated data and to data interpretation.   
Overall, the principal aim of this chapter was to create a valid lung model for examining pulmonary 
delivery.  The results of this chapter confirm the IPRL and its custom dosing method to fulfil this 
criterion allowing for research into the understanding of pulmonary absorption and examination of 
the processes involved.         
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Chapter 4 
Functional significance of an active drug transporter (P-gp) 
upon the substrates delivered to the Isolated Perfused Rat 
Lung 
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4.1. Introduction 
The applicability of the lung as a drug delivery route presents obvious advantages in providing local 
delivery for drugs acting in the lung; enabling reduced drug dosage to the patient, while maximising 
local beneficial effects and minimising systemic adverse effects.  Further, it presents a non-invasive 
(i.e. avoiding injection) route of administration for the systemic delivery of drugs, and in doing so, 
bypasses hepatic first-pass metabolism, and provides for the potential for the rapid onset of drug 
action.  The intrinsic biological properties of the lung, e.g. large epithelial surface area, together with 
the advances made in aerosol science and device technology continue to promote the lung as an 
important route of drug delivery [20, 22, 41, 348, 349].   
The airways of the lung represent a series of bifurcations of decreasing luminal diameter, the 
epithelial surface of which undergoes marked morphological transition from the trachea and major 
bronchi through to the terminal bronchioles and into the gaseous exchange region of the alveoli.  
This complex branching system with the differing nature of the epithelial barrier means that the 
extent of lung epithelial transport for any given inhaled drug dose is highly dependent upon the 
variable patterns of inhaled aerosol deposition.  Beyond this, a number of complex biological 
barriers protect the lung from the external environment.  These include the secretion of mucus onto 
the epithelial surface within the conducting airways of the lung affording subsequent clearance of 
any deposited particles through the actions of the mucociliary escalator.  Further, macrophages 
within the lung undertake phagocytosis to remove any inhaled particulates not cleared by the 
mucociliary barrier [18, 21, 22, 350].   
Drug transporters expressed within the lung epithelial cells can clearly influence drug transport 
across the lung epithelium, with transported drug reaching the submucosal tissue for localised 
effects or progressing to the blood capillaries giving rise to systemic absorption.  It is increasingly 
apparent that the expression of drug transporters within lung epithelium varies throughout the 
conducting and gaseous exchange regions of the lung [351].  It follows that the pattern of deposition 
of inhaled drug within the lung will influence the exposure of drugs to any particular transporter.  
For example, the neonatal transporter for IgG, i.e., FcRn, appears to be predominantly expressed 
within the epithelium of the larger airways, and as such, delivery of antibodies via the lung for the 
purposes of systemic absorption would benefit from targeting the larger proximal airways rather 
than the more peripheral distal airways.  Indeed, Bitonti and Dumont have successfully shown proof 
of concept and have reported delivery of erythropoietin-Fc by inhalation via an immunoglobulin 
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transport pathway; they have also successfully experimented with other Fc-fusion proteins of 
therapeutic relevance [22, 352, 353]. 
For low molecular weight drugs inhaled into lungs for the purposes of local therapeutic benefit or for 
the purposes of achieving systemic absorption, it is the impact of drug transporters belonging to the 
ABC and SLC/SLCO superfamilies of membrane transporters that will be of potential importance. 
There exists increasing literature providing evidence localising several drug transporters to the lung.  
For instance, Bosquillon has reviewed the varying expression of a number of ABC, SLC and SLCO 
transporters in the human lung [354].  Endter et al. [104] have reported the presence of selected 
ABC, SLC and SLCO transporters in human lung epithelial cell models and Bleasby et al. [69] have 
investigated the presence of 50 known xenobiotic transporters in human tissues and reported 32 of 
the examined transporters to display > 25 % absolute intensity within the human lung as determined 
at the level of mRNA [69]. 
Amongst the number of documented drug transporters with a recognised presence within the lung, 
the ABCB drug transporter P-glycoprotein/MDR1 (P-gp) is perhaps the most researched.  P-gp is 170 
kDa glycosylated membrane bound protein and, in consensus with the majority of ABC transporters, 
is comprised of two homologous domains coupled together by a linker region [128].  
P-glycoprotein is expressed in a variety of biological barriers, including most notably the liver and 
epithelial cells of kidney and intestine as well as the brain microvascular cells of the blood-brain 
barrier.  It is apparent that this pattern of expression for P-gp can have a profound effect upon the 
absorption, distribution and elimination of drugs.  P-gp is widely expressed within the body, for 
example, Bleasby et al. [69] reported the presence of P-gp at > 25 % absolute intensity in half of the 
40 human tissues and organs examined.  P-gp has attracted much attention as an efflux transporter 
due to its ability to efflux a plethora of structurally unrelated, clinically relevant substrates [69, 129, 
352]. Table 4.1 illustrates a selection of these clinically relevant substrates, in turn highlighting the 
implicated importance of P-glycoprotein within the fields of drug discovery, drug delivery and 
pharmacokinetics.            
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   Anti-Cancer 
drugs 
Antibiotics 
 
Antiemetics Cardiac 
Drugs 
Ca
2+
 
Blockers 
β-Blockers CNS Drugs 
 
Substrate Daunorubicin 
Irinotecan 
Paclitaxel 
Topotecan 
Doxorubicin 
Mitomycin C 
Tamoxifen 
Vinblastine 
Doxetaxel 
Mitoxantrone 
Tenoposide 
Vincristine 
Cefazolin 
Cefoperazone 
Erythromycin 
Levofloxacin 
Domperidone Amiodarone 
Digitoxin 
Digoxin 
Propafenone 
Quinidine 
Diltiazem 
Mibefradil 
Nicardipine 
Verapamil 
Bunitrolol 
Celiprolol 
Talinolol 
Perphenazine 
Phenoxazine 
Phenytoin 
 
 Antihistamines 
 
HIV Protease 
Inhibitors 
 
Immuno-
Supressants 
 
Lipid 
Lowering 
Drugs 
Morphins Steroids  
Substrate Fexofenadine 
Terfenadine 
Cimetidine 
Ranitidine 
 
 
Amprenavir 
Indinavir 
Nelfinavir 
Ritonavir 
 
Cyclosporine 
Tacrolimus 
Atorvastatin 
Lovastatin 
Simvastatin 
Morphine 
Loperamide 
Aldosterone 
Dexamethasone 
Hydrocortisone 
 
Table 4.1 Several clinically relevant examples of substrates of the ABCB family transporter P-gp.  
Substrates are structurally and functionally diverse highlighting of the importance of P-gp in pharmaceutical 
research.  Adapted from [162, 355]. 
Although P-gp substrates represent a diverse range of therapeutic and chemical properties, the 
localisation of the substrate binding sites for P-gp to the interior of the plasma membrane results in 
P-gp substrates generally displaying hydrophobic properties.  The molecular size of molecules does 
not appear to be highly influential as a limiting factor in P-gp transport and a size range of ~ 200 – 
1900 Da is common [129]. The hydrophobic nature of P-gp substrates required to access P-gp 
binding sites from within the membrane bilayer also provides for a unique balance of factors that 
determine the impact of P-gp efflux upon overall epithelial or endothelial transport.  The factors 
promoting P-gp efflux would include; a higher expression of P-gp in the biological membrane, a 
higher affinity of drug for P-gp, a drug displaying lower intrinsic passive membrane permeability, i.e., 
P-gp efflux is able overcome more readily the drug’s passive membrane permeability.  Conversely, 
factors diminishing the role of P-gp efflux would include; a lower expression of P-gp in the biological 
membrane, a lower affinity of drug for P-gp, a drug displaying higher intrinsic passive membrane 
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permeability, i.e., P-gp efflux is less able to overcome the drug’s passive membrane permeability 
[129, 356].  A further consequence of the above is that the inhibition of P-gp will provide increased 
availability of a drug substrate to cross the biological barrier and reach its target site.  
Initially, the development of modulators for P-gp was sparked by the desire to overcome P-gp 
associated multi-drug resistance in cancer cells [357, 358]; however, wider applicability soon became 
apparent.  Early recognised inhibitors of P-gp, such as verapamil, served as poor substrates but 
nevertheless competitive inhibitors.  However, such 1st generation P-gp inhibitors often exerted their 
own pharmacological effects upon the body, e.g., verapamil and cardio-toxicity, thus limiting their 
applicability as clinical P-gp inhibitors.  Successive generations of P-gp modulators were then 
developed with the aim of optimising specificity and action [129].  Inhibitors of P-gp can be classified 
into one of three generations, First generation inhibitors - clinically active drugs with pharmaceutical 
roles other than the inhibition of P-gp but which are also known to exhibit P-gp inhibitory activity.  
Second generation inhibitors – where the off-target pharmacology of first-generation inhibitors was 
reduced as the molecules were engineered to display increased affinity for P-gp.  Third generation 
inhibitors – novel P-gp modulators, manufactured with high P-gp specificity and low toxicity [357].  
Table 4.2 lists examples of known P-gp inhibitors.           
 P-gp modulators 
1
st
 Generation Cyclosporine A 
Verapamil 
Quinidine 
Tamoxifen 
Toremifene 
Reserpine 
Yohimbine 
2
nd
 Generation SDZ PSC833 (Valspodar) 
S9788 
R-verapamil 
VX-710 
VX-853 
MS-209 
PSC-833 
3
rd
 Generation GF120918 (Elacridar) 
OC144-093 (Ontogen) 
XR9576 (Tariquidar) 
LY335979 (Zosuquidar) 
Table 4.2 Selected P-gp specific transport modulators.  Adapted from [358, 359]. 
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The broad substrate specificity and diverse expression profile displayed by P-glycoprotein implies a 
role in defence through extrusion of xenobiotics.  It therefore follows that P-glycoprotein present in 
the lung would also fulfil this implied protective role.  P-glycoprotein expression throughout the 
respiratory system has become increasing well documented.  In the human lung alone, P-gp has 
been localised to a number of cells at an mRNA and protein level.  For example, MDR1-P-gp has been 
localised to bronchial epithelial cells, bronchial capillary endothelial cells, alveolar epithelia and 
alveolar macrophage [43, 104, 108, 110, 112].  Further, the transporter has been 
immunohistochemically localised to both the apical and basolateral membrane of nasal ciliated 
epithelial cells [109], epithelial cells of the trachea and bronchi [108] and also epithelial cells of the 
distal lung.  Campbell et al., immunohistochemically displayed P-glycoprotein in human AEI cells but 
not AEII and also paralleled this work in rat alveolar epithelia [137].  Further, these authors 
demonstrated polarised P-gp function in the alveolar epithelial cells effluxing P-gp substrate into 
what would be the luminal or airway surface.  Functional P-glycoprotein efflux has also been 
reported to be present in the intact rabbit lung through use of an isolated lung preparation.  Here 
Roerig et al., observed accumulation in the lung of the P-glycoprotein substrate, rhodamine 6G, as 
determined by monitoring the disappearance of rhodamine 6G from circulating perfusate.  The 
accumulation in the lung was increased by the introduction of the P-glycoprotein inhibitor, 
GF120918, into the perfusate [355].   This data of Roerig et al. is indicative that there is an efflux 
mechanism that hinders transport of drug from blood into the lung.  It is yet to be confirmed by 
other investigators in an intact isolated lung model, however, it is of note that there are conflicting 
results regarding studies conducted in mdr1a/mdr1b knockout mice, where following parenteral or 
oral administration, a range of P-gp substrates have shown a greater lung accumulation of these P-
gp substrates over that in wild-type normal mice [360-362].  
Demonstration that P-gp in the lung can affect lung epithelial transport would have significance for 
airway residence and systemic absorption of P-gp substrates administered by the inhaled route and 
also for the accumulation from the systemic circulation of P-gp substrates administered by non-
pulmonary routes. 
Aims and Objectives 
In this chapter, it will be sought to: 
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• Investigate the functional expression of P-glycoprotein in the intact isolated perfused rat 
lung through examining the pulmonary absorption pharmacokinetics of a P-gp substrate and 
the impact of chemical modulation of P-gp activity. 
• The use of an ex vivo isolated perfused rat lung model will be employed to achieve 
maintenance of tissue structure and function while excluding the whole body disposition 
issues that can complicate in vivo pharmacokinetic studies. 
• It is hypothesised that the model will provide for a higher level of precision and will permit 
the use of a novel dosing mechanism to the lung, which has been validated and utilised in a 
previous chapter.   
• In order to demonstrate the functional significance of P-glycoprotein, a number of P-
glycoprotein substrates (rhodamine 123, digoxin, and flunisolide) will be instilled into the 
airways of the IPRL.   
• Further, the known P-gp inhibitor GF120918 will be co-instilled in a parallel treatment arm to 
illustrate inhibition of an active efflux process. 
• It will also be aimed to address the issue of P-gp upon lung accumulation; examined by 
investigating the perfusate to lung accumulation of rhodamine 123 and the subsequent 
affect of GF120918.  
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4.2. Materials and Methods 
4.2.1. Materials 
Consumables and reagents 
Rhodamine 123; Rh123, >98 % electrophoresis grade, (Sigma-Aldrich, Dorset, UK, Cat: R-8004) 
Sodium fluorescein; F-Na, (Fluka, Sigma-Aldrich, Dorset, UK, Cat: 46960) 
Acetonitrile; ACN, 99.6+ %, HPLC grade, (Fisher Scientific, Loughborough, UK, Cat: A/0626/17) 
Sodium acetate buffer, 20 mM, pH 3.6/pH 4.0, (Fisher Scientific, Loughborough, UK, Cat: 
BPE334-       500)      
GF120918; obtained from GlaxoSmithKline, Stevenage, UK. 
Flunisolide, (Sigma-Aldrich, Dorset, UK, Cat: F5021-100MG) 
Formic acid, 98+ %, (Acros Organics, Fisher Scientific, Loughborough, UK, Cat: 14793-2500) 
Dimethyl sulfoxide; DMSO, BioReagent, for molecular biology, ≥99.9 %, (Sigma-Aldrich, Dorset, 
UK, Cat: D8418-50ML) 
HPLC grade H2O, (Fisher Scientific, Loughborough, UK, Cat: W/0106/PB17) 
IPRL perfusate incl. bovine serum albumin; BSA, (Sigma-Aldrich, Dorset, UK, Cat: A7906-1kg; See 
chapter 3) 
HPLC System 
 Thermo Finnigan™ SpectraSYSTEM™ (Thermo Scientific, Loughborough, UK) 
  Solvent degasser - SCM1000 
  Injector - AS3000 
  Pump - P2000 
  UV - UV2000 
  FL - FL3000 
HPLC Column 
4 µm Genesis C18 column, (Grace, Illinois, USA).    
IPRL equipment 
Perfusate lines: Masterflex 96400-14 peroxide cured, (Fisher Scientific, Loughborough, UK, Cat: 
PMM-505-515G) 
 Peristaltic pump: Gilson, Inc., (Middleton, WI, USA, Model: Minipuls 3) 
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Radiochemicals and associated material 
 Digoxin, [3H(G)]-, 1 mCi/mL, specific activity 15-40 Ci/mmol, (PerkinElmer, USA, Cat: 
NET222250UC) 
Mannitol, D-[1-14C]-, 0.5mCi/mL, specific activity 45-60 mCi/mmol, (PerkinElmer, USA, Cat: 
NEC314250UC) 
Scintillation cocktail high performance ScintiSafe 3 (formally known as Optiphase Hi-safe 3) 
liquid scintillation counting, (Fisher Scientific, Loughborough, UK, Cat: SC/9205/21) 
Scintillation vials, (Fisher scientific, Loughborough, UK, Cat: FB72435) 
Animals – Cardiff University 
Male-specified pathogen-free Sprague-Dawley rats (Harlan UK Limited, Bicester, UK) were used 
throughout and housed in rooms controlled between 19 °C – 21 °C and 40-60 % humidity with dark-
light cycling every 12 h.  The animals had free access to food and water and were acclimatised for at 
least 2 days prior to experimentation.  All animal experiments adhered to the Animal (Scientific 
Procedures) Act 1986, UK and were approved by Cardiff University.  
Animals – GSK  
Male Sprague-Dawley rats were used throughout.  All animals were housed in standard holding 
cages.  Water and food were available ad libitum throughout the study.  All animal experiments 
adhered to the Animal (Scientific Procedures) Act 1986, UK and were approved by GlaxoSmithKline 
R&D, Stevenage. 
4.2.2. HPLC analysis:  Rh123/F-Na analytical method development 
Method 
In order to effectively analyse Rh123 and F-Na in perfusate samples post dosing to the IPRL, an 
analytical method utilizing High Performance Liquid Chromatography (HPLC) was developed.  
Further to this, method precision, accuracy and limit of substrate quantitation were assessed. 
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Method development 
Substrate Mobile Phase  Ratio (%) 
Rh123 Acetonitrile 
dH2O 
20 mM Sodium acetate buffer (pH 4.0) 
50 
30 
20 
F-Na Acetonitrile 
dH2O 
20 mM Sodium acetate buffer (pH 3.6) 
45 
45 
10 
 
Mobile phase developed from Iqbal et al., 2005 [363] 
In order to establish the correct wavelength for solute detection, Rh123 (1 µg) was spiked into the 
appropriate mobile phase and fluorometrically scanned using a spectrofluorometer (Aminco-
Bowman; SQ-340).  An excitation scan was performed with wavelength ranging 300 – 600 nm and an 
emission scan performed using a wavelength range of 450 – 650 nm.  Figure 4.1 represents the 
resulting excitation and emission spectra obtained.    
 
Figure 4.1 Excitation and Emission spectra for Rh123 in mobile phase.  (    - Excitation spectrum,                 
- Emission spectrum). 
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From figure 4.2, subsequent solute concentrations were determined fluorometrically, Rh123 analysis 
undertaken at λex 500 nm, λem 540 nm and F-Na analysis undertaken at λex 485 nm, λem 520 nm 
(established from Chapter 3). 
Rh123 and F-Na samples (0.1 mL) were separately injected onto a 4 µm Genesis C18 column (Grace, 
Illinois, USA) and mobile phase was pumped through the HPLC system at an isocratic flow rate of 1 
mL/min with chromatic measurements being performed at room temperature.  Run time for Rh123 
and F-Na was 10 min Chromatogram peak asymmetry of ~ 65 – 135 % was accepted and solute 
retention time was determined as ~ 2.5 min for Rh123 and ~ 3.5 min for F-Na.  Figure 4.2 illustrates a 
typical Rh123 chromatogram. 
 
Figure 4.2 Example of a HPLC chromatogram produced by Rh123 sample. 
HPLC chromatography of IPRL perfusate that had been circulated through rat lungs was compared to 
Rh123/F-Na chromatography to ensure no interference in solute chromatograms as a result of the 
perfusate recirculation.  
Precision and accuracy 
While assays were initially developed with solute dissolved in mobile phase, the assay required that 
solute be analysed from perfusate.   
Deproteinisation was undertaken with the addition of acetonitrile (3:1 v/v Acetonitrile: Perfusate 
sample).  Samples were then equilibrated for 1 h at 37 °C and kept in darkness to avoid sample 
bleaching.  Each sample was subsequently centrifuged for 10 min at 18,000 g and the deproteinated 
sample supernatants (0.1 mL) were injected onto the HPLC column for quantitation.   
Deproteinated perfusate including the presence of spiked Rh123 or F-Na was injected onto the HPLC 
according to the above assays and subsequent chromatograms were deemed acceptable.  In order 
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to assess solute assay precision, Rh123 was spiked into three separate IPRL perfusate samples and a 
calibration curve prepared from the serial dilution of each.  A concentration range of 0.025 µg/mL to 
0.5 µg/mL Rh123 was prepared.  Three separate F-Na calibration curves were prepared in a similar 
manner, concentration range 0.01 µg/mL to 1 µg/mL.  Once sample concentrations were determined 
and individual calibration curves constructed, the coefficient of variation (CV) for each triplicate 
concentration point was determined and represented as a %.  A percentage of ≤ 15 % was deemed 
acceptable.   
Together with assay precision, the accuracy of the assay was also determined.  Three individual 
samples of Rh123 in IPRL perfusate were prepared at three varying concentrations.  This was 
repeated for F-Na.  Samples were prepared by spiking Rh123 or F-Na to perfusate and diluting to the 
concentrations; 0.25 µg/ml, 0.0625 µg/mL, 0.025 µg/mL.  Each sample was deproteinated as above, 
and concentration determined fluorometrically by HPLC.  Actual sample concentration (as 
determined by HPLC) was compared to theoretical (intended sample concentration) and accuracy 
determined.  Accuracy of ≥ 80 % - 120 % (Theoretical/Actual * 100) was deemed acceptable [364]. 
Limit of detection 
In order to establish assay lower limit of detection (LLD) and thus establish lower limit of 
quantitation (LLQ), a range of Rh123 concentrations were prepared by spiking Rh123 to IPRL 
perfusate and were deproteinated as above.  Again, this was repeated for F-Na.  Each set of samples 
was fluorometrically analysed via HPLC and the lowest detectable concentration determined.  A 
peak AUC (Area Under Curve) x3 baseline was accepted.  A concentration range of 0.00025 µg/mL 
(very low) to 1 µg/mL to was prepared to allow establishment of LLQ [364].       
4.2.3. Rh123 protein and tubing binding   
Method 
Rh123 Protein binding 
To assess an approximate extent and consistency of the fluorescent dye, Rh123 (Figure 4.3) binding 
to Bovine Serum Albumin, a range of Rh123 concentrations (0.0125 µg/mL to 5.0 µg/mL) were 
prepared by serial dilution in IPRL perfusate. 
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Figure 4.3 The 2D chemical structure of the fluorescent aromatic cation, rhodamine 123, at neutral pH 
[365]. 
Each individual concentration was prepared in triplicate and acetonitrile added to each at a ratio of 
3:1 (ACN: Sample).  Samples were equilibrated for 1 h in the dark and subsequently centrifuged for 
10 min at 18,000 g.  Sample supernatants were fluorometrically analysed using HPLC (as above). 
To allow comparison, Rh123 samples of the same concentration were also prepared in perfusate 
without the BSA (i.e. Krebs-Henseleit buffer). These samples were exposed to the same 
‘deproteinisation’ step as applied for full perfusate and subjected to fluorometric analysis.  Studies 
were performed in triplicate samples.  
Rh123 tubing binding 
To assess the extent to which IPRL perfusate tubing influenced Rh123 levels in perfusate through 
nonspecific binding, a range of Rh123 concentrations in IPRL perfusate were prepared in triplicate by 
serial dilution (0.01 µg/mL to 1.0 µg/mL).  Two conditions were assessed: (i) Pumping conditions - 
each perfusate sample (25 mL) was placed in a 50 mL glass beaker and passed through the tubing via 
the peristaltic pump in ‘recirculating mode’ for 1 hr.  Perfusate flow rate was set to that of the IPRL 
system; (ii) Static conditions - the same concentration range of perfusate samples were prepared as 
above and introduced to IPRL tubing via a pipette.  Again, samples were left for 1 hr.  
All samples were deproteinated with ACN (3:1; ACN: Sample), centrifuged for 10 min at 18,000 g and 
fluorometrically analysed by HPLC to allow comparison. 
To further establish the influence of the P-gp inhibitor, GF120918 upon Rh123 tubing binding, 
perfusate samples containing a concentration range of Rh123 (0.001 µg/mL to 0.5 µg/mL) were 
spiked with GF120918 (500 nM).  Similarly, perfusate samples containing GF120918 (500 nM) were 
spiked with a concentration range of Rh123 (0.001 µg/mL to 0.5 µg/mL) to ensure order of addition 
had no influence upon Rh123 tubing binding.  All samples were deproteinated with ACN (3:1; ACN: 
Sample), centrifuged for 10 min at 18,000 g and fluorometrically analysed by HPLC to allow 
comparison.   
The P-gp inhibitor, GF120918, was shown to have no influence upon Rh123 HPLC chromatography: 
(See section 4.2.5 for GF120918 analytical method development). 
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4.2.4. Rh123 absorption from airways: Dose-ranging studies 
Method 
Assumptions and assay conditions for determining choice of initial low Rh123 dose to administer into 
the airways of the IPRL: 
The LLQ for Rh123 HPLC is 0.25 ng/mL.  For an IPRL perfusate volume of 50 mL this would mean a 
lower limit of detection for a mass of 0.0125 µg or 12.5 ng of absorbed Rh123 dose.  If we assume a 
low extent of bioavailability for Rh123 and the need to be able to measure Rh123 concentrations 
absorbed into the perfusate throughout the experiment, a 2 µg dose of Rh123 was determined as 
satisfactory.  That is, if 5 % of the Rh123 is absorbed there will be 100 ng of absorbed Rh123 dose.  
Further, the KM of Rh123 for P-gp (at least in some in-vitro cell lines) has been reported to 
approximate 10 µM [366-368].  Next we should consider the lung epithelial fluid lining volume in the 
rat of between 0.35 and 0.5 mL, and add the additional 0.1 mL of dosing volume to give an initial 
volume in the lung of between 0.45 and 0.6 mL. With an instilled Rh123 dose of 2 µg (MW is 380.82) 
or 5 nmoles into the IPRL; this will yield an initial concentration in the airway lining fluid of the IPRL 
of between 8 and 11 µM, i.e. approximating the KM.   
Dose-ranging studies 
Rh123 in dH2O (2 µg, 5 µg, 40 µg and 80 µg dose) was introduced to the IPRL via forced installation 
(As per chapter 3).  Immediately before dosing a perfusate sample (1 mL) was removed from the 
reservoir as the 0 min sample.  This initial sample volume was not replaced.  Perfusate samples (1 
mL) were removed at the following time points, 0, 1, 2, 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, and 
90 min and replaced with fresh perfusate (1 mL).   
Again, Rh123 concentrations in pulmonary perfusate was determined by High Performance Liquid 
Chromatography coupled to a fluorometric detector as described above in 4.2.2 
Data Analysis 
To determine the significance of dose escalation, both the percentage of deposited Rh123 dose 
absorbed at 90 min and the kin (from linear regression) of each transport profile was analysed.  
Subsequently, k01, as determined by non-linear regression was also statistically analysed.   
Pharmacokinetic modeling: 
Background 
Software - The Pharsight (Mountain View, USA) software product WinNonlin was used.  
Intended use - to highlight similarity of Rh123/F-Na transport to that of a first order process*. Also 
used to establish pharmacokinetic parameters such as initial absorption rate and absorption half-life 
*Substrate absorption being proportional to concentration. 
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Model use - Initial parameters are entered into the modelling software and a plot produced.  This 
plot is then utilised by the software programme to establish associated pharmacokinetic parameters 
Non-linear analysis was undertaken by WinNonlin (Pharsight, Mountain View, USA) with the 
following equation: 
tC = DoseV ∗ ( 01k − 10k )
*( 10−k ∗texp − 01−k ∗texp )  
Where k01 is the rate constant describing input into the perfusate; k10 the rate constant describing 
loss from the perfusate; V is the volume of distribution/F; t is the actual time – lagtime for 
absorption.  For Rh123 the initial estimates for the following parameters were set at: k01 = 0.07 min
-1; 
k10 = 0.000001 min
-1;   V = 2 l/kg; lagtime in absorption – 2 min A one way Analysis of Variance 
followed by a post-hoc Duncan’s test was performed on each.  A value of p<0.05 was considered 
significant.  
The analysis was repeated for F-Na data, however, the dose absorbed at 60 min was analysed.   
4.2.5. Rh123 absorption from airways: Effect of GF120918  
Method 
Method development 
To ensure the introduction of GF120918 (in 0.1 % DMSO v/v) to Rh123 samples did not adversely 
affect HPLC chromatography, GF120918 (500 nM) was spiked to a concentration range of Rh123 in 
IPRL perfusate, prepared by serial dilution.  Samples were deproteinated and centrifuged as per 
preparation protocol, see above, and analysed fluorometrically by HPLC according to the above 
developed protocol described for Rh123.  
No obvious significant alteration to the Rh123 chromatograms was observed by the addition of 
GF120918.  When both Rh123 and GF120918 were co-injected into the HPLC a clearly separated 
peak for GF120918 could be clearly distinguished at 4.2 min which was baseline separated from the 
Rh123 peak at 2-2.5 min (Figure 4.4). 
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Figure 4.4 Example of a HPLC chromatogram produced by Rh123 sample spiked with GF120918 
(500nM; 0.1% DMSO)  
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GF120918 Concentration Cell Type  Substrate Inhibitor Solvent Notes  Reference 
GF120918 MW = 600.09;  10 µM = 6.0 µg in 1 mL 
2 µM, 10 µM, 20 µM, 70 
µM 
In vivo - Whole lung 
(Rabbit) 
Rh123 DMSO High Conc? Roerig et al., 2004 [17] 
1 µM (no basis given for 
choice) 
In vitro – HeLa cells Rh123  
N/A 
Cells incubated in 
presence of inhibitor 
Ejendal et al., 2005 [7] 
0.1-10mg/kg 
From Fig 4; Max Inhibitory 
conc. 2-3 mg/kg 
Mouse weight ~ 50-75 g.  
2 mg/kg = 0.2 mg/100 g = 
0.1 mg/mouse = 100 µL 
dose 
In vivo - FVB/NTTafcBr 
Mice 
 
Rh123  N/A Dosed orally.  
Tariquidar IC50 = 38nM.   
Choo et al., 2006 [5] 
0.5-2.0 µM 
 
Primary Rat Hepatocytes 
 
Rh123 N/A Cells pre-incubated Annaert et al., 2001 [3] 
100 nM In vitro - EMT6/P 
H69/LX4 
Rh213 PEG : 5 % Dextrose (3:2 
v/v) 
Cells incubated 
 
Mistry et al., 2001 [11] 
100 mg/kg 
~5 mg/mouse  
 
In vivo - Whole Animal 
(Mice) 
Saquinavir  
 
N/A Dosed orally 2.5 µL/g 
body weight.  Very high 
conc. used.   
Huisman et al., 2003 [8]  
500 mg/kg - Animal 
0.5 µM – Cell culture 
 
In vivo - Whole Animal 
(Rat BBB) 
In vitro – BBCEC 
 
Rh123, Morphine 
 
HPMC: Tween 80: H2O 
(0.5:1.0:98.5) 
 
Dosed orally from 4 days 
before expt.  Cited 20 nM 
effective in-vitro 
 
Letrent et al., 1999 [10] 
25 mg/kg 
 
In vivo - Whole Animal 
(Mice Brain) 
 
Paclitaxel  
 
WFI: 10 g/L HPMC & 2% 
Tween 80 (50:50) 
 
Dosed p.o by gavage 2hr 
before paclitaxel  
 
Kemper et al., 2003 [9] 
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250 mg/kg – Animal 
300 nM, 800 nM – Cell 
Culture 
 
In vivo - Whole Animal 
(Mice) 
In vitro - KB 3-1 
KB 8-5-11 
Coelenterazine  
 
0.5 % HPMC, 1 % Tween 
80 
 
Dosed orally 4 hr before 
imaging 
 
Pichler et al., 2004 [13] 
0.001-10 µM 
 
In vitro – MDCKII 
 
Calcein-AM, colchicine, 
digoxin, prazosin & 
vinblastine  
1% DMSO in Transport 
Buffer 
Cells incubated.  IC50’s 
cited from 20 nM – 100 
nM 
Rautio et al., 2006 [16] 
250 mg/kg – Animal 
300 nM – Cell Culture 
 
In vivo - Whole Animal 
(Rat Brain) 
In vitro - KB 8-5 
NIH3TS 
 
99mTc-sestamibi  
 
0.5 % HPMC & 1 % 
Tween 80 in dH2O 
 
300 nM – max. inhibitory 
concentration 
 
Rao et al., 1999 [15] 
0.5 µM, 2 µM, 10 µM 
 
In vitro - Caco-2 
 
Fexofenadine 
 
N/A No change in Papp from 2-
10 µM suggesting 
complete inhibition of P-
gp at 2 µM? 
 
Petri et al., 2003 [12] 
1 µM 
 
In vitro - MDCKII: WT, P-
gp, MRP1 & MRP2 
 
Saquinavir  
 
DMSO 
 
1 µM – transport 
inhibition concentration 
 
Williams et al., 2002 [18] 
250 mg/kg – Animal 
500 nM – Cell Culture 
 
In vitro - Caco-2 
 
Amprenavir  
 
0.5 % HPMC & 1 % 
Tween 80 in dH20 
 
250 mg/kg to produce P-
gp chemical knockout 
animal 
 
Polli et al., 1999 [14] 
0.1, 0.3, 0.6, 1.0, 2.0 & 3.1 
mg/kg/h 
 
In vivo - Whole Animal 
(Rats & Mice) 
 
Various P-gp substrates 
 
2 % (v/v) 1,2 propanediol 
added to 5 % (w/v) 
glucose aq. containing 10 
% (w/v) Kleptose HPB 
 
2.5 mL/kg/h 24 hr 
infusion to produce P-gp 
chemical knockout 
animal 
 
Cutler et al., 2006 [6] 
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Effect of GF120918 co-instilled and in IPRL perfusate upon the pulmonary absorption of Rh123 
Table 4.3 Efficacious concentrations of GF120918 utilised experimentally for the inhibition of P-gp.  
Key: PEG – Polyethylene glycol, HPMC – Hydroxypropyl methylcellulose, WFI – Water for 
injection, DMSO – Dimethyl sulfoxide. 
Advice from GSK, together with data from table 4.3 resulted in initial use of 500 nM GF120918 
concentration in the perfusate; a lower concentration of GF120918, 150 nM, was also used. 
GF120918 is soluble in DMSO at a concentration of 20 mg/mL.   The solvent DMSO concentration in 
the perfusate was 0.1 % (v/v) upon the advice of GSK. 
Chosen GF120918 concentration of 150 nM: 
150 nM in terms of nmoles/doses.  15 pmoles administered to lung volume (300 uL + 100 uL of 
instillate) = GF120918 concentration in the lung of 40 nMolar, i.e. a dilution of 1 in 3. 
Rh123 (2 µg) was co-instilled into the airways of the IPRL (IPRL, see chapter 3) with either DMSO (0.1 
% v/v) or GF120918 (150 nM and 500 nM) dissolved in DMSO.  Maximum concentration of DMSO in 
instillate was 0.1 % v/v.  In some experiments GF120918 (150 nM and 500 nM) was also present in 
the pulmonary perfusate and was perfused through the lungs for a 30 min period prior to lung 
dosing.  Samples were taken from the perfusate reservoir (1 mL) and replaced with perfusate (1 mL) 
containing either GF120918 (150 nM and 500 nM) or DMSO (0.1 % v/v).  Samples were removed at 
0, 1, 2, 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, and 90 min Samples were deproteinated, 
centrifuged at 18,000 g for 10 min and the resulting supernatant was fluorometrically analysed by 
HPLC, as described above.   
To allow comparison, the passive permeability probe, F-Na (40 µg) was also co-instilled into the 
airways of the IPRL with either DMSO (0.1 % v/v) or GF120918 (150 nM and 500 nM) as a control.  In 
some experiments, the IPRL perfusate also contained either DMSO (0.1 % v/v) or GF120918 (150 nM 
and 500 nM) and was recirculated through the IPRL system for 30 min prior to lung dosing.  Samples 
were removed at 0, 1, 2, 3, 5, 7, 9, 12, 15, 20, 25, 30, 40, 50, 60, 70, 80, and 90 min, were 
deproteinated and were centrifuged at 18,000 g for 10 min Resulting sample supernatant was 
fluorometrically analysed using HPLC as described above.  Sample volumes were replaced with 
either GF120918 (150 nM and 500 nM) or DMSO (0.1 % v/v).  HPLC analysis of F-Na was undertaken 
for these experiments as GF120918 is also fluorescent at similar wavelengths.   
Data Analysis 
To determine the significance of the addition of the GF120918 inhibitor,  in instillate only and in both 
instillate and perfusate, a one way Analysis of Variance followed by a post-hoc Duncan’s test was 
performed upon both the percentage of deposited Rh123 dose absorbed at 90 min, the kin (linear 
regression) and the k01/ka (non-linear regression) of each transport profile.  A value of p<0.05 was 
considered significant.  An independent samples t-test was performed on data sets with only two 
treatment groups i.e. F-Na data or Rh123 +/- GF co-instilled only data.  Again, a value of p<0.05 was 
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considered significant.  For F-Na + 500 nM GF120918 co-instilled alone, percentage deposited dose 
absorbed at 60 not 90 min data was used.    
GraphPad 
Using GraphPad Prism 5 software, the nonlinear model: 
Y=(Ka*Actual dose/Ka)*(1-exp(-Ka*(x-tlag)) 
was applied to the following data; F-Na 4 µg dose ranging data, F-Na 40 µg; instilled GF120918 only 
data and all flunisolide data. 
Where ka initial parameter was set at 0.001 to 0.01 min
-1 and Tlag was 5 min 
4.2.6. Digoxin absorption from airways: Effect of GF120918 co-instilled and in IPRL 
perfusate 
Method  
Effect of GF120918 co-instilled and in IPRL perfusate upon the pulmonary absorption of digoxin  
[3H] digoxin (0.25 pmol/animal containing 1 µCi of [3H] digoxin/animal) was co-instilled to the lungs 
(IPRL, see chapter 3) with either DMSO (0.1 % v/v) or GF120918 (500 nM).  In a similar manner to 
‘Rh123’ experiments, GF120918 (500 nM) or DMSO (0.1 % v/v) was also present in the pulmonary 
perfusate and passed through the lungs of the IPRL for a 30 min period prior to lung dosing.   To 
allow comparison of digoxin absorption to a paracellular passive permeability probe, [14C] mannitol 
(8 pmol/animal) was also co-instilled with all digoxin administrations.  Samples were taken from the 
perfusate reservoir (1 mL) and replaced with perfusate (1 mL) containing either GF120918 (500 nM) 
or DMSO (0.1 % v/v).  Samples were removed at 0, 1, 2, 3, 5, 10, 15, 20, 30, 40, 50, and 60 min 
Samples were immediately analysed by dual channel liquid scintillation counting.     
Liquid scintillation analysis 
Supernatant samples (200 µL) were added to translucent scintillation tubes, scintillation cocktail (3 
mL) added and tubes sealed.  To measure radioactivity, samples were placed in a Tri-Carb 
scintillation counter (Tricarb 2900TR, Perkin Elmer, USA) which was run on dual-counting mode, 
detecting emissions resulting from the decay of [3H] and [14C]. 
Scintillation counter output was given as ‘counts per minute; CPM’ from which corrected values of 
‘decompositions per minute; DPM) were calculated and displayed. 
Data analysis and pharmacokinetic modeling 
To determine the significance of the addition of the GF120918 inhibitor upon the pulmonary 
absorption of [3H] digoxin across the IPRL, an independent samples t-test was performed upon the 
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percentage of deposited [3H] digoxin dose absorbed at 60 min, the kin (determined by linear 
regression of initial slope), and the calculated t½ of each transport profile.  A value of p<0.05 was 
considered significant.   
Further, use of a 1st order pharmacokinetic model was employed to all [3H] digoxin data to 
accurately establish parameters involved in substrate absorption across the IPRL.  This was also 
repeated for all [14C] mannitol data.  The model applied to digoxin/mannitol data was: 
%abs = F*dose*(1-exp^-k01*t) 
(Where dose can be set to 100 %, F = fractional extent, k01 = absorption rate constant, t = time)  
4.2.7. Flunisolide absorption from airways: Effect of GF120918 co-instilled and in IPRL 
perfusate 
Method 
Effect of GF120918 co-instilled and in IPRL perfusate upon the pulmonary absorption of flunisolide  
As in the above IPRL studies, flunisolide (2 µg) was co-instilled to the lungs of the IPRL with either 
DMSO (0.1 % v/v) or GF120918 (500 nM).  GF120918 (500 nM) or DMSO (0.1 % v/v) alone was also 
present in the pulmonary perfusate and passed through the lungs for a 30 min period prior to lung 
dosing.  Samples were taken from the perfusate reservoir (1 mL) and replaced with perfusate (1 mL) 
containing either GF120918 (500 nM) or DMSO (0.1 % v/v).  Samples were removed at 0, 1, 2, 3, 5, 7, 
9, 12, 15, 20, 25, 30, 40, 50, 60, 75, and 90 min Samples were stored at -80 °C for shipping to GSK, 
Stevenage for analysis. 
GSK: Sample analysis by LC/MS/MS (performed by Emma Sherrif at GSK) 
Overview of analytical techniques 
Mass Spectrometry (MS) 
Mass spectrometry is an analytical technique that measures mass-to-charge ratio of charged 
particles and has a number of uses including; determining masses of particles, determining the 
elemental composition of a sample or molecule, and for elucidating the chemical structures of 
molecules.   
In principle, compounds are ionised to generate a charged molecule and then measured according to 
their mass: charge ratio. 
General procedure: 
1. A sample is loaded onto the mass spectrometer and vaporised. 
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2. The components of the sample are ionized (by one of a variety of methods), resulting in the 
formation of ions. 
3. The ions are separated according to their mass-to-charge ratio in an analyzer by 
electromagnetic fields 
4. The ions are detected, usually by a quantitative method, and the signal is processed into 
mass spectra. 
 Traditionally MS instruments consist of three modules: 
1. An ion source - converts gas phase sample molecules into ions.  
2. A mass analyzer - sorts ions by their masses by applying electromagnetic fields 
3. A detector - measures the value of an indicator quantity and provides data for calculating 
the abundances of each ion present. 
Liquid Chromatography Mass Spectrometry 
Definition: A method where a sample mixture is first separated by liquid chromatography before 
being ionised and characterised by mass-to-charge ratio and relative abundance using two mass 
spectrometers in series. 
LC/MS is a technique similar to gas chromatography MS (GC/MS) in that compounds are separated 
chromatographically before they are introduced to the ion source and mass spectrometer. The 
technique differs in that the mobile phase is liquid, usually a mixture of water and organic solvents, 
instead of gas and the ions fragments cannot yield predictable patterns. 
Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS) 
LC/MS/MS is very similar to LC/MS but involves use of tandem mass analysers creating higher 
specificity that LC/MS as there is a second filtering process.   
[369, 370] 
Preparation of buffer calibration standards: 
Two standard curves were prepared to cover the range 0.5 to 5000 ng/mL by serial dilution in 
control buffer (IPRL perfusate) using a TECAN robot, (Genesis, RSP 150).  The TECAN also produced a 
carryover blank following the washes after the top standard was dispensed. 
Preparation of buffer samples for analysis: 
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Flunisolide samples and standards were prepared by protein precipitation with acetonitrile 
containing 200 ng/mL of GSK977617B (internal standard, IS), followed by filtration using Whatman 
protein precipitation plates.  Using a TECAN robot the samples and standards were extracted by 
protein precipitation.  For extraction, 50 µL of buffer from standards and samples was taken and 150 
µL of acetonitrile with internal standard was added.  
The filtered extracts were collected into a 96 well plate and were blown down to dryness under a 
nitrogen stream at 40 oC.  The dry extracts were reconstituted in 200 µl of acetonitrile: water (10: 90 
by volume). 
The plate was then mixed on a plate shaker for at least 5 min before analysis by LC/MS/MS using an 
18 μL injection volume. 
Re-injection of samples to check ion suppression: 
The following samples were injected twice to allow assessment of the effect of ion suppression.  The 
samples used were the 200 ng/mL calibration standard, the 5 min sample from animal 1 and 3 and 
the 15 min sample from animal 2 and 4.  These samples were injected at a 6 μL injection volume and 
then immediately re-injected at the 18 μL injection volume used for the rest of the run. 
LC-MS/MS analytical conditions 
Analytical column: 
Packing type Luna C18 
Particle size 5 µM 
Dimensions 50 x 2.1 mm 
Injection volume 18 µL (6 μL for ion suppression check samples) 
 
HPLC conditions: 
Pump Agilent 1100 
Solvent A  0.1 % Formic acid in HPLC grade water 
Solvent B 0.1 % Formic acid in acetonitrile 
Flow rate 0.8 mL/min. 
Initial divert to waste time 0.5 min. 
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Run time 3 min. 
 
Gradient conditions: 
Start Time (min.) A (%) B (%) 
0 95 5 
0.5 95 5 
1.8 5 95 
2.2 5 95 
2.3 95 5 
3.0 95 5 
 
Detector conditions: 
Detector Applied Biosystems API4000 Mass Spectrometer 
Mode MSMS 
Ion Source TISP (turbo ion spray) 
Ionisation +ve 
Source temperature 650 oC 
 
MRM transitions: 
Compound Cassette Q1 Mass Q3 Mass Declustering 
potential (V) 
(DP) 
Cell entrance 
potential (V) 
(CE) 
Cell exit 
potential  (V) 
(CXP) 
Flunisolide 1 345.101 285.151 66.0 57.0 18.0 
GSK977617B        
(IS) 
1 276.45 131.10 100 40 12 
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Data analysis and pharmacokinetic modeling 
To determine the significance of the addition of the GF120918 inhibitor, in both instillate and 
perfusate, upon the pulmonary absorption of flunisolide across the IPRL, an independent samples t-
test was performed upon the percentage of deposited flunisolide dose absorbed at 90 min, the 
kin(linear regression), and the t½ (nonlinear regression) of each transport profile.  A value of p<0.05 
was considered significant.   
Further, use of a 1st order pharmacokinetic model was employed to all flunisolide data to accurately 
establish parameters involved in substrate absorption across the IPRL. 
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4.3. Results 
4.3.1. Rh123 analytical validation: Precision and accuracy 
The precision of Rh123 and F-Na HPLC assays were illustrated by determining the coefficient of 
variation (% CV) for triplicate samples across a concentration range.  Table 4.4A displays the CV as a 
percentage for each concentration point.  As can be seen, calculated % CV for both the Rh123 
samples and F-Na samples were ≤ 15.0 % and deemed acceptable for precise quantitation [364].  
Rh123  Mean (µg/mL) Standard 
deviation 
Coefficient of 
variation (% CV) 
0.025 µg/mL 0.022 0.003 11.60 
0.0625 µg/mL 0.065 0.006 8.92 
0.125 µg/mL 0.138 0.018 12.73 
0.25 µg/mL 0.435 0.051 11.78 
0.5 µg/mL 0.654 0.044 6.69 
F-Na 
 
   
0.01 µg/mL 0.017 0.002 10.26 
0.05 µg/mL 0.059 0.008 14.03 
0.0125 µg/mL 0.113 0.012 10.59 
0.25 µg/mL 0.243 0.023 9.46 
1.0 µg/mL 0.982 0.119 12.12 
 
Table 4.4A Calculated coefficient of variation (% CV) for sample quantitation across a concentration 
range for the P-gp substrate, Rh123, and the paracellular probe, F-Na. (n=3 for each concentration 
point) 
Table 4.4B displays the calculated accuracy of the same HPLC assays.  Accuracy was calculated from 
three individual concentration samples of Rh123 or F-Na.  An accuracy of within 80 – 120 % of the 
nominal concentration standard was deemed acceptable for accurate quantitation [364]. 
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Rh123  Theoretical 
concentration  
(µg/mL) 
Actual 
concentration  
(µg/mL) 
Accuracy (%) StDev 
0.025  0.023  108.70 1.05 
0.0625  0.058  108.23 2.34 
0.25  0.312  80.22 2.64 
F-Na 
 
    
0.025  0.022  116.06 2.30 
0.0625  0.060  103.93 1.70 
0.25  0.299  83.74 1.91 
 
Table 4.4B Calculated accuracy, expressed as a % of measured concentration / theoretical or nominal 
standard concentration, across a concentration range for Rh123 and F-Na (n=3 for each concentration 
point) 
4.3.2. Rh123 protein and tubing binding 
Here the consistency of deproteination and recovery of Rh123 from the IPRL perfusate was 
examined across a range of Rh123 concentrations.  A range of Rh123 concentrations were prepared 
in IPRL perfusate where BSA was either present or absent.  The extent of Rh123 recovery from the 
perfusate after undertaking a ‘deproteination’ step was compared and expressed as % Rh123 
concentration in ‘protein samples’ to ‘protein-free’ samples.  Table 4.5 illustrates the mean % Rh123 
recovered over a concentration range.  As can be seen, no significant variation in recovered Rh123 
was seen across the concentration range, suggesting that recovery was consistent irrespective of 
Rh123 concentration.  
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Rh123 (µg/mL) Mean % Rh123 recovered 
0.0125 
0.05 
0.1 
1.0 
5.0 
79.61 ± 3.38 
78.83 ± 2.50 
78.06 ± 5.02 
81.99 ± 1.44 
80.14 ± 4.55 
Table 4.5 Mean % Rh123 recovered from Rh123 perfusate samples containing BSA compared to 
perfusate where BSA had not been included.  Data are expressed as mean ± S.D. (n=3 for each 
concentration point) 
To determine the extent and consistency of Rh123 binding to IPRL perfusate tubing, the 
concentration of Rh123 samples recovered from tubing after 90 min was expressed as a percentage 
of Rh123 dose solution.  Table 4.6 illustrates that recovery of Rh123 from the perfusate exposed to 
the tubing for 90 min did not vary significantly (p>0.05) over a Rh123 concentration range.  The 
presence or absence of GF120918 or whether the perfusate was pumped through the tubing or held 
static in the tubing had no influence over the non-specific binding of Rh123 to IPRL tubing.  
 
 
 
 
 
 
 
 
 
p>0.05 
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Nominal concentration 
(µg/mL) 
Rh123 alone Rh123 spiked to 
GF120918 
GF120918 spiked to 
Rh123 
Mean % Rh123 recovered after 90 min. 
0.001 
0.01 
0.1 
0.5 
84.06 ± 5.02 
88.69 ± 5.30 
93.68 ± 5.66 
90.15 ± 4.90 
87.43 ± 2.50 
83.70 ± 6.85 
84.57 ± 8.10 
89.84 ± 2.39 
89.43 ± 14.08 
78.17 ± 12.77 
89.90 ± 5.38 
95.98 ± 3.01 
    
 ‘Static’ ‘Pumped’ Combined 
0.01 90.37 ± 8.86 85.40 ± 5.20 88.24 ± 7.44 
0.1 83.13 ± 5.68 84.12 ± 12.23 83.67 ± 8.85 
1.0 84.53 ± 5.53 78.13 ± 5.74 81.33 ± 6.24 
    
Table 4.6 Mean % Rh123 recovered from perfusate placed in IPRL tubing.  The effect of Rh123 
concentration, presence or absence of GF120918 and the pumped or static nature of the perfusate 
conditions investigated. The order of addition of P-gp inhibitor GF120918 was also investigated.  
Data are expressed as mean ± S.D. (n=3 for each concentration point) 
4.3.3. Rh123 absorption from airways: Dose ranging studies 
As can be seen in figure 4.5A, increasing nominal Rh123 dose to lung from 2 µg to 5 µg resulted in a 
disproportionate increase in percentage deposited Rh123 dose absorbed.  A similar nominal Rh123 
dose increase from 5 µg to 40 µg also exhibited a disproportional relationship, but to a lesser extent.  
However, doubling nominal Rh123 dose from 40 µg to 80 µg did not show this increase in % dose 
absorbed.  This data is consistent with overcoming a saturable barrier to absorption such as an efflux 
transporter restricting transport from the lung lumen into the pulmonary perfusate, i.e. equivalent 
to the blood compartment.  
A similar pattern could not be observed for a comparable dose escalation strategy with F-Na (IPRL 
validation data).  Figure 4.5B shows no significant (p>0.05) increase in percentage deposited dose 
p>0.05 p>0.05 p>0.05 
p>0.05 
p>0.05 p>0.05 p>0.05 
p>0.05 
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p>0.05 
p>0.05 p>0.05 
p>0.05 
absorbed when increasing nominal F-Na dose from 4 µg to 40 µg, nor when increasing nominal F-Na 
dose from 40 µg to 160 µg. 
 
Figure 4.5 Dose-dependencies in cumulative % of lung deposited dose absorbed in the IPRL:  Figure 
4.5A – Cumulative % of deposited Rh123 dose absorbed with time.  Data are expressed as mean ± 
S.D (n=4 for each treatment); Figure 4.5B – Cumulative % of deposited dose of F-Na absorbed with 
time.  The transport of F-Na is not affected by dose escalation.  Data shown are expressed as mean ± 
S.D (n=3 4 µg dose, n=17 40 µg dose, n=3 160 µg dose). 
Treatment 
(Nominal Dose µg) 
Deposited dose 
in lung (µg) 
Cumulative mass of 
Rh123 absorbed by 
90 min(µg) 
Percentage of 
deposited Rh123 dose 
absorbed by 90 min (%) 
Kin (min
-1) 
Rh123 (2 µg) 
Rh123 (5 µg) 
Rh123 (40 µg) 
Rh123 (80 µg) 
1.83 ± 0.30 
4.22 ± 0.62 
39.72 ± 6.76 
85.03 ± 2.75 
0.05 ± 0.01 
0.68 ± 0.15 
9.05 ± 2.31 
19.04 ± 3.77 
2.79 ± 0.58* 
14.19 ± 2.77* 
22.59 ± 2.68 
22.30 ± 4.38 
0.0008 ± 0.0001† 
0.007 ± 0.003† 
0.028 ± 0.009 
0.027 ± 0.011 
F-Na (4 µg) 
F-Na (40 µg) 
F-Na (160 µg) 
2.48 ± 0.04 
37.93 ± 6.75 
162.78 ± 1.70 
1.56 ± 0.39 
22.44 ± 3.95 
103.86 ± 10.45 
63.02 ± 16.36 
67.51 ± 13.38 
63.76 ± 5.74 
 
0.027 ± 0.005 
0.037 ± 0.008 
0.040 ± 0.014 
 
Table 4.7 Transport of airway administered dose of Rh123 and F-Na across the IPRL:  kin was 
determined from the initial linear portion if the absorption plots.  Data are expressed as mean ± S.D 
with n=4 for each Rh123 treatment and n=3 for F-Na 4 µg dose, n=17 for F-Na 40 µg dose and n=3 
for F-Na 160 µg dose.  F-Na data in table 4.7 determined by plate-reader assay (Chapter 3), 
‘cumulative mass’ and ‘percentage’ data are 60 min readings.  * - Cumulative % of deposited Rh123 
dose absorbed by 90 minis statistically different (p<0.05) compared to all other Rh123 treatments.  † - 
Rh123 kin is statistically different (p<0.05) compared to both 40 µg and 80 µg Rh123 nominal doses. 
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From table 4.7 it can be seen that dose escalation of Rh123 affected both the cumulative mass of 
Rh123 absorbed and initial kin.  Specifically, a 2.1-fold increase in deposited dose from 1.83 µg to 
4.22 µg caused a 13.6-fold increase in cumulative mass absorbed by 90 min, while a similar 2.1-fold 
increase in deposited dose from 39.72 µg to 85.03 µg only yielded a 2.1-fold increase in cumulative 
mass transported, i.e. between the latter dose range, the % of dose absorbed remained the same at 
22%.  Further, kin for initial Rh123 absorption followed a similar pattern.  Dose escalation from 2 µg 
to 5 µg nominal Rh123 dose increased kin 8.8-fold from 0.0008 min
-1 to 0.007 min-1.  An increase in 
nominal Rh123 dose from 40 µg to 80 µg did not significantly (p>0.05) alter kin.  
Again, no comparable increase could be observed for F-Na.  Dose escalation of F-Na did not 
significantly (p>0.05) increase the cumulative % dose absorbed nor alter initial kin. 
4.3.4. Rh123 absorption from airways:  Effect of GF120918 co-instilled and in IPRL 
perfusate 
Inclusion of the solvent vehicle alone DMSO (0.1 % v/v) in the pulmonary perfusate and co-
administration in the airway instillate with a 2 µg nominal dose of Rh123 exhibited a similar 
transport profile to that of 2 µg Rh123 dosed alone (i.e. if data is compared from figure 4.5) 
indicating addition of 0.1 % DMSO had no significant effect upon substrate transport.   
As illustrated in figure 4.6A, addition of GF120918 (150 nM) to both pulmonary perfusate and 
instillate resulted in a significant (p<0.05) increase in the % of the deposited Rh123 dose absorbed, 
illustrating an effect of the P-gp inhibitor on Rh123 transport.  Addition of GF120918 (500 nM) also 
showed a significant (p<0.05) increase in the % of the deposited Rh123 dose absorbed compared to 
the 2 µg Rh123 + 0.1 % DMSO control.  However, the increased concentration of GF120918 did not 
significantly (p>0.05) have any greater affect upon Rh123 above that of the 150 nM dose of 
GF120918. 
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Figure 4.6 Effect of the P-gp inhibitor, GF120918 (in perfusate and airway instillate) upon cumulative 
% of lung deposited dose absorbed in the IPRL: Figure 4.6A – Effect of GF120918 at concentrations 
of 150 nM and 500 nM upon cumulative % of deposited Rh123 absorbed with time.  The aqueous 
vehicle for GF120918 contained 0.1 % DMSO.  The GF120918 was present in the pulmonary 
perfusate and co-instilled into the airways with Rh123.  Data shown are expressed as mean ± S.D 
(n=4 for each treatment).  Figure4.6B – Effect of GF120918 at a concentration of 500 nM upon 
cumulative % of deposited F-Na absorbed with time.  Data shown are expressed as mean ± S.D (n=4 
for each treatment). 
The inclusion of P-gp inhibitor resulted in Rh123 absorption kinetics showing similar profiles to high 
dose (40 µg and 80 µg) Rh123 absorption profiles.  Table 4.8 illustrates that, with addition of 
GF120918 (150 nM), cumulative mass Rh123 absorbed by 90 min increases 6-fold in comparison to 
control.  An increase can also be observed for initial kin for each inhibitor treatment.  Increase in 
GF120918 concentration from 150 nM to 500 nM did not significantly (p>0.05) increase any of the 
measured parameters. 
Again, as with previous control experiments, no significant difference (p>0.05) in percentage 
deposited dose absorbed, or other measured parameters, could be observed between control F-Na 
(0.1 % DMSO) and GF120918 treatments.   
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Treatment 
(Nominal dose 
µg) 
Deposited dose 
in lung (µg) 
Cumulative mass Rh123 
absorbed by 90 min(µg) 
Percentage of deposited 
Rh123 dose absorbed by 90 
min (%) 
Kin (min
-1) 
Rh123 (2 µg) + 0.1 
% DMSO 
2.45 ± 0.26 0.06 ± 0.01 2.67 ± 0.62* 0.0005 ± 0.0001† 
Rh123 (2 µg) +   
150 nM 
GF120918 
2.22 ± 0.02 0.36 ± 0.06 16.20 ± 2.95 0.003 ± 0.001 
Rh123 (2 µg) + 
500 nM 
GF120918 
2.25 ± 0.05 0.39 ± 0.04 17.33 ± 1.97 0.003 ± 0.0003 
F-Na (40 µg) + 0.1 
% DMSO 
38.83 ± 2.22 35.62 ± 1.43 91.90 ± 5.95 0.022 ± 0.003 
F-Na (40 µg)+ 500 
nM GF120918 
40.08 ± 1.93 33.13 ± 3.12 82.55 ± 5.26 0.019 ± 0.002 
Table 4.8 Effect of GF120918 upon the transport of Rh123 and F-Na in the IPRL.  The P-gp inhibitor 
was present at 150 nM or 500 nM in the perfusate and in the co-instilled airway doses of either Rh123 
or F-Na.  Data shown are expressed as mean ± S.D (n=4 for each treatment).  F-Na data in table 4.8 
determined by HPLC analysis.  * - Cumulative % of deposited Rh123 dose absorbed by 90 minis 
statistically different (p<0.05) compared to Rh123 + GF120918 treatments.  † - Rh123 kin is 
statistically different (p<0.05) compared to Rh123 + GF120918 treatments. 
4.3.5. Rh123 absorption from airways:  Effect of GF120918 co-instilled with Rh123 
Addition of GF120918 to only the instillate dose was used to explore the possibility of presence of 
spatial effects of P-gp inhibition upon Rh123 absorption.  The airway instillate of GF120918 alone 
(i.e. in the absence of GF120918 in the perfusate) still resulted in a significant (p<0.05) difference in 
the Rh123 absorption compared to control treatment (Figure 4.7).  
With respect to F-Na administration, the co-instillation of GF120918 (500 nM) into the airways with 
F-Na did not have a significant (p>0.05) effect upon F-Na absorption compared to control alone.  
Again, this corroborates a lack of effect of not only the GF120918 upon the general passive 
permeability properties of the pulmonary barrier but also the lack of effect of 0.1 % DMSO upon this 
barrier.  
p>0.05 p>0.05 
p>0.05 p>0.05 
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Figure 4.7 Effect of the P-gp inhibitor, GF120918 (in airway instillate only) upon cumulative % of 
lung deposited dose absorbed in the IPRL: Figure 4.7A - Effect of GF120918 at a concentration of 
500 nM upon the cumulative % of deposited Rh123 absorbed with time.  The aqueous vehicle for 
GF120918 contained 0.1 % DMSO.  The GF120918 was present only in the co-instilled airway dose 
of Rh123.  Data shown are expressed as mean ± S.D (n=4 for each treatment).  Figure 4.7B - Effect of 
GF120918 at a concentration of 500 nM upon cumulative % of deposited F-Na absorbed with time.  
Data shown are expressed as mean ± S.D (n=4 for F-Na (40 µg) + GF120918 (500 nM), n=17 for F-
Na (40 µg) *Dose ranging studies*. 
Table 4.9 shows that inclusion of GF120918 with Rh123 in the airway co-instillate resulted in an 
increase (p>0.05) in both % of the deposited dose absorbed and initial kin.  For example, a 5.8-fold 
increase in % of the deposited dose absorbed and 10-fold increase in initial kin.   
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p>0.05 
Treatment  
(Nominal dose µg) 
Deposited dose 
in lung (µg) 
Cumulative mass 
Rh123 absorbed by 
90 min(µg) 
Percentage of deposited 
Rh123 dose absorbed 
by 90 min (%) 
Kin (min
-1) 
Rh123 (2 µg) + 0.1 
% DMSO 
Rh123 (2 µg) + 500 
nM GF120918 
 
1.93 ± 0.05 
 
 
2.44 ± 0.03 
0.06 ± 0.01* 
 
 
0.44 ± 0.08 
 
3.10 ± 0.36* 
 
 
18.05 ± 3.19 
0.0005 ± 0.0001* 
 
 
0.005 ± 0.001 
F-Na (40µg) *Dose 
ranging data* 
F-Na (40µg) + 
500nM GF120918 
 
37.93 ± 6.75 
 
 
42.99 ± 1.68 
 
22.44 ± 3.95 
 
 
27.57 ± 2.62 
67.51 ± 13.38 
 
 
64.20 ± 6.53 
 
0.037 ± 0.008 
 
 
0.032 ± 0.008 
Table 4.9 Effect of GF120918 upon the lung accumulation of Rh123.  The P-gp inhibitor was present 
at 500 nM in only the co-instilled airway doses of Rh123 or F-Na.  Data shown are expressed as mean 
± S.D (n=4 for Rh123 treatment, n=4 for F-Na + 500 nM GF120918, n=17 for F-Na alone ‘dose 
ranging data’).  * - statistical difference (p<0.05) compared to Rh123 + GF120918 treatments.  F-Na 
(40µg) ‘dose ranging data’ in table 4.9 determined by plate-reader assay (Chapter 3), all F-Na 
‘cumulative mass’ and ‘percentage’ data are 60 min readings.   
4.3.6. Pharmacokinetic modelling:  Rh123 absorption from the IPRL in presence and 
absence of GF120918 
A WinNonlin pharmacokinetic model was applied to all data, i.e. Rh123 treatments and F-Na control 
treatments, in order to accurately establish relevant parameters involved with substrate absorption 
across the IPRL.  See Materials & Methods for details.  Figures 4.8 – 4.11 illustrate examples of the 
plots generated by WinNonlin; all individual plots can be seen in appendix ii.  Parameters such as k01 
and t½ were established from such plots. 
p>0.05 p>0.05 
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Figure 4.8 Example plots generated by fitting a WinNonlin model to Rh123/F-Na dose ranging 
data.
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Figure 4.9 Example plots generated by fitting a WinNonlin model to Rh123 +/- GF120918 data where 
the P-gp inhibitor was both co-instilled with Rh123 dose and present in the IPRL perfusate. 
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Figure 4.10 Example plots generated by fitting a WinNonlin model to F-Na +/- GF120918 data where 
the P-gp inhibitor was both co-instilled with F-Na dose and present in the IPRL perfusate. 
Figure 4.11 Example plots generated by fitting a WinNonlin model to Rh123/F-Na +/- GF120918 
data where the P-gp inhibitor was present only in co-instilled Rh123/F-Na dose. 
Model fitting to IPRL data generated individual k01 values, (comparable to kin calculated by linear 
regression from cumulative absorption data), which were then used to calculate substrate 
absorption half-lives (t½).   
Table 4.10 shows the generated k01 and calculated t½ for each treatment dosed to the IPRL.  As can 
be seen, in contrast to kin, which was determined from the initial linear portion of the absorption 
plots, calculated t½ absorption does not highlight significant differences between the absorption of 
Rh123 in the presence or absence of GF120918.  Only the calculated t½ absorption of Rh123 2 µg 
dose (dose ranging studies) was found to be significantly (p<0.05) different from all other dose 
ranging data absorption half-lives.  Further, the calculated t½ absorption of Rh123 2 µg dose, 24.83 ± 
15.28 min, was found not to be  significantly (p>0.05) different when compared to 2 µg dose + 0.1 % 
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DMSO,  2 µg dose + 150 nM GF120918, 2 µg dose + 500 nM GF120918 and 2 µg dose + 0.1 % DMSO 
co-instilled only data.   
Model fitting to F-Na data showed no significant (p>0.05) difference between any of the calculated 
t½ absorption data regardless of treatment, i.e. presence or absence of GF120918 or DMSO solvent.  
Treatment K01 (min
-1) t½ (min.) absorption 
Rh123 dose ranging 
2 µg dose 0.034 ± 0.014 24.83 ± 15.28* 
5 µg dose 0.163 ± 0.058 4.62 ± 1.39 
40 µg dose 0.240 ± 0.197 6.09 ± 5.44 
80 µg dose 0.148 ± 0.036 4.87 ± 1.05 
F-Na dose ranging  
4 µg dose 0.078 ± 0.014 9.29 ± 1.79 
40 µg dose 0.075 ± 0.016 9.63 ± 2.23 
80 µg dose 0.080 ± 0.021 8.99 ± 2.01 
Rh123 +/- GF120918   
2 µg dose + 0.1 % DMSO 0.019 ± 0.005 37.55 ± 10.28 
2 µg dose + 150 nM GF120918 0.039 ± 0.003 51.01 ± 60.92 
2 µg dose + 500 nM GF120918 0.022 ± 0.006 33.80 ± 10.33 
F-Na +/- GF120918  
40 µg dose + 0.1 % DMSO 0.053 ± 0.002 13.18 ± 0.40 
40 µg dose + 500 nM GF120918 0.049 ± 0.006 14.37 ± 1.72 
Rh123 +/- GF120918 (co-
instilled only) 
 
2 µg dose + 0.1 % DMSO 0.019 ± 0.004 38.47 ± 8.73 
2 µg dose + 500 nM GF120918 0.062 ± 0.014 11.58 ± 2.68 
F-Na +/- GF120918 (co-instilled 
only) 
  
40 µg dose *dose ranging data* 0.075 ± 0.016 9.63 ± 2.23 
40 µg dose + 500 nM GF120918 0.086 ± 0.008 7.63 ± 3.96 
Table 4.10 Pharmacokinetic parameters generated by fitting a WinNonlin model to Rh123/F-Na data 
in the presence and absence of the P-gp inhibitor GF120918. Absorption half-lives calculated as; t½ = 
0.693/K01.  All data used in model fitting yielded from IPRL experiments (above results section).  
Data shown are expressed as mean ± S.D. * - statistically different (p<0.05) t½ compared to all other 
Rh123 dose ranging data.     
Within generated data, kin and k01 differ in the method by which they were calculated.  kin/initial 
slope data is limited as it is generated by analysis of a straight line, whereas k01 takes into account 
the full profile as it is calculated by non-linear regression.  Calculation of kin really is preliminary and 
only poorly represents the initial rate of absorption from the lung.  Once acceptable and 
representative non-linear analysis has been achieved, kin should not be focussed upon.   
p>0.05 
p>0.05 
p>0.05 
p>0.05 
p>0.05 
p>0.05 
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4.3.7. Digoxin absorption from airways:  Effect of GF120918 co-instilled and in IPRL 
perfusate 
As is illustrated in figure 4.12A, the inclusion of GF120918 (500 nM; 0.1 % v/v DMSO) in pulmonary 
perfusate and co-instilled into the airways along with 0.25 pmol nominal dose of digoxin did not 
affect significantly (p>0.05) the transport profile of digoxin when compared to digoxin control.  The 
addition of GF120918 showed no significant (p>0.05) impact upon the % of deposited digoxin dose 
that was absorbed.  Similarly, addition of the P-gp inhibitor did not significantly (p>0.05) influence 
mannitol transport across the IPRL (Figure 4.12B).      
Figure 4.12 Effect of the P-gp inhibitor, GF120918 (in perfusate and airway instillate) upon 
cumulative % of lung deposited dose absorbed in the IPRL: Figure 4.12A – Effect of GF120918 at a 
concentration of 500 nM upon cumulative % of deposited digoxin absorbed with time.  Data shown 
are expressed as mean ± S.D (n=4 for each treatment).  Figure 4.12B – Effect of GF120918 at a 
concentration of 500 nM upon cumulative % of deposited Mannitol absorbed with time.  In this set of 
experiments, mannitol was co-administered along with digoxin dose.  Data shown are expressed as 
mean ± S.D (n=4 for each treatment). 
As can be seen in table 4.11, the presence of the P-gp inhibitor, GF120918 (500 nM), in pulmonary 
perfusate and instilled dose had no significant effect (p>0.05) upon the percentage deposited dose 
absorbed by 60 min, the kin (calculated from the initial linear portion of cumulative transport curves) 
nor the calculated t½ (determined from nonlinear regression) of the P-gp substrate digoxin, when 
dosed to the IPRL.  The inhibitor was also present in the IPRL perfusate 30 min prior to digoxin 
dosing. 
Similarly, GF120918 (500 nM) had no significant effect (p>0.05) upon the absorption of mannitol in 
the IPRL.  No significant difference could be observed for any of the measured parameters, 
suggesting the epithelial barrier to remain intact.   
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Treatment  
Deposited dose 
in lung (DPM) 
Cumulative 
mass of Digoxin 
absorbed by 60 
min(DPM) 
Percentage of 
deposited 
Digoxin dose 
absorbed by 60 
min (%) 
Ka (min
-1) 
Digoxin + 0.1 % 
DMSO  
 
Digoxin + 500 
nM GF120918  
1867344 ± 
636794 
 
1955306 ± 
923943 
  
1240401 ±  
410213 
 
1259509 ± 
570797  
 
68.13 ±  
12.03 
 
 65.59 ± 
 4.05 
0.262 ±  
0.172 
 
0.126 ±  
0.036 
Table 4.11 Effect of GF120918 upon the transport of digoxin.  The P-gp inhibitor was present at 500 
nM in the perfusate and in the co-instilled airway doses of digoxin.  ka was calculated by linear 
regression.  Data shown are expressed as mean ± S.D (n=4 for each treatment).   
4.3.8. Flunisolide absorption from airways:  Effect of GF120918 co-instilled and in IPRL 
perfusate 
As can be seen in figure 4.13A, the addition of GF120918 (500 nM) co-instilled with a dose of 
flunisolide (2 µg) into IPRL perfusate had an apparent opposing effect to that seen with Rh123, in 
that, with flunisolide, the presence of GF120918 resulted in a decrease in the extent of absorption of 
flunisolide.  Figure 4.13B acts as comparison; duplicate of figure 4.6B.   
Figure 4.13 Effect of the P-gp inhibitor, GF120918 (in perfusate and airway instillate) upon 
cumulative % of lung deposited dose of flunisolide absorbed in the IPRL: Figure 4.13A – Effect of 
GF120918 at a concentration of 500 nM upon cumulative % of deposited flunisolide absorbed with 
time.  Data shown are expressed as mean ± S.D (n=4 flunisolide + 0.1 % DMSO, n=5 for flunisolide 
+ GF120918).  Figure 4.13B – Effect of GF120918 at a concentration of 500 nM upon cumulative % 
of deposited F-Na absorbed with time.  Data are of that shown in figure 4.6B and are expressed as 
mean ± S.D (n=4 for each treatment).   
p>0.05 p>0.05 
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Table 4.12 illustrates that, with addition of GF120918 (500 nM), cumulative mass of flunisolide 
absorbed by 90 min decreased, by 1.45-fold in comparison to control.  A decrease can also be 
observed for initial kin (linear regression), when inhibitor is present.  However, while the initial kin of 
flunisolide absorption in presence of inhibitor is significantly different (p<0.05) from that of control, 
the percentage of deposited flunisolide dose absorbed by 90 min does not show a statistically 
significant (p>0.05) difference when comparing control data to inhibitor inclusion data. 
Treatment (Nominal 
dose µg) 
Deposited 
dose in lung 
(µg) 
Cumulative 
mass 
Flunisolide 
absorbed by 90 
min(µg) 
Percentage of 
deposited 
Flunisolide dose 
absorbed by 90 min 
(%) 
Kin (min
-1) t½ (min.) 
Flunisolide (2 µg) + 
0.1 % DMSO 
1.79 ± 0.66 0.625 ± 0.101 35.62 ± 4.74 0.047 ± 0.021* 0.669 ± 0.355† 
Flunisolide (2 µg) +  
500 nM GF120918 
1.92 ± 0.01 0.432 ± 0.170 22.49 ± 8.71 0.015 ± 0.005 0.246 ± 0.064 
      
F-Na (40 µg) + 0.1 % 
DMSO 
38.83 ± 2.22 35.62 ± 1.43 91.90 ± 5.95 0.022 ± 0.003 13.18 ± 0.40 
F-Na (40 µg)+ 500 
nM GF120918 
40.08 ± 1.93 33.13 ± 3.12 82.55 ± 5.26 0.019 ± 0.002 14.37 ± 1.72 
Table 4.12 Effect of GF120918 upon the transport of flunisolide in the IPRL.  The P-gp inhibitor was 
present at 500 nM in the perfusate and in the co-instilled airway doses of flunisolide.  * - statistically 
different (p<0.01) kin when compared to flunisolide + GF120918 data.  † - statistically different 
(p<0.01) t½ when compared to flunisolide + GF120918 data.  Data shown are expressed as mean ± 
S.D (n=4 for flunisolide (2 µg) + 0.1 % DMSO, n=5 for flunisolide (2 µg) +   500 nM GF120918).  F-
Na data are of that displayed in table 4.8 (n=4 for each treatment).   
Despite the lack of significant difference between percentage of deposited flunisolide dose absorbed 
by 90 min(%) in the presence and absence of inhibitor, when comparing the same parameter at a 
number of different timepoints, a consistent significant (p<0.05) difference could be observed, table 
4.13. 
 
  
p>0.05 p>0.05 p>0.05 
p>0.05 
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Treatment (Nominal 
dose µg) 
Percentage of 
deposited 
Flunisolide dose 
absorbed by 20 min 
(%) 
Percentage of 
deposited 
Flunisolide dose 
absorbed by 40 min 
(%) 
Percentage of 
deposited 
Flunisolide dose 
absorbed by 60 min 
(%) 
Percentage of 
deposited 
Flunisolide dose 
absorbed by 90 min 
(%) 
Flunisolide (2 µg) + 
0.1 % DMSO 
31.92 ± 8.56* 44.09 ± 8.00* 35.96 ± 7.05* 35.62 ± 4.74 
Flunisolide (2 µg) +  
500 nM GF120918 
15.91 ± 5.11 12.61 ± 10.41 16.34 ± 9.28 22.49 ± 8.71 
Table 4.13 Comparison of the percentage deposited flunisolide dose in the presence and absence of P-
gp inhibitor over a range of time points.  Data shown are expressed as mean ± S.D (n=4 for flunisolide 
(2 µg) + 0.1 % DMSO, n=5 for flunisolide (2 µg) +   500 nM GF120918).  * - significantly different 
(p<0.05) when compared to corresponding timepoint data where GF120918 was present in instillate 
dose and IPRL perfusate at a concentration of 500 nM. 
Figure 4.14 illustrates the nonlinear regression plots generated when fitting a Michaelis-Menton 
type equation to substrate absorption data.  The model used was analogous to that used previously 
(detailed in materials and methods section). 
 
Figures 4.14 Example of plots generated by nonlinear regression.  Data shown are expressed as mean 
± S.D (n=4 for flunisolide (2 µg) + 0.1 % DMSO, n=5 for flunisolide (2 µg) +   500 nM GF120918).     
p>0.05 
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4.4. Discussion 
Since the discovery of P-glycoprotein by Juliano & Ling in 1976, [70] , functional roles and expression 
patterns for this well studied ABC transporter have been hypothesised and investigated.  The 
expression of P-glycoprotein within the respiratory system as a whole, and more specifically, within 
lung parenchyma, is generally accepted.  Indeed, illustrated expression of this protein to particular 
cell types within parenchymal tissue has been achieved.  Through use of immunohistochemistry in 
normal human lung samples, P-glycoprotein has been localised to both apical and basolateral 
epithelial cell membranes [43].  Further, localisation to alveolar epithelial cells has also been 
demonstrated by Campbell et al., who established expression of P-glycoprotein in both human and 
rat type I alveolar epithelia [137].  
In addition to localisation to several specific lung cell types, P-glycoprotein functionality has been 
illustrated.  In both human and rat cell samples, active P-glycoprotein mediated efflux of a number 
of known substrates has been shown.  Additionally, subsequent inhibition of such transport has also 
been illustrated, confirming P-glycoprotein as an active efflux transporter [113, 137].   
The use of the flurophore dye, rhodamine 123 (Rh123) which is a known P-glycoprotein substrate, 
was chosen to illustrate functional activity of P-gp in the isolated perfused rat lung system.  Of the 
rhodamine analogues, Rh123 is an attractive substrate of choice as it has been widely used as a P-
glycoprotein substrate throughout the literature and in comparison to rhodamine 6G, has a lower 
passive permeability rate constant [367] therefore active efflux should be more pronounced.  
Rhodamine 123 has also previously been used to demonstrate efflux functionality of P-glycoprotein.  
In the human leukaemia cell line, K562, accumulation of the dye into both P-glycoprotein expressing 
and non-P-glycoprotein expressing cells was measured to allow characterisation of drug pumping 
action [371].   
To further demonstrate the functionality of P-glycoprotein in the IPRL system, inclusion of the 
acridine derivative GF120918 (N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]- 
phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide), which is a recognised P-
glycoprotein inhibitor, was studied.  For example, pre-treatment with GF120918 has been shown to 
increase concentrations of morphine, which is generally thought to be a P-glycoprotein substrate, in 
a rat cerebral microdialysis model; the blood brain barrier displays a particularly high expression of 
P-gp, limiting access of a wide range of xenobiotics to the CNS.  Presence of the GF120918 increased 
morphine concentrations in the brain by 3-fold [372].  Moreover, Annaert et al., demonstrated 
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reduced biliary excretion of Rh123 in sandwich-cultured rat hepatocytes in the presence of 
GF120918 [366].  GF120918, like many other 3rd generation P-glycoprotein inhibitors, was designed 
according to  chemical structure-activity relationships in order to avoid limitations of previous 
generations of inhibitors such as toxicity and interaction with cytochrome P450 [373].  It is generally 
believed that GF120918 non-competitively inhibits P-glycoprotein through the inhibition of ATPase 
activity rather than competing as a substrate for the transporter [374].   
In order to ensure the binding of Rh123 to BSA within the IPRL perfusate or indeed Rh123 binding to 
the plastic IPRL tubing did not detrimentally affect the analysis of Rh123 absorption across the IPRL, 
a number of validation experiments were conducted.  Table 4.5 illustrated that, although there is a 
loss of approximately 20 % Rh123 in the post-deproteination supernatant, this loss is not 
concentration-dependent.  Furthermore, this loss is accounted for during construction of the 
calibration curves that involve the same deproteination step.    The 20 % loss suggests that some of 
the Rh123 remains bound to the precipitated and denatured protein.  Moreover, Kajikawa et al., 
reported Rh123 plasma protein binding at ~76 % [375].  Further, Rh123 recovery from IPRL tubing is 
also consistent independent of Rh123 concentration, with neither the presence nor action of a 
peristaltic pump, nor the addition of GF120918 influencing binding. 
The dose escalation of Rh123 (Figure 4.5A) from a nominal dose of 2 µg to 80 µg showed Rh123 
absorption to involve a saturable barrier to absorption, with saturation occurring within the range of 
40 µg and 80 µg Rh123 instilled dose.  Conversely, dose escalation of the paracellular transport 
probe, sodium fluorescein (Figure 4.5B), did not exhibit any dose-dependency in the % of deposited 
F-Na dose absorbed.  This lack of effect of dose upon F-Na absorption supports the lack of any non-
specific events that may have resulted in the observed Rh123 absorption data.  The role of P-gp in 
the saturable barrier to Rh123 absorption within the IPRL was suggested by the experiments co-
administering the P-gp inhibitor GF120918; either in the airway instillate alone or in both the airway 
instillate and the recirculating pulmonary perfusate.  With GF120918 addition to the IPRL, significant 
increases in the amount of Rh123 absorbed were observed (Figure 4.6A).  Increasing the 
concentration of GF120918 from 150 nM to 500 nM did not produce any enhancement in Rh123 
absorption, suggesting a concentration of GF120918 of 150 nM to be sufficient in inhibiting P-gp-
mediated reductions in pulmonary Rh123 absorption.  Within the materials and method section of 
this chapter, an appropriate inhibitor concentration was considered with reference to the literature 
(Table 4.3).  The current finding that inhibition of P-gp could not be improved at a GF120918 
concentration above 150 nM is not inconsistent with the literature where similar concentrations 
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have been employed in order to achieve P-gp inhibition; and suggests P-gp functionality in the lung 
may be comparable to other experimental models [376-378].  As can be seen in figure 4.6B, P-gp 
inhibition had no effect upon F-Na absorption, substantiating that GF120918 has no capacity to 
increase the passive paracellular permeability of the pulmonary barrier.  It is of note that inclusion of 
the P-gp inhibitor co-instilled into the airways with Rh123 or F-Na, i.e. not in the perfusate, resulted 
in a similar increase in Rh123 absorption to a situation where the inhibitor was present in both the 
airway instillate and in the perfusate (Figure 4.7A-B).  This indicates that there is no requirement for 
pre-dosing of the inhibitor and that significant equilibration between perfusate and lung is not 
important in terms of GF120918 bringing about it actions upon P-gp, at least in the IPRL model used 
in these experiments.  
The saturation of P-glycoprotein in the Rh123 dose ranging studies reported here is consistent with 
Cisternino et al., who demonstrated saturation of P-gp at the rodent blood-brain barrier with respect 
to the antitumor agent, TXD258.  On increasing drug dose from 15 to 90 mg m-2, a greater than 
proportional increase in concentration of TXD258 within brain extract was observed [379].  Further, 
saturation of P-gp with a rhodamine analogue, rhodamine-6G (R6G) has been observed in an 
isolated lung system by Roerig et al., [21].  However, the work of Roerig et al., suggested that a 
saturable barrier was present in the lung, limiting transport of R6G into the lung from the perfusate, 
i.e. from the ‘blood’-to-lung direction.  Further, Roerig et al., also reported a ~20 % increase in the 
uptake of the rhodamine analogue, R6G, from perfusate to lung in an isolated perfused rabbit lung 
with the addition of 20 µM GF120918.  The authors concluded that P-gp in the lung is saturable, in 
the blood-to-lung direction and can be modulated by drug substrates and chemical inhibitors [355].   
No other laboratory has yet confirmed a P-gp mediated efflux mechanism limiting access of drug 
from blood to lung in a whole lung i.e. isolated organ preparation.  Indeed systemic pharmacokinetic 
studies in mdr1 knockout mice do not show a differential equilibrium partition between blood and 
lung when comparisons are made between the mdr1 knockout mice and wild-type mice.  If the 
Roerig data was applied to these knockout mice then we would expect to see reduced equilibrium 
partitioning in the lung in the mdr1 (-/-) mice which is not what is observed [362, 380-383].   
Nonlinear modelling of substrate transport data obtained from IPRL experiments was undertaken in 
order to further understand mechanisms involved in absorption in an isolated lung.  
Pharmacokinetic parameters including, k01 (rate of substrate transport from lung to perfusate) and 
absorption half-life (t½) were determined.  The initial absorption rate (kin) of Rh123/F-Na across the 
IPRL, reported in Tables 4.7 – 4.9, was calculated from the initial linear portion of cumulative 
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transport curves and the equation y=mx+c, i.e. kin calculated as kin = m/actual dose to lung.  
However, as the equation of a straight line does not accurately represent substrate absorption by 
the lung, a more descriptive model was applied to all data.  Further, within the literature, many 
reports of substrate pulmonary transport are described via the application of kinetic modelling [328, 
334, 344].  The pharmacokinetic software WinNonlin (Pharsight, Mountain View, USA) was 
employed to all data obtained from IPRL experiments and pharmacokinetic parameters were 
calculated by compartmental analysis.  WinNonlin has been previously utilised by members of the 
Welsh School of Pharmacy [384] and in the wider literature to determine kinetic parameters 
associated with P-gp function [385]. 
Pharmacokinetic modelling of data obtained from Rh123/F-Na IPRL experiments (Table 4.10) 
demonstrated that calculated t½ from all F-Na data showed no significant difference between 
treatments dosed to the IPRL.  Such findings mirror the pattern of calculated kin displayed in tables 
4.7 – 4.9.  The calculated t½ (from nonlinear regression) of Rh123 treatments dosed to the IPRL does 
not mirror the pattern displayed by kin (tables 4.7 – 4.9).  Determination of pharmacokinetic 
parameters, by WinNonlin, associated with Rh123 absorption across the IPRL show no significant 
difference for the k01 (or the absorption rate constant) parameter between the dose treatments, 
with the exception of 2 µg Rh123 data from the dose-ranging study.  There were large standard 
deviations associated with each calculated k01 and t½ highlighting variability within the data set but 
also potential imprecision in the model.  The pharmacokinetic model (see materials and methods) 
applied to all data was described by a first-order one compartment model with an elimination rate 
constant from the perfusate that was constrained to be essentially negligible.  Figure 4.15 represents 
the model applied to IPRL data, both Rh123 and F-Na (top panel), and illustrates a potential model 
(bottom panel) that may improve the accuracy of parameter estimation for the Rh123 data, i.e. it 
provides the potential for a saturable mechanism in the uptake from perfusate to lung.   
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 Rhodamine 123 Digoxin Flunisolide 
KM for P-glycoprotein (µM) 13.5 59 --- 
MW (g.mol
-1) 380.82 780.93 434.49 
LogD 0.53 1.7 1.92 
Figure 4.15 Diagram illustrating pharmacokinetic model describing F-Na and Rh123 transport across 
the IPRL.  The chart illustrates parameters that might affect substrate transport by P-glycoprotein. 
Despite the seemingly unsuitable nature of the employed pharmacokinetic model to Rh123 data, its 
application to this data has highlighted the more complex nature of Rh123 pulmonary absorption in 
comparison to F-Na absorption (i.e. involvement of P-gp), further confirming the functional 
significance of P-gp upon absorption of a substrate delivered to the lung. 
 The cardiac glycoside and well-recognised P-gp substrate digoxin was chosen to dose to the IPRL in 
the presence and absence of GF120918 with the aim of affirming the functional significance of P-gp 
upon substrates delivered into the airways.  While the affinity of digoxin for P-gp appears to be 
lower than other P-gp substrates (Figure 4.15) [386], there is very compelling evidence that the 
cardiac drug is a substrate of this drug transporter [360].  P-glycoprotein mediated efflux of digoxin 
is well established, for example, Djuv and Nilsen reported significant basal – to – apical (B-A) 
transport of digoxin (30 nM) in the Caco-2 cell line which was decreased by 61 % with the 
introduction of the P-gp inhibitor verapamil (100 µM) [387].  In both the wild type MDCK cell line 
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and the MDCK-hMDR1 cell line that over-expresses human P-gp, verapamil has again been shown to 
decrease the efflux ratio (basal – to – apical/apical – to – basal) of digoxin.  In MDCK-WT cells (which 
nevertheless contain canine P-gp), the efflux ratio of digoxin transport was reduced from 5.2 to 2.0 
with the addition of 200 µM verapamil.  This decrease was more significant in MDCK-hMDR1 where 
the efflux transport ratio was reduced from 25.5 to 1.3 with the addition of the P-gp inhibitor [388].  
Within the lung, tissue accumulation of digoxin in mdr1a- mice is approximately twice that of 
mdr1a+ mice suggesting an apparent role of mdr1a in effluxing digoxin from the lung [360].   
Within the isolated perfused rat lung utilised here, it was hypothesised that the inclusion of 
GF120918 co-instilled into the airways and present in IPRL perfusate would increase the percentage 
of deposited digoxin dose absorbed.  As can be seen in figure 4.12, digoxin transport across the IPRL 
was not affected by the presence of GF120918.  The mean percentage deposited dose of digoxin 
transported reached ~45 % by 10 min, in comparison, the maximum percentage deposited dose of 
Rh123 (all treatments) transported by 90 min was ~20 % and the passive permeability probe F-Na 
only reached ~30 % deposited dose transported by 10 min(Figure 4.5B).  When comparing 
pharmacokinetic parameters, the initial k01 of digoxin absorption did not alter significantly (p>0.05) 
with the addition of GF120918 (Table 4.11).  Indeed, comparison of calculated t½ for digoxin and the 
passive permeability probe mannitol revealed mannitol to have a longer absorption half-life in the 
IPRL than digoxin (data not shown).  These results show digoxin to exhibit a more rapid absorption 
profile across the lung suggesting simple diffusion as a transport mechanism.                     
The apparent lack of significance of P-gp upon digoxin transport across the IPRL was initially 
surprising given the clear evidence for P-gp influence over Rh123 transport.  Within the literature, 
Manford et al., also examined the influence of P-gp upon the pulmonary absorption of digoxin.  Here 
digoxin (3.5 mg/kg) was instilled to the lungs of CF-1 mice (which displays an mdr1a -/-, mdr1b +/+ 
phenotype) and the absorption profiles compared to that of digoxin instilled into the lungs of wild-
type mice (mdr1a +/+ and mdr1b +/+ phenotype).  No significant difference in the ‘lung 
concentration vs. time’ or ‘plasma-concentration’ profiles of digoxin absorption were observed 
between the two strains.  The ratio of digoxin: mannitol concentrations within the lung of both 
strains over 90 min was shown to be consistent suggesting lack of an active digoxin absorption 
mechanism [361]. 
The use of CF-1 mice does not take into consideration the contribution of the mdr1b gene isoform to 
digoxin transport within the lung, a tissue within which mdr1b has been shown to be more highly 
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expressed (rat lung) than the mdr1a gene [389, 390].  The apparent lack of P-gp effect upon digoxin 
transport across the lung could be interpreted as the significant influence of the mdr1b isoform 
upon this substrate, effluxing digoxin to the airspace of the lung for the duration of the experiment.  
The concordance of the results of this chapter to those of Manford et al., somewhat reduce the 
likelihood of overlooked mdr1b involvement.  Further, Lanman et al., report similar rapid absorption 
of digoxin from the rat respiratory tract and constant extent of absorption over a concentration 
range, indicating the mechanism of transport to be unsaturable.  These works also interestingly 
noted a relationship between a molecule’s chloroform/water partition coefficient and its absorption 
rate from the lung, i.e., the higher the partition coefficient, the more rapid the absorption rate [391]. 
The association of passive permeability with drug transporter absorption kinetics has been 
increasingly investigated.  The role of passive permeability in influencing a compound’s absorption 
rate is well understood, the interplay with active transport less so.  The promiscuous substrate 
specificity of P-gp only reveals certain substrate physico-chemical properties, such as a degree of 
hydrophobicity, planar structure and for some substrates a slight but depolarised positive charge to 
be of importance.  It is now well recognised that P-gp binds substrates from the lipid phase of the 
plasma membrane before they reach the cytosol, therefore, highlighting relative partitioning into 
the membrane to be of importance [392].  Lentz and co-workers examined the relationship between 
passive permeability and P-gp absorption kinetics and illustrated that, within Caco-2 and MDCK-
hMDR1 cell lines, the transport of both high and low permeability P-gp substrates was not affected 
by the introduction of GF120918 to culture medium.  They postulated that substrates with a high 
passive permeability would dominate over the efflux action of P-gp, while low passive permeability 
substrates would be presented to P-gp only at low concentrations, presenting a negligible drug load 
to P-gp and hence resulting in low impact of this transporter.  Both vinblastine and cimetidine are 
moderately permeable substrates and in the work of Lentz et al., appeared to be affected by the 
presence of GF120918 [393].  Etyan et al., reported that the inconsistent nature of P-gp substrate 
membrane permeability requires P-gp to overcome passive influx rate in order to be successful.  
They highlight that substrates such as gramicidin traverse the membrane in minutes and are 
therefore susceptible to P-gp involvement while substrates such as valinomycin traverse the 
membrane in microseconds, overcoming the efflux ability of the transporter [356].  To give further 
substance to the role of passive permeability within P-gp absorption kinetics, it has been observed 
that poor P-gp substrates commonly act as P-gp modulators possibly as a result of rapid inward 
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permeability, while slower inwardly permeable compounds are available at a rate where P-gp can 
efflux [392].   
The importance of passive permeability upon P-gp absorption directly highlights the importance of 
factors that influence passive permeability.  When comparing Rh123 and digoxin as P-gp substrates, 
Rh123 presents itself as the more attractive as it has a permanent positive charge and is relatively 
hydrophilic creating a more moderate rate of passive permeability, while digoxin has been found to 
have a much higher passive permeable potential that can prevail over P-gp action [367, 394].  The 
herein reported lack of influence of the P-gp inhibitor, GF120918, upon digoxin transport across the 
IPRL does not essentially eradicate the functional significance of P-gp within the lung, but instead 
highlights the intricate relationship between P-gp absorption and passive permeability. 
Although not extensively recognised as a P-gp substrate, the synthetic, topically active 
corticosteroid, flunisolide, represents an appealing substrate for examining P-gp influence upon 
drugs delivered to the lung [395].  Traditionally employed in the treatment of persistent asthma, 
such synthetic corticosteroids were plagued with poor lung and high oropharyngeal deposition - post 
inhalation.  However, in accordance with the Montreal protocol [26], the replacement of CFC 
content with HFA propellant in all MDI devices effectively reversed undesirable deposition problems, 
improving lung delivery and potentially enhancing therapeutic effect.  Increased deposition to the 
lung however, has potential to create side effects such as toxicity and drug-transporter interactions 
[396].  Further, as an uncharged molecule with a moderate hydrophobicity value (ClogP), flunisolide 
presents itself as a candidate P-gp substrate with eligibility for investigation within the IPRL [397, 
398]. 
Flunisolide was introduced to the IPRL in the presence and absence of GF120918.  Since reported 
physico-chemical parameters strongly identify flunisolide as a P-gp substrate, it was hypothesised 
that addition of GF120918 to the IPRL would alter significantly the percentage of deposited 
flunisolide absorbed with time.  As can be seen in table 4.12, the addition of GF120918 (500 nM) 
altered the percentage deposited flunisolide dose absorbed at 90 min by 1.45-fold.  This change, 
however, was not statistically significant (p>0.05) when compared to control (flunisolide + 0.1% 
DMSO).  Tables 4.12 and 4.13 show that the addition of GF120918 to instillate and perfusate did 
however significantly alter (p<0.01) the initial kin, calculated t½, and the percentage deposited 
flunisolide dose absorbed at 20, 40 and 60 min Despite the non-significant (p>0.05) decrease in 
percentage deposited flunisolide dose absorbed by 90 min, when examining the mean percentage of 
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deposited dose absorbed by 60 and 90 min,  flunisolide + 0.1% DMSO control mean percentage 
remained relatively stable suggesting a plateau in absorption was reached pre-90 min time point.   
As a substrate, flunisolide has previously been used in order to assess P-gp influence within the 
pulmonary system.  Florea et al., utilised flunisolide as an example of a synthetic corticosteroid and 
illustrated P-gp influence upon the transport of this drug within the Calu-3 cell line [398].  Within the 
Florea et al. study, clear polarised apical – to – basal transport was shown.  Further, the influence of 
an ATP dependent process, and more specifically, involvement of P-gp was shown with use of 
specific inhibitors (verapamil, SDZ PSC 833 and LY335979) [398].  Florea and co-workers further 
illustrated involvement of P-gp upon flunisolide transport in MDR1-Pgp transfected, LLC-PK1 pig 
kidney epithelial cell lines, however, in this case polarized transport was observed in the basal – to – 
apical direction.  The clear difference in the direction of polarized transport between the lung and 
kidney cell lines was rationalised by immunoblotting and confocal laser scanning microscopy; a 170 
kDa P-gp band was observed in cell lysates from both Calu-3 and LLC-MDR1 cell lines [398].  Where 
P-gp was predominantly localised to the basolateral cell membrane in Calu-3 cells, localisation to the 
apical membrane in the LLC-MDR1 cell line was seen [398].  The findings of Florea and co-workers 
show disparity with the literature, within which P-gp is generally accepted to be apically expressed 
serving a barrier function, i.e., casting doubt over the involvement of P-gp in apical-to-basolateral 
polarised transport [362, 399].  However, Florea et al., attribute the polarised transport of flunisolide 
to P-gp for a number of reasons; the clearly demonstrated involvement of an ATP-dependent 
process that was significantly reduced through the use of P-gp inhibitors, the amphipathic chemical 
structure of flunisolide lending itself to transport via P-gp and the recognised involvement of P-gp in 
the intracellular trafficking of cholesterol, to which flunisolide shares great structural semblance 
[397, 398, 400].  
The preponderance of literature evidence reports P-gp to localise apically in a wide range of cells in a 
number of tissues.  The use of various experimental techniques has localised P-gp to the apical 
membrane of; liver epithelia, small ductules of the pancreas, kidney proximal tubule epithelial cells, 
columnar epithelia of the colon and jejunum, and the apical surface of capillary endothelial cells of 
the blood-brain barrier [401, 402].  Within the deep lung, i.e. predominant deposition location of 
drugs dosed to the IPRL, P-gp has been localised to the apical membrane of type I alveolar epithelial 
cells of human and rat and has also been detected by Western blotting within type II alveolar 
epithelial cells [113, 137].  Cellular localisation of P-gp within the Calu-3 submucosal gland carcinoma 
cell line is less clear, Hamilton et al., report P-gp functional activity consistent with an apical 
  Chapter 4 
 
189 
 
localisation in Calu-3 cells and apical localisation of P-gp within similar cells of bovine olfactory and 
nasal respiratory mucosae have also been reported [403, 404].  However, in a similar vein, Uematsu 
et al. report localisation to the basolateral membrane of serous acinar cells of the salivary gland and 
P-gp mediated basolateral efflux of xenobiotics from interstitial fluid has been demonstrated, 
suggesting a similar mechanism in Calu-3 cells, which are derived from submucosal glands [398, 
405].                  
The disparity in the localisation of P-gp within Calu-3 cells casts doubt over the subsequent efflux 
direction of substrates by this transporter.  Indeed, in a contradictory manner, a 2001 study by 
Hamilton et al., illustrated polarised basal – to – apical transport of Rh123 in Calu-3 cells thus 
supporting apical orientated P-gp effluxing to the lumen of the airways [403].  While a small number 
of studies share some concern over the possible involvement of other transporter proteins in the 
transport of Rh123 [385, 406], this substrate is widely utilised within the literature to examine the 
functional activity of P-gp [371, 375, 407, 408].  In a study with LLC-MDR1 cells, significant B-A 
transport of Rh123 by P-gp was demonstrated which was subsequently inhibited by Amyloid-β 
peptides.  Further, P-gp was shown to be apically expressed within these cells by 
immunofluoresence and confocal laser scanning microscopy [409].  Additional examples of the use 
of Rh123 as a substrate for P-gp transport include, for example, in vivo rat intestines and Caco-2 
cells, Chinese hamster fibroblasts, human leukaemia cell lines and transport to the aqueous humour 
of the rabbit eye [375, 407, 408, 410].  The abundance of available literature illustrating use of 
Rh123 as a P-gp substrate, combined with use of specific P-gp inhibitors in many studies suggests P-
gp as the more likely mechanism for Rh123 transport.  Further, as the results obtained for flunisolide 
transport in this chapter complement the data reported by Florea et al., it is possible that a second 
mechanism of transport exists for the transport of flunisolide in Calu-3 cells and the IPRL rather than 
challenging the exactness of P-gp localisation within Calu-3. Indeed the possibility of a second 
mechanism; potential flunisolide transport by an OCT transporter, for flunisolide transport was 
considered by Florea and colleagues but not further explored.  The involvement of OCT transporters 
OCT1 (SLC22a1) and OCT2 (SLC22a2) in the transport of other P-gp substrates has been illustrated 
within various kidney cell lines [385, 411], further both transporters have been suggested to be 
present in the lung; albeit with contradictory reports.  Bleasby et al., [69]reported moderate (25-50 
% quartile) OCT2 expression and low (0-25 % quartile) OCT1 expression in human lung, Endter et al., 
[104]report OCT1 expression at the mRNA level in a variety of lung cell culture models (they also 
report no OCT2 expression in the same samples).  Within the results of this thesis, both OCT1 and 
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OCT2 mRNA was detected at some level in the rat lung cell samples studied.  In addition, the 
contribution of passive permeability should be considered in the transport of flunisolide.  The 
pharmacokinetics of flunisolide in humans displays a fast absorption phase with a short dwell time in 
pulmonary tissue. The literature reports of LogP or ClogP places flunisolide between Rh123 and 
digoxin in terms of their partition coefficient (Rh123 LogP = 1.06, flunisolide ClogP = 1.71, digoxin = 
LogP = 2.2) [398, 412, 413].  As discussed above passive permeability is likely to be somewhat 
inextricably involved in the susceptibility of molecules to efflux by P-gp.  However, the alteration of 
flunisolide transport by P-gp inhibitors reported by Florea et al. and within this chapter presents the 
involvement of a second active transporter as a more likely mechanism of transport.   
GF120918 is also known to be active upon the ABCG transporter BCRP [374].  Within the study 
conducted by Florea et al., flunisolide transport is linked to ATPase activity and an additional number 
of 3rd generation P-gp inhibitors were used [398].  There exist a number of literature reports 
documenting the presence of a number of other drug transporters within the Calu-3 cell line.  For 
example, Endter and co-workers report the presence of an additional 23 transporters from the ABC, 
SLC and SLCO families in Calu-3 cells in culture and drug transporters MRP1 and CFTR have been 
specifically localised within these cells [242, 414, 415].  From this, the involvement of an alternate 
drug transporter in the transport of flunisolide across Calu-3 cells and the IPRL could be feasible.  In a 
recent literature review by Bosquillon, flunisolide was reported as a substrate of only P-gp [354], 
Florea et al., also dismiss the involvement of alternative transporters, such as MRP1, as flunisolide 
was shown to be transported unmetabolised in the Calu-3 model [398].   However, the presence of 
other drug transporters in Calu-3 cells does enhance the possibility of alternate transporter 
involvement.  The study by Florea and colleagues does itself compare the chemical structure of 
flunisolide to cholesterol, a substrate that is known to be transported by drug transporters of the 
ABCG family.  Further, Endter et al., report the presence of ABCG1 in Calu-3 cells and the results of 
Chapter 2 (RT-PCR studies) also confirm the presence of this transporter in the rat lung [113].  A 
study by Janvilisri has shown the transporter ABCG1 (White-1) to be involved in the transport of 
sterols, including cholesterol and estradiol and the Drosophila ABCG1 homolog white is known to act 
as an importer for eye pigment precursors [156, 416].  Whilst only supposition, it could therefore be 
deduced that flunisolide is a substrate of the ABCG1 transporter, providing polarised A-B transport, 
and that the addition of GF120918 (known inhibitor of the ABCG transporter BCRP) inhibits this 
ABCG transporter reducing the polarised transport observed in Calu-3 cells and within the IPRL.                  
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In conclusion, through initial Rh123 studies performed with the IPRL, the functional expression of P-
glycoprotein has been illustrated.  The functional activity of P-gp shown within such a model as the 
IPRL is more likely to provide a truer representation of an in vivo state thus both illustrating the 
applicability of  an ex vivo model to the investigation of drug transporter influence and also 
highlighting the issues created by the presence of such functional transporters within the lung.  
Further, the addition of additional P-gp substrates has emphasized the complexity of substrate 
absorption mechanisms across the lung highlighting the value in understanding the interplay of such 
mechanisms and the need for extensive further studies in this area of research.  
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Chapter 5 
Efflux functionality at the pulmonary endothelium: limiting 
drug transport from vasculature to lung 
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5.1. Introduction  
The laboratory rat is perhaps the most widely used and well recognised animal model employed in 
scientific research.  Given the widespread role of this animal model in scientific advancement, it is 
sometimes easy to forget some of the underlying anatomy of this species [417].  
This chapter focuses upon the potential for efflux at the pulmonary vascular barrier limiting drug 
uptake from the pulmonary circulation into the lung.  The pulmonary circulation of the rodent is 
essentially similar to that of humans (Figure 5.1).  Aside from the obvious physiological requirement 
of the lungs to receive the entire cardiac output for blood oxygenation, the lung tissue itself is 
perfused by both the bronchial and pulmonary circulations [418]. 
  
Figure 5.1 Major upper thoracic vasculature of the rat.  A – Key upper thoracic arteries of the rat, not 
including pulmonary vasculature.  B – Main upper thoracic veins if the rat, again, pulmonary 
vasculature is not detailed.  C – Diagram of the rodent heart (distal view).  The human heart is 
essentially comparable in architecture.  D - Deposition pattern of Evans blue dye dosed to the IPRL 
via a forced solution instillation technique (Chapter 3; Figure 3.7) [419].   
Perfusion of the lung parenchyma is derived from the pulmonary artery, branching to the right and 
left to perfuse both right and left lobar lung regions.  Both the pulmonary artery and vein, and their 
respective subdivisions spread extensively throughout the lung lobar tissue.  Previous experiments 
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earlier in this thesis have shown that perfusion of the IPRL via the pulmonary artery of Evans blue 
dye results in visible and extensive permeation of the dye throughout in lung parenchyma (Figure 
5.1) demonstrating the overall importance of the pulmonary circulation to lung tissue perfusion.  
The bronchial circulation primarily provides perfusion to the trachea and major bronchi.  In the rat, 
the bronchial arteries arise from the subclavian arteries (Figure 5.1) and are thought to be 
responsible for providing up to 90 % of tracheal blood supply [420, 421]. The above points are 
important when considering the IPRL setup, in that although the IPRL does quite precisely mimic the 
rodent pulmonary system in vivo, there are important differences in lung perfusion.  The surgical 
technique for lung isolation employed within this thesis is relatively universal and whilst efficiently 
isolating the rodent lung, the technique does sever the bronchial circulation [328].  Since bronchial 
circulation perfuses the upper airways, an absence within the IPRL suggests that the trachea and 
major bronchi may be poorly, or indeed lack completely, any vascular perfusion [418, 420].   A study 
by Ferreira et al. has however highlighted that, in rats, anastamoses between the bronchial and 
pulmonary circulations frequently exist (50 % of animals examined and is also somewhat dependent 
upon strain) such that the supply to the trachea and major bronchi is in part from the  pulmonary 
circulation [418, 420, 421].  Conversely, absorption of solutes across tracheal epithelium can, in part, 
drain through the pulmonary vein to be returned to the systemic circulation.  Extending this point 
Sakagami et al. reported the presence of an intact mucociliary escalator within their IPRL model 
(note the exact same model as applied in this thesis) responsible for pulmonary – to – bronchial 
clearance; although they did report negligible tracheo-bronchial transport of a number of varying 
molecular weight compounds both in vivo and the ex vivo model [101].  They concluded that a viable 
mucociliary clearance mechanism is present in the IPRL and is responsible for the ‘pooling’ of 
substrates dosed to the lung within the negligibly functionally active tracheo-bronchial region [344].   
Clearly the pulmonary vasculature and blood flow can impact upon both handling of locally and 
systemically acting drugs within the lung.  For drugs which display perfusion-rate limited membrane 
permeation, changes in the blood flow to the lung parenchyma could enhance or reduce systemic 
bioavailability of pulmonary administered drugs, and/or alter the uptake of drug from the systemic 
circulation into the lung; potentially leading to toxicity issues and drug-drug interactions [422].  
Beyond this, the vasculature itself can have a profound influence upon drug disposition.  No better 
example of this is the presence of active transporters in endothelial cells; the best known example 
being P-gp expression in the vasculature of the blood-brain barrier (BBB) [423].  Within the brain, P-
gp has been localised to capillaries of the BBB in a number of genus.  For example, Schinkel et al., 
reviewed a number of papers and reported immuno-localisation of P-gp to capillary cells in human, 
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rodent and bovine brain [424].  Further, P-gp at the blood-brain barrier is known to mediate the 
extrusion of a wide range of compounds, limiting transfer to the brain and acting in a protective 
manner [423-425].   
From this, a number of companies have developed P-gp modulators whose clinical indications 
extend beyond overcoming multiple drug resistance in cancer cells but also include modulation of P-
gp at absorption or dispositional barriers [426].  For example, Kaddoumi et al., illustrated that, 
through inhibition of P-gp by zosquidar at the BBB of primate brain, the distribution of the HIV-1 
protease inhibitor, nelfinavir, to the brain increased by 146-fold [427].  Further, Syvänen et al., 
reported that, in rats, a significant increase in the brain penetration of the P-gp substrate verapamil 
can be achieved through the inhibition of P-gp by cyclosporin A [428].  While these are just an insight 
in to the opportunity to improve brain and central nervous system pharmacotherapy, the 
modulation of P-gp at the BBB has obvious advantages.  However, as with the control of any number 
of active processes, concern exists surrounding the potential to increase toxic side effects [381]. 
Within the lung, the presence of P-gp at the membrane of endothelial cells is poorly evidenced.  
Demeule et al. reported expression of P-gp in the endothelial cells of the rat lung [429] and  Roerig 
et al. [355] undertook functional studies in an isolated perfused rabbit lung and presented data 
consistent with a P-gp efflux mechanism acting to limit movement of a P-gp substrate from the 
vasculature into the lung itself.  
Aims and Objectives 
In this chapter, it will be sought to: 
• Investigate the influence of P-gp serving as an efflux mechanism limited drug uptake from 
the vasculature into the lung. 
• It is hypothesised that if functional, this could reflect expression of an efflux transporter 
either at vascular endothelial cells or at the basal surfaces of lung epithelial cells. 
• The p-gp substrate Rh123 will be dosed to pulmonary perfusate and disappearance noted.  
Rh123 disappearance will be recorded as a measure of the loss into the lung. 
• The passive permeability marker sodium fluorescein will also be dosed to IPRL perfusate in a 
similar manner and again its disappearance recorded.  
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5.2. Materials and Methods 
5.2.1. Isolated Perfused Rat Lung (IPRL) 
Materials 
Animals 
Male-specified pathogen-free Sprague-Dawley rats (Harlan UK Limited, Bicester, UK) 
Consumables & Reagents 
IPRL perfusate, filter sterilised; see chapter 3 
Method 
The IPRL procedure and forced solution instillation technique have been extensively described in 
Chapter 3.  Briefly, a rat trachea was cannulated between the 4th and 5th cartilage ring using a 
custom made tracheal cannula (Harvard Apparatus Limited, UK). On dissecting the diaphragm, lungs 
were perfused through the pulmonary artery and manually inflated 4-5 times with 5 mL air to 
remove blood.  Lungs were then surgically removed from the animal, with careful attention paid to 
ensure lung integrity was not compromised.  Once removed, lungs were hung horizontally in a 
humidified artificial glass thorax maintained at 37 °C and slight hypobaric pressure.  IPRL perfusate 
consisted of Krebs-Henseleit buffer containing 4 % (w/v) BSA and was buffered to pH 7.4, filtered 
and stored at 4 °C.  IPRL perfusate was re-circulated through the pulmonary circulation at a constant 
flow rate of 15 mL/min Before dosing, lungs were equilibrated for 5 min and ventilated with a tidal 
volume of 2.5 cm2 at a rate of 20 breaths/min Each IPRL was maintained for 90 min with perfusate 
samples being taken from the reservoir and replaced with an equivalent perfusate volume.  IPRL 
viability was confirmed by determining lung wet: dry weight at the end of each experiment.  F-Na 
was also used as a validation probe as a marker of pulmonary epithelial integrity. 
5.2.2. HPLC analysis: Rh123/F-Na levels in perfusate 
Materials 
Consumables and reagents 
Acetonitrile; ACN, 99.6+ %, HPLC grade, (Fisher Scientific, Loughborough, UK, Cat: A/0626/17) 
Sodium acetate buffer, 20 mM, pH 3.6/pH 4.0, (Fisher Scientific, Loughborough, UK, Cat: BPE334-       
500)      
HPLC grade H2O, (Fisher Scientific, Loughborough, UK, Cat: W/0106/PB17) 
HPLC Column 
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4 µm Genesis C18 column, (Grace, Illinois, USA).    
Method 
Sample analysis was conducted as per Chapter 3.  Briefly, perfusate samples were deproteinated 
with acetonitrile (3:1 v/v acetonitrile: perfusate sample) then centrifuged (18,000 g, 10 min.) to yield 
sample supernatant.  Deproteinated samples (0.1 mL) were injected onto a HPLC column.  Mobile 
phase consisted of acetonitrile, dH2O and 20mM sodium acetate buffer (pH 4.0) at a ratio of 
50:30:20 (v/v/v) for Rh123 analysis and acetonitrile: dH2O (50:50) and 20mM sodium acetate buffer 
(pH 3.6) at a ratio of 90:10 (v/v) for F-Na analysis.  Mobile phase was pumped through the HPLC 
system at a flow rate of 1 mL/min with chromatic measurements being performed at room 
temperature.  The substrate content of each supernatant sample was determined using a suitable 
calibration curve constructed in re-circulated perfusate from control IPRL experiments where lungs 
were not instilled.  Perfusate concentrations were determined fluorometrically, Rh123 analysis 
undertaken at λex 500nm, λem 540nm and F-Na analysis undertaken at λex 485nm, λem 520nm.  
Substrate accumulation in lung was calculated as disappearance from IPRL perfusate over time. 
5.2.3. Rh123 accumulation in lung (perfusate to lung): Effect of GF120918 
Materials 
Consumables & Reagents 
Rhodamine 123; Rh123, >98 % electrophoresis grade, (Sigma-Aldrich, Dorset, UK, Cat: R-8004) 
Sodium fluorescein; F-Na, (Fluka, Sigma-Aldrich, Dorset, UK, Cat: 46960) 
GF120918; obtained from GlaxoSmithKline, Stevenage, UK. 
Dimethyl sulfoxide; DMSO, BioReagent, for molecular biology, ≥99.9 %, (Sigma-Aldrich, Dorset, 
UK, Cat: D8418-50ML) 
 
Method 
An IPRL surgery was performed as per protocol, Chapter 3; methods; 3.2.2.  Lungs were perfused 
with either vehicle control, i.e. DMSO (0.1 % v/v) or GF120918 (500 nM) for 30 min After this, Rh123 
was added as a bolus to achieve a final Rh123 concentration in the perfusate 0.01 µg/mL or 0.025 
µg/mL; see dose ranging comments below.  The Rh123 concentrations were chosen by analyzing the 
actual concentration (µg/mL) in perfusate at 90 min after dosing of Rh123 (5 µg nominal dose which 
was recognised from previous experiments not to cause saturation of efflux transport, at least from 
the airways).  A perfusate sample (1 mL) was immediately taken to determine initial Rh123 perfusate 
concentration.  Samples were removed from the reservoir at 0, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 
80, and 90 min and centrifuged at 18,000 g for 10 min Sample volumes were replaced with perfusate 
containing either DMSO (0.1 % v/v) or GF120918 (500 nM).  Resulting supernatant was 
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fluorometrically analysed using HPLC and Rh123 accumulation in lung was determined by calculating 
Rh123 remaining in IPRL perfusate. 
In a separate experiment, F-Na (0.1 µg/mL) was also dosed to IPRL perfusate and lung accumulation 
determined to act as a control.   
5.2.4. Data Analysis 
To determine the significance of GF120918 addition upon the loss of Rh123 from the perfusate: (1) 
Based upon the % of RH123 dose remaining in the perfusate compartment an initial rate of Rh123 
disappearance was determined by linear regression to calculate (kperf); (2) Based upon mass of Rh123 
remaining in the perfusate compartment a disappearance rate constant (KNL) was calculated by 
nonlinear regression.  
Nonlinear regression analysis was undertaking using Graphpad software, the below equation was 
employed to model the mass of Rh123 remaining in the perfusate as a function of time.  
tM = 0M ∗ NL−K
∗texp  
Where Mt is the mass of Rh123 at any time (t);  M0 is the mass of Rh123 in the perfusate 
immediately at the start of the experiment;  kNL  is the first-order rate constant describing the loss of 
Rh123 from the perfusate.  A t1/2 can be calculated from the first-order rate constant as 0.698/KNL.  
The model is a monoexponential one and therefore represents the simplest approach. 
 
Figure 5.2 Monoexponential model applied to all Rh123 perfusate loss data  
An independent samples t-test was performed on each criterion and a value of p<0.05 was 
considered significant.   
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5.3. Results 
5.3.1. Rh123 accumulation in lung (perfusate to lung):  Effect of GF120918 
Inclusion of Rh123 at 1 µg (to achieve an initial Rh123 concentration of 0.01 µg/ml) or at 2.5 µg (to 
achieve an initial Rh123 concentration of 0.025 µg/ml) nominal dose along with DMSO (0.1 % v/v) in 
the pulmonary perfusate reservoir resulted in Rh123 loss profiles that showed a more rapid decline 
in levels during the first 15-20 minutes and then plateaued off.  As can be seen from figure 5.3A, the 
plateau achieved by 30 minutes of experimentation for 2.5 µg nominal dose, was not significantly 
(p>0.05) altered with the addition of GF120918 (500 nM).  There is however, evidence that the 
addition of GF120918 (500 nM) significantly (p<0.05) altered the perfusate plateau level for Rh123 at 
the 1 µg nominal dose, (Figure 5.3B)    
 
Figure 5.3  Effect of P-gp inhibitor, GF120918, upon the % Rh123 dose remaining in the pulmonary 
perfusate of the IPRL: Fig 5.3A -   Rh123 dose (2.5 µg nominal dose) was added to the pulmonary 
perfusate (volume ~100 mL) to achieve an initial nominal concentration of 0.025 µg/mL.  GF120918 
(500 nM) in the IPRL perfusate did not significantly (p>0.05) modify plateau levels of Rh123 in IPRL 
perfusate.  GF120918 did modify (p<0.05) the initial (times 0 to 20 min.) rate of loss of Rh123 from 
perfusate.  Data shown are expressed as mean ± S.D (n=3 for each treatment).  Fig 5.3B – Rh123 dose 
(1 µg nominal dose) added to ~100 mL (as measured by marking 100 mL increment on perfusate 
reservoir) perfusate to achieve an initial nominal concentration of 0.01 µg/mL.  Addition of 
GF120918 (500 nM) significantly (p<0.05) altered both perceived plateau of Rh123 levels and initial 
rate of Rh123 loss from the perfusate.  Data shown are expressed as mean ± S.D (n=3 for each 
treatment). 
The paracellular probe, F-Na, was introduced to IPRL perfusate (10 µg nominal dose) to act as a 
comparison for Rh123 data.  As can be seen in figure 5.4, no substantial loss of F-Na from pulmonary 
perfusate was observed over a 60 min experimental time period indicating minimal uptake into the 
lung of F-Na from pulmonary perfusate.  
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Figure 5.4 Loss of F-Na from pulmonary perfusate over time. The addition of GF120918 was not 
included as GF120918 nor its vehicle, DMSO, have previously been shown not to influence transport 
of F-Na.  Data shown are expressed as mean ± S.D (n=3).   
Table 5.1 shows some of the key data for the Rh123 perfusate loss experiments: 
At the nominal dose of 2.5 µg, the % of Rh123 dose remaining in the perfusate showed no significant 
(p>0.05) difference between control and inhibitor treatment, at both the 60 min and 90 min 
measurements.  However at this dose of 2.5 µg, the initial rate of Rh123 disappearance (kperf) as 
calculated by linear regression; was affected (p<0.05) by the inclusion of GF120918 (500 nM) with a 
greater (kperf) determined, i.e. faster rate of loss, in GF120918 presence.  
In contrast, at the nominal dose of 1 µg, the % of Rh123 dose remaining in the perfusate was 
significantly (p<0.05) lower in the inhibitor treatment experiment than in control, at both the 60 min 
and 90 min measurements.  At this dose of 1 µg, the initial rate of Rh123 disappearance (kperf) was 
similarly affected (p<0.05) by the inclusion of GF120918 (500 nM) with a significantly greater (kperf) 
determined in inhibitor presence. 
Of note is the % of Rh123 in the perfusate at plateau appearing markedly different even in the 
control treatments between the 2.5 µg and 1 µg doses (i.e., approximately 55 % and 72 % 
respectively). 
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 Rh123 (0.025 µg/mL) Rh123 (0.01 µg/mL) 
+ 0.1% DMSO + 500 nM 
GF120918 
+ 0.1% DMSO + 500 nM 
GF120918 
Percentage of initial Rh123 
dose in IPRL perfusate at 
60min(%) 
 
55.6 ± 8.3 47.4 ± 2.9 72.6 ± 3.4 49.5 ± 7.7† 
Percentage of initial Rh123 
dose in IPRL perfusate at 
90min(%) 
 
57.7 ± 10.0 47.5 ± 4.7 72.7 ± 4.5 44.6 ± 5.5† 
Initial rate of Rh123 loss from 
perfusate (Kperf; min
-1) 
0.016 ± 0.005 0.025 ± 0.003* 0.035 ± 0.001 0.093 ± 0.002† 
Table 5.1.  Effect of GF120918 upon the lung accumulation of Rh123.  Rh123 dose (2.5µg or 1 µg 
nominal dose) was added to pulmonary perfusate (volume 100mL) and loss of Rh123 from perfusate 
monitored. The P-gp inhibitor GF120918 (500nM) was included in IPRL perfusate to assess the effect 
of P-gp upon Rh123 accumulation.  *GF120918 treatment resulted in a statistically greater (p<0.05) 
initial rates of loss (kperf) of Rh123 from perfusate compared to the respective control.  † GF120918 
treatment resulted in a statistically lower (p<0.05) Rh123 plateau levels when compared to the 
respective control.  Data shown are expressed as mean ± S.D (n=3 for each treatment). 
In order to explore more fully pharmacokinetic parameter for the loss of Rh123 from perfusate the 
data was also subjected to nonlinear regression analysis (as detailed in materials and methods 
section).  Figure 5.5 highlights typical model fit to mean data.   
As can be seen in table 5.2, the initial rate of loss of Rh123 (kNL) from pulmonary perfusate calculated 
by nonlinear regression analysis varies in absolute magnitude from the calculated initial rate through 
linear regression (kperf), although the pattern of change from control remains the same.  Specifically 
the incorporation of GF120918 resulted in significantly (p<0.05) greater calculated kNL values i.e. 
faster rates of proportional Rh123 loss from the perfusate, giving a shorter t1/2 for both the 2.5 µg 
and 1 µg doses.  
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Figure 5.5  Non-linear regression modelling of Rh123 perfusate disappearance data.  The model 
applied to all data was described in Chapter 5 Materials and Methods section. Figure 5.5A -  Non-
linear regression of data representing Rh123 loss from perfusate (1 µg nominal dose) in the presence 
of 0.1 % DMSO.   Figure 5.5B – Non-linear regression of data representing Rh123 loss from 
perfusate (1 µg nominal dose) in the presence of 500 nM GF120918.  Fig 5.5C – Non-linear 
regression of data representing Rh123 loss from perfusate (2.5 µg nominal dose) in the presence of 
0.1 % DMSO.  Figure 5.5D – Non-linear regression of data representing Rh123 loss from perfusate 
(2.5 µg nominal dose) in the presence of 500 nM GF120918.  Data are expressed as mean ± S.D. (n=3 
for each treatment). 
  kperf (min
-1)  
[from table 5.1] 
kNL(min
-1) t½ (min.) from kNL 
Rh123 (0.01 
µg/mL) 
+ 0.1 % DMSO 0.035 ± 0.001 0.080 ± 0.020 9.05 ± 2.50 
+ 500 nM GF120918 0.093 ± 0.002* 0.167 ± 0.038* 4.32 ± 1.09* 
Rh123 (0.025 
µg/mL) 
+ 0.1 % DMSO 0.016 ± 0.005 0.059 ± 0.005 11.83 ± 0.92 
+ 500 nM GF120918 0.025 ± 0.003* 0.092 ± 0.005* 7.58 ± 0.45* 
Table 5.2.  Effect of GF120918 upon parameters reflecting Rh123 loss from pulmonary perfusate.  * 
The addition of GF120918 significantly altered (p<0.05) the initial rate of loss of Rh123, calculated 
by both linear (kperf) and nonlinear (kNL) regression and the disappearance half-life (t½) of Rh123 from 
pulmonary perfusate.  Data shown are expressed as mean ± S.D (n=3 for each treatment). 
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5.4. Discussion 
To examine the relative influence of an efflux mechanism acting from lung to perfusate, the P-gp 
substrate Rh123 was introduced to the pulmonary perfusate of the IPRL and its disappearance 
recorded.  To explore P-gp involvement in any such disappearance, the P-gp inhibitor GF120918 was 
also introduced to pulmonary perfusate and the effects monitored.  This element of the work was 
part stimulated by the flunisolide results in the previous chapter of this thesis and the and data of 
Florea et al. [398] which suggested flunisolide to be actively transported in the lung in an apical - to - 
basal direction, by P-gp.  Furthermore the work of Roerig et al. [355] also has reported a lung to 
vasculature efflux mechanism in an isolated perfused rabbit lung model. 
Within our IPRL system, Rh123 transport from pulmonary perfusate was monitored over a 90 min 
period.  Employing an initial Rh123 concentration in perfusate of 0.025 µg/mL (2.5 µg dose), no 
significant difference between the plateau levels of Rh123 in the presence and absence of GF120918 
(500 nM) could be observed.  In contrast, when we utilised a lower perfusate concentration of 0.01 
µg/mL (1 µg dose), the % of Rh123 dose remaining in the perfusate was significantly lowered by 
inhibitor treatment.  Such plateau levels reflect the equilibrium achieved between perfusate and 
lung tissue (after 20-30 min of experimentation).  The plateau level reflects the distribution volume 
for Rh123 for both perfusate and lung tissue combined, and accounts for the volume of the 
perfusate, the binding of Rh123 in the perfusate and the accumulation and binding of Rh123 within 
the lung.  A lower plateau level (or % of Rh123 dose remaining) in the perfusate can be interpreted 
in the context of: (i) decreased specific binding within the perfusate (e.g. decreased protein binding) 
allowing more Rh123 to passively accumulate in the lung, (ii) an increase in the apparent volume of 
distribution of the lung toward Rh123; (iii) overcoming of a Rh123 transport barrier from perfusate 
to lung.   
One possible explanation by which the 2.5 µg dose of Rh123 fails to show a difference between  
control and P-gp inhibitor treatments with respect to plateau levels while the 1 µg dose appears to 
show a difference, is one that relates to the 2.5 µg dose of Rh123 saturating any potential efflux 
mechanism from lung to perfusate.  Thus suggesting that the 1 µg dose is still susceptible to efflux 
until co-administered with the P-gp inhibitor.  Indeed the perfusate concentrations of Rh123 present 
at the end of the dose escalation Rh123 absorption experiments for either 40 µg or 80 µg Rh123 
(Chapter 4) (doses which saturated the airway to perfusate efflux mechanism) are comparable to  
the plateau concentrations achieved here for the 2.5 µg dose of Rh123 directly administered into the 
perfusate.  
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However, the % of Rh123 in the perfusate at plateau was markedly different even in the control 
treatments between the 2.5 µg and 1 µg doses (i.e. approximately 55 % and 72 % respectively). This 
could imply a greater proportional loss of Rh123 from perfusate at the higher dose.  This difference 
in % remaining at plateau between the control groups is not easily explained by a non-specific 
binding phenomenon (i.e. tubing) or by an increased capacity for specific binding within the lung 
tissue as both of these would have affected the lower dose Rh123 proportionally more.  A closer 
inspection of the actual mass remaining data (Figure 5.3) however, reveals a marked difference 
between the time zero Rh123 mass remaining in the perfusate between the Rh123 control and 
GF120918 treatments for the 1 µg dose.  This should not be the case and implies a lack of reliability 
in the % plateau calculation for the Rh123 1 µg dose, i.e. the 72 % of Rh123 remaining at plateau is 
likely to be an over-estimation.  Indeed the actual plateau levels by mass between the control and 
GF120918 treatments for the 1 µg dose are very similar (Figure 5.3).  
Nevertheless addition of GF120918 did significantly alter initial rate of Rh123 disappearance (kperf) 
from perfusate and also the calculated rate constant for loss from non-linear regression (kNL) (and 
disappearance half-life t½) for both the 2.5 µg and 1 µg doses of Rh123.  This could arise from protein 
binding displacement of Rh123 from the albumin in the perfusate allowing more Rh123 to more 
rapidly accumulate by passive mechanisms in the lung; both GF120918 and Rh123 are known to 
display high protein binding.  Further, it could reflect functional inhibition, at least initially, of P-gp 
mediated efflux which would normally limit the rate of transport of Rh123 into the lung from 
perfusate.  However, one may expect functional inhibition of a lung to perfusate – directed P-gp 
efflux to also alter equilibrium levels between lung and perfusate when comparing control of 
inhibitor experiments.  Clearly this issue needs further research.  
The passive permeability marker, F-Na, was introduced to pulmonary perfusate at a nominal 
concentration of 0.1 µg/mL in order to examine the comparative apparent volume of distribution for 
F-Na and Rh123.  Results demonstrated F-Na to predominantly remain within perfusate for the 
duration of the experiment, i.e. no significant F-Na disappearance from perfusate/lung accumulation 
was observed.  This contrasts markedly to the lung accumulation of Rh123 where 30-50 % of Rh123 
would appear to be lost to the lung from the perfusate.  This is perhaps not surprising as F-Na is a 
polar but charged molecule not subject to significant protein binding.  Indeed F-Na, when 
administered into the airways of the IPRL, displays extents of absorption of between 70-90 % within 
the initial 80 min In the rat, the lung weight approximates to 0.6 % of total body weight such that for 
a 300 g rat the lung would weigh about 2 grams. With a density of 1 g/mL we would anticipate for a 
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drug not subject to binding within the lung to display an apparent volume of distribution for the lung 
itself of approximately 2 mL [417]. Against a perfusate volume of 100 mL such a volume would 
represent only a small proportion and certainly within the realms of experimental variance.  Rh123 is 
a cationic molecule and positively charged molecules are known to accumulate in the lung and 
indeed the absorption of Rh123 from the airways is low [367].    
Previously, Roerig et al. have sought to investigate P-gp activity within lung vasculature through use 
of an Isolated Perfused Rabbit Lung preparation.  They used a rhodamine analogue, rhodamine 6G 
(R6G), and introduced this to perfusate in increasing concentrations from 1.25 µM to 12.6 µM.  They 
showed disproportionate loss of R6G from the perfusate, i.e. greater loss as the concentrations in 
the perfusate increased.  From this, they concluded that transport of R6G into the lung was a 
saturable process.  Through the inclusion of GF120918 in perfusate, an approximate 21 % increase in 
R6G lung accumulation was observed compared to control.  From this they concluded the 
involvement of P-gp [355]. 
The results of this chapter partly complement those of Roerig et al., in that a P-gp inhibitor was 
observed to modulate the perfusate kinetics of Rh123 in a IPRL model.  While Roerig demonstrated 
an increase in lung accumulation of a rhodamine dye with the inhibition of P-gp, the results of this 
current work remain equivocal as far as % accumulation data is concerned.  Certainly, Roerig et al. 
reported a much higher percentage of R6G accumulation within the lung, which then increases 
further with the addition of GF120918, this second observation also true Rh123.  For example after 
introducing a nominal concentration of 2.5 µM to perfusate, Roerig et al. report R6G lung 
accumulation of 66.6 ± 2.6 % (S.E), this increased to 87.5 ± 1.1 % (S.E) with the addition of GF120918 
[355].  The analogue R6G is recognised to display a higher affinity for P-gp than Rh123 [356].  While 
Rh123 is also more highly protein bound than R6G and displays a lower passive permeability rate 
constant [367, 375].  Therefore, there may be a greater proportion of R6G ‘free’ in the isolated 
perfused rabbit lung system that also has a greater ability to passively diffuse across the endothelial 
barrier, thus displaying higher percentage transfers than Rh123. 
As mentioned in the introduction to this chapter, ‘endothelial P-gp’ in the BBB is highly significant, 
influencing the brain penetration of such substrates as synthetic glucocorticoids, antihistamines, and 
a number of drugs with relevance to neurological disorders such as epilepsy, Alzheimer's disease, 
Parkinson’s disease and brain cancer [430-434].  From this, the induction or modulation of P-gp at 
the BBB represents a real therapeutic target to enhance the treatment of a number of neurological-
related health conditions [431].  
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The results of this chapter do not discount that P-gp within the pulmonary vasculature can display 
functionality.  While we have focused the discussion so far on Rh123, there may also be merit in 
considering the influence of ‘endothelial P-gp’ upon results of the previous chapter concerning the 
transport of flunisolide within the IPRL.  While it was hypothesised that an alternative drug 
transporter may be responsible for the observed polarised apical – to - basolateral transport of 
flunisolide, when comparing the relatively varied physico-chemical properties of other known P-gp 
substrates examined within this thesis and the integral relationship between passive diffusion rate 
and active transport mediated by P-gp, there is potential to relate the ‘unconventional’ directional 
transport of flunisolide to ‘endothelially’ expressed P-gp.  Figure 5.6 diagrammatically represents the 
hypothesised transport of P-gp substrates, mediated by P-gp, in the isolated perfused rat lung.   
 
Figure 5.6 Proposed transport of Rh123 and flunisolide within the IPRL, mediated by P-gp.  Letter 
‘A’ relates to Rh132 transport within the IPRL after intra-tracheal instillation, i.e. transport from lung 
– to – perfusate.  Letter ‘B’ relates to flunisolide transport within the IPRL, (lung – to – perfusate) 
post intra-tracheal instillation of dose.  Letter ‘C’ relates to Rh123 transport, (perfusate – to – lung), 
after introduction of Rh123 dose to pulmonary perfusate.  All variations of dashed arrows denote the 
predominant direction of substrate transport, ‘white background’ of diagram represents transport in 
the absence of GF120918, ‘grey background’ relates to transport in the presence of GF120918.  Each 
cumulative transport plot, labelled A, B, or C, illustrates the % of substrate in perfusate over time and 
corresponds to respective letters relating to substrate transport within the IPRL (left panels of 
diagram).      
As can be seen in figure 5.6;  
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A. When considering Rh123 transport after intra-tracheal instillation, the presence of active P-
gp would reduce perfusate concentrations of substrate by retaining Rh123 within the lung.  
A degree of abolition of P-gp action through addition of GF120918 would increase Rh123 
perfusate concentrations by removing the limiting efflux activity of P-gp and therefore 
limiting active retention of Rh123 within the lung.  
B. Transport of flunisolide to perfusate in the presence of active P-gp could be enhanced by the 
action of P-gp present in endothelial cells propelling substrate to perfusate at a rate 
exceeding that of passive diffusion.  Modulation of P-gp activity through introduction of the 
GF120918 inhibitor could thus reduce the rate of flunisolide transport over the experimental 
time period by eliminating the active propulsion of flunisolide from the cytosol of capillary 
endothelial cells to pulmonary perfusate. 
C. With similar focus, the transport of Rh123 dosed to pulmonary perfusate in the presence of 
functional P-gp could be constrained by active, ‘endothelially’ localised P-gp.  Modulation of 
P-gp could therefore increase passage of Rh123 to the isolated lung by suppression of active 
efflux of Rh123 and retention of substrate within the pulmonary perfusate.   
The results of this chapter and those of Roerig et al. [355] continue the intrigue over endothelial P-
gp functionality within the complex mechanisms of absorption in the lung.  However, it should not 
be forgotten that published investigations performed in vivo in mdr1 (-/-) transgenic knockout mice 
can provide further insight.  Specifically, the lung to blood distribution data generated in mdr1a(-/-) 
or mdr1a/1b(-/-) mice all indicate that for those P-gp substrates so far studied, the mdr1(-/-) 
knockout phenotype has little to no impact upon drug accumulation in the lung from the systemic 
circulation (reviewed in [117]).  There is obvious scope for further study with regards to the 
influence of P-gp located in the lung.  This would include: (i) electronic microscopy assessment of P-
gp within the entire pulmonary tissue to localise with sufficient resolution P-gp to endothelial and 
epithelial membranes; (ii) uses of an isolated perfused mouse lung model with mdr1a and mdr1b 
knockout; and if (ii) is not possible then the conduct of quantitative kinetic studies within an IPRL 
using a range of substrates and inhibitors.  
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Chapter 6 
Investigating the impact of pulmonary P-gp upon airway 
instilled substrates within an industrial setting; Use of an in 
situ IPRL model 
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6.1. Introduction 
The history of P-glycoprotein, in terms of definitive literature references, dates back to its 
documentation within scientific literature by Juliano and Ling in 1976 [70].  By the mid-eighties, 
many literature reports were describing the drug resistance capacity of P-gp and by the later stages 
of the 80s, reports of P-gp inhibition were emerging [435, 436].  It is from this period onwards that 
industrial interest in the impact of P-gp upon drug absorption and disposition began and indeed the 
concept of developing chemical inhibitors of P-gp was formed.  For example, In 1991 Fling and co-
workers, based at Burroughs Wellcome in North Carolina, reported comparability between P-gp and 
a C. albicans gene conveying resistance to benomyl and methotrexate [437].  Following this, a team 
based at GLAXO in France documented the pharmacological activity of the inhibitor GF120918 upon 
P-gp and reported reversal of multidrug resistance both in vitro (CHRC5 cells) and in vivo (mice) 
[373].   Industrial contributions to the literature have been significant, for example, the work of 
Joseph W. Polli [438].  To date, within the biomedical and life sciences literature archive PubMed 
Central, (http://www.ncbi.nlm.nih.gov/pubmed), Joseph W. Polli has authored or co-authored 24 
articles relating to P-glycoprotein and continues to work at GSK [439]. 
This chapter describes studies undertaken at GSK within their respiratory Centre of Excellence for 
Drug Discovery (CEDD).  The work was undertaken as part of as part of my studentship using GSK’s 
own in-house developed in situ isolated perfused rat lung model; with the airway instillation of test 
compounds to determine the potential of P-glycoprotein to modulate pulmonary absorption.  More 
specifically, experiments were conducted in order to consider the applicability and viability of such 
an isolated model within the pharmaceutical industry. 
Of GSK’s 101 trademarked prescription drugs currently available in the UK/EU and USA, 18 % are 
marketed for use in the treatment of pulmonary conditions (Figure 6.1 illustrates this [440]).  
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Figure 6.1. Graphical presentation of all (101 in UK/EU & USA) trademark products currently 
produced by GSK.  Figure 6.1A – Percentage of drugs targeting specific disease/condition areas.  
Figure 6.1B – Generic composition of pulmonary targeted drugs presented as % of total trademark 
pulmonary drugs produced by GSK.  Figure 6.1C – Specific pulmonary-associated diseases and 
conditions treatable via trademark GSK ‘pulmonary drugs’, expressed as % of total trademark 
pulmonary drugs produced by GSK [440].   
Given the prevalence of ‘pulmonary drugs’ within the portfolio of GSK trademark products, it is very 
important that the numerous factors a target drug molecule is confronted with in the dynamic 
environment of the lungs are understood.  Further, as it is common for 80-90 % of an inhaled dose to 
be swallowed, understanding the disposition of the remaining dose is vitally important and this can 
vary according to a number of factors (e.g. particle size, patient health).  In order to achieve high-
quality candidate inhaled medicines, proper pharmacokinetic profiles for each drug; poor oral 
absorption, short plasma half-life, high plasma clearance (reducing systemic exposure thus 
undesirable side effects), sustained lung retention and therefore pharmacologically active levels of 
candidate drug, is highly desirable and necessary for successful candidate selection [441].  To allow 
the appropriate selection and further development of such drug treatments for targeting specific 
diseases and conditions, the requirement for appropriate experimental models is essential.  Within 
GSK an isolated perfused rat lung preparation (IPRLu) has been developed in order to generate 
biopharmaceutics information relevant to drug candidate selection for pulmonary disease.  
For use as an experimental model to aid pulmonary drug discovery, an in situ IPRLu setup was 
constructed by GSK research and development scientists.  The isolated perfused and respiring rat 
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lung (IPRLu) model is essentially desirable within the field of drug discovery because it allows deeper 
understanding of the transport of a drug molecule across the lung “in situ” via the inherent nature of 
the isolated model.  By isolating the pulmonary blood system from that of the systemic circulation 
whilst maintaining perfusion and integrity of the vascular network surrounding the lung and 
manually ventilating the lungs, it is reasonable to assume that any compound dosed to the isolated 
lung via the trachea which is not present in the pulmonary vein must either be retained by the lung 
or metabolised/broken down in the lung tissue or mucus.  From this, the IPRLu at GSK can be, and is, 
used as a ‘ranking tool’ i.e. a screen, to allow development of drug treatments for targeting specific 
pulmonary diseases and conditions, thus fulfilling the essential requirement for an appropriate 
experimental model [441].   
Within the literature, in situ IPRL models are often employed in experiments with aims and 
objectives that are physiologically focussed.  For example, Tschumperlin and co-workers exploited a 
similar model to that at GSK to examine alveolar surface area-volume relationships [442].  Within 
this research area, the main use of in situ IPRL models appears to be within the study of pulmonary 
ischaemia-reperfusion injury.  Again, lung isolation protocol appears to be comparable to other 
studies; while retention of the lung within the thoracic cavity allows the maintenance of whole body 
integrity with relation to the pulmonary system and allows for permeations of injury cause and 
duration of ischaemic attack over the time course of the experiment [443, 444].     
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Figure 6.2 Image representing the in situ isolated perfused rat lung setup employed at GSK. 
The in situ model employed by GSK functions as a single-pass model with ease of use (‘single-pass’ 
samples collected incrementally i.e. not ‘pooled’ in reservoir; easier sample analysis) in the 
examination of lung retention and metabolic activity upon candidate drug substrates.  The model is 
however comparable to other published models in terms of its maintenance of tissue functionality 
and architecture and ability to assess post-deposition events and pharmacokinetics within the lung 
[23].  The image in figure 6.2 illustrates the setup established at GSK.  As can be seen, overall, this 
model resembles that of the Cardiff IPRL with regards to equipment requirement and setup.  
Obvious differences include the lack of artificial thorax, the need for an angled dosing platform and 
the lack of water-jacketed glass equipment to maintain perfusate and preparation temperature.  The 
lack of a recirculating perfusion system is also apparent, however, a single-pass perfusion method is 
employed at GSK as this allows for simple calculation of initial pharmacokinetic parameters.     
Aims and Objectives 
The studentship investigations using the GSK model included; 
• Validation of dosing technique by introducing Evans blue dye to the IPRLu via the trachea. 
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• Examination of the functional significance of P-gp upon drugs instilled to the lung, substrates 
Rh123 (also tested in Cardiff) and flunisolide were dosed to the GSK IPRLu and dose 
escalation conducted to establish saturation of an active transporter 
• Further, the P-gp inhibitor GF120918 will be introduced to IPRLu experiments to assess the 
effect of P-gp modulation upon instilled substrates. 
• Examination of lung weight and dose mass balance will also be recorded to add to data 
analysis and data will be subjected to pharmacokinetic modelling in order to establish initial 
pharmacokinetic parameters in the presence and absence of an active efflux transporter.       
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6.2. Materials and Methods 
6.2.1. Single-pass perfusion Isolated Perfused Rat Lung model 
Materials 
Animals 
Species: Rat 
Strain: Sprague Dawley (CD) 
Sex & Number: 8  Male (2 for surgery, 5 for control blood, 1 spare) 
Weight : 300-500 g.  Animals were weighed prior to dosing 
Husbandry: Routine animal husbandry methods were applied. Animals were housed 
in standard holding cages. Water and food was available ad libitum 
throughout. 
 
Consumables and reagents 
Single animal, volume controlled ventilator, (Starling Ideal, Harvard Apparatus Ltd, UK,  Cat: 
401003) 
Peristaltic pump, Harvard rodent blood pump/Model: 1407, (Harvard Apparatus Ltd, UK) 
Round bottom, 3 neck flask, borosilicate, 50 mL, Quickfit, (Fisher Scientific, Loughborough, UK, 
Cat: QFM-230-W) 
Magnetic stirrer hot plate with temperature probe, (Cole Palmer, UK) 
Perfusate line; (Large: 0.187” ID x 0.063” WALL, type SFM1-4450, VWR code 228-0235) 
         (Medium : 0.104” ID x 0.044” WALL, type SFM1-3250, VWR code 228-0236) 
         (Small : 1.98mm ID x 3.17mm OD, VWR code 228-0239) 
Syringes (Sterile; various volume capacities), (Fisher Scientific, Loughborough, UK) 
Heparin Sodium (administered 0.5 mL of 100 u/mL i.v. via tail vein) 
Ketamine, (100 mg/mL ketamine Hydrochloride), (Dodge Laboratories, Inc., Fort Dodge, Iowa, 
USA, Ref: 440728) 
Dormitor®, (1 mg/mL medetomidine hydrochloride), Pfizer, UK) 
Reagents (for buffer) 
Potassium chloride; KCl, (Fisher Scientific, Loughborough, UK, Cat: P/4280/53) 
Magnesium sulphate heptahydrate; MgSO4.7H2O, (Fisher Scientific, Loughborough, UK, Cat: 
M/0600/53) 
Sodium Bicarbonate; NaHCO3, (Fisher Scientific, Loughborough, UK, Cat: S/4200/60) 
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Calcium chloride dihydrate; CaCl2.2H2O, (Fisher Scientific, Loughborough, UK, Cat: C/1500/50) 
Sodium chloride; NaCl, (Fisher Scientific, Loughborough, UK, Cat: S/3105/63)   
Potassium dihydrogen phosphate; KH2PO4, (Fisher Scientific, Loughborough, UK, Cat:       
P/4800/53) 
Bovine serum albumin; BSA, (Sigma-Aldrich, Dorset, UK, Cat: A7906-1kg) 
Method 
Preparation of Krebs-Ringer bicarbonate buffer 
To prepare 1 L 
The below listed chemicals and solutions were added to distilled water (~ 600 mL) and the final 
volume adjusted to 1000 mL.  Order of addition: 
1) KCl    0.35 g  
2) MgSO4.7H2O   0.29 g  
3) NaHCO3   2.10 g 
4) CaCl2.2H2O   0.37 g  
5) NaCl    6.92 g 
6) KH2PO4    0.16 g  
7) BSA    30.0 g  
Order of addition of buffer components is very important, isotonicity and pH are critical.     
Buffer solution was prepared and adjusted to pH 7.4. 
Preparation of diluted blood/buffer for single-pass perfusion 
A total of 5 animals were exanguinated under terminal anesthesia and control blood collected.  
Control blood was diluted with buffer (1:9; blood: buffer) and this diluted blood used for lung 
perfusion.  Diluted blood was stored at 4 °C until required and a minimum of 200 mL was necessary 
for each single-pass perfusion preparation. 
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Surgery
 
Figure 6.3.  Diagrammatic representation of single-pass IPRL preparation.  Diagram also illustrates in 
situ cannulation of the heart to produce an isolated pulmonary perfusion system and position of 
animal and dosing method employed.   
Following an IP injection (7.5 mL/kg ketamine & 0.5 mL/kg Dormitor) to provide terminal general 
anaesthesia, heparin was administered (0.5 mL of 100 U/mL) intravenously via a tail vein.  The 
trachea was then cannulated and respiration transferred to the positive pressure ventilator and 
maintained at 40 breaths per min with a 1.8 mL tidal volume.  (The ventilator was set at 4 mL volume 
to allow for dead space in the tubing).  The rat was then exsanguinated via the abdominal aorta. 
The pulmonary artery and vein were then cannulated through incisions in the left and right 
ventricles respectively (Figure 6.3).  Following cannulation, the rat was raised and maintained at a 
fixed angle using the custom made elevating chamber (Figure 6.3).   
Recirculating blood-based perfusate (10 % animal blood v/v; see perfusate preparation above) at 
37 oC was then used to perfuse the lung preparation.  The flow was gradually increased until a 
rate of 10 mL/min was achieved.  This was measured by weighing the perfusate collected over a 
  Chapter 6 
217 
 
30 second period.  The predose flow rate was documented and the preparation left to equilibrate 
for 10 minutes.  One spare animal was allocated for surgery, if not required this animal was 
returned to stock.   
Dosing 
Following equilibrium of the preparations and attainment of the required flow rate, 100 µL of the 
cassette dose suspension/solution was administered to the trachea slightly above the bifurcation 
point by introducing a Hamilton syringe (50 mm needle) into the tracheal cannula followed by 3 x 1 
mL syringe fulls of air.  The trachea was then be immediately reattached to the ventilator. 
Sampling 
Immediately following dosing, the exit cannula (pulmonary vein cannula) from the lungs was 
removed from the reservoir and the perfusion was switched to single pass.  The perfusate was then 
collected to universal tubes over a 1 min interval for 20 min (the total length of the experiment was 
20 min). 
Sample collection tubes (universal tube or equivalent) were weighed and recorded (to determine the 
sample volume collected).  Tubes were weighed periodically (5, 10 & 15 min.) throughout the 
experiment to ensure collection volume and thus the perfusate flow rate was constant.  Any 
deviations were rectified by altering the pumping capacity.   
1 mL of perfusate was removed from each collection tube and placed in an eppendorf tube.  This 
sample was centrifuged to yield perfusate plasma.  The cell pellets were discarded and the plasma 
transferred into a second eppendorf tube and stored frozen until analysis.  The bulk collected 
perfusate samples were discarded following weighing and preparation of a perfusate plasma sample. 
At 20 min, the experiment was terminated. 
The lungs were detached from the ventilator and the perfusion apparatus and excised from the 
thorax of the rat and retained.  The trachea was removed and lungs and trachea separately stored 
frozen prior to analysis. 
Plasma, lungs and residual dose were transferred to a -20 °C freezer as soon as possible following 
collection. Samples remained frozen until analysis. 
Samples were subsequently analysed by LC/MS/MS after suitable preparation. 
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6.2.2. Evans blue lobar deposition 
Materials 
Consumables 
Evans blue, (Fluka, Sigma-Aldrich, Dorset, UK, Cat: 46160-5G-F) 
Method 
In order to assess dose deposition pattern across the lung, Evans blue (3 mg/mL in dH2O, filter 
sterilised) was instilled to the IPRL using the Hamilton instillation technique.  Immediately after 
dosing, the experiment was terminated and the lung tissue removed to allow visual assessment of 
deposition pattern.   
6.2.3. Rh123 absorption in the single-pass perfusion model 
Dose preparation 
Consumables and reagents 
Rhodamine 123; Rh123, >98 % electrophoresis grade, (Sigma-Aldrich, Dorset, UK, Cat: R-8004) 
GF120918; obtained from GlaxoSmithKline, Stevenage, UK. 
Dimethyl sulfoxide; DMSO, BioReagent, for molecular biology, ≥99.9 %, (Sigma-Aldrich, Dorset, 
UK, Cat: D8418-50ML) 
Method 
2 µg nominal dose airway administration of Rh123 (100 µL instilled dose volume) 
I. Rh123 was weighed out and dissolved in 10 mL H2O and sonicated to achieve a 
homogeneous solution at 2.27 mg/mL 
II. This was diluted 1:100 with H2O to produce a stock at 22.7 µg/mL 
III. To achieve 20 µg/mL, 0.12 mL H2O was added to 0.88 mL '22.7 µg/mL stock solution' 
40 µg nominal dose airway administration of Rh123 (100 µL instilled dose volume)  
I. Rh123 was weighed out and dissolved in 10 mL H2O and sonicated to achieve a 
homogeneous solution at 2.27 mg/mL  
II. This was diluted 1:5 with H2O to produce a stock at 454 µg/mL 
III. To achieve 400 µg/mL, 0.12 mL H2O was added to 0.88 mL '454 µg/mL stock solution' 
2 µg nominal dose airway administration of Rh123 co-administered with GF120918 (500 nM, 100 µL 
instilled dose volume) 
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GF120918: 500nM = 281.9 ng/mL (using 563.7 as MW) 
I. GF120918 was weighed out and dissolved in 10 mL H2O (containing 10 % DMSO) and 
sonicated to achieve a homogeneous solution at 28.19 µg/mL. 
II. 100 µL of this stock solution was spiked to 900 µL of a ~20 µg/mL Rh123 solution in order to 
achieve a solution of ~ 20µg/mL Rh123, 500nM GF120918 as a dose. 
 
GF120918 to be present in the perfusate at same concentration i.e 500 nM.   
I. GF120918 wanted at a concentration of 500 nM in IPRL perfusate; 500 nM = 5x10-7 M 
II. 5x10-7 * 563.7 (GF120918 MW) * 500 mL = 0.140925 g = 140.93 µg/500 mL perfusate 
Rh123 transport in the single-pass IPRL 
Single-pass isolated perfused rat lungs were prepared as per above protocol and equilibrated with 
diluted blood perfusate +/- GF120918 for 30 min.  Following this, Rh123 (2 µg, 40 µg or 2 µg + 
GF120918 nominal dose) was introduced to individual IPRL preparations and each 1 min fraction 
collected via the single-pass setup.   
6.2.4. Perfusate plasma Sample and Dose Solution Preparation for Analysis (automated) 
Consumables 
Rhodamine 123; Rh123, >98 % electrophoresis grade, (Sigma-Aldrich, Dorset, UK, Cat: R-8004) 
Rolipram, (Sigma-Aldrich, Dorset, UK, Cat: R6520) 
Acetonitrile; ACN, 99.6+ %, HPLC grade, (Fisher Scientific, Loughborough, UK, Cat: A/0626/17) 
  
Control rat perfusate plasma and study samples were collected and stored frozen until analysis. On 
the day of analysis samples and control perfusate plasma were removed from the freezer and 
thawed.  
Once defrosted all control perfusate plasma was vortexed and then centrifuged at 13000 rpm for 10 
min to pellet down fibrin clots. 
Preparation of perfusate plasma calibration standards: 
A 1 mg/mL H2O stock details: 
Compound OI 
Mass 
(mg) 
From 2.27 mg/mL 
stock 
Date 
Prepared 
Rh123 SC/159651 1.0 
44 µL stock to 56 
µL H2O 25/09/2007 
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 B Dilute 10 µL of A (1 mg/mL) for each compound and 20 µL of B (0.5 mg/mL) into 450 µL 
acetonitrile: water (1:1) = 20 µg/mL. 
A 200 ng/mL stock solution was prepared in control rat perfusate plasma. 
Add 10 µL B (20 µg/mL) to 990 µL control rat perfusate plasma. 
Control rat perfusate plasma was made up by adding 1 part of control rat plasma to 9 parts of Krebs-
Ringer bicarbonate buffer, pH 7.4, containing 3 % BSA.  
Standard curves were prepared, to cover the range 0.02 to 200 ng/mL, by serial dilution in 
centrifuged control rat perfusate plasma using the 0.2 µg/mL perfusate plasma standards and a 
TECAN robot (Genesis RSP150). The TECAN also produced a carryover blank following the washes 
post-highest standard preparation. 
Preparation of perfusate plasma samples for analysis: 
The samples and standards were prepared by protein precipitation with acetonitrile containing 15 
ng/mL of rolipram (internal standard).  Followed by filtration using a TECAN robot the samples and 
standards were extracted by protein precipitation. For extraction, 100 µL of perfusate plasma from 
standards and samples was taken and 300 µL of acetonitrile with internal standard was added.  
The filtered extracts were collected into a 96 well plate and were blown down to dryness under a 
nitrogen stream at 40 oC.  The dry extracts were reconstituted in 150 µl of acetonitrile: water 
(25:75). 
The plate was then mixed on a plate shaker for at least 5 min before analysis by LC/MS/MS. 
Preparation of dose check samples: 
Dose:  Rh123 20 µg/mL 
Dilute in triplicate to: 
C 200 ng/mL:  Take 10 µL dose and add to 990 µL H2O. 
D 20 ng/mL: Take 50 µL C and add to 450 µL H2O. 
E 2 ng/mL: Take 50 µL E and add to 450 µL H2O. 
Dose check samples were extracted and analysed following the same procedure used for study 
samples. 
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Re-injection of samples to check ion suppression: 
The following samples were re-injected to allow assessment of the effect of ion suppression. The 
samples used were the 8 and 80 ng/mL calibration standard and 3-4 min and 15-16 min samples 
from rat #1. These samples were injected at a 10 μL injection volume and then immediately re-
injected at the 30 μL injection volume used for the rest of the run. 
LC-MS/MS analytical conditions 
(Method development – Rh123 in dH2O) sample was introduced to the LC/MS/MS via a pump and 
Hamilton syringe and the compound molecular weight used to set a MQ ion ‘window’ within which 
to scan via a manual tuning setting.  Once complete a set of quantitation values were retrieved, from 
which optimum results were selected and inputted as MRM transitions to be used for sample 
analysis.  See Figure 6.4 for example peaks obtained.) 
Analytical Column: 
Packing Type Luna C18 
Particle Size 5 µM 
Dimensions 50 x 2.1 mm 
Injection volume 30 µL (10 μL for ion suppression check samples) 
HPLC Conditions: 
Pump Agilent 1100 
Solvent A  0.1 % Formic acid in HPLC grade water 
Solvent B 0.1 % Formic acid in Acetonitrile 
Flow rate 0.8 mL/min. 
Initial divert to waste time 0.5 min. 
Run time 3 min. 
Gradient conditions: 
Start Time (min.) A (%) B (%) 
0 95 5 
0.5 95 5 
1.8 5 95 
2.2 5 95 
2.3 95 5 
3.0 95 5 
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Detector Conditions: 
Detector Applied Biosystems API4000 Mass Spectrometer 
Mode MSMS 
Ion Source TISP (turbo ion spray) 
Ionisation +ve 
Source Temperature 650 oC 
MRM Transitions: 
Compound Cassette Q1 Mass Q3 Mass Declustering 
potential (V) 
(DP) 
Cell entrance 
potential (V) 
(CE) 
Cell exit 
potential (V) 
(CXP) 
Rh123 1 345.101 285.151 66.0 57.0 18.0 
Rolipram (IS) 1 276.45 131.10 100 40 12 
 
6.2.5. Flunisolide absorption in the single-pass perfusion model 
Dose preparation 
Consumables and reagents 
Flunisolide, (Sigma-Aldrich, Dorset, UK, Cat: F5021-100MG) 
GF120918; obtained from GlaxoSmithKline, Stevenage, UK. 
Dimethyl sulfoxide; DMSO, BioReagent, for molecular biology, ≥99.9 %, (Sigma-Aldrich, Dorset, 
UK, Cat: D8418-50ML) 
Method 
2 µg nominal dose (100 µL instilled dose volume) 
I. Flunisolide was weighed out to give 1.07 mg/mL flunisolide in H2O inc. 10 % DMSO 
II. 1.07 mg/mL = 1070 µg/mL 
III. 1:10 dilution: (100 µL '1070 µg/mL solution' to 900 µL H2O and vortexed to mix) = 107 µg/mL 
in H2O inc. 1 % DMSO 
IV. 20 µg/mL / 107 µg/mL * 2 mL = 0.37 mL '107 µg/mL solution' up to 2 mL with H2O 
 
5 µg nominal dose (100 µL instilled dose volume) 
 
I. Flunisolide was weighed out to give 5.39 mg/mL flunisolide in H2O inc. 10 % DMSO 
II. 5.39 mg/mL = 5390 µg/mL 
III. 1:100 dilution (10 µL '539 0µg/mL solution' to 990 µL H2O and vortexed to mix) = 53.90 
µg/mL in H2O inc 0.1 % DMSO 
IV. 50 µg/mL / 53.90 µg/mL*2 mL= 1.86 mL ' 53.90 µg/mL solution' up to 2 mL with H2O 
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40 µg nominal dose (100 µL instilled dose volume) 
 
I. Flunisolide was weighed out to give 5.39 mg/mL  flunisolide in H2O inc. 10 % DMSO 
II. 5.39 mg/mL = 5390 µg/mL   
III. 1:10 dilution: (100µL '5390 µg/mL solution' to 900 µL H2O and vortexed to mix) = 539.0 
µg/mL in H2O inc. 1 % DMSO 
IV. 400 µg/mL / 539.0 µg/mL*2 mL = 1.48 mL '539.0 µg/mL solution' up to 2 mL with H2O 
80 nominal dose (100 µL instilled dose volume) 
I. Flunisolide was weighed out to give 5.39 mg/mL flunisolide in H2O inc. 10 % DMSO 
II. 5.39 mg/mL = 5390 µg/mL 
III. 800 µg mL/5390 µg mL*2 mL = 0.29 mL '5390 µg/mL solution'  up to 2 mL in H2O  
 
2 µg nominal dose of flunisolide inc. GF120918 (500 nM; 100 µL instilled dose volume) 
 
I. GF120918: 500nM = 281.9 ng/mL (using 563.7 as MW) 
II. GF120918 was weighed out and dissolved in 10 mL H2O (containing 10 % DMSO) and 
sonicated to achieve a homogeneous solution @ 28.19 µg/mL. 
III. 100 µL of this stock solution was spiked to 900 µL of a ~20 µg/mL flunisolide solution in 
order to achieve a solution of ~ 20µg/mL flunisolide, 500nM GF120918 as a dose. 
 
GF120918 to be present in the perfusate at same concentration i.e 500 nM. 
   
I. GF120918 wanted at a concentration of 500 nM in IPRL perfusate; 500 nM = 5x10-7 M 
II. 5x10-7 * 563.7 (GF120918 MW) * 500 mL = 0.140925 g = 140.93 µg/500 mL perfusate 
 
Flunisolide transport in the single-pass IPRL 
 
Method 
Single-pass isolated perfused rat lungs were prepared as per above protocol and equilibrated with 
diluted blood perfusate +/- GF120918 for 30 minutes.  Following this, flunisolide (2 µg, 5 µg 40 µg 80 
µg or 2 µg + GF120918 nominal dose) was introduced to individual IPRL preparations and each 1 
minute fraction collected via the single-pass setup.   
6.2.6.  Perfusate plasma Sample and Dose Solution Preparation for Analysis (automated) 
Consumables 
Flunisolide, (Sigma-Aldrich, Dorset, UK, Cat: F5021-100MG) 
Rolipram, (Sigma-Aldrich, Dorset, UK, Cat: R6520) 
Acetonitrile; ACN, 99.6+ %, HPLC grade, (Fisher Scientific, Loughborough, UK, Cat: A/0626/17) 
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Sample preparation was conducted as per protocol for ‘Rh123 samples and dose solutions’. 
Preparation of perfusate plasma calibration standards: 
A 1 mg/mL H2O stock details: 
Compound OI 
Mass 
(mg) 
From 1.07 mg/mL 
stock 
Date 
Prepared 
CCI18772 SC/160270 1.0 
470 µL stock up to 
500 µL with H2O 15/11/07 
 
 B Dilute 10 µL of A (1 mg/mL) into 990 µL acetonitrile: water (1:1) = 20 µg/mL. 
A 200 ng/mL stock solution was prepared in control rat perfusate plasma. 
Add 10 µL B (20 µg/mL) to 990 µL control rat perfusate plasma. 
Similarly, perfusate plasma samples, dose check samples and ion suppression samples were 
prepared and analysed as per ‘Rh123 protocol’ above.   
LC-MS/MS analytical conditions 
(Method development – Flunisolide (in dH2O) sample was introduced to the LC/MS/MS via a pump 
and Hamilton syringe and the compound molecular weight used to set a MQ ion ‘window’ within 
which to scan via a manual tuning setting.  Once complete a set of quantitation values were 
retrieved, from which optimum results were selected and inputted as MRM transitions to be used 
for sample analysis.  See Figure 6.4 for example peaks obtained.) 
Analytical Column: 
Packing Type Luna C18 
Particle Size 5 µM 
Dimensions 50 x 2.1 mm 
Injection volume 30 µL (10 μL for ion suppression check samples) 
HPLC Conditions: 
Pump Agilent 1100 
Solvent A  0.1 % Formic acid in HPLC grade water 
Solvent B 0.1 % Formic acid in Acetonitrile 
Flow rate 0.8 mL/min. 
Initial divert to waste time 0.5 min. 
Run time 3 min. 
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Gradient conditions: 
Start Time (min.) A (%) B (%) 
0 95 5 
0.5 95 5 
1.8 5 95 
2.2 5 95 
2.3 95 5 
3.0 95 5 
Detector Conditions: 
Detector Applied Biosystems API4000 Mass Spectrometer 
Mode MSMS 
Ion Source TISP (turbo ion spray) 
Ionisation +ve 
Source Temperature 650 oC 
MRM Transitions: 
Compound Cassette Q1 Mass Q3 Mass Declustering 
potential (V) 
(DP) 
Cell entrance 
potential (V) 
(CE) 
Cell exit 
potential (V) 
(CXP) 
Flunisolide 
(CCI18772) 
1 435.175 320.95 41.0 21.0 18.0 
Rolipram (IS) 1 276.45 131.10 100 40 12 
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6.2.7. Mass balance studies 
Materials and Method 
Consumables 
Flunisolide, (Sigma-Aldrich, Dorset, UK, Cat: F5021-100MG) 
Rhodamine 123; Rh123, >98 % electrophoresis grade, (Sigma-Aldrich, Dorset, UK, Cat: R-8004) 
Acetonitrile; ACN, 99.6+ %, HPLC grade, (Fisher Scientific, Loughborough, UK, Cat: A/0626/17) 
Lung Sample Preparation 
‘Study lungs’ were from IPRLu preparations, ‘Control lungs’ from donor blood animals.  All lung 
samples and control rat lungs were thawed.  
Mean empty tube weight and study lung plus tube weight was determined. 
Preparation of compound standards in lung homogenate: 
A H2O stock details: 
Compound  Conc. mg/mL  Date prepared 
Rh123/Flunisolide 1 25/09/07 
 
B Dilute 50 µL of A in 450 µL MeCN:H2O (1:1) = 100 µg/mL 
C Dilute 40 µL of B in 360 µL MeCN:H2O (1:1) = 10 µg/mL. 
D Dilute 40 µL of C in 360 µL MeCN:H2O (1:1) = 1 µg/mL. 
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Table 6.1.  Each calibration line was prepared by spiking into control rat lung homogenate: 
 
 
(The calibration range was 0.01 - 20 µg/Lung and was calculated for lung homogenate. The stock 
solutions were spiked onto control rat lungs after homogenising with the acetonitrile solution). 
Lung Sample extraction 
♦ Acetonitrile:Water (90:10), 10 mL, was added to each sample and homogenised using a 
TOMTEC Autogiser or equivalent.  The dispersion tool was washed between each sample 
with water or alternative solvent. 
♦ Control homogenate (10 mL) was spiked with Rh123 or flunisolide according to table 6.1 and 
vortexed to mix thoroughly. 
♦ Each homogenate solution ~250 µL was placed in an Eppendorf tube and centrifuged at 
13000 rpm for 10 min 
♦ The control lungs (2 used for dilutions if necessary) were centrifuged in falcon tubes at 3500 
rpm for 10 min.  
♦ Using the Tecan (Genesis RSP 150) 100 µL of the supernatant was transferred from each 
eppendorf and 100 µL of a 15 ng/mL rolipram solution (15 ng/mL rolipram in MeCN) as 
internal standard was introduced to a 96 well filter plate and filtered to a 96 well plate. 
♦ H2O (200 µL) was added to give final ratio of ~50:50 acetonitrile: water. 
♦ 96 well plates were then shaken for 5 min before analysis by LC/MS/MS 
The resulting lung samples were analysed by LC/MS/MS using a 30 μL injection volume according to 
protocols outlined above i.e. the LC/MS/MS protocol appropriate for dose substrate.  Levels of 
Rh123/flunisolide in lung homogenate (ng) were adjusted for the individual lung sample weights to 
give results in ng/g. 
Concentration Volume of Stock Solutions Required (µL) 
µg/lung 
(10 mL Homogenate) 
1 µg/mL 10 µg/mL 100 µg/mL 
0.0 - - - 
0.01 10 - - 
0.05 50   
0.1 100 - - 
0.5 - 50  
1 - 100 - 
5 - - 50 
10 - - 100 
20 - - 200 
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6.2.8. Data Analysis 
Noncompartmental analysis of Pharmacokinetic parameters 
The pharmacokinetic modelling software PKTools was utilised in order to estimate pharmacokinetic 
parameters for all generated data.  Input data existed in the form of ‘concentration remaining vs. 
time’ as a percentage of dose to lung.  Other input parameters included the molecular weight of 
substrate and dosing method.  Model fits were extrapolated from observed data and 
pharmacokinetic parameters such as AUC, t½ and CL/F estimated.  See appendix iii for PKTools 
output. 
Statistical analysis 
To determine the significance of dose escalation of Rh123 and the inclusion of GF120918 within the 
IPRL preparation, a one way Analysis of Variance followed by a post-hoc Duncan’s test was 
performed upon both the percentage of deposited Rh123 dose absorbed at 20 min and the t½ (as 
calculated by PKTools)of each transport profile.  A value of p<0.05 was considered significant.   
Power Analysis 
In order to calculate the appropriate number of subjects required for each study performed with the 
IPRL to have adequate power, AUC calculations summarising data over various time points were 
conducted.   
AUC calculations: 
Estimates of area under the curve were calculated using the trapezium rule, splitting up the curve 
into trapeziums and approximating the AUC by calculating the area of each trapezium.   
Power curves 
To assess the number of animals that were required to give the experiment adequate power, power 
curves were created.  Ideally, ~ 80 % power was preferred.  See appendix iii for full Power analysis 
output. 
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Figure 6.4  Example molecular ion peaks for substrates dosed to the single-pass IPRL (Analysed by 
LC/MS/MS). 
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6.3.  Results 
6.3.1. Evans blue distribution following intra-tracheal instillation 
The instillation of Evans blue dye to the single-pass IPRL was conducted at GSK in order to establish 
the probable deposition pattern of substrates delivered via intra-tracheal instillation.  Figure 6.5 
clearly illustrates the distribution of Evans blue within much of the lung parenchyma; each individual 
lobe exhibiting a degree of colouration as a result of the dye.  
 
Figure 6.5 Lobar distribution of Evans blue dye in isolated lungs of the single-pass IPRL following 
intra-tracheal instillation with a Hamilton syringe.  Left-hand panel shows anterior view of lung 
parenchyma.  Right-hand panel shows posterior view of lung parenchyma. 
When comparing the deposition of Evans blue within the tissue of the single-pass IPRL with that of 
the recirculating IPRL at Cardiff, (Figure 3.7, Chapter 3), a greater proportion of Evans blue was 
present in the trachea following ‘Hamilton instillation’ than following ‘forced solution instillation’.  
However, as is also the case with instillation of dye to the ‘Cardiff’ model, much of the Evans blue 
administered to each IPRL was found to be present within lobar regions of the isolated tissue. 
6.3.2. Rh123 absorption in the single-pass perfusion model 
From figure 6.6, it can be seen that increasing nominal Rh123 dose to lung from 2 µg to 40 µg 
resulted in a disproportionate increase in percentage deposited Rh123 dose transported to 
pulmonary perfusate.  Further, addition of the P-gp inhibitor GF120918 (500 nM) to pulmonary 
perfusate and instilled dose of Rh123 (2 µg) resulted in a similar disproportionate increase of 
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percentage deposited dose absorbed.  From this it can be stated that inclusion of GF120918 in 
Rh123 dose and perfusate significantly (p<0.05) altered the percentage of deposited Rh123 dose 
absorbed in the single-pass IPRL.    
 
Figure 6.6 Cumulative increase in percentage deposited dose transported to pulmonary perfusate.  The 
percentage of deposited dose is influenced by both nominal dose concentration and inclusion of 
GF120918 (in perfusate and airway instillate).  Data shown are expressed as mean ± S.D (n=4 for 
each treatment).  
As can be seen in table 6.2, dose escalation of Rh123 from a nominal dose of 2 µg to 40 µg resulted 
in significant (p<0.05) alteration of percentage deposited dose absorbed and calculated t½.  A 20-fold 
increase in nominal dose caused a 89.1-fold increase in cumulative mass absorbed from 0.084 µg to 
7.482 µg.  Further, calculated t½ exhibited a comparative trend in that increase of nominal Rh123 
dose resulted in a significant (p<0.05) decrease in calculated t½.  The addition of GF120918 (500 nM) 
also resulted in significant alteration of documented parameters when comparison was made to the 
equivalent nominal Rh123 dose minus the inhibitor (‘control’).  Addition of GF120918 (500 nm) 
resulted in an almost 4-fold increase in percentage deposited Rh123 dose absorbed in comparison to 
control.  Similarly, inclusion of GF120918 significantly (p<0.05) decreased the calculated t½ from 
594.0 ± 482.1 min to 101.8 ± 58.8 min, a 5.8-fold decrease. 
Further, as is illustrated in both figure 6.6 and table 6.2, comparison of the results of the higher dose 
Rh123 experiment (Rh123 40 µg) to the data obtained in the presence of the P-gp inhibitor (Rh123 
(2 µg) + GF120918 (500 nM)) demonstrate that introduction of GF120918 to the IPRL resulted in a 
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lack of statistical significance (p>0.05) between these treatments in both the percentage deposited 
dose Rh123 absorbed and calculated t½.     
Treatment 
(Nominal Dose µg) 
Cumulative mass of 
Rh123 absorbed by 20 
min(µg) 
Percentage of 
deposited Rh123 dose 
absorbed by 20 min 
(%) 
t½ (min) 
Rh123 (2 µg) 
 
0.084 ± 0.072 4.2 ± 3.6 594.0 ± 482.1 
Rh123 (40 µg) 
 
7.482 ± 3.311 18.7 ± 8.3 78.8 ± 43.8 
Rh123 (2 µg) + 
500 nM GF120918 
0.239 ± 0.130 15.0 ± 7.5 101.8 ± 58.8 
  
Table 6.2 Dose escalation of Rh123 and the effect of GF120918 upon the transport of Rh123 in the 
single-pass IPRL.  The P-gp inhibitor was present at 500 nM in the perfusate and in the co-instilled 
airway doses of Rh123.  Data shown are expressed as mean ± S.D (n=4 for each treatment).   
6.3.3. Flunisolide absorption in the single-pass perfusion model: Influence of GF120918  
As can be seen in figure 6.7, the addition of GF120918 (500 nM) to flunisolide dose and pulmonary 
perfusate resulted in a decrease in the percentage deposited flunisolide dose absorbed with time, an 
opposing effect to that observed in conjunction with Rh123 dose.  Further, dose escalation of 
flunisolide (in a similar experimental rationale to Rh123 dose escalation; chapter 4) exhibited a 
comparable if opposite trend to that observed with Rh123.  Increase of nominal flunisolide dose 
from 2 µg to 40 µg caused a significant (p<0.05) decrease in percentage deposited dose absorbed.  A 
further increase in nominal dose to 80 µg did not bring about an additional decrease in percentage 
deposited dose transported, suggesting saturation of an active process.   
p>0.05 p>0.05 
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Figure 6.7 Effect of dose escalation and addition of GF120918 (500 nM), in perfusate and instillate, 
upon cumulative % of deposited flunisolide dose in the IPRL.  Data shown are expressed as mean ± 
S.D (n=4  for each treatment).  
Table 6.3 illustrates that, increase of nominal flunisolide dose introduced to the single-pass IPRL 
resulted in a disproportionate increase in cumulative mass Flunisolide absorbed by 20 min.  This 
disproportionate increase in cumulative mass absorbed translated to a disproportionate decrease in 
percentage deposited dose absorbed.  An increase in nominal flunisolide dose from 2 µg to 40 µg 
resulted in a 1.89-fold decrease in percentage deposited dose absorbed.  A comparable trend can 
also be observed for calculated t½ in that nominal flunisolide dose increase resulted in a 
disproportionate increase in absorption half-life.  A further doubling of nominal flunisolide dose, 
from 40 µg to 80 µg, did not result in a similar change recorded parameters, i.e. the percentage 
deposited dose absorbed at 20 min and the calculated t½ relating to 80 µg flunisolide dose are not 
statistically different (p>0.05) to those recorded for 40 µg dose.   
The inclusion of GF120918 with instilled flunisolide dose and IPRL perfusate produced analogous 
results to those achieved through dose escalation.  As can be seen in table 6.3, the percentage of 
deposited flunisolide dose absorbed by 20 min or ‘40 µg dose’, ‘80 µg dose’ and ‘2 µg + GF120918’ 
are statistically indistinguishable (p>0.05) from each other and yet  all remained statistically different 
(p<0.05) to ‘2 µg dose’ results.  Further, the calculated t½ for treatments ‘40 µg dose’, ‘80 µg dose’ 
and ‘2 µg + GF120918’ also displayed similarity to each other, however, ‘80 µg dose’ is not 
statistically comparable to ‘2 µg + GF120918’.  Again ‘2 µg dose’ calculated t½ is statistically different 
(p<0.05) to all other treatments.    
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Treatment 
(Nominal Dose µg) 
Cumulative mass of 
Flunisolide absorbed 
by 20 min(µg) 
Percentage of 
deposited Flunisolide 
dose absorbed by 20 
min(%) 
t½ (min.) 
Flunisolide (2 µg) 
 
0.33 ± 0.01 73.05 ± 16.12 5.17 ± 0.88 
Flunisolide (40 µg) 
 
6.60 ± 0.85 38.57 ± 1.69 16.39 ± 1.58 
Flunisolide (80 µg) 
 
26.50 ± 0.71 32.05 ± 1.20 18.96 ± 0.49 
Flunisolide (2 µg) + 
500 nM GF120918 
0.15 ± 0.07 37.10 ± 1.48 14.32 ± 0.13 
 
Table 6.3 Effect of dose escalation and addition of GF120918 upon the transport of flunisolide in the 
single-pass IPRL.  The P-gp inhibitor was present at 500 nM in the perfusate and in the co-instilled 
airway doses of flunisolide.  Data shown are expressed as mean ± S.D (n=4 for each treatment).  
6.3.4. Power Analysis 
The data in table 6.4 documents the mean calculated AUC values for all Rh123 data obtained with 
the single-pass IPRL.  A complete experimental data set was analysed in order to estimate required 
subject number to achieve adequate study power.   Both ‘dose transported’ and ‘dose remaining’ 
are included within this table however, preliminary power curve calculations revealed ‘dose 
remaining’ data to produce the same results as ‘dose transported’ data and were therefore excluded 
from future analysis. 
 
 
 
 
 
 
 
 
 
p>0.05 
p>0.05 
p>0.05 
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Rh123 dose to lung 
(nominal; µg) 
AUC Mean (n=4) StDev 
2 µg Dose Transported AUC 52.2 44.6 
40 µg Dose Transported AUC 240.8 108 
2 µg + GF120918 Dose Transported AUC 169.7 74.9 
2 µg Dose Remaining AUC 1947.8 44.6 
40 µg Dose Remaining AUC 1759.2 108 
2 µg + GF120918 Dose Remaining AUC 1830.3 74.9 
 
Table 6.4 Corresponding AUC data for all ‘single-pass Rh123’ data as calculated using the trapezium 
rule.  AUC calculations were employed as a convenient way to summarise the data gathered over 
various time points.  (n=4 for each treatment). 
The plots in figure 6.8 depict power curves extrapolated from Rh123 data.  Each power curve 
represents a comparison between two dose treatments.  The dashed lines intersecting each power 
curve estimate the sample size needed in order to make comparisons between groups.  For example, 
the power curve related to ‘Dose transported – Rh123 (2 µg) vs. Rh123 (40 µg) estimates that, in 
order to achieve 80 % power, approximately 5 subjects are required.  The same is true for ‘Dose 
transported – Rh123 (2 µg) vs. Rh123 (2 µg) + GF120918. 
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Figure 6.8 Power curves modelled from mean and S.D AUC data.  N1 = number of subjects.  Each power 
curve represents a comparison between two data sets to allow estimation of meaningfulness of 
comparison between each Rh123 treatment. (n=4 for each treatment)   
The data in table 6.5 represents calculated AUC values for each Rh123 dose treatment within the dose 
ranging study conducted with the recirculating IPRL at Cardiff.  Only data relating to ‘dose transported’ 
AUCs are reported as it was previously decided that this data set yields comparable data to ‘dose 
remaining’ values. 
Treatment 
Rh123 dose to lung 
(nominal; µg) No. Obs 
AUC 
Mean 
AUC 
StDev 
Rh123 (20 µg/mL) 2 12 424.02 423.81 
Rh123 (50 µg/ml) 5 4 1040.67 158.69 
Rh123 (400 µg/mL) 40 4 1762.39 371.26 
Rh123 (800 µg/mL) 80 4 1685.36 295.30 
 
Table 6.5 Calculated AUC values and summary statistics for individual Rh123 dose-ranging treatments 
(Cardiff data). 
In a similar approach to that employed with ‘GSK’ data, power curves were generated allowing 
estimation of the number of subjects required to give adequate experimental power to individual 
treatment comparisons.  Figure 6.9 represent the power curves modelled against mean AUC data 
relating to each Rh123 treatment.  Again, dashed lines highlight the adequate number of subjects 
required to achieve 80 % experimental power. 
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Figure 6.9 Generated power curves comparing individual dose treatments of the Cardiff dose-ranging 
study.  N1 = number of subjects.  Only those plots allowing meaningful comparison between treatments 
(i.e. comparison between non-saturable and saturable dose) were included within these results. 
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6.4. Discussion 
Originating from the published discovery of P-glycoprotein by Juliano and Ling in 1976 [70], 
documented research into and around this significant active drug transporter has flourished.  Today, 
the impact of drug transporters, and especially P-gp, upon pharmacokinetics, pharmacodynamics 
and drug safety are well recognized if not fully understood [354].  The in vivo roles of P-glycoprotein 
in drug disposition, therapeutic efficacy and drug-drug interactions has led much research to be 
focused upon functional impact in organs such as the intestine, liver, kidney and brain where the 
influence of P-gp upon drug absorption and disposition is now well characterised [68, 354]. 
As has been discussed in previous chapters, within the literature there exists an abundance of 
research concerning P-gp, with much focus upon reversal of drug resistance and foetal drug 
exposure, polymorphisms of the P-gp gene, transport substrates of P-gp and their interactions and 
the impact of the transporter upon diseases such as Alzheimer’s disease and in particular disease 
treatments.   
As this thesis has suggested, the existence and location of P-gp within the pulmonary system is now 
well accepted and table 6.6 summarises current understanding of P-gp localisation within the lung 
based upon knowledge obtained from contemporary literature reports [354].  
Evidence of Immunohistochemical localisation of P-glycoprotein within cells of the lung 
Cell Type Reference 
Bronchial and Bronchiolar epithelium 
(Apical localisation)  
Lechapt-Zalcman et al., 1997 [112] 
Scheffer et al., 2002 [43] 
Van der Valk et al., 1990 [110] 
Cordon-Cardo et al., 1990 [108] 
Bronchial capillary endothelial cells 
(Apical localisation) 
Schinkel et al., 2003 [60] 
Alveolar macrophage 
(Apical localisation) 
Scheffer et al., 2002 [43] 
Van der Valk et al., 1990 [110] 
Alveolar epithelial cells: 
(Apical localisation) 
Type I 
 
 
Type II 
 
 
Campbell et al., 2003 [137] 
Endter et al., 2007 [113] 
 
Endter et al., 2007 [113] 
 
Table 6.6 Cellular localisation of P-gp within a variety of lung-specific cells.  Localisation in all cases 
was determined by immunohistochemistry. 
Together with a developing expression profile of ‘pulmonary P-gp’, distinct roles of P-gp within the 
lung are also emerging.  Traditionally it is thought that ‘pulmonary P-gp’ acts to remove 
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environmental toxins from the lung and prevent accumulation of these within the lung lumen [43].  
When regarding P-gp from a pharmacological viewpoint, it is the interaction of P-gp with drugs 
introduced to the lung that is important, again, with the aspects of drug-drug interactions, drug 
accumulation, toxicity and drug disposition being of relevance [445]. 
In a parallel manner to that employed at the Welsh School of Pharmacy (WSOP), this current work 
was undertaken using GSK’s own in-house developed in situ isolated perfused rat lung model  
(IPRLu) with the airway instillation of test compounds to determine the potential of P-glycoprotein 
to modulate pulmonary absorption.  Specifically, to consider the applicability and viability of such an 
isolated model within the pharmaceutical industry. 
In a similar approach to that employed at WSOP, the P-gp substrates, Rh123 and flunisolide and 
inhibitor, GF120918, were introduced to the IPRLu and the influence of P-gp upon substrate 
examined.  Within the literature there are many reports of Rh123 use as a P-gp substrate and the 
dye continues to be utilised in such a way.  For example, there are recent published works of Rh123 
being used as a P-gp substrate to illustrate multidrug resistance (MDR) reversal in mice with psoriatic 
arthritis and also to illustrate the novel applicability of ultrasound in altering P-gp gene expression in 
MDR cells [288, 446].  Similarly, there are many literature reports regarding the use of GF120918 as 
a P-gp inhibitor; ranging from its first published use by Letrent et al. to current use in examining the 
influence of P-gp upon drug substrates such as Tandutinib and Darunavir [372, 447, 448].  However, 
while there is significant evidence rationalising the use of such drugs within this chapters studies, 
Rh123 and GF120918 were primarily used to also allow comparison of results between the IPRL at 
WSOP and the IPRLu at GSK.  Further, as has been discussed in a previous chapter (Chapter 4), while 
there is little literature evidence supporting the use of Flunisolide as a P-gp substrate, the steroid 
was previously used to highlight P-gp functionality in the WSOP IPRL and within the R&D facilities of 
GSK at Stevenage, flunisolide has also been identified as a substrate of P-gp via in-house GSK MDCK 
assays.        
While the use of an isolated and perfused rat lung was employed both at WSOP and GSK, the main 
differences between the WSOP IPRL and the GSK IPRLu are obvious, i.e., in situ versus ex vivo, open-
circuit (single pass) versus closed-circuit (recirculating).  However, the variations employed at GSK 
have been used previously within the literature and highlight the diversity of such a model.  Most 
obviously, each of the isolated lung preparations varies in the positioning of the lungs.  As discussed 
in Chapter 3, the removal of the isolated lungs to a humidified glass chamber allows greater control 
over experimental parameters; however, use of an in situ isolated lung setup is also common.  In situ 
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isolated lung setups allow for simpler experimental arrangement, provide accurate cell-cell 
interactions, in vivo-like lung positioning within the thorax and less tissue disruption whilst also 
providing isolation of the lung form surrounding tissue vasculature for lung specific investigations 
[449].  Within the literature, use of the in situ isolated perfused lung appears to be focussed towards 
innate physiological and biochemical studies while the ex vivo setup seems to be related more to 
studies examining the effects of external stressors or drugs delivered to the lung [444, 450, 451].  
Similarly, use of an open-circuit perfusion method compared to that that of a closed-circuit method 
appears also to be ‘experimental-aim’ dependent.  There are many pros and cons regarding each 
perfusion method and the use of an open-circuit model would allow for easy acquisition of perfusate 
samples, a somewhat simpler setup in terms of perfusion circuit and the simpler determination of 
initial pharmacokinetic parameters.  It is therefore apparent that despite the versatile nature of the 
IPRL, specific experimental parameters are linked to specific experimental aims hence the 
differences between WSOP and GSK models.  By mirroring the P-gp studies performed at WSOP, this 
chapter aimed to allow comparison of data, to highlight variability and efficiencies of each IPRL 
model and ultimately to emphasize the importance of P-gp within drug discovery and drug delivery. 
In order to assess the extent of dose distribution in the IPRLu, a solution of the azo-dye Evans blue 
was introduced to the isolated lung via the trachea by means of a Hamilton syringe.  Despite a lack of 
direct corroborating evidence within the literature, techniques such as Evans blue dye distribution 
have been utilised previously by researchers as a simple means to visually illustrate adequate dose 
distribution, organ perfusion and intracellular damage within an isolated organ system [452, 453].  
Although traditionally employed as a marker of extracellular leakage, the application of Evans blue 
for alternative purposes within isolated organ preparations is common.  For example, Evans blue 
staining has recently been used to monitor myocardial contractility within the isolated rabbit heart 
and in the isolated lung has been employed as a means to measure permeability-surface area 
product [216, 454].   
Within this chapter, the introduction of Evans blue was used as a simple and effective means to 
assess dose distribution.  As can be seen in figure 6.5, the dye could be visualised throughout the 
isolated lung parenchyma, highlighting extensive dose distribution.  In comparison to results 
obtained with the WSOP IPRL, (Figure 3.7), much more Evans blue could be seen in the trachea of 
the IPRLu following Hamilton syringe instillation than in the IPRL following forced solution 
instillation.  This simple evaluation of results suggests that the application of a forced solution dosing 
method is more effective at immediately introducing dose to the deep lung.  However, as can be 
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seen in figure 6.3, the isolated lung at GSK is elevated to a 45° angle in order to overcome the lack of 
initial dose propulsion to the deep lung.   
The use of intra-tracheal instillation as a method of introducing particles to an experimental animal 
is widespread; further, there are many studies that document the similarity in drug plasma profile 
following intra-tracheal instillation or aerosol administration to the lung and pharmacokinetic 
analysis of data has also indicated overall similarity in absorption [455].  When comparing the WSOP 
IPRL to the GSK IPRLu studies, dosing method essentially vary only in the presence of a pMDI 
creating forced instillation in the WSOP model.  Both dosing methods present a simple, rapid and 
reproducible means of introducing dose to the isolated lung and when considering the similarity in 
Evans blue distribution profile and literature evidence regarding resemblance between intra-tracheal 
instillation and aerosol administration (to which forced-solution instillation is loosely comparable), it 
is likely that this difference in dosing technique would impact minimally on data comparison and 
result interpretation [456].           
To rationalise the development of an IPRLu at GSK it was important to functionally validate the setup 
in terms of its P-glycoprotein drug transporter activity and thus provide assurance of the value of 
such a setup in the determination of the impact of P-gp upon drug discovery.  The functional activity 
of P-gp as an efflux transporter is unquestionable and its influence upon multi-drug resistance, drug-
drug interactions and drug pharmacokinetics well recognised [73].  In a comparable experimental 
method employed at WSOP, the functional activity of P-gp in the IPRLu was assessed through 
substrate dose escalation and transporter modulation.  As has been reasoned in Chapter 4, the use 
of the P-gp substrate, Rh123, and inhibitor, GF120918, were employed together with the IPRLu; 
experimental doses also mimicked those at WSOP [366, 367, 371, 372].  Although a number of 
techniques for transporter inhibition exist, (e.g. siRNA knockdown, genetic knockout animals, 
irradiation, transcriptional regulation), the use of chemical inhibitors remains the simplest within the 
experimental setting [358, 457, 458].  The use of flunisolide as a P-gp substrate was also duplicated 
with the IPRLu as, although previously only confirmed as a P-gp substrate by Florea and co-workers 
[398], the corticosteroid did display an altered IPRL absorption profile via the influence of GF120918 
in the WSOP IPRL.  As a consequence of the unexpected results documented with the IPRL, the 
replication of this experiment would provide further evidence as to the influence of P-gp upon 
flunisolide transport in the lung.   
The dosing of Rh123 to the IPRLu yielded comparable results to those obtained with the WSOP IPRL.  
Increasing nominal Rh123 from 2 µg to 40 µg resulted in a disproportionate increase in the 
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percentage of deposited dose transported, deemed statistically significant by one way Analysis of 
Variance.  Further, the addition of GF120918 (500 nM) produced a similar disproportionate increase 
in percentage of deposited dose transported, suggesting inhibition of P-gp as an active efflux 
transporter.  Demonstration of active transporter functionality via dose escalation and eventual 
transporter saturation is standard and P-gp literature is strewn with examples of the involvement of 
P-gp upon drug substrate pharmacokinetics via interaction and efflux of transporter substrates [459, 
460].  The results of this chapter concerning Rh123 dose escalation substantiate the hypothesis of P-
gp functionality within the lung and mimic those results displayed in Chapter 4 and within the 
literature [355].  When comparing results obtained at WSOP to those documented at GSK, significant 
similarities can be noted.  As can be seen in figure 6.10, when comparing the percentage deposited 
Rh123 dose transported over a 20 min period, no significant differences between isolated lung 
setups can be drawn.  Essentially, the existence and functional influence of an active transporter 
within the isolated rat lung has been demonstrated via two individual setups by illustrating dose 
independent, non-linear transport of a transporter substrate. 
 
Figure 6.10 Comparison of initial transport profile of Rh123 delivered to the WSOP IPRL and the 
GSK IPRLu.  Data are expressed as mean ± S.D. 
While initial Rh123 transport profiles are comparable, the overall percentage of deposited Rh123 
dose transported over the lifetime of the experimental is also comparable, highlighting not only the 
analogous nature of Rh123 transport within an isolated rat lung but also the significant binding of 
Rh123 to lung tissue.  The resulting transport profiles of Rh123 in the presence of GF120918 are also 
considerably similar, cementing the presence of a functional transporter, i.e. P-gp, within the 
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isolated rat lung and mimicking trends illustrated by Roerig et al., [355], thus further emphasizing 
the authenticity of those results displayed in the IPRLu.  
The transport of flunisolide across the IPRLu also replicates trends observed at WSOP.  Escalation of 
nominal flunisolide dose from 2 µg ultimately to 80 µg resulted in a disproportionate decrease in the 
percentage of deposited dose transported through the IPRLu.  Figure 6.7 illustrates that introduction 
of a 2 µg nominal dose to the IPRLu resulted in a very high percentage of flunisolide being 
transported to perfusate (73.05 ± 16.12 % by 20 min.) while introduction of a 40-fold higher nominal 
dose resulted in only 32.05 ± 1.20 % flunisolide dose transported within the same time period.  
Transporter saturation could be deemed to be reached between 40 µg and 80 µg nominal dose as 
there was no significant difference in percentage deposited dose transported within this dose 
escalation; both 40 µg and 80 µg nominal dose ‘percentage of deposited dose transported’ being 
significantly different from that of the 2 µg dose.  Again, the addition of P-gp inhibitor GF120918 
caused a significant alteration in the percentage of deposited dose transported, decreasing mean 
results from 73.05 ± 16.12 % of 2 µg nominal dose transported in the absence of inhibitor to 37.10 ± 
1.48 % of 2 µg nominal dose transported in its presence. 
However surprising the flunisolide results from both isolated lung preparations appear, they do 
illustrate the presence of an active process, capable of influencing the transport of flunisolide, within 
the rat lung.  Within Chapter 4, the possibilities of the involvement of other active transporters were 
discussed, however, not only do the results obtained in the IPRLu diminish the likelyhood of the 
observed trends being a artefact of the WSOP IPRL, the combination of substrate and inhibitor used 
does confirm the presence of at least one functionally active transporter within the rat lung.     
To facilitate the understanding of the significance of pulmonary P-gp upon the mechanisms of drug 
absorption and distribution in the IPRLu, substrate transport data was subjected to analysis by 
PKtools pharmacokinetic modelling software.  While the concept of pharmacokinetics is much more 
ancient than that of P-gp, the development of modern pharmacokinetics and pharmacokinetic 
modelling grew in parallel to P-gp knowledge in the 1960s and 70s [461] and throughout this period 
and beyond it has been of great importance to estimate and understand the contribution of drug 
transporters to the pharmacokinetic parameters of ADME [462].  Within the literature there are 
numerous accounts of active P-gp influence upon pharmacokinetics, however, to illustrate this same 
impact within an isolated lung model would be incredibly valuable to the field of pulmonary drug 
discovery [226, 462, 463].  By the use of PKtools, it could be determined that the results of this 
chapter mimic those in the literature where P-gp has been chemically modulated and the functional 
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activity of P-gp has been proved to influence pharmacokinetic parameters [464-466].  Within this 
chapter, it was demonstrated that the initial absorption half-life of both Rh123 and flunisolide was 
significantly affected by the non-linear increase in dose and the addition of P-gp inhibitor suggesting 
influence of P-gp upon the initial absorption of substrate drugs dosed to the lung.  Again such 
findings mirror those reported in the WSOP IPRL and yet again verify the functional impact of P-gp 
upon drugs delivered to the lung through its function as an efflux transporter. 
Through conducting substrate transport studies with the IPRLu, results have shown that the model is 
robust and sensitive enough to differentiate between substrate transport profiles in the presence 
and absence of a chemical modulator.  Further, data obtained from this model have proven to be 
comparative to that obtained via the WSOP IPRL suggesting reproducibility between individual 
isolated lung preparations and substantiating credibility of findings from each model.  Within the 
realm of a pharmaceutical company such as GSK, the IPRLu has proved to be a suitable model for 
lead optimisation programmes focussing upon pulmonary drug discovery and development and also 
as a tool for selecting drug analogues based upon lung retention following intra-tracheal instillation. 
The existence of two parallel data sets, performed in isolated lung preparations with distinct 
experimental variations, presented an opportunity for model comparison.  Highlighted in table 6.7 
are key differences between the WSOP IPRL and the GSK IPRLu.   
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IPRL (WSOP model) IPRLu (GSK model) 
ONLY Pulmonary artery cannulated – Simpler 
surgery and avoids build-up of back pressure in 
pulmonary vein 
Both Pulmonary artery and pulmonary vein 
cannulated  - More complicated, prolonged 
surgery 
Fast surgery time (≤10 min) - Aids in maintaining 
lung integrity through swift placement in AGT 
Longer surgery time - Need for quick surgery as 
prep. can be maintained for only ~2-4 h i.e. 
prolonged surgery encroaches upon this  
Perfused with 4 % BSA.  No blood - Easier to 
monitor degree of lung perfusion.  Fewer animals 
needed for prep. 
Perfused with 3 % blood.  No glucose - More 
realistic.  Difficult to visually monitor degree of 
perfusion.  More animals needed for prep. 
Lungs removed and suspended in AGT - Allows 
greater control of expt. variables.  Easy to visually 
monitor lung integrity 
Lungs remain in cadaver - Less trauma.  
Difficult to visually monitor lung integrity.  Does 
afford some tissue protection from external 
environment  
Prep. maintained at 37 °C - More representative of 
in vivo state 
Prep. maintained at room temperature - Simpler 
equipment setup 
AGT humidified - Lung tissue shielded from 
laboratory environment e.g. Air conditioning 
Lung tissue exposed to laboratory environment - 
Tissue damage as lungs dry out over experiment 
period 
Heparin injected during surgery Heparin injected before surgery - enhanced 
circulation of heparin prior to surgery; reduced 
likelihood of coagulation during expt. 
Prep. ventilated with 2.5 mL tidal volume, 20 bpm Prep. ventilated with 1.8 mL tidal volume, 40 bpm 
15mL min
-1 
perfusate flow rate 10 mL min
-1 
perfusate flow rate 
Negative pressure ventilation - More 
representative of in vivo state 
Positive pressure ventilation 
95/5% O2/CO2 bubbled into perfusate – To 
maintain buffered pH of perfusate 
No addition of O2/CO2 to perfusate 
Recirculating perfusion - simpler to maintain 
prolonged experiment 
Single pass perfusion - easier to calculate initial PK 
parameters 
Dosing:  Dosing rod & propellant only pMDI - 
Potential damage to lungs during forced inflation. 
Dosing:  Hamilton syringe - Deposition of 
proportion of dose in trachea 
Observation sheet used - allows documentation of 
difficulties in surgery, lung appearance, dosing 
proficiency etc   
No observation sheet - no accompanying evidence 
to offer explanation for  anomalous results 
 
Table 6.7 Key differences in experimental setup and procedure between two isolated perfused rat lung 
preparations.     
As can be seen in the above table (Table 6.7), a number of distinct variations exist between each 
model, many of which can be linked to the experimental setup as a whole.  Two main and obvious 
differences were noted to be the in situ versus ex situ placement of the isolated lungs and model 
perfusion circuit, i.e., single-pass versus recirculating.  As has been discussed above and in Chapter 3, 
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isolated perfused lung experimental variations can be related to experimental purpose and 
individual variations between models justified according to experiment rationale and design.  When 
comparing GSK IPRLu model to that of WSOP, a number of significant issues were identified;  
• There exists a requirement for faster surgery - IPRLu was viable for up to 4 h once perfused, 
however, prolonged time taken to complete surgery may have impacted upon tissue 
viability, therefore overshadowing benefit of retaining lungs in situ.  
• Use of an observation sheet - Recording factors such as; tissue touching (in WSOP lungs are 
transported to AGT via trachea), surgery time, difficulty in cannulating blood vessels 
(prolonged difficulty in cannulating pulmonary artery may compromise overall integrity of 
tissue) and lung appearance (glassy = poor perfusion, enlarged = oedema occurrence.  Such 
observations would allow accurate data interpretation by study directors.  
• Exposure of less pulmonary tissue during isolation surgery - Removal of a smaller proportion 
of rib cage would help prevent the lungs from ‘drying out’ due to exposure to air 
conditioning.  If lungs must be kept moist during experiment suggest light covering with 
spare perfusate rather than tissue dabbing. (WSOP believe that touching the lungs damages 
integrity). 
As a further comparison between isolated lung preparations, a power analysis study was performed 
upon data generated via use of each model.  Such a study was undertaken to uncover the sample 
size needed to allow accurate statistical judgements of each data set.  On examining figures 6.8-6.9, 
the graphical output of each study comparison, it was concluded that a larger sample size would be 
required to allow comparison of ‘GSK data’ that that of ‘WSOP data’ thus, a larger degree of 
variability was found to exist within and between GSK data sets.  Table 6.8 highlights this. 
Treatment Estimated n value 
IPRLu (GSK)  
Rh123 (2 µg) vs. Rh132 (40 µg) 5 
Rh123 (2 µg) vs. Rh132 + GF120918 5 
IPRL (WSOP)  
Rh123 (2 µg) vs. Rh132 (40 µg) 3 
Rh123 (2 µg) vs. Rh132 (80 µg) 3 
Rh123 (5 µg) vs. Rh132 (80 µg) 3 
 
Table 6.8 Summary of a power analysis study, from which necessary experiment sample sizes to 
allow reliable statistical analysis were graphically determined. 
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While the power analysis study does seem to suggest a requirement for a higher treatment sample 
sizes when utilising the GSK IPRLu, the study does not include interpersonal variability.  All power 
analysis data considered from WSOP IPRL was generated by a single study operator, while GSK IPRLu 
data considered was generated by 1+ researcher.  Further, data yielded through use of the IPRLu 
was generated by one seasoned and one novice IPRLu operator, somewhat rationalizing the 
existence of a larger degree of variability within such ‘GSK data sets’.  
Overall, the replication of drug transport studies performed at WSOP through use of the IPRLu at 
GSK support data trends and conclusions drawn from ‘WSOP data’.     In summary, the hypothesis of 
functionally active drug transporter presence in the isolated rat lung, also assumed in vivo, was 
substantiated via drug substrate dose escalation and drug transporter inhibition studies in the IPRLu.  
The use of P-gp substrate drugs and a specific P-gp chemical inhibitor strongly suggests P-gp to be 
the transporter protein responsible for trends observed.  All data generated via the IPRLu mimics 
that generated via the IPRL in terms of overall observations outlined providing an exceptional 
collection of data from which to further understand the influence of an active transporter upon 
drugs delivered to the lung.  In addition, the merits of the isolated and perfused rat lung at GSK 
present this model as an excellent specific and relatively high throughput model for use in the fast 
paced field of pharmaceutical research.   
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Chapter 7 
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7.0. General Discussion 
In 2006 alone, the global value of the ‘inhaled drug’ market was estimated at US $ 18.5 billion with 
the respiratory market as a whole representing the 4th largest therapeutic area within 
pharmaceutical sales.  With ~65 % of this market being occupied by drugs for asthma/COPD 
treatment, it was expected that such treatments would generate US $ 21.9 billion in sales in 2010, 
highlighting the significant revenue pulmonary drug delivery can create [467].  Today there are at 
least 65 inhaled drugs available for the treatment of respiratory diseases.  While most drugs are 
generated for local targeting of diseases such as asthma, COPD, influenza and TB, there are also a 
number of drugs (particularly biotechnology molecules) in development whose delivery to the 
systemic circulation via the lungs is being examined [468].  The delivery of drugs via the lung for 
diseases and conditions that do not involve the pulmonary system has been an increasing focus over 
the last 20+ years.  The lung offers a number of beneficial physiological characteristics (i.e. expansive 
surface area, thin barrier at the alveolar epithelium, high vascularisation) that can be exploited to 
provide non-invasive access to the systemic circulation [469].  Already there have been a number of 
success stories, most famously inhaled insulin, Exubera, which reached the market in 2006 for the 
treatment of diabetes but due to its limited approved indications it was later withdrawn.  Small 
molecule drugs have also been the subject of systemic delivery via the lungs, for example, both 
morphine and fentanyl have been reported and have been successfully delivered via the lung for 
pain relief and ergotamine has been delivered through the lung for the treatment of migraine.  Such 
examples serve to highlight the opportunities manifested by pulmonary drug delivery.  Further, 
encouraging research is progressing developments in this area and that will undoubtedly lead to 
more efficacious inhaled therapies for the treatment of a variety of diseases [468, 469]. 
The lungs are constantly exposed to xenobiotics notably from the environment.  From this, the lungs 
possess a number of barriers and defence mechanism, including the airway geometry promoting 
particle deposition, mucus and mucociliary clearance, as well as immune defence and the physical 
cell barrier itself, all of which will limit inhaled drug delivery to submucosal sites [469].  The presence 
of active drug transporters within the many cells of the lung provides a further barrier to drug 
delivery.  Drug transporter proteins are increasingly recognised as important determinants in drug 
disposition and response, with impact upon the pharmacokinetics of drugs [45].   
There is a growing body of knowledge on the presence of drug transporters in the lung.  Through 
exploitation of RT-PCR techniques a surprisingly large number of transporters, from a variety of 
families, have been localised to the cells of the lung.  Less is known on the actual spatial expression 
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of drug transporter proteins in the lung and as a consequence predictions of how a given transporter 
may impact upon pulmonary drug absorption and disposition are highly speculative.  Generally, 
literature reports constrain drug transporter localisation to the apical side of pulmonary-specific 
cells, suggesting a role in defence via extrusion of inhaled toxins and pathogens to the airspace for 
expulsion [104, 354].   
The overall objective of this thesis was to explore the functional significance of P-glycoprotein upon 
pulmonary absorption using an isolated perfused lung preparation as a model system.  An initial 
objective of this was to positively establish an accurate expression profile for a selection of relevant 
active drug transporters within the rodent lung.  The rodent lung was chosen as it represents a 
commonly utilised and well recognised experimental species, and the isolated perfused lung 
preparation that was developed and used in this thesis was based around the rat [23, 417].  Initially, 
‘drug transporter experiments’ mimicked those performed by others, such as Endter et al. and 
Bleasby et al. [69, 104] and sought to determine the presence of individual drug transporters at the  
mRNA level within different rat lung cell samples.  Uniquely we investigated the expression, not only 
in whole rat lung tissue, but also in primary cultures of rat alveolar epithelial cells which retain many 
morphological and biochemical features of their in-vivo counterparts, i.e. the isolated cuboidal ATII 
cell able to undergo cell division, produce surfactant and display significant metabolic capacity, while 
the non-dividing squamous ATI-like cell displaying a more limited metabolic capacity.  Perhaps not 
surprisingly we found variable patterns of expression between whole lung, freshly isolated AEII cells 
and day 8 AEI-like cells across the various transporters.  Figure 7.1 is a graphical summary or profile 
of the findings.  The generation of such an expression profile in rat lung and AE cells helped to 
provide a platform for further work, i.e., understanding the functional impact of drug transporters 
upon an airway-administered drug substrate. 
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Figure 7.1 Graphical presentation of drug transporter expression in the rat lung.  Black bars (front-
most bars) represent perceived expression in whole rat lung samples.  Light grey (middle bars) 
represent mRNA expression in freshly isolated AEII cells and dark grey (furthermost bars) represent 
expression in AEI-‘like’ cells at day 8 of culture.  Data are expressed as mean, n=3 for each 
transporter) 
As can be seen from figure 7.1, almost all ABC transporters studied could be detected via mRNA in 
whole rat lung samples, in many cases expression decreased from strong (+++/interpreted as ‘3’ in 
order to generate the above figure) in whole lung samples to a lower level of expression in freshly 
isolated and ‘day 8’ AE II cells.  This trend does not transfer to SLC transporters studied, where 
proportionately; fewer transporters were detected in rat lung cell samples.  It is worthwhile to note 
that investigated drug transporters were chosen upon their relevance to drug discovery as a whole 
and not specifically for their theoretical expression within the lung.  For example, when examining 
glucose transporters in the lung, only those with reported ubiquitous/broad expression patterns 
were detected.  Further, of the five glucose transporters studied, three were recognised in the 
literature as transporters that display a more specific localisation pattern; i.e. Glut4 specific to brown 
and white adipose tissue and skeletal and cardiac muscle [209], Glut5 specific to the jejunal region of 
the small intestine [209, 221] and GLT-1 specific to the proximal tubule of nephrons [211].  
Therefore, it is perhaps unsurprising that these individual transporters were found to be absent from 
the lung cell samples studied.  In a contrary manner, however, the renal isoform of the proton-
coupled oligopeptide transporter, PEPT2, (named as such due to expression in kidney tubular cells 
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and therefore supposed not to be expressed in pulmonary tissue), is well documented to be present 
in the lung [251]. 
Once a comprehensive expression profile of drug transporters in rodent lung had been established, 
it was then sought to examine the functional significance of a drug transporter protein in the intact 
lung.    
Attention was focussed upon the P-glycoprotein drug transporter as this transporter alone is at the 
centre of a large proportion of drug transporter research.  The positioning of P-gp within mucosal 
barriers and indeed within the BBB represents an important challenge to drug absorption and 
disposition.  The role of P-gp in pharmacokinetics is now quite well established and there exists 
much evidence of the ability of this drug transporter to influence greatly drug discovery and delivery 
processes.  For example, through interaction with a drug substrate, P-gp has the capacity to 
influence a drugs bioavailability, to bring about drug-drug interactions, to limit or enhance tissue 
penetration, to influence drug elimination, to create adverse side effects through unexpected drug 
retention and to generate issues of toxicity through unpredicted variability in whole-body or tissue 
specific drug concentrations [72]. 
In order to examine the influence of P-gp upon drugs delivered to the lung, an adequate model was 
required.  In the literature, there exist a number of models applicable to the investigation of drug 
absorption in the lung.  Within a review authored by Sakagami, such models are compared and 
contrasted and their relevance to specific experimental requirements and goals discussed [23].  The 
isolated perfused rat lung has emerged over time as an excellent model for examining drug 
absorption.  This model has been promoted within biopharmaceutical research as one that 
surmounts negative aspects of other pulmonary models where the mechanisms of drug absorption 
and disposition are indistinguishable.  The isolated perfused rat lung offers a well-designed 
resolution to the problems presented by other models in that it allows the partitioning of complex 
whole-body pharmacokinetic processes whilst maintaining accurately the architecture and innate 
functionality of the lung [23].  In a similar vein to P-gp, the isolated perfused rat lung is also featured 
in abundance in the literature.  Initial uses for such a model include exploitation as a ‘respirator’ for 
an isolated heart preparation, while today use ranges from examination of distribution of a range of 
inhaled toxins to more physiological examinations such as the effect of altered end-expiratory 
pressure and tidal volume upon alveolar stability [36, 470].   
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Within the scope of this thesis, P-gp functionality was examined systematically through use of the 
isolated perfused rat lung, several known P-gp substrates and a specific P-gp inhibitor designed by 
GSK.  Initially, presence of an active efflux process, (assumed to be mediated by P-gp via use of a P-
gp substrate), was illustrated by dose independent transport of Rh123 and flunisolide.  It was 
hypothesised that, if influenced by P-gp, such substrates would display nonlinear transport profiles 
as P-gp actively effluxed substrate to the airspace of the lung thus slowing appearance in perfusate.  
Figure 7.2 summarises the non-linear transport of these P-gp substrates, presence of an active 
transport process is assumed since the transport profile of each substrate does not resemble that of 
a substrate transported by passive diffusion alone.              
     
Figure 7.2 Transport profiles of two P-gp substrates, Rh123 and flunisolide, after dosing to the IPRL.  
Each profile illustrates non-linear substrate transport across the IPRL, as dose deposited to the lung 
increases; the percentage of deposited dose transported to perfusate does not alter linearly suggesting 
involvement of an active transport process.  Data are expressed as mean ± S.D, n=4 for each 
treatment. 
In order to aid in confirmation of P-gp as responsible for the active efflux of substrates observed in 
the IPRL, the addition of a 3rd generation P-gp inhibitor was included with instilled dose and/or with 
recirculating perfusate.  It was believed that, through modulation of P-gp via a chemical inhibitor, 
dose independent transport of P-gp substrates would be abolished thus rendering substrate 
transport to be influenced only by passive diffusional processes.  Figure 7.3 reviews the effect of the 
P-gp inhibitor, GF120918, upon the transport of Rh123, flunisolide and digoxin.  
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Figure 7.3 Transport profiles of three P-gp substrates across the IPRL in the presence of GF120918.  
Both Rh123 and flunisolide displayed altered transport profiles in the presence of the P-gp inhibitor 
suggesting influence of P-gp upon transport its absence.  Data are expressed as mean ± S.D, n=4 for 
each treatment, ‘INS’ represents presence of GF120918 in instilled dose only.   
As can be seen from figure 7.3, in the presence of P-gp inhibitor, (in instillate and perfusate or 
instillate only), Rh123 and flunisolide displayed a transport profile similar to that of high substrate 
doses where P-gp saturation is presumed, thus confirming the presence of an active transporter in 
the absence of a chemical P-gp inhibitor.  The transport of the P-gp substrate digoxin did not alter in 
the presence of P-gp inhibitor, however, rapid transport has been observed elsewhere and it is 
hypothesised that this substrate displays such a high rate of passive diffusion that it overcomes the 
efflux capacity of P-gp [361]. 
In order to confirm findings achieved with the Cardiff IPRL, complementary experiments were 
conducted at GSK utilising a single-pass IPRLu model.  Results obtained from this isolated lung 
preparation enhanced the power of those obtained at Cardiff through their similar findings, figure 
7.4 summarises these.   
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Figure 7.4 Mean transport profiles of Rh123 and flunisolide across the IPRLu.  Substrate transport 
was monitored in the presence and absence of GF120918.  The presence of this inhibitor caused an 
alteration in observed transport profile of each substrate.  Data are expressed as mean ± S.D, n= 4 for 
each treatment.   
 
In addition to graphically analysing P-gp substrate transport across isolated and perfused rat lung 
models, pharmacokinetic data, generated by nonlinear modelling, was evaluated.  The non-linear 
modelling of transport data was difficult and revealed complex processes involved in the active 
transport of substrates in the lung.  While much pharmacokinetic modelling was lacking in its 
accuracy, highlighted was the presence of intricate and multifaceted transport processes involved in 
the absorption of substrates in the lung.  My results and data interpretations ultimately indicate the 
presence of at least one active efflux transporter, deduced to be P-gp, to be present in the lung and 
to be significant in the transport of Rh123 and flunisolide.  Such findings add to the reliability of 
literature data, where P-gp is suggested to be present and functionally active within the lung. 
Although the potential of P-gp to influence drug discovery and development is realised, function and 
localisation within the lung is poorly investigated and knowledge of the impact upon drug absorption 
and disposition is limited.  In a recent review by Gumbleton et al., current literature regarding the 
spatial expression of P-gp was reviewed and the potential impact of P-gp, as well as several other 
drug transporters, was considered. 
Within the literature, P-gp has been localised at protein and mRNA level within the lung, suggesting 
presence to be conclusive [43, 108, 110, 112, 113, 137].  Further, the potential for P-gp to impact 
upon drug absorption, retention within the lung, activity, and a number of other ADME aspects is 
recognised.  To confirm the influence of P-gp upon the transport profile of substrates examined 
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within these chapters, another, more specific inhibitor could have been implemented.  Further, 
there is potential for an alternative drug transporter to be responsible for the observed alterations 
in transport profile.  There is evidence within the literature to support the presence of other drug 
transporters within the lung.  Transporters such as BCRP, PEPT1, MRP1 and OCT have all localised to 
lung tissue [39, 43, 115, 119]. Additionally, it is understood that BCRP can act as a transporter of 
Rh123 and can be inhibited by GF120918.  In order to exclude the influence of BCRP upon Rh123 
transport, the BCRP selective inhibitor fumitremorgin C could have been introduced to the IPRL 
together with Rh123, thus inhibiting BCRP action and allowing comparison of Rh123 transport 
profiles to those where GF120918 was present.  It could also be argued that BCRP was not 
responsible for the alterations in Rh123 transport observed as, within the studies of this thesis, 
GF120918 was only present at concentrations capable of inhibiting P-gp and not BCRP action.   
Overall, the findings of this thesis have underlined the presence of at least one active efflux 
transporter within the rodent lung.  However, the findings of many experiments have proposed new 
questions and have thus created the need for future works.  There is a great need to achieve 
consensus in the presence and extent of drug transporters within pulmonary tissue.  Expanding from 
the RT-PCR profile generated within chapter 2, both a quantitative analysis of the abundance of 
individual transporters and their specific spatial localisation is needed in order to aid in data 
interpretation and in determining the potential impact of specific transporters upon drugs delivered 
to the lung.  While the literature suggests predominant apical localisation within pulmonary specific 
cells, the results regarding Flunisolide transport across the IPRL and IPRLu are interesting and 
accurate localisation of P-gp within the alveolar region of the lung would enhance interpretation of 
this data.  Further, there is scope to expand studies examining the influence of P-gp upon substrates 
delivered to the lung.  Firstly, the involvement of P-gp alone should be confirmed and a range of 
other drugs should be examined to evaluate the extent of this influence.  From this, it would also be 
of interest to examine the presence and functional significance of active influx transporters in the 
IPRL and to determine the relative influence of such transporters upon the absorption and 
disposition of inhaled drugs.   
 
Ultimately, the findings of this thesis have acknowledged the presence of an active efflux transporter 
within the rodent lung and have enhanced the need for accurate and comprehensive knowledge of 
the impact of such transporters upon drug delivery and development.  Complete understanding of 
drug transporters within the lung is vital for many reasons; to allow assessment of the impact of an 
active transporter upon the absorption and disposition of a drug candidate, to integrate knowledge 
of species-specific variations for data extrapolation, to approximate impact upon any drug delivered 
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to the lung, to allow for inter-individual patient variation, drug-drug interactions and to compensate 
for altered drug transporter profile within specific disease states.  Only once such a level of 
knowledge is achieved can the potential for drug transporters to transform drug discovery and 
development be fully exploited. 
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Appendicies 
Appendix i 
Transporter expression intensities - raw data 
 
Table A.2.1 Individual expression intensity results for 12 ABC drug transporters in 5 rat lung cell samples.  n=3 for each drug transporter 
 
 
 
 Whole 
Lung 
SPOC-1 AEII – Freshly Isolated AEII – Day 2 of Culture AEI-‘like’ Day 8 of Culture 
mdr1a ++ + ++ ± + + + + + + + + + + ± 
mdr1b ++ + ++ + + + + + ± + + ± ++ + ++ 
mrp1 +++ + +++ ++ ++ ++ + + + +++ +++ +++ +++ ++ ++ 
mrp2 ± ± ± ± ± ± + ± + ++ + + ± ± ± 
mrp3 + ++ + ++ +++ ++ ++ + ++ ++ ++ ++ ± + + 
mrp4 ± ++ + ± ± ± ± ± ± ± ± ± ± ± ± 
mrp5 +++ ++ +++ + + ± + + + ++ +++ ++ +++ ++ +++ 
mrp6 ++ ++ + ± ± + + + + + ± ± ± + + 
CFTR + ± ± + + + ± + + + + + + + + 
mrp8 +++ +++ +++ + ++ + + + + ± ± ± +++ + ++ 
White1 ++ ++ ++ ++ + ++ ++ ++ ++ +++ +++ ++ ++ +++ +++ 
BCRP + + + ± ± ± + + + + ++ + +++ ++ ++ 
β-actin +++ +++ +++ + + + + ++ ++ ++ ++ ++ ++ +++ +++ 
  Appendix i 
281 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Whole 
Lung 
SPOC-1 AEII – Freshly Isolated AEII – Day 2 of Culture AEI-‘like’ Day 8 of Culture 
rBAT ± ± ± + ± ± + + + + ± ± ± ± ± 
SNAT3 ± ± ± ++ ++ ++ ++ ++ ++ ++ ++ + ++ ++ ++ 
Asc-1 ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± 
ASCT2 ++ +++ ++ + + + + + + ± ++ + ++ ++ + 
Eaac1 +++ +++ ++ ± ± ± ± +++ ++ +++ +++ ++ +++ +++ + 
Lyaat1  + ± ± ± ± ± ± + + +++ ++ ++ + ++ + 
SNAT1 ± ± ± ± ± ± ± ± ± ++ ++ + + ++ + 
PHT1 ± ± ± ± ± ± ± ± ± ± + ± ± ± ± 
GLYT2 ± ± ± ± ± ± ± ± ± + + ± ± ± + 
Cat-1 + + + ++ ++ + ++ + + ++ ++ + + ++ + 
Cat-3 ± ± ± ± ± ± ± ± ± + ± ± ± ± ± 
β-actin ++ ++ +++ ++ ++ ++ ++ ++ ++ ++ +++ ++ +++ +++ ++ 
 
 
 
 
          
   
 
Whole 
Lung 
SPOC-1 AEII – Freshly Isolated AEII – Day 2 of Culture AEI-‘like’ Day 8 of Culture 
Glut1 ± ± ± + + + + ++ + + + + + + + 
Glut2 ± ± ± ++ ++ + ± ± ± ± ± ± ± ± ± 
Glut4 ± ± ± ± ± + ± ± ± ± ± ± ± ± ± 
Glt-1 ± ± ± ± ± + ± ± ± ± ± ± ± ± ± 
Glut5 ± ± ± ± + ± ± ± ± ± ± ± ± ± ± 
β-actin + ++ ++ +++ +++ ++ ++ ++ ++ +++ ++ +++ ++ +++ +++ 
Table A.2.3 Individual expression intensity results for 5 glucose drug transporters in 5 rat lung cell samples.  n=3 for each drug transporter 
Table A.2.2 Individual expression intensity results for 11 amino acid drug transporters in 5 rat lung cell samples.  n=3 for each drug transporter 
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 Whole 
Lung 
SPOC-1 AEII – Freshly Isolated AEII – Day 2 of Culture AEI-‘like’ Day 8 of Culture 
MCT + + + ++ ++ ++ +++ +++ ++ + ++ ++ + ++ ++ 
MCT1 +++ ++ ++ ++ ++ +++ +++ +++ +++ +++ +++ +++ +++ ++ +++ 
Mct7B ++ + + + + + ++ +++ +++ + ++ ++ ++ ++ ++ 
β-actin + + ++ ++ +++ +++ +++ +++ +++ ++ ++ +++ +++ ++ +++ 
 
 
 Whole 
Lung 
SPOC-1 AEII – Freshly Isolated AEII – Day 2 of Culture AEI-‘like’ Day 8 of Culture 
rENT1 + + ++ + + + ± ± + + ++ + + + + 
Cnt1 ± ± ± ± ± ± ± ± + ± ± + ± + ± 
NUC2 ± ± ± ± ± ± ± ± + + + ± ± ± + 
Ent3 + ± + ± ± + + + + ++ ++ ++ ++ ++ ++ 
β-actin +++ ++ +++ ++ +++ +++ +++ +++ +++ +++ +++ ++ +++ +++ ++ 
 
 
 Whole 
Lung 
SPOC-1 AEII – Freshly Isolated AEII – Day 2 of Culture AEI-‘like’ Day 8 of Culture 
Pept1 ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± 
Pept2 ++ ++ ++ ++ +++ ++ + ++ ++ ++ ++ +++ + ++ ++ 
β-actin +++ +++ ++ +++ +++ ++ ++ +++ +++ +++ ++ +++ + +++ ++ 
 
 
Table A.2.4 Individual expression intensity results for 3 monocarboxylate drug transporters in 5 rat lung cell samples.  n=3 for each drug transporter 
Table A.2.5 Individual expression intensity results for 4 nucleoside drug transporters in 5 rat lung cell samples.  n=3 for each drug transporter 
Table A.2.6 Individual expression intensity results for 2 peptide drug transporters in 5 rat lung cell samples.  n=3 for each drug transporter 
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 Whole 
Lung 
SPOC-1 AEII – Freshly Isolated AEII – Day 2 of Culture AEI-‘like’ Day 8 of Culture 
Oct1 ± + ± ± ± ± + ± + + + + ± + ± 
rOCT2 ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± 
OCTN2 + + + ++ ++ + + ++ + ++ ++ ++ ++ ++ ++ 
β-actin ++ +++ ++ +++ +++ ++ ++ +++ +++ +++ +++ +++ +++ +++ +++ 
 
 
 Whole 
Lung 
SPOC-1 AEII – Freshly Isolated AEII – Day 2 of Culture AEI-‘like’ Day 8 of Culture 
oatp1 ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± 
oatp2 ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± 
oatp3a1 + + ± ± ± + + + + + + + + + ++ 
oatp-H + + + ± ± ± + + + + + + + ++ ++ 
oatp-E ± ± ± ++ ++ ++ + + + + + + + + ++ 
moat1 ± + ± + ± + + + ± + ± ± + + + 
β-actin ++ ++ ++ +++ +++ +++ +++ ++ +++ ++ ++ +++ +++ +++ +++ 
 
 
 
Table A.2.7 Individual expression intensity results for 3 organic cation drug transporters in 5 rat lung cell samples.  n=3 for each drug transporter 
Table A.2.8 Individual expression intensity results for 6 organic anion drug transporters in 5 rat lung cell samples.  n=3 for each drug transporter 
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Appendix ii 
Chapter 4: Rh123 analytical validation: Precision and accuracy 
Precision and accuracy calibration curves 
Individual calibration plots used to assess Rh123 HPLC assay precision 
 
 Individual calibration plots used to assess F-Na HPLC assay precision 
 
Chapter 4: Functional significance of a drug transporter on instilled substrates to the IPRL 
Individual nonlinear regression plots for IPRL substrate transport data 
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Rh123 dose ranging
Rh123 (2 µg; #2)
Rh123 (2 µg; #3)
Rh123 (2 µg; #4)
 
Rh123 dose ranging
Rh123 (5 µg; #1)
Rh123 (5 µg; #2)
Rh123 (5 µg; #3)
Rh123 (5 µg; #4)
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Rh123 dose ranging
Rh123 (40 µg; #1)
Rh123 (40 µg; #2)
Rh123 (40 µg; #3)
Rh123 (40 µg; #4)
 
Rh123 dose ranging
Rh123 (80 µg; #1)
Rh123 (80 µg; #2)
Rh123 (80 µg; #3)
Rh123 (80 µg; #4)
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F-Na dose ranging
F-Na (40 µg; #2)
F-Na (40 µg; #3)
F-Na (40 µg; #4)
F-Na (40 µg; #5)
 
F-Na dose ranging
F-Na (40 µg; #6)
F-Na (40 µg; #7)
F-Na (40 µg; #8)
F-Na (40 µg; #9)
 
  Appendix ii 
288 
 
F-Na dose ranging
F-Na (40 µg; #10)
F-Na (40 µg; #11)
F-Na (40 µg; #12)
F-Na (40 µg; #13)
 
F-Na dose ranging
F-Na (40 µg; #14)
F-Na (40 µg; #15)
F-Na (40 µg; #16)
F-Na (40 µg; #17)
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Rh123 +/- GF120918 co-instilled and in perfusate
Rh123 (2 µg + 0.1 
% DMSO; #2)
Rh123 (2 µg + 0.1 
% DMSO; #3)
Rh123 (2 µg + 0.1 
% DMSO; #4)
 
Rh123 +/- GF120918 co-instilled and in perfusate
Rh123 (2 µg + 150 
nM GF120918; #3)
Rh123 (2 µg + 150 
nM GF120918; #2)
Rh123 (2 µg + 150 
nM GF120918; #4)
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Rh123 +/- GF120918 co-instilled and in perfusate
Rh123 (2 µg + 500 
nM GF120918; #4)
Rh123 (2 µg + 500 
nM GF120918; #3)
Rh123 (2 µg + 500 
nM GF120918; #2)
 
F-Na +/- GF120918 co-instilled and in perfusate
F-Na (40 µg + 0.1 
% DMSO; #2)
F-Na (40 µg + 0.1 
% DMSO; #3)
F-Na (40 µg + 0.1 
% DMSO; #4)
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F-Na +/- GF120918 co-instilled and in perfusate
F-Na (40 µg + 500 
nM GF120918; #2)
F-Na (40 µg + 500 
nM GF120918; #3)
F-Na (40 µg + 500 
nM GF120918; #4)
 
Rh123 +/- GF120918 co-instilled only
Rh123 (2 µg + 0.1 
% DSMO; #2)
Rh123 (2 µg + 0.1 
% DSMO; #3)
Rh123 (2 µg + 0.1 
% DSMO; #4)
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Rh123 +/- GF120918 co-instilled only
Rh123 (2 µg + 500 
nM GF120918; #2)
Rh123 (2 µg + 500 
nM GF120918; #3)
Rh123 (2 µg + 500 
nM GF120918; #4)
 
0
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Predicted
Expt=GFINS1
F-Na  + GF120918 co-instilled only
F-Na (40 µg 
+ 500 nM
GF120918; 
#2)
F-Na (40 µg 
+ 500 nM
GF120918; 
#3)
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Digoxin  +/- GF120918 co-instilled 
and in IPRL perfusate
Digoxin + 0.1 
% DMSO; #2
Digoxin + 0.1 % 
DMSO; #3
Digoxin + 0.1 % 
DMSO; #4
 
Digoxin  +/- GF120918 co-
instilled and in IPRL perfusate
Digoxin + 500 nM
GF120918; #2
Digoxin + 500 nM
GF120918; #3
Digoxin + 500 nM
GF120918; #4
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Mannitol +/- GF120918 co-
instilled and in IPRL perfusate
Mannitol + 0.1 
% DMSO; #2
Mannitol + 0.1 
% DMSO; #3
Mannitol + 0.1 
% DMSO; #4
 
Mannitol +/- GF120918 co-
instilled and in IPRL perfusate
Mannitol + 
500 nM
GF120918; #2
Mannitol + 
500 nM
GF120918; #3
Mannitol + 
500 nM
GF120918; #4
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Flunisolide  +/- GF120918 co-
instilled and in IPRL perfusate
Flunisolide + 
0.1 % DMSO; 
#2
Flunisolide + 
0.1 % DMSO; 
#3
Flunisolide + 
0.1 % DMSO; 
#4
 
Flunisolide  +/- GF120918 co-instilled and in IPRL perfusate
Flunisolide + 500 
nM GF120918; 
#2
Flunisolide + 500 
nM GF120918; 
#3
Flunisolide + 500 
nM GF120918; 
#4
Flunisolide + 500 
nM GF120918; 
#5
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Appendix iii 
Chapter 6: Functional significance of drug transporters in a first-pass IPRL 
Individual PKTools output for data generated using the first-pass IPRL  
Noncompartmental analysis of experiment: Rh123 (2 µg dose) n=4 
 
  Appendix iii 
297 
 
 
 
  Appendix iii 
298 
 
 
Noncompartmental analysis of experiment: Rh123 (40 µg dose) 
n=4
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Noncompartmental analysis of experiment: Rh123 (2 µg dose)+ GF120918 n=4 
  Appendix iii 
301 
 
 
  Appendix iii 
302 
 
 
 
 
  Appendix iii 
303 
 
Noncompartmental analysis of experiment: Flunisolide (2 µg dose) n=2 
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Noncompartmental analysis of experiment: Flunisolide (40 µg dose) n=2 
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Noncompartmental analysis of experiment: Flunisolide (80 µg dose) n=2 
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Noncompartmental analysis of experiment: Flunisolide (2 µg dose ) + GF120918 n=2 
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Complete Power analysis output – conducted at GSK 
Power analysis of GSK Rh123 data 
Conducted at GSK by L. Wallis 
 
Aims and Objectives 
To calculate the appropriate number of subjects required for the study to have adequate power. 
This will be done using AUC calculations as this is a convenient way to summarise data over various 
time points.  
AUC data 
The calculated AUC’s are in the table below. I have excluded two sets of the data, the run on 21/9 
pm, and also 12/10 am due to problems with the test and inconsistent results being produced. 
Including these would skew the results and make them unreliable. 
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Date am/pm surgeon dose conc (μg/mL) 
dose 
lung(μg) 
dose transported 
AUC dose remaining AUC 
20/09/2007 am PJB 20 2 76.5 1923.5 
20/09/2007 pm DF 20 2 14.9 1985 
02/11/2007 am DF 20 2 14.6 1985.4 
02/11/2007 am DF 20 2 102.9 1897.1 
21/09/2007 am DF 400 40 122.7 1877.3 
26/10/2007 am PJB 400 40 382.9 1617 
26/10/2007 am PJB 400 40 245.4 1754.6 
07/11/2007 am DF 400 40 212.3 1787.7 
12/10/2007 pm DF 
20 + 500nM GF120918 
inhibitor 2 127.3 1872.7 
06/11/2007 am DF 
20 + 500nM GF120918 
inhibitor 2 266.9 1733.1 
06/11/2007 am PJB 
20 + 500nM GF120918 
inhibitor 2 97.1 1902.9 
07/11/2007 am PJB 
20 + 500nM GF120918 
inhibitor 2 187.6 1812.4 
 
For ease from here onwards I have referred to the dose groups by category, which I have named 
‘dose_conc’ rather than specifying dose concentration and dose to lung every time. 
 
dose conc (μg/mL) dose lung(μg) Dose_conc 
20 2 1 
400 40 2 
20 + 500nM GF120918 inhibitor 2 3 
 
For each of the dosage categories the mean and standard deviation was calculated and then used to 
produce power curves. 
 
dose_conc AUC Mean StdDev 
1 dose transported AUC 52.2 44.6 
2 dose transported AUC 240.8 108 
3 dose transported AUC 169.7 74.9 
1 dose remaining AUC 1947.8 44.6 
2 dose remaining AUC 1759.2 108 
3 dose remaining AUC 1830.3 74.9 
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Power Curves 
Power curves are used to estimate how large the sample needs to be in order to make comparisons 
between groups.  I have looked at the comparisons between dose groups 1 and 2, and also groups 1 
and 3. The other possible comparison was to look at groups 2 and 3 but this isn’t very useful and a 
direct comparison cannot be made. 
 
Dose Transported  
1v2 
Power vs N1 with M1=52.3 M2=240.8 S1=44.6 S2=108.0
Alpha=0.05 N2=N1 2-Sided T Te
Po
w
e
r
N1
0.0
0.2
0.4
0.6
0.8
1.0
1 3 5 7 9 11
 
In order to compare dose categories 1 and 2 at 80% power you will need 5 animals, the same is true 
with comparing 1 and 3 for the dose transported data. 
1v3 
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Power vs N1 with M1=52.3 M2=169.7 S1=44.6 S2=74.9
Alpha=0.05 N2=N1 2-Sided T Tes
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The same findings are true for the dose remaining data as well. There appears to be a high 
correlation in the data, and so is producing the same results. I do not feel it is necessary in future in 
analyse both data sets.  
 
Dose Remaining 
1v2 
Power vs N1 with M1=1947.8 M2=1759.2 S1=44.6
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1v3 
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Conclusion 
It is advisable to use a minimum sample size of 5 for the study.  This will produce power of around 
80% so will achieve reliable results. 
 
Power analysis of Cardiff Rh123 dose-ranging data 
 
Conducted at GSK by L. Wallis  
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Analysis Outline 
To calculate the appropriate number of subjects required for the study to have adequate power. 
This will be done using AUC calculations as this is a convenient way to summarise data over various 
time points.  
I am only looking at dose transported as we found previously that the two measurements yielded 
the same results. 
AUC calculations 
AUC is an estimate of the area under the curve.  It is calculated using the trapezium rule. This splits 
up the curve into trapeziums and approximates the area by calculating the area of these. 
 
For ease I have referred to the various treatments for the rest of the report by number. 
 
Rh123 Dose Conc. (µg/mL) Rh123 Dose to lung (µg) Treatment 
20 2 1 
50 5 2 
400 40 3 
800 80 4 
 
 
Then AUC has been calculated for each data set then summary statistics have been obtained for 
each treatment group. 
 
 
Treatment No. obs AUC mean AUC std dev AUC min AUC max 
1 12 424.02 423.81 104.43 1148.37 
2 4 1040.67 158.69 902.78 1267.36 
3 4 1762.39 371.26 1415.96 2132.29 
4 4 1685.36 295.30 1331.12 2052.96 
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Power curves 
To assess the number of animals that are required to give the experiment adequate power I have 
created power curves. Ideally we would like to have around 80% power. 
 
Treatment 1 vs. 2 
Power vs N1 with M1=424.0 M2=1040.7 S1=423.8
S2=158.7 Alpha=0.05 N2=N1 2-Sided T
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So to be able to compare treatments 1 and 2 you would need approximately 6 animals in each group 
to have 80% power. 
 
Treatment 1 vs. 3 
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Power vs N1 with M1=424.0 M2=1762.4 S1=423.8
S2=371.3 Alpha=0.05 N2=N1 2-Sided T
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Treatments 1 and 3 are very powerful, it is only necessary to have 3 animals in each group for 
adequate power. 
 
Treatment 1 vs. 4 
Power vs N1 with M1=424.0 M2=1685.4 S1=423.8
S2=295.3 Alpha=0.05 N2=N1 2-Sided T
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This is also a very powerful comparison, only 3 animals are needed for almost 90% power. 
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Treatment 2 vs. 4 
Power vs N1 with M1=1040.7 M2=1685.4 S1=158.7
S2=295.3 Alpha=0.05 N2=N1 2-Sided
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For comparing treatments 2 and 4 we need 3-4 animals for 80% power. 
Treatment 2 vs. 3 
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Power vs N1 with M1=1040.7 M2=1762.4 S1=158.7
S2=371.3 Alpha=0.05 N2=N1 2-Sided
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4 animals are required to compare treatments 2 and 3. 
 
Treatment 3 vs. 4 
Power vs N1 with M1=1685.4 M2=1762.4 S1=295.3
S2=371.3 Alpha=0.05 N2=N1 2-Sided
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To compare treatments 3 and 4 there is very low power. This comparison isn’t really possible 
without using 12+ animals. 
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Conclusions 
Using 3-4 animals across the groups is generally acceptable and produces power of approx 80%. 
Though to be confidently able to compare treatment groups 1 and 2 you would need a minimum of 
6 animals per group. Also the comparison between treatment groups 3 and 4 is not possible without 
using 12+ animals, and even here using 12 only produces power of 8% so it is not an adviable 
comparison to make. 
 
 
 
 
